<urn:linkedspls:uuid:9258FFBC-DCDC-4C6C-A375-9FC03C323B54>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:4D27D69B-2F63-4940-AD74-710454AA1E6A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:B7B25E99-EE57-41AC-BDE2-45DCC1447471>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"poor-metabolizer" .
<urn:linkedspls:uuid:BF7AF633-8B36-41BF-AC4F-0BA548A0DB2F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:domeoclient:uuid:375DD3AE-F16E-43E9-BB3E-D521613E10AF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:875F6756-255E-43CC-8CA5-19D63561F59A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:72D8F9E8-4B4D-4FC2-81A2-A19C5BF05098>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:6B4C9D47-E3BF-4D75-A661-0D5A649108C6>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:9CA1FBF8-5D9F-4C89-9F89-2BC4E3DB1BF5>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16bda7b5-a5a5-4478-9df3-beb396bd677f" .
<urn:domeoclient:uuid:1A89E704-ECDB-4495-8848-DB89566FFC2E>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf" .
<urn:domeoclient:uuid:51CDF79D-8F09-44DB-AE3B-91C93D13095C>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:7BC21EEB-9DB7-4481-AB5F-CDF2B8C45D96> .
<urn:linkedspls:uuid:F5AE3B3E-B864-4A19-B48C-DC1343C799A3>	<http://semanticscience.org/resource/SIO_000111>	"66106-6 PHARMACOGENOMICS SECTION" .
<urn:linkedspls:uuid:D6235B22-042E-4C36-A104-B353CF92CEB8>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00675" .
<urn:domeoclient:uuid:20FD83E0-8F9F-409B-BA60-7D4A2F8A54AF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:78CB3193-D01C-49AA-B39B-C35887919EED>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:028082D6-59BF-44E8-9117-CC155DA8D008>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:028082D6-59BF-44E8-9117-CC155DA8D008> .
<urn:linkedspls:uuid:44A37F21-E420-40D5-A9E0-5CEDEFAEF40B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00758" .
<urn:linkedspls:uuid:D26DCABA-C665-4147-A57B-F26195C0188E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:3A77F5FE-EF65-4FF1-9BCD-E358D4D5BC82>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"TPMT" .
<urn:linkedspls:uuid:4D27D69B-2F63-4940-AD74-710454AA1E6A>	<http://semanticscience.org/resource/SIO_000111>	"42231-1 SPL MEDGUIDE SECTION" .
<urn:domeoclient:uuid:51CDF79D-8F09-44DB-AE3B-91C93D13095C>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:51C4FEDD-5F25-4F57-92BC-5456BC2E4846> .
<urn:domeoclient:uuid:BBD1EA14-A142-47FF-A3B5-D848FFAED44F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:94F5EFA2-DEF5-444E-B4C2-7268B36AF650>	<http://www.w3.org/ns/oa#exact>	"Application of HLA-B*1502 genotyping as a screening tool has important limitations and must never substitute for appropriate clinical vigilance and patient management. Many HLA-B*1502-positive Asian patients treated with carbamazepine will not develop SJS/TEN, and these reactions can still occur infrequently in HLA-B*1502-negative patients of any ethnicity." .
<urn:domeoclient:uuid:F30A3592-1EDA-414B-8C7B-2B931B766619>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:136CA05A-B32D-4CAF-B985-0FB9EF4F0455>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:2BEFD527-0C92-4B61-A2B9-12F931EDC707>	<http://www.w3.org/ns/oa#exact>	"The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional. CYP2C19*2 and *3 account for the majority of reduced function alleles in white (85%) and Asian (99%) poor metabolizers. Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6, *7, and *8. A patient with poor metabolizer status will possess two loss-of-function alleles as defined above. Published frequencies for poor CYP2C19 metabolizer genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese." .
<urn:domeoclient:uuid:98226070-C5AF-407A-B6D1-D521CD001163>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:98226070-C5AF-407A-B6D1-D521CD001163> .
<urn:linkedspls:uuid:F5AE3B3E-B864-4A19-B48C-DC1343C799A3>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:FC766D1F-0C5B-4C57-8386-30CC6B3408B5>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*1502" .
<urn:domeoclient:uuid:DF92C1E1-A223-4737-8028-06DD03B558D2>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:108444AC-C8D7-42EE-A011-BE98A3F592F0> .
<urn:domeoclient:uuid:10D9A112-25CB-425E-899B-C3AAA3CF633A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:36FDCB4E-5E54-4CBA-BC44-04B836C019F0>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Recommend" .
<urn:domeoclient:uuid:DEE1B9FD-09F4-4AD6-9BEB-55CF10F2FDDB>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf" .
<urn:domeoclient:uuid:D888391C-2CE3-4955-850C-C8FA6291737A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:CFEF239C-B763-4864-8DD8-A917EFD12673>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:74B97B42-8CF1-41BB-84AD-CF0995E7508C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:6F731CE1-E6B4-41AA-98C6-30C94B771E61>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:60CFE292-6834-41FC-8255-B81A3D584EE2>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:60CFE292-6834-41FC-8255-B81A3D584EE2> .
<urn:domeoclient:uuid:B6570F9A-45F9-4786-BDA7-9D6B899F45DB>	<http://www.w3.org/ns/oa#exact>	"Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir." .
<urn:domeoclient:uuid:5464F1B8-CF3D-4DA9-99F4-5F156C14CE70>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:BDEED6AF-6C6D-44F0-8470-40D3A54778C5> .
<urn:linkedspls:uuid:EF919E4C-C0B0-4D8B-A273-2F4A806A828D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:9C09D2F8-83BE-446D-A17A-75402666EE4B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Tamoxifen" .
<urn:domeoclient:uuid:45B95464-0287-435F-86B4-0253D73E6DA8>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:B9375CD1-7E67-42D6-B380-D95AD08BF64B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:23663" .
<urn:domeoclient:uuid:5B91F78A-EEB0-41A3-8995-90B920D09520>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:5B91F78A-EEB0-41A3-8995-90B920D09520> .
<urn:domeoclient:uuid:910F9AE9-8398-400D-8505-D971512A67C6>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:F2C1F1F7-17ED-4AE1-91F9-3A2EE9802A65>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:69B50E0E-4BB4-49DC-AE8B-4326D0F0A959>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:D26DCABA-C665-4147-A57B-F26195C0188E> .
<urn:linkedspls:uuid:86480047-DD43-4A54-B258-3772C18237F7>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:763ABA1D-A316-42DE-AA02-A7123411CD6C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:D62A1217-AE83-41D2-B678-FDCD04344D8B>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:B30B41E3-5A67-4530-BC81-938E6B016FDF> .
<urn:linkedspls:uuid:29A5252E-79CA-41F6-BF34-26789C947F8D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00675" .
<urn:domeoclient:uuid:BF8C1810-3B2F-446D-95FB-F6382AEE1DC0>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:87B8F5B0-8381-4CA7-AE0B-30C481D164B4>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"CYP2C19*1 " .
<urn:domeoclient:uuid:E014618E-3373-4F61-BAF6-4ABD45885081>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:D62A1217-AE83-41D2-B678-FDCD04344D8B>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:7E2CB9FD-6E66-4D71-8B92-4AE2C557E1A3> .
<urn:linkedspls:uuid:8C44EE5A-5A11-4743-B389-617115FC82BB>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:420A3DFE-8247-4E9B-8E6C-368F1A2C415C>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:903F27DB-914A-44A2-B01F-A36164AAC4DB> .
<urn:domeoclient:uuid:1DB91157-FBA4-4FE0-BAB1-68BB8A5A145E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:0AB99582-A22B-403F-9604-C35A9897CE91>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:0AB99582-A22B-403F-9604-C35A9897CE91> .
<urn:linkedspls:uuid:0F7B1E31-9D8A-45AA-8F34-A942EE6FBB80>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:23663" .
<urn:domeoclient:uuid:EBA440A2-4EF9-40CD-89BF-56AB858385E6>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:14BA7077-8D33-42DD-A380-DD27F50087AD>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:AC5F1BAD-8B6A-49DB-8147-AB1394EC169F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"poor-metabolizer" .
<urn:domeoclient:uuid:0F8A06DC-D6FE-466C-AF73-CF9E7A8C2707>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:A460766E-6EF1-468A-A8D7-D8163DEDE490> .
<urn:domeoclient:uuid:ABB77F0A-DE6D-4F3D-87F3-CFA59807AA63>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:FC766D1F-0C5B-4C57-8386-30CC6B3408B5>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:domeoclient:uuid:A74CD0BB-2B56-45FC-B50D-C7952B9C9AE4>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:5229A912-1F9A-40AD-9994-79886D701F6C>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:850F3B60-ADC8-42A5-8E7E-B50B1E9D39BE> .
<urn:linkedspls:uuid:B24A699D-7127-47C1-BFAE-C1ABB6819E2F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:linkedspls:uuid:763ABA1D-A316-42DE-AA02-A7123411CD6C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1, PGR" .
<urn:domeoclient:uuid:240C39EC-A129-42D3-8602-5C743EC412D2>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:EF919E4C-C0B0-4D8B-A273-2F4A806A828D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1, PGR" .
<urn:linkedspls:uuid:75D456DC-1DB0-4F96-A11F-551CC8425889>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:7CE2D02E-F446-465D-9CBE-27C213ACCC89>	<http://semanticscience.org/resource/SIO_000111>	"42231-1 SPL MEDGUIDE SECTION" .
<urn:linkedspls:uuid:8026784E-DC9A-4F18-963D-495E0532BB97>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:5464F1B8-CF3D-4DA9-99F4-5F156C14CE70>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:F10DDB11-A5F0-4B5E-B3CE-47B1F2145E34> .
<urn:linkedspls:uuid:E06F2653-44AD-435F-AB2C-133712B039A6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00564" .
<urn:domeoclient:uuid:216A1896-63FD-45FE-ACBB-80F82EB9ACE5>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:9F0CE910-4782-4E6D-B7E2-C7C784B10B90>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:D66FA8C3-8BAB-4A6F-8234-6DD134876578>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:2EDDDF15-34C4-4321-9EF6-7ACDEBEFD237>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:0496C268-8D3F-4D44-95D9-8D7250579EBE> .
<urn:domeoclient:uuid:90E4AF52-01F4-4371-B3ED-D400FF8B1C1E>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:FE1B382B-9F39-4CAA-8A59-17376ED6F061> .
<urn:domeoclient:uuid:E1199968-6650-4D2A-A5E4-EDFBFE7733AE>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16bda7b5-a5a5-4478-9df3-beb396bd677f" .
<urn:domeoclient:uuid:524C3AB2-2955-4538-A46C-63CDD0BC11D2>	<http://purl.org/pav/createdOn>	"2014-03-22 22:03:47 -0400" .
<urn:domeoclient:uuid:7673EC96-E39E-4D34-A8B6-A31AD2825C94>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:3A77F5FE-EF65-4FF1-9BCD-E358D4D5BC82>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:7673EC96-E39E-4D34-A8B6-A31AD2825C94>	<http://www.w3.org/ns/oa#exact>	" Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction." .
<urn:domeoclient:uuid:8B50CE5B-C2BB-4D97-838E-E1C2600020BC>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:3C75F25B-730C-424C-8A4A-C55F0D242716> .
<urn:domeoclient:uuid:ABB77F0A-DE6D-4F3D-87F3-CFA59807AA63>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:A74CD0BB-2B56-45FC-B50D-C7952B9C9AE4>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:7673EC96-E39E-4D34-A8B6-A31AD2825C94>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:481D46BB-D4FB-4587-B147-C2FC166A7A51>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:481D46BB-D4FB-4587-B147-C2FC166A7A51> .
<urn:linkedspls:uuid:74BDDF82-70E1-44A8-B130-17D04DE86798>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"intermediate-activity" .
<urn:domeoclient:uuid:1DB91157-FBA4-4FE0-BAB1-68BB8A5A145E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:9F0CE910-4782-4E6D-B7E2-C7C784B10B90>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:216A1896-63FD-45FE-ACBB-80F82EB9ACE5>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:8026784E-DC9A-4F18-963D-495E0532BB97>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:linkedspls:uuid:9258FFBC-DCDC-4C6C-A375-9FC03C323B54>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"TPMT" .
<urn:linkedspls:uuid:4D27D69B-2F63-4940-AD74-710454AA1E6A>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"how do we code \\\\\\\\\\\\\\\"tell your doctor\\\\\\\\\\\\\\\"" .
<urn:linkedspls:uuid:F5AE3B3E-B864-4A19-B48C-DC1343C799A3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:domeoclient:uuid:BF8C1810-3B2F-446D-95FB-F6382AEE1DC0>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:9C2B48AD-A4E0-4C6C-9246-E6FD6CF712C8>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:9C2B48AD-A4E0-4C6C-9246-E6FD6CF712C8> .
<urn:domeoclient:uuid:240C39EC-A129-42D3-8602-5C743EC412D2>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:E6578AA5-3295-46D7-B3F2-55CD3CFB5B0F>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:D2A8C2D7-9A3E-4307-BC2B-4EA4FC30E8A5> .
<urn:linkedspls:uuid:B7B25E99-EE57-41AC-BDE2-45DCC1447471>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:domeoclient:uuid:C1BF7FF6-707B-4750-BA47-274111148F96>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:009DEEE9-9289-445E-8C79-81457BE96692> .
<urn:linkedspls:uuid:0B39F957-E88F-427C-AC41-F1B9DC711A02>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>	"Decrease from baseline" .
<urn:domeoclient:uuid:EBA440A2-4EF9-40CD-89BF-56AB858385E6>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:14BA7077-8D33-42DD-A380-DD27F50087AD>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:F19D3DA9-E091-415D-A43E-483BEC7B68FB>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:9BD38C7E-B2D9-4C83-903C-F86556F46EF2> .
<urn:domeoclient:uuid:CE4F247F-F7CB-4776-A379-05B0401FC08D>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:FBEDA24D-50C7-407C-9337-9A08D9456999> .
<urn:linkedspls:uuid:1532F8ED-1CF3-45D5-8A36-00FA8FD6060D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:3D5B3334-40F5-4B23-8773-AFED2978DC1D>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:86480047-DD43-4A54-B258-3772C18237F7> .
<urn:domeoclient:uuid:09730EE5-3645-4E22-8362-E17C60539840>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:0F7B1E31-9D8A-45AA-8F34-A942EE6FBB80> .
<urn:domeoclient:uuid:E014618E-3373-4F61-BAF6-4ABD45885081>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:E1E45497-D882-456B-B573-7A640A307AFB>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:964EBF55-DC67-43A9-93E2-DBC843BB8D2A> .
<urn:domeoclient:uuid:F5C240E5-0680-4CDA-ACC9-4DB8C5A0984B>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:BC59C368-6171-459A-BA88-9B57AAC67FD8> .
<urn:domeoclient:uuid:75A79304-2BD1-4F33-9391-4BB93929D4E6>	<http://purl.org/pav/createdOn>	"2014-06-30 13:22:05 -0400" .
<urn:linkedspls:uuid:CE3D1055-4EAF-4F2F-A2ED-AA9B95C45024>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:F5C240E5-0680-4CDA-ACC9-4DB8C5A0984B>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:53541A7F-ACF6-4030-A4B7-7BA865CDF82F> .
<urn:domeoclient:uuid:910F9AE9-8398-400D-8505-D971512A67C6>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:F2C1F1F7-17ED-4AE1-91F9-3A2EE9802A65>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:AAB53C8F-FB14-4216-82D9-D7CD0AB15000>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:55544593-2536-44D4-B561-50DB89250F52> .
<urn:linkedspls:uuid:396CB021-3C85-4E20-B020-3714CE558E2D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:5D7649B4-7723-40DE-B9AD-4926156D8C0A>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:70BE7DEB-6A8B-41E9-9333-F1F47AC7E1A0> .
<urn:domeoclient:uuid:99AB6350-6929-4C24-B144-7B97EBF09B3F>	<http://purl.org/pav/createdOn>	"2014-04-14 14:20:44 -0400" .
<urn:domeoclient:uuid:8A35BACC-77B7-4822-A677-4D72A3B91942>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf" .
<urn:linkedspls:uuid:F0F7787E-5F9C-47A4-86B2-D64F1B7602B6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:linkedspls:uuid:4D27D69B-2F63-4940-AD74-710454AA1E6A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:domeoclient:uuid:64BC1D21-CAE1-4F85-A596-73342A9D5388>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:64BC1D21-CAE1-4F85-A596-73342A9D5388> .
<urn:domeoclient:uuid:D888391C-2CE3-4955-850C-C8FA6291737A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:10D9A112-25CB-425E-899B-C3AAA3CF633A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:45B95464-0287-435F-86B4-0253D73E6DA8>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:945EB72E-5C75-41B0-B8FC-637E1EF0AE7D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:F3C6E27C-CBBA-4B36-810C-D42C3FA4AB93>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:F3C6E27C-CBBA-4B36-810C-D42C3FA4AB93> .
<urn:domeoclient:uuid:BBD1EA14-A142-47FF-A3B5-D848FFAED44F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:09730EE5-3645-4E22-8362-E17C60539840>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:E8587041-73D9-4727-A9F5-7445BAF204E3> .
<urn:domeoclient:uuid:CE3C3FF6-F83D-47D2-8C4F-944687265F2B>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:55BCCCDC-ED3F-427D-AFFE-0E80E459C63A> .
<urn:linkedspls:uuid:BF7AF633-8B36-41BF-AC4F-0BA548A0DB2F>	<http://semanticscience.org/resource/SIO_000111>	"42231-1 SPL MEDGUIDE SECTION" .
<urn:domeoclient:uuid:C97CADE4-3861-4CB6-A21E-09BF0AEB1F88>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:43B85AB2-533A-4A3B-932F-7CD7177449ED> .
<urn:linkedspls:uuid:6B4C9D47-E3BF-4D75-A661-0D5A649108C6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:linkedspls:uuid:74BB3F3E-AD24-438C-9250-4357E959069E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"did not use low or absent phenotype as these terms are not used with this drug.  It's all poor metabolizer for CYPs" .
<urn:domeoclient:uuid:74B97B42-8CF1-41BB-84AD-CF0995E7508C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:CFEF239C-B763-4864-8DD8-A917EFD12673>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:375DD3AE-F16E-43E9-BB3E-D521613E10AF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:136CA05A-B32D-4CAF-B985-0FB9EF4F0455>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:F30A3592-1EDA-414B-8C7B-2B931B766619>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:F30A3592-1EDA-414B-8C7B-2B931B766619>	<http://www.w3.org/ns/oa#exact>	"CYP2C9 GenotypeNS-Warfarin Clearance/Lean Body Weight(mL/min/kg)Mean (SD)**SD=standard deviation.p<0.001. Pairwise comparisons indicated significant differences among all 3 genotypes.*1/*11180.065 (0.025)*1/*2 or*1/*3590.041 (0.021)*2/*2, *2/*3or *3/*3110.020 (0.011)Total188Other CYP2C9 alleles associated with reduced enzymatic activity occur at lower frequencies, including *5, *6, and *11 alleles in populations of African ancestry and *5, *9 and *11 alleles in Caucasians." .
<urn:domeoclient:uuid:74B97B42-8CF1-41BB-84AD-CF0995E7508C>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0" .
<urn:linkedspls:uuid:1769615F-FAC0-4900-9DC6-5021630F8524>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:AC5F1BAD-8B6A-49DB-8147-AB1394EC169F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:linkedspls:uuid:151DFA13-B2DF-4857-AAE9-51CADEC9A12F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:domeoclient:uuid:51CDF79D-8F09-44DB-AE3B-91C93D13095C>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:domeoclient:uuid:20FD83E0-8F9F-409B-BA60-7D4A2F8A54AF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:78CB3193-D01C-49AA-B39B-C35887919EED>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:C9CADF5C-CD94-4A8C-B6CF-12220ED65397>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006120" .
<urn:linkedspls:uuid:BCCF3F22-38AE-4F01-87D0-22C1B07EC947>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:D5CF7A64-E07F-419A-8900-15F969F2D51F>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:domeoclient:uuid:C1908624-6F0B-47BD-8D70-8EACD877F4A9>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:875F6756-255E-43CC-8CA5-19D63561F59A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:72D8F9E8-4B4D-4FC2-81A2-A19C5BF05098>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:763ABA1D-A316-42DE-AA02-A7123411CD6C>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"biomarker-positive" .
<urn:domeoclient:uuid:8B50CE5B-C2BB-4D97-838E-E1C2600020BC>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:domeoclient:uuid:878D746A-3252-462C-AA1E-A857E2FC63AF>	<http://www.w3.org/ns/oa#exact>	"TPMT genotyping or phenotyping can help identify patients with low or absent TPMT activity (homozygous for non-functional alleles) who are at increased risk for severe, life-threatening myelosuppression from azathioprine tablets (see CLINICAL PHARMACOLOGY, WARNINGSand PRECAUTIONS: Laboratory Tests). Death associated with pancytopenia has been reported in patients with absent TPMT activity receiving azathioprine." .
<urn:domeoclient:uuid:1FCB6C74-C406-41C1-8A44-C9D033D5834C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:CF0F356A-4BD3-4AB3-80E4-DF7EF3CD5F00>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:0D634683-D28C-42DC-9911-DFD0C9EB289D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:375DD3AE-F16E-43E9-BB3E-D521613E10AF>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0" .
<urn:domeoclient:uuid:5464F1B8-CF3D-4DA9-99F4-5F156C14CE70>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:domeoclient:uuid:A1F7627F-2636-46AA-A344-F9978C2AA71C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:563CB9E8-A4E7-43EF-9686-1F5B71F4169D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:10B1EB06-38FD-41C2-A3B7-625B2825B889>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:87D0F0C2-6038-41AA-B84E-85497D292836>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:A3C1B92C-CBE0-4BA8-A41C-D3C3CD26FA51>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"TPMT" .
<urn:domeoclient:uuid:878D746A-3252-462C-AA1E-A857E2FC63AF>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:878D746A-3252-462C-AA1E-A857E2FC63AF> .
<urn:linkedspls:uuid:70BE7DEB-6A8B-41E9-9333-F1F47AC7E1A0>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:74791FAB-E4B4-4EA3-9557-BD68EDB49B01>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:396CB021-3C85-4E20-B020-3714CE558E2D> .
<urn:linkedspls:uuid:1B973C15-149D-4D98-90E2-4A06A2F30ABD>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"CYP2C9*2, CYP2C9*3" .
<urn:domeoclient:uuid:CE5D6919-6972-4689-B658-C5432A02F905>	<http://purl.org/pav/createdOn>	"2014-03-22 22:00:21 -0400" .
<urn:domeoclient:uuid:C09E3379-98EF-4D6C-8046-8C000B4A6C99>	<http://purl.org/pav/createdOn>	"2014-04-21 13:32:07 -0400" .
<urn:domeoclient:uuid:3D5B3334-40F5-4B23-8773-AFED2978DC1D>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:201331AB-54CD-4BE2-81C9-806CCB6E5915> .
<urn:domeoclient:uuid:D3B78E07-8B27-4774-B221-CC47DAC8365E>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:domeoclient:uuid:C7EAEB14-8213-4EF8-AC67-469D0609826B>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:BD33E8D1-8AEF-4E43-9C57-35AB0263305D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:224ACECA-832C-4CE1-B586-4BB3E2AC8018>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:224ACECA-832C-4CE1-B586-4BB3E2AC8018> .
<urn:linkedspls:uuid:92FA8990-60EF-4140-9F60-C12E57E3B114>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:87D0F0C2-6038-41AA-B84E-85497D292836>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0" .
<urn:linkedspls:uuid:1769615F-FAC0-4900-9DC6-5021630F8524>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1, PGR" .
<urn:linkedspls:uuid:D939C426-7E0B-4A32-80F1-7344D702AA97>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Citalopram" .
<urn:domeoclient:uuid:942AE26F-116C-4165-9118-723E840DFB17>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:F45F585A-05C5-49B5-BABB-73BFBE9E9753> .
<urn:domeoclient:uuid:524C3AB2-2955-4538-A46C-63CDD0BC11D2>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:domeoclient:uuid:2D0B9A22-6129-4786-B0A4-7384B3324DF0>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:E06F2653-44AD-435F-AB2C-133712B039A6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:domeoclient:uuid:0496C268-8D3F-4D44-95D9-8D7250579EBE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:DF92C1E1-A223-4737-8028-06DD03B558D2>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:domeoclient:uuid:009DEEE9-9289-445E-8C79-81457BE96692>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:F1D12488-2CA1-4EAD-9A8A-C92106847342>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:E17574BF-3BA6-48DA-B0DA-6E8DF716A03D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:4663B6D5-B11D-4039-8F32-F7E3BFC2537E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:563CB9E8-A4E7-43EF-9686-1F5B71F4169D>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0" .
<urn:domeoclient:uuid:7BFF4A61-D45D-4C1F-9599-BD435EF039B8>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:7BFF4A61-D45D-4C1F-9599-BD435EF039B8> .
<urn:domeoclient:uuid:7D8A9803-9C09-4301-8254-AF8BCE7E83F8>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:1532F8ED-1CF3-45D5-8A36-00FA8FD6060D> .
<urn:domeoclient:uuid:89320F5F-262D-4657-8A52-4432EC0101F8>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:domeoclient:uuid:3C75F25B-730C-424C-8A4A-C55F0D242716>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:D5C1D543-12A2-4AD2-973F-CFDA436726C9>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:FC766D1F-0C5B-4C57-8386-30CC6B3408B5>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00564" .
<urn:linkedspls:uuid:45844BA9-29ED-4EC6-94C0-81C9883F880F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:2CE69763-0812-4DFF-A359-2A8D8FF706AD>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:DF1A2A13-1CD9-47EC-A75C-192353959653>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf" .
<urn:domeoclient:uuid:9CA1FBF8-5D9F-4C89-9F89-2BC4E3DB1BF5>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:59E6E4F8-DCB3-4875-86B2-D5885FD80EF7>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:38B0D49A-8B7C-4D71-B2CE-0388425D3B66> .
<urn:domeoclient:uuid:398416DB-3813-458C-AEAD-1E703244DEC7>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:6A2E1BD4-3863-4A37-AD9D-6B54F3CF3E54>	<http://purl.org/pav/createdOn>	"2014-06-02 14:21:06 -0400" .
<urn:domeoclient:uuid:E1199968-6650-4D2A-A5E4-EDFBFE7733AE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:7D50A614-4F2B-42C6-A175-0BF3C158B5DA>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:7FD03E69-B442-41B6-B8EB-38BD572E8F45>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:FBD3A076-17BF-416E-9EEC-89C39FD558A3>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:F7D9EE5F-E5C0-4296-9825-534C2F768855>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:F7D9EE5F-E5C0-4296-9825-534C2F768855> .
<urn:domeoclient:uuid:EE8AF84A-98F2-4EED-8B54-4312A50FBA31>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:domeoclient:uuid:14BA7077-8D33-42DD-A380-DD27F50087AD>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0" .
<urn:linkedspls:uuid:A48D46C7-8F7E-4426-8C3D-CCA08F946DB0>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:D5CF7A64-E07F-419A-8900-15F969F2D51F>	<http://purl.org/pav/createdOn>	"2014-03-31 09:05:56 -0400" .
<urn:linkedspls:uuid:74BB3F3E-AD24-438C-9250-4357E959069E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:domeoclient:uuid:1924E2D5-9E52-46A8-925D-043869F8F777>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:domeoclient:uuid:5A997B78-0557-4495-BDBD-42F5B4B30412>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:5A997B78-0557-4495-BDBD-42F5B4B30412> .
<urn:domeoclient:uuid:2F3B0124-31A3-451B-BA81-5652303A452C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:D92166A3-0B32-4545-B4CA-719FEDAF410D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:98743D23-3B02-4029-840D-D16A4F390F95>	<http://purl.org/pav/createdOn>	"2014-04-14 14:45:02 -0400" .
<urn:linkedspls:uuid:D1D85749-709E-4FD8-A464-C8E7CD8158BB>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:68B37481-F382-41B9-AEF5-DB241FA9325F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Increase" .
<urn:domeoclient:uuid:E8587041-73D9-4727-A9F5-7445BAF204E3>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:FC7D109F-F404-4287-BE4A-D7C5AA057401>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:domeoclient:uuid:903F27DB-914A-44A2-B01F-A36164AAC4DB>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:139D3D04-C6A8-40B1-A6F1-5FBFB1B6B7CE>	<http://purl.org/pav/createdOn>	"2014-04-21 13:25:55 -0400" .
<urn:domeoclient:uuid:9A5666BB-F43D-45F3-A856-0BDB0E745589>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:BCAE5E0C-30F2-4E8B-8D8E-687ADD4CA18B>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:31115D88-2436-4D8C-B5E2-A7636A9DA498>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:0A10CE73-592A-4D92-84AF-63395C43C0F9>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:0A10CE73-592A-4D92-84AF-63395C43C0F9> .
<urn:domeoclient:uuid:38B0D49A-8B7C-4D71-B2CE-0388425D3B66>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:DF1A2A13-1CD9-47EC-A75C-192353959653>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:B24A699D-7127-47C1-BFAE-C1ABB6819E2F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:B752346E-6167-497D-B585-83983FA71DA2>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:domeoclient:uuid:E826D255-0A7E-4F3C-A59F-675E8A9B606E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:CE5D6919-6972-4689-B658-C5432A02F905>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:910F9AE9-8398-400D-8505-D971512A67C6> .
<urn:domeoclient:uuid:9E02315A-EB6D-4693-B3E4-4FB4B99D4253>	<http://purl.org/pav/createdOn>	"2014-04-21 12:33:30 -0400" .
<urn:linkedspls:uuid:9BD38C7E-B2D9-4C83-903C-F86556F46EF2>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:59E6E4F8-DCB3-4875-86B2-D5885FD80EF7>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:C2A76A18-A463-4D7B-9A00-33BEFE84F768> .
<urn:linkedspls:uuid:1DA28968-6C74-475E-AB4F-5E6E22DFF8BD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER and PgR_receptor" .
<urn:domeoclient:uuid:65BD7CC9-2CFA-43C3-A5F0-FBC0221449BF>	<http://purl.org/pav/createdOn>	"2014-04-28 15:38:40 -0400" .
<urn:domeoclient:uuid:55F59962-81BB-4F69-B3DD-6B65B3526228>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:D62A1217-AE83-41D2-B678-FDCD04344D8B>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:linkedspls:uuid:C2A76A18-A463-4D7B-9A00-33BEFE84F768>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:74EA2B44-40D9-44F0-90BA-33EFF2D1B5AA>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:217B566B-E501-4A3D-A7B5-BFA5CE66147B>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:94F5EFA2-DEF5-444E-B4C2-7268B36AF650> .
<urn:domeoclient:uuid:C97CADE4-3861-4CB6-A21E-09BF0AEB1F88>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:240C39EC-A129-42D3-8602-5C743EC412D2> .
<urn:domeoclient:uuid:61BA8ACB-D63A-46FF-8B5D-79E9326A61A3>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:B6B4A58C-16B0-408F-A838-47FC8649B72D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:21B282F1-F0CA-488A-B703-88611F099D16>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:98FB995B-3B3B-4C86-ACA3-EE4F9F310F41>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:98FB995B-3B3B-4C86-ACA3-EE4F9F310F41> .
<urn:domeoclient:uuid:55BCCCDC-ED3F-427D-AFFE-0E80E459C63A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:7FDE7EC5-68D1-4D11-A164-0B2DA9D73292>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:194FD718-B3CA-4D25-B3D2-56D36C1ECB60> .
<urn:domeoclient:uuid:EEA90F54-8E00-4B5E-B685-11848BFBA55A>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:EEA90F54-8E00-4B5E-B685-11848BFBA55A> .
<urn:linkedspls:uuid:3616601B-9F53-4ECD-985B-8205444D8F7C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:94B53E9F-5329-43D3-AD42-03C430F6E877>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"TPMT" .
<urn:domeoclient:uuid:B35B25D3-31CE-48B5-885E-844B46E97203>	<http://purl.org/pav/createdOn>	"2014-04-14 15:04:17 -0400" .
<urn:domeoclient:uuid:720F1FAF-C317-4375-8323-04DFEE0FAAFE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:75D456DC-1DB0-4F96-A11F-551CC8425889>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:linkedspls:uuid:071CEC58-02E9-4DA2-8259-93E87A6EFD3B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2625" .
<urn:domeoclient:uuid:0A45211F-B49B-48F5-A9B9-D593DF301DA5>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:D64C9075-1FB5-47EA-9312-70A065865D71> .
<urn:domeoclient:uuid:4EEB4B8C-B4AE-42C6-9E9C-805907F3A548>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:4EEB4B8C-B4AE-42C6-9E9C-805907F3A548> .
<urn:domeoclient:uuid:1F2D1F90-DA97-42FE-836C-EBF3BAC56349>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:FC766D1F-0C5B-4C57-8386-30CC6B3408B5>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:1DA28968-6C74-475E-AB4F-5E6E22DFF8BD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Tamoxifen" .
<urn:domeoclient:uuid:75A79304-2BD1-4F33-9391-4BB93929D4E6>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:C9CADF5C-CD94-4A8C-B6CF-12220ED65397> .
<urn:domeoclient:uuid:976BDFF3-2BFA-4838-B6A0-327B2921E1B7>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:F10DDB11-A5F0-4B5E-B3CE-47B1F2145E34>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:E6578AA5-3295-46D7-B3F2-55CD3CFB5B0F>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:7673EC96-E39E-4D34-A8B6-A31AD2825C94> .
<urn:domeoclient:uuid:95EEC2FF-D292-48FE-8FD7-FEF64E2F00E4>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:855697DF-EBFA-4343-B2F2-023B6F284D48> .
<urn:linkedspls:uuid:1B973C15-149D-4D98-90E2-4A06A2F30ABD>	<http://semanticscience.org/resource/SIO_000111>	"66106-6 PHARMACOGENOMICS SECTION" .
<urn:domeoclient:uuid:D32E2B19-3891-4F8B-98F3-B65344B0F6A8>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:6347DAEC-6E58-45D7-9A9D-16BE602F4930>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:855697DF-EBFA-4343-B2F2-023B6F284D48>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:43B85AB2-533A-4A3B-932F-7CD7177449ED>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:CE4F247F-F7CB-4776-A379-05B0401FC08D>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:C1908624-6F0B-47BD-8D70-8EACD877F4A9> .
<urn:domeoclient:uuid:F54825B6-3CF9-4465-A4BE-7C6747734A6E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:9E003EB3-2B97-41C7-BD14-5EAF744BB5F2>	<http://purl.org/pav/createdOn>	"2014-04-21 12:43:51 -0400" .
<urn:domeoclient:uuid:D9543430-9668-4C09-8709-B8D20B095EEA>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:2510C893-9155-453B-922C-CF116136DD88>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:0F8A06DC-D6FE-466C-AF73-CF9E7A8C2707>	<http://purl.org/pav/createdOn>	"2014-06-30 12:25:51 -0400" .
<urn:domeoclient:uuid:D9543430-9668-4C09-8709-B8D20B095EEA>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:F54825B6-3CF9-4465-A4BE-7C6747734A6E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:4C36F11A-E282-4BFB-849D-B93A233A50FB>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:13F3B206-EA87-463E-9DA8-93AA056A9117>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-negative" .
<urn:domeoclient:uuid:720F1FAF-C317-4375-8323-04DFEE0FAAFE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:9F45C51D-C093-4FEB-A57B-7D59EB1E01DA>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:linkedspls:uuid:F0B7C43C-792D-49E5-B282-D2303F858889>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:linkedspls:uuid:1B973C15-149D-4D98-90E2-4A06A2F30ABD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006120" .
<urn:domeoclient:uuid:6347DAEC-6E58-45D7-9A9D-16BE602F4930>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:8D91E7D5-B379-4649-9834-0D01A948DFF8>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:FEF94E24-725D-433B-8F55-9E75E14CECB9> .
<urn:domeoclient:uuid:D32E2B19-3891-4F8B-98F3-B65344B0F6A8>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:C8824A36-9C96-4389-B215-2638B48B5437>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:C8824A36-9C96-4389-B215-2638B48B5437> .
<urn:linkedspls:uuid:B9375CD1-7E67-42D6-B380-D95AD08BF64B>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:B2CCF84A-A981-4564-8227-DE5688CB1FED>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:7AE1124F-F104-4EB3-9415-257F81B2E3CE> .
<urn:domeoclient:uuid:5949C0ED-ECE8-4C36-B91D-8E58F7A36AAC>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:558D142F-DBE9-4EB9-9F46-4244D63F2FAF> .
<urn:domeoclient:uuid:DBCD24FF-6ABB-4810-A5CA-DF8F85FF2241>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:DBCD24FF-6ABB-4810-A5CA-DF8F85FF2241> .
<urn:domeoclient:uuid:F10DDB11-A5F0-4B5E-B3CE-47B1F2145E34>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:976BDFF3-2BFA-4838-B6A0-327B2921E1B7>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:CE3C3FF6-F83D-47D2-8C4F-944687265F2B>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:4777BC06-68FA-4171-A52D-68668AD25547> .
<urn:domeoclient:uuid:1F2D1F90-DA97-42FE-836C-EBF3BAC56349>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:5949C0ED-ECE8-4C36-B91D-8E58F7A36AAC>	<http://purl.org/pav/createdOn>	"2014-03-22 22:22:30 -0400" .
<urn:linkedspls:uuid:FED638A3-F491-4246-B5EC-651C306CF76E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:F0B7C43C-792D-49E5-B282-D2303F858889>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:55F59962-81BB-4F69-B3DD-6B65B3526228>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:BC0C42BD-3C98-4864-9F9C-50F72712CEC9>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:BC0C42BD-3C98-4864-9F9C-50F72712CEC9> .
<urn:domeoclient:uuid:55BCCCDC-ED3F-427D-AFFE-0E80E459C63A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:D64C9075-1FB5-47EA-9312-70A065865D71>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"TPMT" .
<urn:domeoclient:uuid:CF0F356A-4BD3-4AB3-80E4-DF7EF3CD5F00>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0" .
<urn:linkedspls:uuid:0F7B1E31-9D8A-45AA-8F34-A942EE6FBB80>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:87B8F5B0-8381-4CA7-AE0B-30C481D164B4>	<http://semanticscience.org/resource/SIO_000111>	"66106-6 PHARMACOGENOMICS SECTION" .
<urn:linkedspls:uuid:44A37F21-E420-40D5-A9E0-5CEDEFAEF40B>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:84646AA6-8E85-4656-8515-E49CB15EADB4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2625" .
<urn:domeoclient:uuid:3419ECAE-A4FF-4BE4-8679-16B52BA748AC>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:2BEFD527-0C92-4B61-A2B9-12F931EDC707> .
<urn:domeoclient:uuid:B6B4A58C-16B0-408F-A838-47FC8649B72D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:61BA8ACB-D63A-46FF-8B5D-79E9326A61A3>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:FB17C9EA-111C-4784-80AC-30417D974CE8>	<http://purl.org/pav/createdOn>	"2014-04-21 12:30:00 -0400" .
<urn:linkedspls:uuid:FBEDA24D-50C7-407C-9337-9A08D9456999>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:BF7AF633-8B36-41BF-AC4F-0BA548A0DB2F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:domeoclient:uuid:38B0D49A-8B7C-4D71-B2CE-0388425D3B66>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:E8587041-73D9-4727-A9F5-7445BAF204E3>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:903F27DB-914A-44A2-B01F-A36164AAC4DB>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:E826D255-0A7E-4F3C-A59F-675E8A9B606E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:F880CCED-A2A0-4330-B02F-070F7BF5AF00>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:A48D46C7-8F7E-4426-8C3D-CCA08F946DB0> .
<urn:domeoclient:uuid:136CA05A-B32D-4CAF-B985-0FB9EF4F0455>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0" .
<urn:domeoclient:uuid:0AB99582-A22B-403F-9604-C35A9897CE91>	<http://www.w3.org/ns/oa#exact>	"The patient's CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose. Table 5 describes the range of stable maintenance doses observed in multiple patients having different combinations of CYP2C9 and VKORC1 gene variants. Consider these ranges in choosing the initial dose." .
<urn:linkedspls:uuid:F45F585A-05C5-49B5-BABB-73BFBE9E9753>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:EEA90F54-8E00-4B5E-B685-11848BFBA55A>	<http://www.w3.org/ns/oa#exact>	" Numerous factors, alone or in combination, including changes in diet, medications, botanicals and genetic variations in the CYP2C9 and VKORC1 enzymes (seeCLINICAL PHARMACOLOGY,Pharmacogenomics) may influence the response of the patient to warfarin." .
<urn:linkedspls:uuid:D2A8C2D7-9A3E-4307-BC2B-4EA4FC30E8A5>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:2F3B0124-31A3-451B-BA81-5652303A452C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:DF1A2A13-1CD9-47EC-A75C-192353959653>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:8C44EE5A-5A11-4743-B389-617115FC82BB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Do not restart" .
<urn:linkedspls:uuid:8C0132CB-1BA7-4320-8C5F-E55761BC596E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:407F8565-3B9C-4CF8-B785-C8286BCD86A2>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:0F7B1E31-9D8A-45AA-8F34-A942EE6FBB80>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"VKORC1" .
<urn:domeoclient:uuid:BCAE5E0C-30F2-4E8B-8D8E-687ADD4CA18B>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:9A5666BB-F43D-45F3-A856-0BDB0E745589>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:6F731CE1-E6B4-41AA-98C6-30C94B771E61>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Increase" .
<urn:linkedspls:uuid:855BF4FE-7082-466C-AEC2-BA37C5A2F93C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000017303" .
<urn:linkedspls:uuid:D1D85749-709E-4FD8-A464-C8E7CD8158BB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Citalopram" .
<urn:linkedspls:uuid:905B00B5-CD9F-4F5A-BDCD-2E0771AC9B73>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:domeoclient:uuid:E1199968-6650-4D2A-A5E4-EDFBFE7733AE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:D92166A3-0B32-4545-B4CA-719FEDAF410D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:47718F61-F7FA-4A83-BB17-C13189D5E884>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:ECE9E8AD-BAEE-4FC0-A880-67D03D8D2EED> .
<urn:domeoclient:uuid:86565D69-8F9C-4519-9A52-CD2A2980DEE3>	<http://purl.org/pav/createdOn>	"2014-06-30 12:14:50 -0400" .
<urn:domeoclient:uuid:BCAE5E0C-30F2-4E8B-8D8E-687ADD4CA18B>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf" .
<urn:linkedspls:uuid:B9375CD1-7E67-42D6-B380-D95AD08BF64B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"VKORC1" .
<urn:domeoclient:uuid:7D50A614-4F2B-42C6-A175-0BF3C158B5DA>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:7FD03E69-B442-41B6-B8EB-38BD572E8F45>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:38655F0E-DB25-4C1E-A99A-7E2B18134930>	<http://purl.org/pav/createdOn>	"2014-04-21 12:54:12 -0400" .
<urn:linkedspls:uuid:964EBF55-DC67-43A9-93E2-DBC843BB8D2A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:8BDFDC96-47AF-489E-8F96-DF9B26C6ECBE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:linkedspls:uuid:9A15D029-5B02-4107-A829-E2BD1B1219FE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:domeoclient:uuid:0496C268-8D3F-4D44-95D9-8D7250579EBE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:398416DB-3813-458C-AEAD-1E703244DEC7>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:9CA1FBF8-5D9F-4C89-9F89-2BC4E3DB1BF5>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:09071EE6-03DB-49CA-BA67-1589B0E2FDBD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1, PGR" .
<urn:linkedspls:uuid:42FA1C17-B780-423F-B993-EAF8D8DF0329>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:35B89AC4-DAE5-4207-B319-F9479AE77CDE>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:8BEEBA62-C519-4421-9038-113DCDFC9B2C> .
<urn:domeoclient:uuid:7084C584-8C84-42A3-AFAB-F66F243A2817>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:1B973C15-149D-4D98-90E2-4A06A2F30ABD> .
<urn:linkedspls:uuid:61B14255-647D-4AA2-83E5-B81256BF7A50>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:linkedspls:uuid:407F8565-3B9C-4CF8-B785-C8286BCD86A2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:domeoclient:uuid:88C2CEB5-469C-451E-8436-788ABE4338F5>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:A3C1B92C-CBE0-4BA8-A41C-D3C3CD26FA51> .
<urn:linkedspls:uuid:86480047-DD43-4A54-B258-3772C18237F7>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000017303" .
<urn:domeoclient:uuid:D5C1D543-12A2-4AD2-973F-CFDA436726C9>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:3C75F25B-730C-424C-8A4A-C55F0D242716>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:C2A76A18-A463-4D7B-9A00-33BEFE84F768>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*1502" .
<urn:domeoclient:uuid:5D85FB52-BA95-409A-8974-2E14C9527722>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:1FAA2AB1-96D9-4225-A9E1-763F045EE2CD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"TPMT" .
<urn:domeoclient:uuid:F1D12488-2CA1-4EAD-9A8A-C92106847342>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:009DEEE9-9289-445E-8C79-81457BE96692>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:1D33EB0C-A03D-481F-991D-B71848865C38>	<http://www.w3.org/ns/oa#exact>	"TPMT genotyping or phenotyping can help identify patients who are at an increased risk for developing azathioprine toxicity." .
<urn:domeoclient:uuid:CE5D6919-6972-4689-B658-C5432A02F905>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:A903F38F-38D4-4052-A673-7FF19407E3DB> .
<urn:domeoclient:uuid:AC31138E-D96E-46FA-AD16-E8C5C6855989>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:94B53E9F-5329-43D3-AD42-03C430F6E877> .
<urn:linkedspls:uuid:53541A7F-ACF6-4030-A4B7-7BA865CDF82F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:D64C9075-1FB5-47EA-9312-70A065865D71>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"intermediate-activity" .
<urn:linkedspls:uuid:44E81086-BA17-4D23-BE19-3D545D7F1B9D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:23FACDDB-003E-40B5-AB79-B52F5FD124B3>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:EF919E4C-C0B0-4D8B-A273-2F4A806A828D> .
<urn:domeoclient:uuid:BCC8E4C0-518C-4CB7-86BA-64CE75086359>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:1A89E704-ECDB-4495-8848-DB89566FFC2E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:5E02C5AB-C35D-4ACA-8EF0-DF0F481E6A00>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Carbamazepine" .
<urn:linkedspls:uuid:61B14255-647D-4AA2-83E5-B81256BF7A50>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Decreased Efficacy" .
<urn:domeoclient:uuid:BC59C368-6171-459A-BA88-9B57AAC67FD8>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:9A15D029-5B02-4107-A829-E2BD1B1219FE>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Decreased Efficacy" .
<urn:linkedspls:uuid:D64C9075-1FB5-47EA-9312-70A065865D71>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Decrease" .
<urn:domeoclient:uuid:DEE1B9FD-09F4-4AD6-9BEB-55CF10F2FDDB>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:7BC21EEB-9DB7-4481-AB5F-CDF2B8C45D96>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:74BDDF82-70E1-44A8-B130-17D04DE86798>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"TPMT" .
<urn:linkedspls:uuid:F0F7787E-5F9C-47A4-86B2-D64F1B7602B6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006120" .
<urn:domeoclient:uuid:408C86B9-FFBA-4A7F-A6EC-ECD348FD4782>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:9A15D029-5B02-4107-A829-E2BD1B1219FE> .
<urn:domeoclient:uuid:38CB7B79-EA55-443D-8F52-A694D541E5E3>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:850F3B60-ADC8-42A5-8E7E-B50B1E9D39BE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:3542" .
<urn:domeoclient:uuid:4F5C1D0C-9AFC-4B3A-83EC-AC9CB72FB0C9>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:4663B6D5-B11D-4039-8F32-F7E3BFC2537E> .
<urn:linkedspls:uuid:461FDA58-8FAB-4951-B04A-F969D73C634D>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"CYP2C9*3" .
<urn:linkedspls:uuid:691E83A1-1BFF-4939-996A-35C56D0CF2DF>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"CYP2C9*2, CYP2C9*3" .
<urn:linkedspls:uuid:0BEDE64D-11D3-4746-9532-E747F6A427E0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:86218E9C-9C50-4CF1-BDF5-7480485335DE>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:52601F35-C2AB-4602-BD13-6B9999A0266A> .
<urn:linkedspls:uuid:6B9F2EDD-8EC9-441C-9B9C-6DE4ED079F50>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"TPMT" .
<urn:linkedspls:uuid:194FD718-B3CA-4D25-B3D2-56D36C1ECB60>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000017303" .
<urn:domeoclient:uuid:1042FEEA-5AF3-4E50-B2A1-053451F2236C>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:61B14255-647D-4AA2-83E5-B81256BF7A50> .
<urn:linkedspls:uuid:53541A7F-ACF6-4030-A4B7-7BA865CDF82F>	<http://semanticscience.org/resource/SIO_000111>	"BOXED WARNING (34066-1)" .
<urn:linkedspls:uuid:108444AC-C8D7-42EE-A011-BE98A3F592F0>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:402D9368-C611-4289-8004-8EEC1A409CCF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:3CB531B1-A267-4A03-A0C5-D852AB638802>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:1706E63C-45AC-467E-80FD-06108C69A93D> .
<urn:domeoclient:uuid:977E5F5B-8852-45BE-A6FC-8DEB91191DED>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:0961EB1D-39A9-4A01-9D9B-C2BC3222987E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:C904A0A3-252D-4872-B966-44B63E18E430>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:domeoclient:uuid:239D0F43-DA9B-4ED8-A683-6BF29DB82241>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:FBA8BE44-2409-4673-8D2F-0E2947538FCE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:29A5252E-79CA-41F6-BF34-26789C947F8D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:9992ADBC-4BAB-4529-BAC4-9D7AFD34F098>	<http://purl.org/pav/createdOn>	"2014-04-14 14:28:54 -0400" .
<urn:domeoclient:uuid:0ED7B264-E15A-44A2-9037-2D21B5180CD2>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:B2CCF84A-A981-4564-8227-DE5688CB1FED>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:616A0715-5B79-4DD8-8392-1FDEF99E9911> .
<urn:domeoclient:uuid:79C530FF-637A-43C8-AECE-CA81458FB5EE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:7FA5409D-3EA5-4F92-B738-8577DCEB4D97>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:0ED7B264-E15A-44A2-9037-2D21B5180CD2> .
<urn:domeoclient:uuid:3C75F25B-730C-424C-8A4A-C55F0D242716>	<http://www.w3.org/ns/oa#exact>	" Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible." .
<urn:domeoclient:uuid:8E738FB7-477C-4524-B024-29343F2936EA>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:9739D8D8-F16D-4FF9-BD63-1945B116EEC4>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:25348450-1CCF-4BEC-84EF-0EA92F67DD3A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:9D01B1F5-3775-4CA3-BDFA-97BF6089AE2E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:8B036858-70F5-4077-8333-F34F19A042EC>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:9837A225-376D-44A6-959D-05A7DCB03CCE> .
<urn:domeoclient:uuid:30201CA6-94D8-4A83-9451-AF1497A97E75>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:9A074D82-152F-415F-84A1-93EDCC8179B1>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:0DA7AAE6-C82C-4935-9D33-40D96FDB2416>	<http://www.w3.org/ns/oa#exact>	" The variant alleles CYP2C9*2 and CYP2C9*3 result in decreased in vitro CYP2C9 enzymatic 7-hydroxylation of S-warfarin. The frequencies of these alleles in Caucasians are approximately 11% and 7% for CYP2C9*2 and CYP2C9*3, respectively1. Patients with one or more of these variant CYP2C9 alleles have decreased S-warfarin clearance (Table 1)." .
<urn:domeoclient:uuid:CE1DC1EA-085A-4CF9-8165-5A14A411A633>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:42FA1C17-B780-423F-B993-EAF8D8DF0329> .
<urn:linkedspls:uuid:ED9FC62F-6F5A-4AEC-B2EB-900F4C21E312>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:4DD1AE8C-CB2C-4887-993E-A8A44B2A06CB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"TPMT" .
<urn:domeoclient:uuid:86218E9C-9C50-4CF1-BDF5-7480485335DE>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:037A2873-CACE-474F-B3EB-1EF6E0A58FCF> .
<urn:domeoclient:uuid:8CD7F86F-C041-47B7-B7D2-F7B48F523F56>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:3846BD3B-067C-4D62-AAA4-6A53131A2A2B> .
<urn:domeoclient:uuid:7E2CB9FD-6E66-4D71-8B92-4AE2C557E1A3>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:45EDCED8-9B43-464F-AC7F-898A9009649D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:E6B02E4B-FDE8-473A-A978-02F98D0FE07D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER and PgR_receptor" .
<urn:domeoclient:uuid:8A35BACC-77B7-4822-A677-4D72A3B91942>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:977E5F5B-8852-45BE-A6FC-8DEB91191DED>	<http://www.w3.org/ns/oa#exact>	"For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outweighs the risk." .
<urn:linkedspls:uuid:D939C426-7E0B-4A32-80F1-7344D702AA97>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:4364906C-8414-403A-BB1D-1DDCC5F6A4DA>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:933C6C55-0C1F-4A1C-B72F-98683FD68184> .
<urn:linkedspls:uuid:461FDA58-8FAB-4951-B04A-F969D73C634D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>	"Decrease from baseline" .
<urn:linkedspls:uuid:D6235B22-042E-4C36-A104-B353CF92CEB8>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:EE534BB0-3042-44F4-9B63-01291E28FA45>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*1502" .
<urn:domeoclient:uuid:35B89AC4-DAE5-4207-B319-F9479AE77CDE>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:9692B313-0E4E-4D52-9D7C-456D2EE68F54> .
<urn:linkedspls:uuid:D939C426-7E0B-4A32-80F1-7344D702AA97>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:domeoclient:uuid:4364906C-8414-403A-BB1D-1DDCC5F6A4DA>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:4A5BB36A-D20C-4306-8958-609D3F9A13D0> .
<urn:linkedspls:uuid:74BB3F3E-AD24-438C-9250-4357E959069E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"poor-metabolizer-positive" .
<urn:linkedspls:uuid:36FDCB4E-5E54-4CBA-BC44-04B836C019F0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:4777BC06-68FA-4171-A52D-68668AD25547>	<http://semanticscience.org/resource/SIO_000111>	"WARNINGS AND PRECAUTIONS (43685-7)" .
<urn:linkedspls:uuid:56D95EC4-D0D7-4BD6-B13C-E145F6A4E568>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:6E680A49-5B91-4058-A09E-25A6ED988EFC>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:CE3D1055-4EAF-4F2F-A2ED-AA9B95C45024>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-negative" .
<urn:domeoclient:uuid:F2C1F1F7-17ED-4AE1-91F9-3A2EE9802A65>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf" .
<urn:linkedspls:uuid:D939C426-7E0B-4A32-80F1-7344D702AA97>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"poor-metabolizer" .
<urn:linkedspls:uuid:75D988CE-7527-421D-AAA6-0C9C0D4B30DF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:F0F7787E-5F9C-47A4-86B2-D64F1B7602B6>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:169DB9DD-C966-431C-85FE-C3AC1F8E31D3>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:1706E63C-45AC-467E-80FD-06108C69A93D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"TPMT" .
<urn:linkedspls:uuid:C904A0A3-252D-4872-B966-44B63E18E430>	<http://semanticscience.org/resource/SIO_000111>	"66106-6 PHARMACOGENOMICS SECTION" .
<urn:linkedspls:uuid:27F9E2A8-C54A-4F87-A02D-4F8EFF5D382F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:44BBF444-A1D4-4182-8B05-775BFFCA0DF4>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:6B4C9D47-E3BF-4D75-A661-0D5A649108C6> .
<urn:linkedspls:uuid:CE76789E-AB5D-4F50-AF22-F3C2D4249992>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:396CB021-3C85-4E20-B020-3714CE558E2D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Decrease" .
<urn:linkedspls:uuid:B30B41E3-5A67-4530-BC81-938E6B016FDF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:A6AED276-0422-482B-8802-87BDABE2C035>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:24265221-E0B1-4F13-A2EB-0E9D9DC6F5D4> .
<urn:linkedspls:uuid:5E02C5AB-C35D-4ACA-8EF0-DF0F481E6A00>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:domeoclient:uuid:9D01B1F5-3775-4CA3-BDFA-97BF6089AE2E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:8A35BACC-77B7-4822-A677-4D72A3B91942>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:46C63D3B-0000-404E-BC76-FB01C42DC7B2>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:BBD1EA14-A142-47FF-A3B5-D848FFAED44F> .
<urn:domeoclient:uuid:95EEC2FF-D292-48FE-8FD7-FEF64E2F00E4>	<http://purl.org/pav/createdOn>	"2014-04-21 12:38:07 -0400" .
<urn:linkedspls:uuid:461FDA58-8FAB-4951-B04A-F969D73C634D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C9" .
<urn:linkedspls:uuid:F5AE3B3E-B864-4A19-B48C-DC1343C799A3>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Decrease" .
<urn:linkedspls:uuid:05DBF40D-ECCF-4BC6-9077-742EBADF41F9>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1, PGR" .
<urn:domeoclient:uuid:7E2CB9FD-6E66-4D71-8B92-4AE2C557E1A3>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:1706E63C-45AC-467E-80FD-06108C69A93D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:F5AE3B3E-B864-4A19-B48C-DC1343C799A3>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Decreased Efficacy" .
<urn:domeoclient:uuid:5B7239DA-6BB5-450F-B107-37E66914C66D>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:CE76789E-AB5D-4F50-AF22-F3C2D4249992> .
<urn:linkedspls:uuid:13F3B206-EA87-463E-9DA8-93AA056A9117>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:6E680A49-5B91-4058-A09E-25A6ED988EFC>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"TPMT" .
<urn:linkedspls:uuid:055AAAC1-3544-4B8E-BF06-C99328A12B6E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:domeoclient:uuid:0ED7B264-E15A-44A2-9037-2D21B5180CD2>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:30201CA6-94D8-4A83-9451-AF1497A97E75>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:9A074D82-152F-415F-84A1-93EDCC8179B1>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:75D988CE-7527-421D-AAA6-0C9C0D4B30DF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"TPMT" .
<urn:domeoclient:uuid:8E738FB7-477C-4524-B024-29343F2936EA>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:46C63D3B-0000-404E-BC76-FB01C42DC7B2>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:0D634683-D28C-42DC-9911-DFD0C9EB289D> .
<urn:linkedspls:uuid:2185EE39-FD81-4C83-ABDF-E5D59B789F96>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:linkedspls:uuid:27F9E2A8-C54A-4F87-A02D-4F8EFF5D382F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"TPMT" .
<urn:domeoclient:uuid:79C530FF-637A-43C8-AECE-CA81458FB5EE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:A753145C-8800-49A8-BE99-D558A1390DAE>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:CE3D1055-4EAF-4F2F-A2ED-AA9B95C45024> .
<urn:domeoclient:uuid:A753145C-8800-49A8-BE99-D558A1390DAE>	<http://purl.org/pav/createdOn>	"2014-04-14 14:56:50 -0400" .
<urn:domeoclient:uuid:F2C1F1F7-17ED-4AE1-91F9-3A2EE9802A65>	<http://www.w3.org/ns/oa#exact>	"WARNING: DEATH RELATED TO ULTRA-RAPID METABOLISM OF CODEINE TO MORPHINE\\nRespiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism." .
<urn:linkedspls:uuid:3746E014-4500-4C39-A007-7B912571A900>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:910F9AE9-8398-400D-8505-D971512A67C6>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:910F9AE9-8398-400D-8505-D971512A67C6> .
<urn:domeoclient:uuid:239D0F43-DA9B-4ED8-A683-6BF29DB82241>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:FBA8BE44-2409-4673-8D2F-0E2947538FCE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:EE534BB0-3042-44F4-9B63-01291E28FA45>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:45EDCED8-9B43-464F-AC7F-898A9009649D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"TPMT" .
<urn:domeoclient:uuid:977E5F5B-8852-45BE-A6FC-8DEB91191DED>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:240C39EC-A129-42D3-8602-5C743EC412D2>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:240C39EC-A129-42D3-8602-5C743EC412D2> .
<urn:linkedspls:uuid:51C4FEDD-5F25-4F57-92BC-5456BC2E4846>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:5EE59E00-2977-4F09-A933-867C3E165210>	<http://purl.org/pav/createdOn>	"2014-06-30 13:20:01 -0400" .
<urn:domeoclient:uuid:38CB7B79-EA55-443D-8F52-A694D541E5E3>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:14BA7077-8D33-42DD-A380-DD27F50087AD>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:14BA7077-8D33-42DD-A380-DD27F50087AD> .
<urn:linkedspls:uuid:407F8565-3B9C-4CF8-B785-C8286BCD86A2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006120" .
<urn:domeoclient:uuid:3C852929-ADD4-4383-A351-2D9CF492A6E9>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:945EB72E-5C75-41B0-B8FC-637E1EF0AE7D> .
<urn:linkedspls:uuid:FE990D63-4739-43A5-B062-7A946346B2AF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:A460766E-6EF1-468A-A8D7-D8163DEDE490>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:FB3C226D-314F-473A-AA0D-98DCD192D7AF>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:13F3B206-EA87-463E-9DA8-93AA056A9117> .
<urn:domeoclient:uuid:7673EC96-E39E-4D34-A8B6-A31AD2825C94>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:7673EC96-E39E-4D34-A8B6-A31AD2825C94> .
<urn:domeoclient:uuid:9F0CE910-4782-4E6D-B7E2-C7C784B10B90>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:9F0CE910-4782-4E6D-B7E2-C7C784B10B90> .
<urn:linkedspls:uuid:151DFA13-B2DF-4857-AAE9-51CADEC9A12F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:B7B25E99-EE57-41AC-BDE2-45DCC1447471>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"poor-metabolizer-positive" .
<urn:domeoclient:uuid:DEE1B9FD-09F4-4AD6-9BEB-55CF10F2FDDB>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:7BC21EEB-9DB7-4481-AB5F-CDF2B8C45D96>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:DB8F110F-7415-4B13-AB5B-23F1D7A1C6BF>	<http://www.w3.org/ns/oa#exact>	"n an observational study, the risk of achieving INR >3 during the first 3 weeks of warfarin therapy was determined in 219 Swedish patients retrospectively grouped by CYP2C9 genotype. The relative risk of over anticoagulation as measured by INR >3 during the first 2 weeks of therapy was approximately doubled for those patients classified as *2 or *3 compared to patients who were homozygous for the *1 allele." .
<urn:linkedspls:uuid:4DD1AE8C-CB2C-4887-993E-A8A44B2A06CB>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:87D0F0C2-6038-41AA-B84E-85497D292836>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:87D0F0C2-6038-41AA-B84E-85497D292836> .
<urn:domeoclient:uuid:3C852929-ADD4-4383-A351-2D9CF492A6E9>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:10D9A112-25CB-425E-899B-C3AAA3CF633A> .
<urn:domeoclient:uuid:5D85FB52-BA95-409A-8974-2E14C9527722>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:BC59C368-6171-459A-BA88-9B57AAC67FD8>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:36D17D73-1169-4131-94F5-24AFD369088A>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:4DD1AE8C-CB2C-4887-993E-A8A44B2A06CB> .
<urn:linkedspls:uuid:BDEED6AF-6C6D-44F0-8470-40D3A54778C5>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:29A5252E-79CA-41F6-BF34-26789C947F8D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"biomarker-positive" .
<urn:domeoclient:uuid:1FCB6C74-C406-41C1-8A44-C9D033D5834C>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:1FCB6C74-C406-41C1-8A44-C9D033D5834C> .
<urn:linkedspls:uuid:D3EDFFC9-9EE3-45DD-B147-801DAB72DF3D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2625" .
<urn:domeoclient:uuid:DBBF90A0-6468-4792-B1CC-02DDD21B4A08>	<http://purl.org/pav/createdOn>	"2014-06-09 16:02:14 -0400" .
<urn:domeoclient:uuid:1A89E704-ECDB-4495-8848-DB89566FFC2E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:2D0B9A22-6129-4786-B0A4-7384B3324DF0>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:2D0B9A22-6129-4786-B0A4-7384B3324DF0> .
<urn:domeoclient:uuid:BCC8E4C0-518C-4CB7-86BA-64CE75086359>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:2446A882-2020-42F8-AD24-FE3B4F839958>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"VKORC1" .
<urn:linkedspls:uuid:ED9FC62F-6F5A-4AEC-B2EB-900F4C21E312>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*1502" .
<urn:domeoclient:uuid:8B4BE2A8-5AB2-47D3-A46D-2D1D5E7AC42F>	<http://purl.org/pav/createdOn>	"2014-06-30 12:27:38 -0400" .
<urn:domeoclient:uuid:BD33E8D1-8AEF-4E43-9C57-35AB0263305D>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:BD33E8D1-8AEF-4E43-9C57-35AB0263305D> .
<urn:linkedspls:uuid:9258FFBC-DCDC-4C6C-A375-9FC03C323B54>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Decrease" .
<urn:linkedspls:uuid:5239657F-5948-4803-B690-76D953D60764>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:linkedspls:uuid:AC5F1BAD-8B6A-49DB-8147-AB1394EC169F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"poor-metabolizer-positive" .
<urn:domeoclient:uuid:74B97B42-8CF1-41BB-84AD-CF0995E7508C>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:74B97B42-8CF1-41BB-84AD-CF0995E7508C> .
<urn:linkedspls:uuid:1532F8ED-1CF3-45D5-8A36-00FA8FD6060D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C9" .
<urn:domeoclient:uuid:5B7239DA-6BB5-450F-B107-37E66914C66D>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:375DD3AE-F16E-43E9-BB3E-D521613E10AF> .
<urn:domeoclient:uuid:F30A3592-1EDA-414B-8C7B-2B931B766619>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:F30A3592-1EDA-414B-8C7B-2B931B766619> .
<urn:linkedspls:uuid:2446A882-2020-42F8-AD24-FE3B4F839958>	<http://semanticscience.org/resource/SIO_000111>	"66106-6 PHARMACOGENOMICS SECTION" .
<urn:linkedspls:uuid:0B39F957-E88F-427C-AC41-F1B9DC711A02>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:domeoclient:uuid:D5C1D543-12A2-4AD2-973F-CFDA436726C9>	<http://www.w3.org/ns/oa#exact>	"Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function." .
<urn:domeoclient:uuid:20FD83E0-8F9F-409B-BA60-7D4A2F8A54AF>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:20FD83E0-8F9F-409B-BA60-7D4A2F8A54AF> .
<urn:domeoclient:uuid:FE154A72-C1D3-4027-8C73-C71A948D0F52>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:1769615F-FAC0-4900-9DC6-5021630F8524> .
<urn:linkedspls:uuid:396CB021-3C85-4E20-B020-3714CE558E2D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C9" .
<urn:linkedspls:uuid:08308CA2-E50D-41DB-873B-E57372B5FBDB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2625" .
<urn:linkedspls:uuid:BC70D092-5124-4A5C-87C3-EA34E4868C05>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:linkedspls:uuid:7C3837BB-DAF7-4544-9D2C-A63E2F406BAC>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"ultra-metabolizer-positive" .
<urn:domeoclient:uuid:875F6756-255E-43CC-8CA5-19D63561F59A>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:875F6756-255E-43CC-8CA5-19D63561F59A> .
<urn:linkedspls:uuid:81525CE9-0714-4D48-9149-6C8B8671E117>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:10B1EB06-38FD-41C2-A3B7-625B2825B889>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:10B1EB06-38FD-41C2-A3B7-625B2825B889> .
<urn:domeoclient:uuid:9E02315A-EB6D-4693-B3E4-4FB4B99D4253>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:A74CD0BB-2B56-45FC-B50D-C7952B9C9AE4> .
<urn:linkedspls:uuid:2510C893-9155-453B-922C-CF116136DD88>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ConcomitantMedicationOfConcern>	"Concomitant medication concern" .
<urn:linkedspls:uuid:F270E3B3-9983-425D-98FB-66F62E36340F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:domeoclient:uuid:CF0F356A-4BD3-4AB3-80E4-DF7EF3CD5F00>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:CF0F356A-4BD3-4AB3-80E4-DF7EF3CD5F00> .
<urn:domeoclient:uuid:9CA1FBF8-5D9F-4C89-9F89-2BC4E3DB1BF5>	<http://www.w3.org/ns/oa#exact>	"20 mg/day is the maximum recommended dose for patients who are greater than 60 years of age, patients with hepatic impairment, and for CYP2C19 poor metabolizers or those patients taking cimetidine or another CYP2C19 inhibitor" .
<urn:domeoclient:uuid:9E02315A-EB6D-4693-B3E4-4FB4B99D4253>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:3A77F5FE-EF65-4FF1-9BCD-E358D4D5BC82> .
<urn:linkedspls:uuid:5E02C5AB-C35D-4ACA-8EF0-DF0F481E6A00>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00564" .
<urn:linkedspls:uuid:A24FCBC0-9830-43DC-87D5-5716D3136B02>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2625" .
<urn:linkedspls:uuid:F9A68240-FAD6-4604-8DEE-1B0E4AF9BD21>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"TPMT" .
<urn:domeoclient:uuid:C692DA9C-1ECF-4A5B-867C-ABAF23492F10>	<http://purl.org/pav/createdOn>	"2014-04-28 15:45:35 -0400" .
<urn:domeoclient:uuid:CFEF239C-B763-4864-8DD8-A917EFD12673>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:CFEF239C-B763-4864-8DD8-A917EFD12673> .
<urn:domeoclient:uuid:60281E0C-D291-4163-9B6F-E83A4142CB8E>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:75D988CE-7527-421D-AAA6-0C9C0D4B30DF> .
<urn:linkedspls:uuid:87B8F5B0-8381-4CA7-AE0B-30C481D164B4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:linkedspls:uuid:5D87AC20-773F-4241-AA52-57BF86A4A93A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:domeoclient:uuid:136CA05A-B32D-4CAF-B985-0FB9EF4F0455>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:136CA05A-B32D-4CAF-B985-0FB9EF4F0455> .
<urn:domeoclient:uuid:15924106-592A-47E7-A01C-764A16E257DC>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0" .
<urn:domeoclient:uuid:C89E80EC-0820-406B-99C8-D495EC5F054E>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:68B37481-F382-41B9-AEF5-DB241FA9325F> .
<urn:domeoclient:uuid:78CB3193-D01C-49AA-B39B-C35887919EED>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:78CB3193-D01C-49AA-B39B-C35887919EED> .
<urn:linkedspls:uuid:F5AE3B3E-B864-4A19-B48C-DC1343C799A3>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"add test result to drop down; check search of location using magnifying glass to make sure it comes up correct. It should be the same as the next one with and additional sentence for intermediate metabolizer." .
<urn:domeoclient:uuid:72D8F9E8-4B4D-4FC2-81A2-A19C5BF05098>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:72D8F9E8-4B4D-4FC2-81A2-A19C5BF05098> .
<urn:domeoclient:uuid:45B95464-0287-435F-86B4-0253D73E6DA8>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:45B95464-0287-435F-86B4-0253D73E6DA8> .
<urn:domeoclient:uuid:FB3C226D-314F-473A-AA0D-98DCD192D7AF>	<http://purl.org/pav/createdOn>	"2014-06-23 14:34:14 -0400" .
<urn:domeoclient:uuid:F2C1F1F7-17ED-4AE1-91F9-3A2EE9802A65>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:F2C1F1F7-17ED-4AE1-91F9-3A2EE9802A65> .
<urn:linkedspls:uuid:74BB3F3E-AD24-438C-9250-4357E959069E>	<http://semanticscience.org/resource/SIO_000111>	"66106-6 PHARMACOGENOMICS SECTION" .
<urn:linkedspls:uuid:4B11E300-2DF5-4B21-9D43-4D0A02109A59>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:domeoclient:uuid:56ECCD1C-D5DA-4A5F-A470-A96F404E1CB8>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:3616601B-9F53-4ECD-985B-8205444D8F7C> .
<urn:domeoclient:uuid:E014618E-3373-4F61-BAF6-4ABD45885081>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:E014618E-3373-4F61-BAF6-4ABD45885081> .
<urn:domeoclient:uuid:745C184B-12B3-435F-99C5-252556EB53B9>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0" .
<urn:linkedspls:uuid:75D456DC-1DB0-4F96-A11F-551CC8425889>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MonitoringRecommendation>	"Recommended" .
<urn:domeoclient:uuid:9992ADBC-4BAB-4529-BAC4-9D7AFD34F098>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:C7EAEB14-8213-4EF8-AC67-469D0609826B> .
<urn:linkedspls:uuid:964EBF55-DC67-43A9-93E2-DBC843BB8D2A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ConcomitantMedicationOfConcern>	"Concomitant medication concern" .
<urn:linkedspls:uuid:BCCF3F22-38AE-4F01-87D0-22C1B07EC947>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:616A0715-5B79-4DD8-8392-1FDEF99E9911>	<http://www.w3.org/ns/oa#exact>	"Patients taking ZIAGEN may have a serious allergic reaction (hypersensitivity reaction) that can cause death. Your risk of this allergic reaction is much higher if you have a gene variation called HLA-B*5701 than if you do not. Your doctor can determine with a blood test if you have this gene variation. " .
<urn:domeoclient:uuid:D888391C-2CE3-4955-850C-C8FA6291737A>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16bda7b5-a5a5-4478-9df3-beb396bd677f" .
<urn:domeoclient:uuid:EBA440A2-4EF9-40CD-89BF-56AB858385E6>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:EBA440A2-4EF9-40CD-89BF-56AB858385E6> .
<urn:domeoclient:uuid:FA0C425E-2A1E-4059-BAC2-34BD4239836F>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0" .
<urn:linkedspls:uuid:855697DF-EBFA-4343-B2F2-023B6F284D48>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"TPMT" .
<urn:domeoclient:uuid:1E6D8BE7-AC23-449A-83E2-9806683F8162>	<http://purl.org/pav/createdOn>	"2014-04-14 15:01:13 -0400" .
<urn:domeoclient:uuid:3665D7A9-FCD1-4278-8B7F-5EA5B3CC19D3>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:EF161740-C79C-4D2A-9002-4B0A139BF81E>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0" .
<urn:domeoclient:uuid:216A1896-63FD-45FE-ACBB-80F82EB9ACE5>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:216A1896-63FD-45FE-ACBB-80F82EB9ACE5> .
<urn:linkedspls:uuid:2510C893-9155-453B-922C-CF116136DD88>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"TPMT" .
<urn:domeoclient:uuid:5B7239DA-6BB5-450F-B107-37E66914C66D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:D640727D-6442-4274-B453-64F04BD595E3>	<http://purl.org/pav/createdOn>	"2014-04-14 14:08:25 -0400" .
<urn:domeoclient:uuid:E826D255-0A7E-4F3C-A59F-675E8A9B606E>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:E826D255-0A7E-4F3C-A59F-675E8A9B606E> .
<urn:linkedspls:uuid:D66FA8C3-8BAB-4A6F-8234-6DD134876578>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:1A9E2879-AD9B-48F5-B672-AB5C06A28080>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1, PGR" .
<urn:domeoclient:uuid:6D4DAD4D-1B63-4482-8060-787D97F917D2>	<http://purl.org/pav/createdOn>	"2014-04-21 12:57:37 -0400" .
<urn:linkedspls:uuid:D1D85749-709E-4FD8-A464-C8E7CD8158BB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:domeoclient:uuid:FE154A72-C1D3-4027-8C73-C71A948D0F52>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:61BA8ACB-D63A-46FF-8B5D-79E9326A61A3>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:61BA8ACB-D63A-46FF-8B5D-79E9326A61A3> .
<urn:linkedspls:uuid:461FDA58-8FAB-4951-B04A-F969D73C634D>	<http://semanticscience.org/resource/SIO_000111>	"66106-6 PHARMACOGENOMICS SECTION" .
<urn:domeoclient:uuid:C37B19E6-A2FE-4CF4-9914-61A4EF8E7827>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:194FD718-B3CA-4D25-B3D2-56D36C1ECB60>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"VKORC1" .
<urn:domeoclient:uuid:91050818-2692-4B82-B3D8-A52A364F00D7>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:0B3E23EF-1696-4FF7-BEEB-8158BDA84294>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C9" .
<urn:domeoclient:uuid:976BDFF3-2BFA-4838-B6A0-327B2921E1B7>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:976BDFF3-2BFA-4838-B6A0-327B2921E1B7> .
<urn:linkedspls:uuid:9DCD19CE-D636-45D6-B994-A9BDBCA32621>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2625" .
<urn:domeoclient:uuid:9E02315A-EB6D-4693-B3E4-4FB4B99D4253>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:407F8565-3B9C-4CF8-B785-C8286BCD86A2>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>	"Decrease from baseline" .
<urn:linkedspls:uuid:7E666CF4-DD19-4B4B-AE7B-EF4BCEA0181C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2625" .
<urn:domeoclient:uuid:C89E80EC-0820-406B-99C8-D495EC5F054E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:F54825B6-3CF9-4465-A4BE-7C6747734A6E>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:F54825B6-3CF9-4465-A4BE-7C6747734A6E> .
<urn:linkedspls:uuid:FE990D63-4739-43A5-B062-7A946346B2AF>	<http://semanticscience.org/resource/SIO_000111>	"BOXED WARNING (34066-1)" .
<urn:linkedspls:uuid:8C44EE5A-5A11-4743-B389-617115FC82BB>	<http://semanticscience.org/resource/SIO_000111>	"WARNINGS AND PRECAUTIONS (43685-7)" .
<urn:linkedspls:uuid:CE3D1055-4EAF-4F2F-A2ED-AA9B95C45024>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:6347DAEC-6E58-45D7-9A9D-16BE602F4930>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:6347DAEC-6E58-45D7-9A9D-16BE602F4930> .
<urn:domeoclient:uuid:9992ADBC-4BAB-4529-BAC4-9D7AFD34F098>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:9CA1FBF8-5D9F-4C89-9F89-2BC4E3DB1BF5>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:9CA1FBF8-5D9F-4C89-9F89-2BC4E3DB1BF5> .
<urn:domeoclient:uuid:1F2D1F90-DA97-42FE-836C-EBF3BAC56349>	<http://www.w3.org/ns/oa#exact>	"TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING AZATHIOPRINE TABLETS. TPMT genotyping or phenotyping can be used to identify patients with absent or reduced TPMT activity." .
<urn:domeoclient:uuid:CE483709-CD8C-4493-A2B7-8E589B98BF31>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:FBA8BE44-2409-4673-8D2F-0E2947538FCE>	<http://www.w3.org/ns/oa#exact>	"Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen citrate tablet therapy." .
<urn:domeoclient:uuid:7D50A614-4F2B-42C6-A175-0BF3C158B5DA>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:7D50A614-4F2B-42C6-A175-0BF3C158B5DA> .
<urn:domeoclient:uuid:5A997B78-0557-4495-BDBD-42F5B4B30412>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16bda7b5-a5a5-4478-9df3-beb396bd677f" .
<urn:domeoclient:uuid:405A5AAA-08FD-470C-9B50-67E44ED1462F>	<http://purl.org/pav/createdOn>	"2014-04-21 12:27:23 -0400" .
<urn:linkedspls:uuid:53B64B1F-739B-46F0-99EE-89EF4131A8D2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2625" .
<urn:domeoclient:uuid:55ED86AA-B414-4220-94FD-868AFE2D1278>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:461FDA58-8FAB-4951-B04A-F969D73C634D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006120" .
<urn:linkedspls:uuid:2423954D-96B2-404E-8B04-9609825C795A>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MonitoringRecommendation>	"Recommended" .
<urn:linkedspls:uuid:964EBF55-DC67-43A9-93E2-DBC843BB8D2A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:domeoclient:uuid:F1D12488-2CA1-4EAD-9A8A-C92106847342>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:F1D12488-2CA1-4EAD-9A8A-C92106847342> .
<urn:domeoclient:uuid:0E9FF6AD-98CE-4932-AD5D-E657F3B363B3>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:FC766D1F-0C5B-4C57-8386-30CC6B3408B5>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*1502" .
<urn:linkedspls:uuid:05DBF40D-ECCF-4BC6-9077-742EBADF41F9>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER and PgR_receptor" .
<urn:domeoclient:uuid:D5C1D543-12A2-4AD2-973F-CFDA436726C9>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:D5C1D543-12A2-4AD2-973F-CFDA436726C9> .
<urn:linkedspls:uuid:F45F585A-05C5-49B5-BABB-73BFBE9E9753>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:domeoclient:uuid:36D17D73-1169-4131-94F5-24AFD369088A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:0BEDE64D-11D3-4746-9532-E747F6A427E0>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:21B282F1-F0CA-488A-B703-88611F099D16>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:232C5C6E-F6FE-44B8-AE5A-7E1BD427D626>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:7AE1124F-F104-4EB3-9415-257F81B2E3CE>	<http://semanticscience.org/resource/SIO_000111>	"PATIENT MEDICATION INFORMATION (68498-5)" .
<urn:domeoclient:uuid:BCAE5E0C-30F2-4E8B-8D8E-687ADD4CA18B>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:BCAE5E0C-30F2-4E8B-8D8E-687ADD4CA18B> .
<urn:linkedspls:uuid:94B53E9F-5329-43D3-AD42-03C430F6E877>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:5D85FB52-BA95-409A-8974-2E14C9527722>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:0D044EC4-5762-411E-A3D7-4BF4908C494F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:C8824A36-9C96-4389-B215-2638B48B5437>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0" .
<urn:linkedspls:uuid:1706E63C-45AC-467E-80FD-06108C69A93D>	<http://semanticscience.org/resource/SIO_000111>	"34075-2 LABORATORY TESTS SECTION" .
<urn:domeoclient:uuid:D92166A3-0B32-4545-B4CA-719FEDAF410D>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:D92166A3-0B32-4545-B4CA-719FEDAF410D> .
<urn:linkedspls:uuid:E719DBCC-60BF-47C9-A2A6-B5AD564ED472>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1, PGR" .
<urn:domeoclient:uuid:86565D69-8F9C-4519-9A52-CD2A2980DEE3>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:0F7B1E31-9D8A-45AA-8F34-A942EE6FBB80>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000017303" .
<urn:linkedspls:uuid:24265221-E0B1-4F13-A2EB-0E9D9DC6F5D4>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:AC5F1BAD-8B6A-49DB-8147-AB1394EC169F>	<http://semanticscience.org/resource/SIO_000111>	"66106-6 PHARMACOGENOMICS SECTION" .
<urn:linkedspls:uuid:FED638A3-F491-4246-B5EC-651C306CF76E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:domeoclient:uuid:1A89E704-ECDB-4495-8848-DB89566FFC2E>	<http://www.w3.org/ns/oa#exact>	"\\nRisk of death in ultra-rapid metabolizers: Conversion of codeine into its active metabolite, morphine, may occur more rapidly and completely resulting in higher than expected morphine levels and respiratory depression or death. " .
<urn:domeoclient:uuid:FB3C226D-314F-473A-AA0D-98DCD192D7AF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:398416DB-3813-458C-AEAD-1E703244DEC7>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:398416DB-3813-458C-AEAD-1E703244DEC7> .
<urn:linkedspls:uuid:44E81086-BA17-4D23-BE19-3D545D7F1B9D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:53B64B1F-739B-46F0-99EE-89EF4131A8D2>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MonitoringRecommendation>	"Recommended" .
<urn:linkedspls:uuid:92FA8990-60EF-4140-9F60-C12E57E3B114>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:7BC21EEB-9DB7-4481-AB5F-CDF2B8C45D96>	<http://www.w3.org/ns/oa#exact>	" Patients taking ZIAGEN may have a serious allergic reaction (hypersensitivity reaction) that can cause death. Your risk of this allergic reaction is much higher if you have a gene variation called HLA-B*5701 than if you do not. " .
<urn:linkedspls:uuid:44A37F21-E420-40D5-A9E0-5CEDEFAEF40B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:domeoclient:uuid:56ECCD1C-D5DA-4A5F-A470-A96F404E1CB8>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:55F59962-81BB-4F69-B3DD-6B65B3526228>	<http://www.w3.org/ns/oa#exact>	"Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration. Not all patients with these conditions develop necrosis, and tissue necrosis occurs in patients without these deficiencies." .
<urn:linkedspls:uuid:96D6F8F1-F51A-4EBC-BFF7-C799690B4401>	<http://semanticscience.org/resource/SIO_000111>	"BOXED WARNING (34066-1)" .
<urn:domeoclient:uuid:7E2CB9FD-6E66-4D71-8B92-4AE2C557E1A3>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:38CB7B79-EA55-443D-8F52-A694D541E5E3>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:2CE69763-0812-4DFF-A359-2A8D8FF706AD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:7FD03E69-B442-41B6-B8EB-38BD572E8F45>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:7FD03E69-B442-41B6-B8EB-38BD572E8F45> .
<urn:linkedspls:uuid:C9CADF5C-CD94-4A8C-B6CF-12220ED65397>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C9" .
<urn:domeoclient:uuid:55700EE9-88B8-49B7-BD64-1A87D99DCC15>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:009DEEE9-9289-445E-8C79-81457BE96692>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:009DEEE9-9289-445E-8C79-81457BE96692> .
<urn:domeoclient:uuid:30201CA6-94D8-4A83-9451-AF1497A97E75>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:9D01B1F5-3775-4CA3-BDFA-97BF6089AE2E>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:A753145C-8800-49A8-BE99-D558A1390DAE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:3C75F25B-730C-424C-8A4A-C55F0D242716>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:3C75F25B-730C-424C-8A4A-C55F0D242716> .
<urn:domeoclient:uuid:7FD03E69-B442-41B6-B8EB-38BD572E8F45>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02" .
<urn:linkedspls:uuid:4DD1AE8C-CB2C-4887-993E-A8A44B2A06CB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"intermediate-activity" .
<urn:domeoclient:uuid:5B91F78A-EEB0-41A3-8995-90B920D09520>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf" .
<urn:domeoclient:uuid:46C63D3B-0000-404E-BC76-FB01C42DC7B2>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:B9375CD1-7E67-42D6-B380-D95AD08BF64B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000017303" .
<urn:domeoclient:uuid:398416DB-3813-458C-AEAD-1E703244DEC7>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02" .
<urn:domeoclient:uuid:DF1A2A13-1CD9-47EC-A75C-192353959653>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:DF1A2A13-1CD9-47EC-A75C-192353959653> .
<urn:domeoclient:uuid:0ED7B264-E15A-44A2-9037-2D21B5180CD2>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:C692DA9C-1ECF-4A5B-867C-ABAF23492F10>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:29A5252E-79CA-41F6-BF34-26789C947F8D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Efficacy" .
<urn:linkedspls:uuid:70BE7DEB-6A8B-41E9-9333-F1F47AC7E1A0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*1502" .
<urn:domeoclient:uuid:0A10CE73-592A-4D92-84AF-63395C43C0F9>	<http://www.w3.org/ns/oa#exact>	"Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer." .
<urn:domeoclient:uuid:BD33E8D1-8AEF-4E43-9C57-35AB0263305D>	<http://www.w3.org/ns/oa#exact>	"Patients with intermediate thiopurine S-methyl transferase (TPMT) activity may be at an increased risk of myelotoxicity if receiving conventional doses of azathioprine." .
<urn:domeoclient:uuid:9A5666BB-F43D-45F3-A856-0BDB0E745589>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:9A5666BB-F43D-45F3-A856-0BDB0E745589> .
<urn:domeoclient:uuid:44BBF444-A1D4-4182-8B05-775BFFCA0DF4>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:E06F2653-44AD-435F-AB2C-133712B039A6>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*1502" .
<urn:linkedspls:uuid:0D634683-D28C-42DC-9911-DFD0C9EB289D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*1502" .
<urn:linkedspls:uuid:25348450-1CCF-4BEC-84EF-0EA92F67DD3A>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:75D988CE-7527-421D-AAA6-0C9C0D4B30DF>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"intermediate-activity" .
<urn:linkedspls:uuid:7C3837BB-DAF7-4544-9D2C-A63E2F406BAC>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2625" .
<urn:domeoclient:uuid:481D46BB-D4FB-4587-B147-C2FC166A7A51>	<http://www.w3.org/ns/oa#exact>	"Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of the vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide. The degree of depression is dependent upon the dosage administered and, in part, by the patient's VKORC1 genotype. " .
<urn:domeoclient:uuid:3C852929-ADD4-4383-A351-2D9CF492A6E9>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:D2A8C2D7-9A3E-4307-BC2B-4EA4FC30E8A5>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Do not restart" .
<urn:linkedspls:uuid:68B37481-F382-41B9-AEF5-DB241FA9325F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:CA417E62-D7D9-4F45-8359-10CCF8D13F90>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:945EB72E-5C75-41B0-B8FC-637E1EF0AE7D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*1502" .
<urn:linkedspls:uuid:E6B02E4B-FDE8-473A-A978-02F98D0FE07D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"biomarker-positive" .
<urn:linkedspls:uuid:FEF94E24-725D-433B-8F55-9E75E14CECB9>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:1B973C15-149D-4D98-90E2-4A06A2F30ABD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C9" .
<urn:domeoclient:uuid:DCF9A15D-3781-426E-B12E-C37A11772BAD>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:BC0C42BD-3C98-4864-9F9C-50F72712CEC9>	<http://www.w3.org/ns/oa#exact>	"The most common non-functional alleles associated with reduced levels of TPMT activity are TPMT*2, TPMT*3A and TPMT*3C. Patients with two non-functional alleles (homozygous) have low or absent TPMT activity and those with one non-functional allele (heterozygous) have intermediate activity." .
<urn:domeoclient:uuid:E7B4486A-24AB-4642-ADB0-B78FF5AF0E42>	<http://purl.org/pav/createdOn>	"2014-06-02 14:00:00 -0400" .
<urn:linkedspls:uuid:A24FCBC0-9830-43DC-87D5-5716D3136B02>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"We chose 1 annotation here.\n\nHow do we code for dose adjustment is needed? (does this mean time or a catch-all term)" .
<urn:domeoclient:uuid:60281E0C-D291-4163-9B6F-E83A4142CB8E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:8026784E-DC9A-4F18-963D-495E0532BB97>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"poor-metabolizer" .
<urn:domeoclient:uuid:B6B4A58C-16B0-408F-A838-47FC8649B72D>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:B6B4A58C-16B0-408F-A838-47FC8649B72D> .
<urn:linkedspls:uuid:402D9368-C611-4289-8004-8EEC1A409CCF>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:3C70DFC4-2BEA-46AE-A49C-D4BE3E7466B8>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:E719DBCC-60BF-47C9-A2A6-B5AD564ED472>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER and PgR_receptor" .
<urn:linkedspls:uuid:1B973C15-149D-4D98-90E2-4A06A2F30ABD>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:55BCCCDC-ED3F-427D-AFFE-0E80E459C63A>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:55BCCCDC-ED3F-427D-AFFE-0E80E459C63A> .
<urn:domeoclient:uuid:A6AED276-0422-482B-8802-87BDABE2C035>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:7E666CF4-DD19-4B4B-AE7B-EF4BCEA0181C>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"ultra-metabolizer-positive" .
<urn:domeoclient:uuid:F10DDB11-A5F0-4B5E-B3CE-47B1F2145E34>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:F10DDB11-A5F0-4B5E-B3CE-47B1F2145E34> .
<urn:linkedspls:uuid:1FAA2AB1-96D9-4225-A9E1-763F045EE2CD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Azathioprine" .
<urn:domeoclient:uuid:6FC50BDC-78A6-4D50-8D6E-7FEB6DAFF0E2>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf" .
<urn:domeoclient:uuid:1F2D1F90-DA97-42FE-836C-EBF3BAC56349>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:1F2D1F90-DA97-42FE-836C-EBF3BAC56349> .
<urn:linkedspls:uuid:F0F7787E-5F9C-47A4-86B2-D64F1B7602B6>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>	"Decrease from baseline" .
<urn:linkedspls:uuid:9DCD19CE-D636-45D6-B994-A9BDBCA32621>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"ultra-metabolizer-positive" .
<urn:domeoclient:uuid:7B209F2D-47BE-4267-B895-92D67A47AE61>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:AC5F1BAD-8B6A-49DB-8147-AB1394EC169F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:linkedspls:uuid:42FA1C17-B780-423F-B993-EAF8D8DF0329>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:8F4ED235-6F4A-4BDD-A23F-6F2D9FC7A396>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:6F731CE1-E6B4-41AA-98C6-30C94B771E61> .
<urn:domeoclient:uuid:6D4DAD4D-1B63-4482-8060-787D97F917D2>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:2510C893-9155-453B-922C-CF116136DD88> .
<urn:linkedspls:uuid:61B14255-647D-4AA2-83E5-B81256BF7A50>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:D9543430-9668-4C09-8709-B8D20B095EEA>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:D9543430-9668-4C09-8709-B8D20B095EEA> .
<urn:domeoclient:uuid:43CE071E-85A3-4BC0-AEAC-4FC4DCBB3D02>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:CF0E7639-6AE6-4519-9A14-41BF8AB6A508>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:D888391C-2CE3-4955-850C-C8FA6291737A> .
<urn:linkedspls:uuid:933C6C55-0C1F-4A1C-B72F-98683FD68184>	<http://semanticscience.org/resource/SIO_000111>	"CONTRAINDICATIONS (34070-3)" .
<urn:linkedspls:uuid:3A77F5FE-EF65-4FF1-9BCD-E358D4D5BC82>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"TPMT" .
<urn:linkedspls:uuid:74BDDF82-70E1-44A8-B130-17D04DE86798>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Azathioprine" .
<urn:domeoclient:uuid:D32E2B19-3891-4F8B-98F3-B65344B0F6A8>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:D32E2B19-3891-4F8B-98F3-B65344B0F6A8> .
<urn:domeoclient:uuid:FB8FC7BE-DF14-4ABF-B790-607DABB38F49>	<http://purl.org/pav/createdOn>	"2014-04-14 14:07:33 -0400" .
<urn:linkedspls:uuid:53B64B1F-739B-46F0-99EE-89EF4131A8D2>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"ultra-metabolizer-positive" .
<urn:linkedspls:uuid:0B3E23EF-1696-4FF7-BEEB-8158BDA84294>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"CYP2C9*2, CYP2C9*3" .
<urn:domeoclient:uuid:7BC21EEB-9DB7-4481-AB5F-CDF2B8C45D96>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:7BC21EEB-9DB7-4481-AB5F-CDF2B8C45D96> .
<urn:linkedspls:uuid:0B3E23EF-1696-4FF7-BEEB-8158BDA84294>	<http://semanticscience.org/resource/SIO_000111>	"66106-6 PHARMACOGENOMICS SECTION" .
<urn:domeoclient:uuid:8B036858-70F5-4077-8333-F34F19A042EC>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:98B929B0-EA85-44FF-B8CA-9D5AC804EBBB>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:38CB7B79-EA55-443D-8F52-A694D541E5E3> .
<urn:linkedspls:uuid:2446A882-2020-42F8-AD24-FE3B4F839958>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:23663" .
<urn:linkedspls:uuid:36FDCB4E-5E54-4CBA-BC44-04B836C019F0>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:9C09D2F8-83BE-446D-A17A-75402666EE4B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:domeoclient:uuid:8CD7F86F-C041-47B7-B7D2-F7B48F523F56>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:DBCD24FF-6ABB-4810-A5CA-DF8F85FF2241>	<http://www.w3.org/ns/oa#exact>	"For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outweighs the risk." .
<urn:domeoclient:uuid:9F23E4DD-C825-4CCC-BD6E-1514188AFFA7>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:D1D85749-709E-4FD8-A464-C8E7CD8158BB> .
<urn:domeoclient:uuid:BCC8E4C0-518C-4CB7-86BA-64CE75086359>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:BCC8E4C0-518C-4CB7-86BA-64CE75086359> .
<urn:domeoclient:uuid:CDE45635-21AB-4AC7-89FF-C772F3A15A2C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:BC59C368-6171-459A-BA88-9B57AAC67FD8>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:BC59C368-6171-459A-BA88-9B57AAC67FD8> .
<urn:domeoclient:uuid:977E5F5B-8852-45BE-A6FC-8DEB91191DED>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:40B2A403-27A7-43FE-A0AC-5D87E3545981>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:A1F7627F-2636-46AA-A344-F9978C2AA71C> .
<urn:domeoclient:uuid:38655F0E-DB25-4C1E-A99A-7E2B18134930>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:239D0F43-DA9B-4ED8-A683-6BF29DB82241>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:239D0F43-DA9B-4ED8-A683-6BF29DB82241> .
<urn:domeoclient:uuid:239D0F43-DA9B-4ED8-A683-6BF29DB82241>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:CA417E62-D7D9-4F45-8359-10CCF8D13F90>	<http://purl.org/pav/createdOn>	"2014-06-30 13:09:12 -0400" .
<urn:domeoclient:uuid:3D5D3473-95BD-41AF-81E6-ED19E81798E9>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:3746E014-4500-4C39-A007-7B912571A900>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Efficacy" .
<urn:domeoclient:uuid:5949C0ED-ECE8-4C36-B91D-8E58F7A36AAC>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:977E5F5B-8852-45BE-A6FC-8DEB91191DED>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:977E5F5B-8852-45BE-A6FC-8DEB91191DED> .
<urn:linkedspls:uuid:6B9F2EDD-8EC9-441C-9B9C-6DE4ED079F50>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Azathioprine" .
<urn:linkedspls:uuid:FE990D63-4739-43A5-B062-7A946346B2AF>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:E719DBCC-60BF-47C9-A2A6-B5AD564ED472>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:domeoclient:uuid:83E53A9A-8702-4167-A12D-1370E2D26E06>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:B6570F9A-45F9-4786-BDA7-9D6B899F45DB> .
<urn:linkedspls:uuid:E06F2653-44AD-435F-AB2C-133712B039A6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Carbamazepine" .
<urn:domeoclient:uuid:D9543430-9668-4C09-8709-B8D20B095EEA>	<http://www.w3.org/ns/oa#exact>	"The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) conducted worldwide overviews of systemic adjuvant therapy for early breast cancer in 1985, 1990, and again in 1995. In 1998, 10 year outcome data were reported for 36,689 women in 55 randomized trials of adjuvant tamoxifen using doses of 20 to 40 mg/day for 1 to 5+ years. Twenty-five percent of patients received one year or less of trial treatment, 52% received 2 years, and 23% received about 5 years. Forty-eight percent of tumors were estrogen receptor (ER) positive (> 10 fmol/mg), 21% were ER poor (< 10 fmol/l), and 31% were ER unknown. Among 29,441 patients with ER positive or unknown breast cancer, 58% were entered into trials comparing tamoxifen to no adjuvant therapy and 42% were entered into trials comparing tamoxifen in combination with chemotherapy vs. the same chemotherapy alone." .
<urn:domeoclient:uuid:BC59C368-6171-459A-BA88-9B57AAC67FD8>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:1DA28968-6C74-475E-AB4F-5E6E22DFF8BD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1, PGR" .
<urn:domeoclient:uuid:F880CCED-A2A0-4330-B02F-070F7BF5AF00>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:CF35511B-7BED-446A-B970-33FEE5C13C88>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:9C843591-806D-42E0-88A9-58DC59076B3D> .
<urn:linkedspls:uuid:9837A225-376D-44A6-959D-05A7DCB03CCE>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:7BC21EEB-9DB7-4481-AB5F-CDF2B8C45D96>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:408C86B9-FFBA-4A7F-A6EC-ECD348FD4782>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:31115D88-2436-4D8C-B5E2-A7636A9DA498>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Efficacy" .
<urn:linkedspls:uuid:B7B25E99-EE57-41AC-BDE2-45DCC1447471>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:linkedspls:uuid:0B3E23EF-1696-4FF7-BEEB-8158BDA84294>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006120" .
<urn:domeoclient:uuid:D640727D-6442-4274-B453-64F04BD595E3>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:F5C240E5-0680-4CDA-ACC9-4DB8C5A0984B>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:3728C2D2-73B4-4F3A-A648-FD42247BA4EE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2623" .
<urn:linkedspls:uuid:F9A68240-FAD6-4604-8DEE-1B0E4AF9BD21>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Azathioprine" .
<urn:linkedspls:uuid:B30B41E3-5A67-4530-BC81-938E6B016FDF>	<http://semanticscience.org/resource/SIO_000111>	"WARNINGS AND PRECAUTIONS (43685-7)" .
<urn:linkedspls:uuid:C904A0A3-252D-4872-B966-44B63E18E430>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:linkedspls:uuid:74BB3F3E-AD24-438C-9250-4357E959069E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:domeoclient:uuid:1042FEEA-5AF3-4E50-B2A1-053451F2236C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:9A074D82-152F-415F-84A1-93EDCC8179B1>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:9A074D82-152F-415F-84A1-93EDCC8179B1> .
<urn:domeoclient:uuid:83E53A9A-8702-4167-A12D-1370E2D26E06>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:36FDCB4E-5E54-4CBA-BC44-04B836C019F0> .
<urn:domeoclient:uuid:CE5D6919-6972-4689-B658-C5432A02F905>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:86218E9C-9C50-4CF1-BDF5-7480485335DE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:9258FFBC-DCDC-4C6C-A375-9FC03C323B54>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"TPMT" .
<urn:linkedspls:uuid:13F3B206-EA87-463E-9DA8-93AA056A9117>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:3C75F25B-730C-424C-8A4A-C55F0D242716>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:2185EE39-FD81-4C83-ABDF-E5D59B789F96>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"poor-metabolizer-positive" .
<urn:domeoclient:uuid:9DDE5A30-59ED-49D7-B9B6-316245562477>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:5630014D-C820-4E31-A061-529A1A06548B>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:009DEEE9-9289-445E-8C79-81457BE96692>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:0496C268-8D3F-4D44-95D9-8D7250579EBE>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:30201CA6-94D8-4A83-9451-AF1497A97E75>	<http://www.w3.org/ns/oa#exact>	"HLA-B*5701-negative patients may develop a hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients." .
<urn:domeoclient:uuid:D3CF5A34-A1A9-4AFC-83F2-A5A1DD6DBB7F>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:55F59962-81BB-4F69-B3DD-6B65B3526228> .
<urn:domeoclient:uuid:C1BF7FF6-707B-4750-BA47-274111148F96>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:2083D2DB-07EF-4969-A4BB-F5823A134875>	<http://purl.org/pav/createdOn>	"2014-04-14 15:03:24 -0400" .
<urn:domeoclient:uuid:8E738FB7-477C-4524-B024-29343F2936EA>	<http://www.w3.org/ns/oa#exact>	"A meta-analysis of 9 qualified studies including 2775 patients (99% Caucasian) was performed to examine the clinical outcomes associated with CYP2C9 gene variants in warfarin-treated patients.3 In this meta-analysis, 3 studies assessed bleeding risks and 8 studies assessed daily dose requirements. The analysis suggested an increased bleeding risk for patients carrying either the CYP2C9*2 or CYP2C9*3 alleles." .
<urn:domeoclient:uuid:8A35BACC-77B7-4822-A677-4D72A3B91942>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:8A35BACC-77B7-4822-A677-4D72A3B91942> .
<urn:domeoclient:uuid:9E003EB3-2B97-41C7-BD14-5EAF744BB5F2>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:9258FFBC-DCDC-4C6C-A375-9FC03C323B54> .
<urn:domeoclient:uuid:7E2CB9FD-6E66-4D71-8B92-4AE2C557E1A3>	<http://www.w3.org/ns/oa#exact>	"HLA-B*5701-negative patients may develop a hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients." .
<urn:domeoclient:uuid:5CCA20AA-4D3C-40F4-BAED-C832E665FA35>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:F54825B6-3CF9-4465-A4BE-7C6747734A6E>	<http://www.w3.org/ns/oa#exact>	"Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir." .
<urn:linkedspls:uuid:0B39F957-E88F-427C-AC41-F1B9DC711A02>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Citalopram" .
<urn:domeoclient:uuid:E6578AA5-3295-46D7-B3F2-55CD3CFB5B0F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:903F27DB-914A-44A2-B01F-A36164AAC4DB>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:9E9B14EC-233F-4ABE-B627-6150C0C5A5A4>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:6347DAEC-6E58-45D7-9A9D-16BE602F4930>	<http://www.w3.org/ns/oa#exact>	"Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir." .
<urn:domeoclient:uuid:C97CADE4-3861-4CB6-A21E-09BF0AEB1F88>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:46A370D2-9D5B-4964-96D7-FECDB2FC0ED4>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd" .
<urn:domeoclient:uuid:CE1DC1EA-085A-4CF9-8165-5A14A411A633>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:79C530FF-637A-43C8-AECE-CA81458FB5EE>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:79C530FF-637A-43C8-AECE-CA81458FB5EE> .
<urn:domeoclient:uuid:35B89AC4-DAE5-4207-B319-F9479AE77CDE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:EF919E4C-C0B0-4D8B-A273-2F4A806A828D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:AC31138E-D96E-46FA-AD16-E8C5C6855989>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:ECE9E8AD-BAEE-4FC0-A880-67D03D8D2EED>	<http://www.w3.org/ns/oa#exact>	"Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir. " .
<urn:domeoclient:uuid:B2CCF84A-A981-4564-8227-DE5688CB1FED>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:FC766D1F-0C5B-4C57-8386-30CC6B3408B5>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Carbamazepine" .
<urn:linkedspls:uuid:9258FFBC-DCDC-4C6C-A375-9FC03C323B54>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"TPMT*2, TPMT*3A, TPMT*3C" .
<urn:domeoclient:uuid:DEA4B73A-145A-4D61-A6E1-ABAE37F63480>	<http://purl.org/pav/createdOn>	"2014-04-14 14:36:29 -0400" .
<urn:domeoclient:uuid:8E738FB7-477C-4524-B024-29343F2936EA>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:8E738FB7-477C-4524-B024-29343F2936EA> .
<urn:domeoclient:uuid:55BCCCDC-ED3F-427D-AFFE-0E80E459C63A>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:46A370D2-9D5B-4964-96D7-FECDB2FC0ED4>	<http://www.w3.org/ns/oa#exact>	"TPMT activity is controlled by a genetic polymorphism.1, 2, 3 For Caucasians and African Americans, approximately 10% of the population inherit one non-functional TPMT allele (heterozygous) conferring intermediate TPMT activity, and 0.3% inherit two TPMT non-functional alleles (homozygous) for low or absent TPMT activity. Non-functional alleles are less common in Asians. " .
<urn:linkedspls:uuid:1A9E2879-AD9B-48F5-B672-AB5C06A28080>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER and PgR_receptor" .
<urn:linkedspls:uuid:8BDFDC96-47AF-489E-8F96-DF9B26C6ECBE>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"poor-metabolizer-positive" .
<urn:domeoclient:uuid:7084C584-8C84-42A3-AFAB-F66F243A2817>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:875F6756-255E-43CC-8CA5-19D63561F59A>	<http://www.w3.org/ns/oa#exact>	"The most common non-functional alleles associated with reduced levels of TPMT activity are TPMT*2, TPMT*3A and TPMT*3C. Patients with two non-functional alleles (homozygous) have low or absent TPMT activity and those with one non-functional allele (heterozygous) have intermediate activity." .
<urn:linkedspls:uuid:691E83A1-1BFF-4939-996A-35C56D0CF2DF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C9" .
<urn:domeoclient:uuid:4364906C-8414-403A-BB1D-1DDCC5F6A4DA>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:4CFDD438-5250-4D24-9933-43397A6F2E0F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Do not restart" .
<urn:linkedspls:uuid:F5AE3B3E-B864-4A19-B48C-DC1343C799A3>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:30201CA6-94D8-4A83-9451-AF1497A97E75>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:30201CA6-94D8-4A83-9451-AF1497A97E75> .
<urn:linkedspls:uuid:08308CA2-E50D-41DB-873B-E57372B5FBDB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"poor-metabolizer-positive" .
<urn:domeoclient:uuid:7FA5409D-3EA5-4F92-B738-8577DCEB4D97>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:CE3C3FF6-F83D-47D2-8C4F-944687265F2B>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:6F731CE1-E6B4-41AA-98C6-30C94B771E61>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:7E2CB9FD-6E66-4D71-8B92-4AE2C557E1A3>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:7E2CB9FD-6E66-4D71-8B92-4AE2C557E1A3> .
<urn:domeoclient:uuid:88C2CEB5-469C-451E-8436-788ABE4338F5>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:47718F61-F7FA-4A83-BB17-C13189D5E884>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:FB17C9EA-111C-4784-80AC-30417D974CE8>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:720F1FAF-C317-4375-8323-04DFEE0FAAFE> .
<urn:linkedspls:uuid:855697DF-EBFA-4343-B2F2-023B6F284D48>	<http://semanticscience.org/resource/SIO_000111>	"34075-2 LABORATORY TESTS SECTION" .
<urn:domeoclient:uuid:CFEF239C-B763-4864-8DD8-A917EFD12673>	<http://www.w3.org/ns/oa#exact>	"Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction." .
<urn:domeoclient:uuid:8525CDF6-1EFA-4AA5-BD43-C9DDE92E0196>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:D26DCABA-C665-4147-A57B-F26195C0188E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:BDEED6AF-6C6D-44F0-8470-40D3A54778C5>	<http://semanticscience.org/resource/SIO_000111>	"WARNINGS AND PRECAUTIONS (43685-7)" .
<urn:domeoclient:uuid:3CB531B1-A267-4A03-A0C5-D852AB638802>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:40B2A403-27A7-43FE-A0AC-5D87E3545981>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:4C36F11A-E282-4BFB-849D-B93A233A50FB> .
<urn:domeoclient:uuid:72D8F9E8-4B4D-4FC2-81A2-A19C5BF05098>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd" .
<urn:linkedspls:uuid:855BF4FE-7082-466C-AEC2-BA37C5A2F93C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"VKORC1" .
<urn:linkedspls:uuid:9C09D2F8-83BE-446D-A17A-75402666EE4B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:3467" .
<urn:domeoclient:uuid:EED39F7C-032A-4628-9022-2253559E7FEE>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:169DB9DD-C966-431C-85FE-C3AC1F8E31D3> .
<urn:linkedspls:uuid:A3C1B92C-CBE0-4BA8-A41C-D3C3CD26FA51>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"TPMT" .
<urn:domeoclient:uuid:F10DDB11-A5F0-4B5E-B3CE-47B1F2145E34>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:98B929B0-EA85-44FF-B8CA-9D5AC804EBBB>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:25348450-1CCF-4BEC-84EF-0EA92F67DD3A> .
<urn:domeoclient:uuid:79AEDAF0-0AC0-4A44-9F6D-05B14ECEF74F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:DEE1B9FD-09F4-4AD6-9BEB-55CF10F2FDDB>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:DEE1B9FD-09F4-4AD6-9BEB-55CF10F2FDDB> .
<urn:domeoclient:uuid:E34142C5-1680-4612-AC76-D96D8F82364F>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:402D9368-C611-4289-8004-8EEC1A409CCF> .
<urn:linkedspls:uuid:2446A882-2020-42F8-AD24-FE3B4F839958>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:domeoclient:uuid:23FACDDB-003E-40B5-AB79-B52F5FD124B3>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:86480047-DD43-4A54-B258-3772C18237F7>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"VKORC1" .
<urn:domeoclient:uuid:1A89E704-ECDB-4495-8848-DB89566FFC2E>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:1A89E704-ECDB-4495-8848-DB89566FFC2E> .
<urn:domeoclient:uuid:99AB6350-6929-4C24-B144-7B97EBF09B3F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:D3CF5A34-A1A9-4AFC-83F2-A5A1DD6DBB7F>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:56D95EC4-D0D7-4BD6-B13C-E145F6A4E568> .
<urn:linkedspls:uuid:A903F38F-38D4-4052-A673-7FF19407E3DB>	<http://semanticscience.org/resource/SIO_000111>	"BOXED WARNING (34066-1)" .
<urn:domeoclient:uuid:231E14A4-5E1D-443C-B50C-8E3E00BBAF15>	<http://purl.org/pav/createdOn>	"2014-04-21 12:30:56 -0400" .
<urn:domeoclient:uuid:6347DAEC-6E58-45D7-9A9D-16BE602F4930>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:FE1B382B-9F39-4CAA-8A59-17376ED6F061>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"F2" .
<urn:linkedspls:uuid:C904A0A3-252D-4872-B966-44B63E18E430>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"poor-metabolizer-positive" .
<urn:domeoclient:uuid:4F5C1D0C-9AFC-4B3A-83EC-AC9CB72FB0C9>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:691E83A1-1BFF-4939-996A-35C56D0CF2DF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2623" .
<urn:domeoclient:uuid:A1F7627F-2636-46AA-A344-F9978C2AA71C>	<http://www.w3.org/ns/oa#exact>	"Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration. Not all patients with these conditions develop necrosis, and tissue necrosis occurs in patients without these deficiencies." .
<urn:linkedspls:uuid:0D634683-D28C-42DC-9911-DFD0C9EB289D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:E34142C5-1680-4612-AC76-D96D8F82364F>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:60CFE292-6834-41FC-8255-B81A3D584EE2> .
<urn:domeoclient:uuid:F54825B6-3CF9-4465-A4BE-7C6747734A6E>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:FBA8BE44-2409-4673-8D2F-0E2947538FCE>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:FBA8BE44-2409-4673-8D2F-0E2947538FCE> .
<urn:linkedspls:uuid:108444AC-C8D7-42EE-A011-BE98A3F592F0>	<http://semanticscience.org/resource/SIO_000111>	"WARNINGS AND PRECAUTIONS (43685-7)" .
<urn:domeoclient:uuid:3419ECAE-A4FF-4BE4-8679-16B52BA748AC>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:E7B4486A-24AB-4642-ADB0-B78FF5AF0E42>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:7C3837BB-DAF7-4544-9D2C-A63E2F406BAC> .
<urn:linkedspls:uuid:70BE7DEB-6A8B-41E9-9333-F1F47AC7E1A0>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:E826D255-0A7E-4F3C-A59F-675E8A9B606E>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:8D91E7D5-B379-4649-9834-0D01A948DFF8>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:4019443F-CB02-40D7-BB18-37DDB00B1548>	<http://www.w3.org/ns/oa#exact>	"Studies have shown that carriage of the HLA-B*5701 allele is associated with a significantly increased risk of a hypersensitivity reaction to abacavir." .
<urn:domeoclient:uuid:5229A912-1F9A-40AD-9994-79886D701F6C>	<http://purl.org/pav/createdOn>	"2014-06-30 12:35:15 -0400" .
<urn:linkedspls:uuid:BCCF3F22-38AE-4F01-87D0-22C1B07EC947>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:A24FCBC0-9830-43DC-87D5-5716D3136B02>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"poor-metabolizer-positive" .
<urn:domeoclient:uuid:AF427FC6-54B8-4CA4-9C51-233E64726500>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0" .
<urn:domeoclient:uuid:BF8C1810-3B2F-446D-95FB-F6382AEE1DC0>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd" .
<urn:domeoclient:uuid:6A2E1BD4-3863-4A37-AD9D-6B54F3CF3E54>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:9DCD19CE-D636-45D6-B994-A9BDBCA32621> .
<urn:domeoclient:uuid:E7B4486A-24AB-4642-ADB0-B78FF5AF0E42>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:CF0E7639-6AE6-4519-9A14-41BF8AB6A508>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:D3EDFFC9-9EE3-45DD-B147-801DAB72DF3D> .
<urn:domeoclient:uuid:FC7D109F-F404-4287-BE4A-D7C5AA057401>	<http://purl.org/pav/createdOn>	"2014-03-31 08:58:47 -0400" .
<urn:linkedspls:uuid:169DB9DD-C966-431C-85FE-C3AC1F8E31D3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:599459E0-8D98-4627-BC38-BA5B6BEC6B33>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:domeoclient:uuid:E34142C5-1680-4612-AC76-D96D8F82364F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:55F59962-81BB-4F69-B3DD-6B65B3526228>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:55F59962-81BB-4F69-B3DD-6B65B3526228> .
<urn:linkedspls:uuid:945EB72E-5C75-41B0-B8FC-637E1EF0AE7D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:A24FCBC0-9830-43DC-87D5-5716D3136B02>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2D6" .
<urn:domeoclient:uuid:29B0BAC9-227E-4C4D-96D2-143CC457E50C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:9F23E4DD-C825-4CCC-BD6E-1514188AFFA7>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:5A997B78-0557-4495-BDBD-42F5B4B30412> .
<urn:domeoclient:uuid:98B929B0-EA85-44FF-B8CA-9D5AC804EBBB>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:7CE2D02E-F446-465D-9CBE-27C213ACCC89>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"The search magnifying glass does not work to find this one." .
<urn:domeoclient:uuid:720F1FAF-C317-4375-8323-04DFEE0FAAFE>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:720F1FAF-C317-4375-8323-04DFEE0FAAFE> .
<urn:linkedspls:uuid:CE3D1055-4EAF-4F2F-A2ED-AA9B95C45024>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:A74CD0BB-2B56-45FC-B50D-C7952B9C9AE4>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd" .
<urn:linkedspls:uuid:4B11E300-2DF5-4B21-9D43-4D0A02109A59>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:domeoclient:uuid:FE154A72-C1D3-4027-8C73-C71A948D0F52>	<http://purl.org/pav/createdOn>	"2014-06-30 12:25:05 -0400" .
<urn:domeoclient:uuid:2F3B0124-31A3-451B-BA81-5652303A452C>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:7CE2D02E-F446-465D-9CBE-27C213ACCC89>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:linkedspls:uuid:94B53E9F-5329-43D3-AD42-03C430F6E877>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"TPMT" .
<urn:domeoclient:uuid:9E003EB3-2B97-41C7-BD14-5EAF744BB5F2>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:028082D6-59BF-44E8-9117-CC155DA8D008>	<http://www.w3.org/ns/oa#exact>	"For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outweighs the risk." .
<urn:linkedspls:uuid:E6B02E4B-FDE8-473A-A978-02F98D0FE07D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1, PGR" .
<urn:linkedspls:uuid:08308CA2-E50D-41DB-873B-E57372B5FBDB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2D6" .
<urn:linkedspls:uuid:5D87AC20-773F-4241-AA52-57BF86A4A93A>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:linkedspls:uuid:96D6F8F1-F51A-4EBC-BFF7-C799690B4401>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Decreased Toxicity Risk" .
<urn:domeoclient:uuid:9F23E4DD-C825-4CCC-BD6E-1514188AFFA7>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:44BBF444-A1D4-4182-8B05-775BFFCA0DF4>	<http://purl.org/pav/createdOn>	"2014-04-28 15:21:52 -0400" .
<urn:domeoclient:uuid:6D4DAD4D-1B63-4482-8060-787D97F917D2>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:396CB021-3C85-4E20-B020-3714CE558E2D>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"CYP2C9*1/*1, CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2, CYP2C9*2/*3, CYP2C9*3/*3, CYP2C9*5, CYP2C9*6, CYP2C9*11, CYP2C9*9" .
<urn:domeoclient:uuid:61BA8ACB-D63A-46FF-8B5D-79E9326A61A3>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:linkedspls:uuid:933C6C55-0C1F-4A1C-B72F-98683FD68184>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Do not restart" .
<urn:domeoclient:uuid:1FCB6C74-C406-41C1-8A44-C9D033D5834C>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:875F6756-255E-43CC-8CA5-19D63561F59A>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd" .
<urn:domeoclient:uuid:9E003EB3-2B97-41C7-BD14-5EAF744BB5F2>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:BC0C42BD-3C98-4864-9F9C-50F72712CEC9> .
<urn:domeoclient:uuid:55F59962-81BB-4F69-B3DD-6B65B3526228>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:linkedspls:uuid:6F731CE1-E6B4-41AA-98C6-30C94B771E61>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"Did not annotate normal separately in this case." .
<urn:linkedspls:uuid:D66FA8C3-8BAB-4A6F-8234-6DD134876578>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:3A77F5FE-EF65-4FF1-9BCD-E358D4D5BC82>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:75C4424E-2C9D-40D9-82CF-7E02CFDCA301>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:E8587041-73D9-4727-A9F5-7445BAF204E3>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:E8587041-73D9-4727-A9F5-7445BAF204E3> .
<urn:linkedspls:uuid:D64C9075-1FB5-47EA-9312-70A065865D71>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"TPMT" .
<urn:domeoclient:uuid:BD33E8D1-8AEF-4E43-9C57-35AB0263305D>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd" .
<urn:domeoclient:uuid:8F4ED235-6F4A-4BDD-A23F-6F2D9FC7A396>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:6FC50BDC-78A6-4D50-8D6E-7FEB6DAFF0E2> .
<urn:domeoclient:uuid:6A2E1BD4-3863-4A37-AD9D-6B54F3CF3E54>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:2F3B0124-31A3-451B-BA81-5652303A452C>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:2F3B0124-31A3-451B-BA81-5652303A452C> .
<urn:domeoclient:uuid:86218E9C-9C50-4CF1-BDF5-7480485335DE>	<http://purl.org/pav/createdOn>	"2014-03-22 22:18:30 -0400" .
<urn:linkedspls:uuid:BF7AF633-8B36-41BF-AC4F-0BA548A0DB2F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:C09E3379-98EF-4D6C-8046-8C000B4A6C99>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:5E02C5AB-C35D-4ACA-8EF0-DF0F481E6A00> .
<urn:linkedspls:uuid:2185EE39-FD81-4C83-ABDF-E5D59B789F96>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Alternative Recommended" .
<urn:linkedspls:uuid:B24A699D-7127-47C1-BFAE-C1ABB6819E2F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:domeoclient:uuid:82F247F1-5E0B-472B-8C42-4074C2A25CD0>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16bda7b5-a5a5-4478-9df3-beb396bd677f" .
<urn:linkedspls:uuid:5239657F-5948-4803-B690-76D953D60764>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:domeoclient:uuid:CF0E7639-6AE6-4519-9A14-41BF8AB6A508>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:071CEC58-02E9-4DA2-8259-93E87A6EFD3B>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"ultra-metabolizer-positive" .
<urn:linkedspls:uuid:3728C2D2-73B4-4F3A-A648-FD42247BA4EE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C9" .
<urn:domeoclient:uuid:F19D3DA9-E091-415D-A43E-483BEC7B68FB>	<http://purl.org/pav/createdOn>	"2014-06-09 16:03:11 -0400" .
<urn:domeoclient:uuid:BCC8E4C0-518C-4CB7-86BA-64CE75086359>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02" .
<urn:linkedspls:uuid:53B64B1F-739B-46F0-99EE-89EF4131A8D2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2D6" .
<urn:linkedspls:uuid:CD7BE61C-D111-48EB-A232-1241D41AB8BC>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:linkedspls:uuid:0F7B1E31-9D8A-45AA-8F34-A942EE6FBB80>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"VKORC1" .
<urn:domeoclient:uuid:40B2A403-27A7-43FE-A0AC-5D87E3545981>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:FB17C9EA-111C-4784-80AC-30417D974CE8>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:1FAA2AB1-96D9-4225-A9E1-763F045EE2CD> .
<urn:domeoclient:uuid:720C5233-AF5F-4538-891A-259FD3EE6895>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:05DBF40D-ECCF-4BC6-9077-742EBADF41F9> .
<urn:linkedspls:uuid:9258FFBC-DCDC-4C6C-A375-9FC03C323B54>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Azathioprine" .
<urn:domeoclient:uuid:147B38AF-9E51-4D8A-B5CF-D7FAE7375257>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0" .
<urn:linkedspls:uuid:8BDFDC96-47AF-489E-8F96-DF9B26C6ECBE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Citalopram" .
<urn:linkedspls:uuid:9BD38C7E-B2D9-4C83-903C-F86556F46EF2>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:BC70D092-5124-4A5C-87C3-EA34E4868C05>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:domeoclient:uuid:C09E3379-98EF-4D6C-8046-8C000B4A6C99>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:0496C268-8D3F-4D44-95D9-8D7250579EBE>	<http://www.w3.org/ns/oa#exact>	"Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir." .
<urn:domeoclient:uuid:720C5233-AF5F-4538-891A-259FD3EE6895>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:910F9AE9-8398-400D-8505-D971512A67C6>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:D2A8C2D7-9A3E-4307-BC2B-4EA4FC30E8A5>	<http://semanticscience.org/resource/SIO_000111>	"WARNINGS AND PRECAUTIONS (43685-7)" .
<urn:domeoclient:uuid:8F4ED235-6F4A-4BDD-A23F-6F2D9FC7A396>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:0496C268-8D3F-4D44-95D9-8D7250579EBE>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:0496C268-8D3F-4D44-95D9-8D7250579EBE> .
<urn:linkedspls:uuid:08308CA2-E50D-41DB-873B-E57372B5FBDB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Citalopram" .
<urn:linkedspls:uuid:7E666CF4-DD19-4B4B-AE7B-EF4BCEA0181C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2D6" .
<urn:domeoclient:uuid:5BA0362C-1EF8-4647-8A30-017F5378F48F>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf" .
<urn:domeoclient:uuid:FB17C9EA-111C-4784-80AC-30417D974CE8>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:D2A8C2D7-9A3E-4307-BC2B-4EA4FC30E8A5>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:domeoclient:uuid:7D50A614-4F2B-42C6-A175-0BF3C158B5DA>	<http://www.w3.org/ns/oa#exact>	"Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is achieved through an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by genetic variations in CYP2C19 [see Boxed Warning] and by concomitant medications that interfere with CYP2C19." .
<urn:linkedspls:uuid:A48D46C7-8F7E-4426-8C3D-CCA08F946DB0>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:9DCD19CE-D636-45D6-B994-A9BDBCA32621>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2D6" .
<urn:domeoclient:uuid:903F27DB-914A-44A2-B01F-A36164AAC4DB>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:903F27DB-914A-44A2-B01F-A36164AAC4DB> .
<urn:domeoclient:uuid:CF35511B-7BED-446A-B970-33FEE5C13C88>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:B9375CD1-7E67-42D6-B380-D95AD08BF64B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"VKORC1" .
<urn:domeoclient:uuid:524C3AB2-2955-4538-A46C-63CDD0BC11D2>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:D1D85749-709E-4FD8-A464-C8E7CD8158BB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:7673EC96-E39E-4D34-A8B6-A31AD2825C94>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:1A9E2879-AD9B-48F5-B672-AB5C06A28080>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"biomarker-positive" .
<urn:linkedspls:uuid:558D142F-DBE9-4EB9-9F46-4244D63F2FAF>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:domeoclient:uuid:39A685C2-1AA3-415F-8F2F-3F82C6914A2D>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf" .
<urn:linkedspls:uuid:42FA1C17-B780-423F-B993-EAF8D8DF0329>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:84646AA6-8E85-4656-8515-E49CB15EADB4>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"ultra-metabolizer-positive" .
<urn:domeoclient:uuid:83E53A9A-8702-4167-A12D-1370E2D26E06>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:41CC62A5-5C3A-449F-B7A3-675F76FA4085>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:0B39F957-E88F-427C-AC41-F1B9DC711A02> .
<urn:linkedspls:uuid:CD7BE61C-D111-48EB-A232-1241D41AB8BC>	<http://semanticscience.org/resource/SIO_000111>	"BOXED WARNING (34066-1)" .
<urn:linkedspls:uuid:691E83A1-1BFF-4939-996A-35C56D0CF2DF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006120" .
<urn:domeoclient:uuid:D3B78E07-8B27-4774-B221-CC47DAC8365E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:720C5233-AF5F-4538-891A-259FD3EE6895>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:0A10CE73-592A-4D92-84AF-63395C43C0F9> .
<urn:domeoclient:uuid:EED39F7C-032A-4628-9022-2253559E7FEE>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:028082D6-59BF-44E8-9117-CC155DA8D008> .
<urn:domeoclient:uuid:E1199968-6650-4D2A-A5E4-EDFBFE7733AE>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:E1199968-6650-4D2A-A5E4-EDFBFE7733AE> .
<urn:domeoclient:uuid:EED39F7C-032A-4628-9022-2253559E7FEE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:89320F5F-262D-4657-8A52-4432EC0101F8>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:240C39EC-A129-42D3-8602-5C743EC412D2>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:1924E2D5-9E52-46A8-925D-043869F8F777>	<http://purl.org/pav/createdOn>	"2014-03-22 22:01:09 -0400" .
<urn:domeoclient:uuid:E8587041-73D9-4727-A9F5-7445BAF204E3>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:domeoclient:uuid:41CC62A5-5C3A-449F-B7A3-675F76FA4085>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:38B0D49A-8B7C-4D71-B2CE-0388425D3B66>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:38B0D49A-8B7C-4D71-B2CE-0388425D3B66> .
<urn:domeoclient:uuid:121CDD92-5195-42C0-A613-F40D095DA06D>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:74BDDF82-70E1-44A8-B130-17D04DE86798> .
<urn:domeoclient:uuid:DF92C1E1-A223-4737-8028-06DD03B558D2>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:4663B6D5-B11D-4039-8F32-F7E3BFC2537E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:231E14A4-5E1D-443C-B50C-8E3E00BBAF15>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:D5CF7A64-E07F-419A-8900-15F969F2D51F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:51C4FEDD-5F25-4F57-92BC-5456BC2E4846>	<http://semanticscience.org/resource/SIO_000111>	"PATIENT MEDICATION INFORMATION (68498-5)" .
<urn:linkedspls:uuid:2446A882-2020-42F8-AD24-FE3B4F839958>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"VKORC1" .
<urn:linkedspls:uuid:2CE69763-0812-4DFF-A359-2A8D8FF706AD>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:45844BA9-29ED-4EC6-94C0-81C9883F880F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:055AAAC1-3544-4B8E-BF06-C99328A12B6E>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:linkedspls:uuid:FED638A3-F491-4246-B5EC-651C306CF76E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Clopidogrel" .
<urn:linkedspls:uuid:1706E63C-45AC-467E-80FD-06108C69A93D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:6FC50BDC-78A6-4D50-8D6E-7FEB6DAFF0E2>	<http://www.w3.org/ns/oa#exact>	" In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeine\u2019s active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including death, in nursing infants." .
<urn:domeoclient:uuid:BC0A4D53-4B45-488A-8775-B46BF1E9B010>	<http://purl.org/pav/createdOn>	"2014-06-30 13:19:32 -0400" .
<urn:domeoclient:uuid:29B0BAC9-227E-4C4D-96D2-143CC457E50C>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:9098E55C-952E-46DF-904C-2A3E63492B3A> .
<urn:domeoclient:uuid:51CDF79D-8F09-44DB-AE3B-91C93D13095C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:92FA8990-60EF-4140-9F60-C12E57E3B114>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:9A074D82-152F-415F-84A1-93EDCC8179B1>	<http://www.w3.org/ns/oa#exact>	"Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy" .
<urn:domeoclient:uuid:5464F1B8-CF3D-4DA9-99F4-5F156C14CE70>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:6D4DAD4D-1B63-4482-8060-787D97F917D2>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:33D89E0F-4370-431E-8DB5-094F3AF78C75> .
<urn:domeoclient:uuid:216A1896-63FD-45FE-ACBB-80F82EB9ACE5>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:1DB91157-FBA4-4FE0-BAB1-68BB8A5A145E>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:3746E014-4500-4C39-A007-7B912571A900>	<http://semanticscience.org/resource/SIO_000111>	"34067-9 INDICATIONS AND USAGE SECTION" .
<urn:domeoclient:uuid:E7B4486A-24AB-4642-ADB0-B78FF5AF0E42>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:1A89E704-ECDB-4495-8848-DB89566FFC2E> .
<urn:linkedspls:uuid:2185EE39-FD81-4C83-ABDF-E5D59B789F96>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:domeoclient:uuid:38CB7B79-EA55-443D-8F52-A694D541E5E3>	<http://www.w3.org/ns/oa#exact>	"NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status" .
<urn:domeoclient:uuid:D3CF5A34-A1A9-4AFC-83F2-A5A1DD6DBB7F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:8B50CE5B-C2BB-4D97-838E-E1C2600020BC>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:C09E3379-98EF-4D6C-8046-8C000B4A6C99>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:9F0CE910-4782-4E6D-B7E2-C7C784B10B90> .
<urn:domeoclient:uuid:29B0BAC9-227E-4C4D-96D2-143CC457E50C>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:D939C426-7E0B-4A32-80F1-7344D702AA97> .
<urn:linkedspls:uuid:08308CA2-E50D-41DB-873B-E57372B5FBDB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Not Important" .
<urn:domeoclient:uuid:6F41EB64-7E4B-4DAA-86FE-348F6836D46E>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf" .
<urn:domeoclient:uuid:121CDD92-5195-42C0-A613-F40D095DA06D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:6A2E1BD4-3863-4A37-AD9D-6B54F3CF3E54>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:BCAE5E0C-30F2-4E8B-8D8E-687ADD4CA18B> .
<urn:linkedspls:uuid:42FA1C17-B780-423F-B993-EAF8D8DF0329>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:E03CFE71-0FEF-4840-A587-1D360CBF035C>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf" .
<urn:linkedspls:uuid:F45F585A-05C5-49B5-BABB-73BFBE9E9753>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Clopidogrel" .
<urn:linkedspls:uuid:75D988CE-7527-421D-AAA6-0C9C0D4B30DF>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:FC7D109F-F404-4287-BE4A-D7C5AA057401>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:45B95464-0287-435F-86B4-0253D73E6DA8>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:7C3837BB-DAF7-4544-9D2C-A63E2F406BAC>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2D6" .
<urn:domeoclient:uuid:D62A1217-AE83-41D2-B678-FDCD04344D8B>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:5B91F78A-EEB0-41A3-8995-90B920D09520>	<http://www.w3.org/ns/oa#exact>	"Deaths have also occurred in nursing infants who were exposed to high levels of morphine in breast milk because their mothers were ultra-rapid metabolizers of codeine " .
<urn:domeoclient:uuid:9098E55C-952E-46DF-904C-2A3E63492B3A>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16bda7b5-a5a5-4478-9df3-beb396bd677f" .
<urn:linkedspls:uuid:9258FFBC-DCDC-4C6C-A375-9FC03C323B54>	<http://semanticscience.org/resource/SIO_000111>	"34075-2 LABORATORY TESTS SECTION" .
<urn:linkedspls:uuid:E719DBCC-60BF-47C9-A2A6-B5AD564ED472>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"biomarker-positive" .
<urn:domeoclient:uuid:D32E2B19-3891-4F8B-98F3-B65344B0F6A8>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:domeoclient:uuid:B752346E-6167-497D-B585-83983FA71DA2>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:8C0132CB-1BA7-4320-8C5F-E55761BC596E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:E014618E-3373-4F61-BAF6-4ABD45885081>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:720F1FAF-C317-4375-8323-04DFEE0FAAFE>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd" .
<urn:linkedspls:uuid:56D95EC4-D0D7-4BD6-B13C-E145F6A4E568>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:1F2D1F90-DA97-42FE-836C-EBF3BAC56349>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd" .
<urn:linkedspls:uuid:74EA2B44-40D9-44F0-90BA-33EFF2D1B5AA>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:domeoclient:uuid:CF35511B-7BED-446A-B970-33FEE5C13C88>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:74B97B42-8CF1-41BB-84AD-CF0995E7508C> .
<urn:linkedspls:uuid:964EBF55-DC67-43A9-93E2-DBC843BB8D2A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Clopidogrel" .
<urn:linkedspls:uuid:4DD1AE8C-CB2C-4887-993E-A8A44B2A06CB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:1924E2D5-9E52-46A8-925D-043869F8F777>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:BDEED6AF-6C6D-44F0-8470-40D3A54778C5>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:9C09D2F8-83BE-446D-A17A-75402666EE4B>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"biomarker-positive" .
<urn:linkedspls:uuid:B24A699D-7127-47C1-BFAE-C1ABB6819E2F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:3A77F5FE-EF65-4FF1-9BCD-E358D4D5BC82>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Azathioprine" .
<urn:domeoclient:uuid:EE8AF84A-98F2-4EED-8B54-4312A50FBA31>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:B6B4A58C-16B0-408F-A838-47FC8649B72D>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:domeoclient:uuid:CFEF239C-B763-4864-8DD8-A917EFD12673>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:E17574BF-3BA6-48DA-B0DA-6E8DF716A03D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:A48D46C7-8F7E-4426-8C3D-CCA08F946DB0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2D6" .
<urn:linkedspls:uuid:EE534BB0-3042-44F4-9B63-01291E28FA45>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:8BDFDC96-47AF-489E-8F96-DF9B26C6ECBE>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"Again, refers to increased exposure; we infer metabolism.  Said decrease from baseline as added a max dose." .
<urn:linkedspls:uuid:43B85AB2-533A-4A3B-932F-7CD7177449ED>	<http://semanticscience.org/resource/SIO_000111>	"WARNINGS AND PRECAUTIONS (43685-7)" .
<urn:domeoclient:uuid:69B50E0E-4BB4-49DC-AE8B-4326D0F0A959>	<http://purl.org/pav/createdOn>	"2014-06-30 12:22:01 -0400" .
<urn:linkedspls:uuid:51C4FEDD-5F25-4F57-92BC-5456BC2E4846>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:94B53E9F-5329-43D3-AD42-03C430F6E877>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Azathioprine" .
<urn:linkedspls:uuid:53541A7F-ACF6-4030-A4B7-7BA865CDF82F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:linkedspls:uuid:1FAA2AB1-96D9-4225-A9E1-763F045EE2CD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:domeoclient:uuid:C7EAEB14-8213-4EF8-AC67-469D0609826B>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:21B282F1-F0CA-488A-B703-88611F099D16>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:43B85AB2-533A-4A3B-932F-7CD7177449ED>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:domeoclient:uuid:231E14A4-5E1D-443C-B50C-8E3E00BBAF15>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:BD33E8D1-8AEF-4E43-9C57-35AB0263305D> .
<urn:linkedspls:uuid:87B8F5B0-8381-4CA7-AE0B-30C481D164B4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:7AE1124F-F104-4EB3-9415-257F81B2E3CE>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:domeoclient:uuid:B8BA0ADB-2437-4F14-9102-2EC16B13EE4C>	<http://purl.org/pav/createdOn>	"2014-06-09 15:40:26 -0400" .
<urn:linkedspls:uuid:D3EDFFC9-9EE3-45DD-B147-801DAB72DF3D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Citalopram" .
<urn:linkedspls:uuid:4C36F11A-E282-4BFB-849D-B93A233A50FB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:4663B6D5-B11D-4039-8F32-F7E3BFC2537E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2D6" .
<urn:linkedspls:uuid:7C3837BB-DAF7-4544-9D2C-A63E2F406BAC>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:B9375CD1-7E67-42D6-B380-D95AD08BF64B>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:9837A225-376D-44A6-959D-05A7DCB03CCE>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MonitoringRecommendation>	"Recommended" .
<urn:linkedspls:uuid:E06F2653-44AD-435F-AB2C-133712B039A6>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Not Important" .
<urn:linkedspls:uuid:2CE69763-0812-4DFF-A359-2A8D8FF706AD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:domeoclient:uuid:121CDD92-5195-42C0-A613-F40D095DA06D>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:875F6756-255E-43CC-8CA5-19D63561F59A> .
<urn:linkedspls:uuid:0B3E23EF-1696-4FF7-BEEB-8158BDA84294>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2623" .
<urn:linkedspls:uuid:92FA8990-60EF-4140-9F60-C12E57E3B114>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:75C4424E-2C9D-40D9-82CF-7E02CFDCA301>	<http://semanticscience.org/resource/SIO_000111>	"BOXED WARNING (34066-1)" .
<urn:linkedspls:uuid:0961EB1D-39A9-4A01-9D9B-C2BC3222987E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:domeoclient:uuid:9A5666BB-F43D-45F3-A856-0BDB0E745589>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd" .
<urn:linkedspls:uuid:8026784E-DC9A-4F18-963D-495E0532BB97>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"poor-metabolizer-positive" .
<urn:linkedspls:uuid:4777BC06-68FA-4171-A52D-68668AD25547>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:linkedspls:uuid:87B8F5B0-8381-4CA7-AE0B-30C481D164B4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:domeoclient:uuid:7D37999E-F183-41DD-8FEF-19696FD23D30>	<http://purl.org/pav/createdOn>	"2014-04-28 15:27:38 -0400" .
<urn:linkedspls:uuid:D6235B22-042E-4C36-A104-B353CF92CEB8>	<http://semanticscience.org/resource/SIO_000111>	"34067-9 INDICATIONS AND USAGE SECTION" .
<urn:linkedspls:uuid:52601F35-C2AB-4602-BD13-6B9999A0266A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:169DB9DD-C966-431C-85FE-C3AC1F8E31D3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:239D0F43-DA9B-4ED8-A683-6BF29DB82241>	<http://www.w3.org/ns/oa#exact>	"NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status" .
<urn:linkedspls:uuid:6F731CE1-E6B4-41AA-98C6-30C94B771E61>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006121" .
<urn:linkedspls:uuid:D64C9075-1FB5-47EA-9312-70A065865D71>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Azathioprine" .
<urn:linkedspls:uuid:B30B41E3-5A67-4530-BC81-938E6B016FDF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:05DBF40D-ECCF-4BC6-9077-742EBADF41F9>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"biomarker-positive" .
<urn:linkedspls:uuid:6B9F2EDD-8EC9-441C-9B9C-6DE4ED079F50>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:domeoclient:uuid:720C5233-AF5F-4538-891A-259FD3EE6895>	<http://purl.org/pav/createdOn>	"2014-06-09 15:35:34 -0400" .
<urn:linkedspls:uuid:FBD3A076-17BF-416E-9EEC-89C39FD558A3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:9739D8D8-F16D-4FF9-BD63-1945B116EEC4>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:domeoclient:uuid:4364906C-8414-403A-BB1D-1DDCC5F6A4DA>	<http://purl.org/pav/createdOn>	"2014-03-22 22:05:18 -0400" .
<urn:domeoclient:uuid:40B2A403-27A7-43FE-A0AC-5D87E3545981>	<http://purl.org/pav/createdOn>	"2014-06-30 13:15:04 -0400" .
<urn:domeoclient:uuid:64BC1D21-CAE1-4F85-A596-73342A9D5388>	<http://www.w3.org/ns/oa#exact>	"HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients." .
<urn:domeoclient:uuid:DF92C1E1-A223-4737-8028-06DD03B558D2>	<http://purl.org/pav/createdOn>	"2014-03-22 22:15:05 -0400" .
<urn:domeoclient:uuid:0ED7B264-E15A-44A2-9037-2D21B5180CD2>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:0ED7B264-E15A-44A2-9037-2D21B5180CD2> .
<urn:linkedspls:uuid:74BDDF82-70E1-44A8-B130-17D04DE86798>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:9692B313-0E4E-4D52-9D7C-456D2EE68F54>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:7E666CF4-DD19-4B4B-AE7B-EF4BCEA0181C>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"alleles = multiple copies?" .
<urn:linkedspls:uuid:51C4FEDD-5F25-4F57-92BC-5456BC2E4846>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:domeoclient:uuid:1B1E4FE2-11FA-4FB0-85F2-014750705FED>	<http://purl.org/pav/createdOn>	"2014-04-21 13:29:03 -0400" .
<urn:domeoclient:uuid:3665D7A9-FCD1-4278-8B7F-5EA5B3CC19D3>	<http://purl.org/pav/createdOn>	"2014-06-02 14:34:06 -0400" .
<urn:domeoclient:uuid:41CC62A5-5C3A-449F-B7A3-675F76FA4085>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:9CA1FBF8-5D9F-4C89-9F89-2BC4E3DB1BF5> .
<urn:domeoclient:uuid:9D01B1F5-3775-4CA3-BDFA-97BF6089AE2E>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:9D01B1F5-3775-4CA3-BDFA-97BF6089AE2E> .
<urn:linkedspls:uuid:EE534BB0-3042-44F4-9B63-01291E28FA45>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00564" .
<urn:linkedspls:uuid:F0F7787E-5F9C-47A4-86B2-D64F1B7602B6>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:linkedspls:uuid:81525CE9-0714-4D48-9149-6C8B8671E117>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MonitoringRecommendation>	"Recommended" .
<urn:linkedspls:uuid:75D456DC-1DB0-4F96-A11F-551CC8425889>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:9739D8D8-F16D-4FF9-BD63-1945B116EEC4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:3846BD3B-067C-4D62-AAA4-6A53131A2A2B>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:933C6C55-0C1F-4A1C-B72F-98683FD68184>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:A903F38F-38D4-4052-A673-7FF19407E3DB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:linkedspls:uuid:5239657F-5948-4803-B690-76D953D60764>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Discontinue/Do not restart" .
<urn:linkedspls:uuid:BDEED6AF-6C6D-44F0-8470-40D3A54778C5>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:ED9FC62F-6F5A-4AEC-B2EB-900F4C21E312>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:D3EDFFC9-9EE3-45DD-B147-801DAB72DF3D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Not Important" .
<urn:linkedspls:uuid:4D27D69B-2F63-4940-AD74-710454AA1E6A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:0B39F957-E88F-427C-AC41-F1B9DC711A02>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:linkedspls:uuid:1769615F-FAC0-4900-9DC6-5021630F8524>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"biomarker-level-high" .
<urn:linkedspls:uuid:BC70D092-5124-4A5C-87C3-EA34E4868C05>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Discontinue/Do not restart" .
<urn:linkedspls:uuid:3728C2D2-73B4-4F3A-A648-FD42247BA4EE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006120" .
<urn:linkedspls:uuid:169DB9DD-C966-431C-85FE-C3AC1F8E31D3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:domeoclient:uuid:5D85FB52-BA95-409A-8974-2E14C9527722>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:5D85FB52-BA95-409A-8974-2E14C9527722> .
<urn:linkedspls:uuid:108444AC-C8D7-42EE-A011-BE98A3F592F0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:231E14A4-5E1D-443C-B50C-8E3E00BBAF15>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:45EDCED8-9B43-464F-AC7F-898A9009649D> .
<urn:linkedspls:uuid:2185EE39-FD81-4C83-ABDF-E5D59B789F96>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:B30B41E3-5A67-4530-BC81-938E6B016FDF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:domeoclient:uuid:39A685C2-1AA3-415F-8F2F-3F82C6914A2D>	<http://www.w3.org/ns/oa#exact>	"WARNING: DEATH RELATED TO ULTRA-RAPID METABOLISM OF CODEINE TO MORPHINE\\nRespiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism." .
<urn:linkedspls:uuid:0961EB1D-39A9-4A01-9D9B-C2BC3222987E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:D3CF5A34-A1A9-4AFC-83F2-A5A1DD6DBB7F>	<http://purl.org/pav/createdOn>	"2014-06-30 13:16:49 -0400" .
<urn:linkedspls:uuid:4CFDD438-5250-4D24-9933-43397A6F2E0F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:DCF9A15D-3781-426E-B12E-C37A11772BAD>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:403ED560-E6D3-4B1C-BAF1-DD0E0D87AA3F> .
<urn:linkedspls:uuid:A3C1B92C-CBE0-4BA8-A41C-D3C3CD26FA51>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Azathioprine" .
<urn:linkedspls:uuid:53541A7F-ACF6-4030-A4B7-7BA865CDF82F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:8B74A738-1124-4DAC-BE25-F15C78CFBA15>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:9F45C51D-C093-4FEB-A57B-7D59EB1E01DA>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:domeoclient:uuid:BF8C1810-3B2F-446D-95FB-F6382AEE1DC0>	<http://www.w3.org/ns/oa#exact>	"Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine tablets." .
<urn:linkedspls:uuid:4C36F11A-E282-4BFB-849D-B93A233A50FB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:linkedspls:uuid:74BDDF82-70E1-44A8-B130-17D04DE86798>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"TPMT*2, TPMT*3A, TPMT*3C" .
<urn:domeoclient:uuid:3846BD3B-067C-4D62-AAA4-6A53131A2A2B>	<http://www.w3.org/ns/oa#exact>	"Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir." .
<urn:domeoclient:uuid:237CBF43-3113-4746-AC7C-0EEE2CD7D926>	<http://www.w3.org/ns/oa#exact>	"CNA106030 (PREDICT-1), a randomized, double-blind study, evaluated the clinical utility of prospective HLA-B*5701 screening on the incidence of abacavir hypersensitivity reaction in abacavir-naive HIV-1-infected adults (n\u00A0=\u00A01,650). In this study, use of pre-therapy screening for the HLA-B*5701 allele and exclusion of subjects with this allele reduced the incidence of clinically suspected abacavir hypersensitivity reactions from 7.8% (66/847) to 3.4% (27/803)." .
<urn:linkedspls:uuid:1DA28968-6C74-475E-AB4F-5E6E22DFF8BD>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Influences Drug Response" .
<urn:linkedspls:uuid:071CEC58-02E9-4DA2-8259-93E87A6EFD3B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2D6" .
<urn:linkedspls:uuid:9BD38C7E-B2D9-4C83-903C-F86556F46EF2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Letrozole" .
<urn:domeoclient:uuid:38CB7B79-EA55-443D-8F52-A694D541E5E3>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:38CB7B79-EA55-443D-8F52-A694D541E5E3> .
<urn:domeoclient:uuid:A753145C-8800-49A8-BE99-D558A1390DAE>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:4743B32B-A374-4701-B3BA-DD766AB522F6> .
<urn:linkedspls:uuid:461FDA58-8FAB-4951-B04A-F969D73C634D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:domeoclient:uuid:C692DA9C-1ECF-4A5B-867C-ABAF23492F10>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:AC5F1BAD-8B6A-49DB-8147-AB1394EC169F> .
<urn:domeoclient:uuid:D888391C-2CE3-4955-850C-C8FA6291737A>	<http://www.w3.org/ns/oa#exact>	"Citalopram steady state levels were not significantly different in poor metabolizers and extensive metabolizers of CYP2D6." .
<urn:domeoclient:uuid:DCF9A15D-3781-426E-B12E-C37A11772BAD>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:599459E0-8D98-4627-BC38-BA5B6BEC6B33> .
<urn:domeoclient:uuid:FE154A72-C1D3-4027-8C73-C71A948D0F52>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:FA0C425E-2A1E-4059-BAC2-34BD4239836F> .
<urn:domeoclient:uuid:E014618E-3373-4F61-BAF6-4ABD45885081>	<http://www.w3.org/ns/oa#exact>	"Screening for carriage of the HLA -B*5701 allele is recommended prior to initiating treatment with abacavir. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir." .
<urn:domeoclient:uuid:1042FEEA-5AF3-4E50-B2A1-053451F2236C>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:D5C1D543-12A2-4AD2-973F-CFDA436726C9> .
<urn:domeoclient:uuid:46A370D2-9D5B-4964-96D7-FECDB2FC0ED4>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:46A370D2-9D5B-4964-96D7-FECDB2FC0ED4> .
<urn:domeoclient:uuid:20FD83E0-8F9F-409B-BA60-7D4A2F8A54AF>	<http://www.w3.org/ns/oa#exact>	"Poor metabolizers treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function." .
<urn:linkedspls:uuid:9739D8D8-F16D-4FF9-BD63-1945B116EEC4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:42FA1C17-B780-423F-B993-EAF8D8DF0329>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:7B209F2D-47BE-4267-B895-92D67A47AE61>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:071CEC58-02E9-4DA2-8259-93E87A6EFD3B> .
<urn:domeoclient:uuid:CE483709-CD8C-4493-A2B7-8E589B98BF31>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:53B64B1F-739B-46F0-99EE-89EF4131A8D2> .
<urn:domeoclient:uuid:3C70DFC4-2BEA-46AE-A49C-D4BE3E7466B8>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:E17574BF-3BA6-48DA-B0DA-6E8DF716A03D> .
<urn:domeoclient:uuid:0D044EC4-5762-411E-A3D7-4BF4908C494F>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:4EEB4B8C-B4AE-42C6-9E9C-805907F3A548> .
<urn:linkedspls:uuid:BDEED6AF-6C6D-44F0-8470-40D3A54778C5>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:linkedspls:uuid:D26DCABA-C665-4147-A57B-F26195C0188E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER_receptor" .
<urn:linkedspls:uuid:D2A8C2D7-9A3E-4307-BC2B-4EA4FC30E8A5>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:1706E63C-45AC-467E-80FD-06108C69A93D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:29A5252E-79CA-41F6-BF34-26789C947F8D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:3467" .
<urn:linkedspls:uuid:FBEDA24D-50C7-407C-9337-9A08D9456999>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"FIX TABLE" .
<urn:domeoclient:uuid:8E738FB7-477C-4524-B024-29343F2936EA>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:domeoclient:uuid:56ECCD1C-D5DA-4A5F-A470-A96F404E1CB8>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:147B38AF-9E51-4D8A-B5CF-D7FAE7375257> .
<urn:domeoclient:uuid:C692DA9C-1ECF-4A5B-867C-ABAF23492F10>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:141D5512-1FE5-4684-BAA6-CA59DA362006> .
<urn:linkedspls:uuid:F0B7C43C-792D-49E5-B282-D2303F858889>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"FIX TABLE" .
<urn:linkedspls:uuid:2423954D-96B2-404E-8B04-9609825C795A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:B6570F9A-45F9-4786-BDA7-9D6B899F45DB>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:ED9FC62F-6F5A-4AEC-B2EB-900F4C21E312>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00564" .
<urn:domeoclient:uuid:55ED86AA-B414-4220-94FD-868AFE2D1278>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:9C2B48AD-A4E0-4C6C-9246-E6FD6CF712C8> .
<urn:linkedspls:uuid:A3C1B92C-CBE0-4BA8-A41C-D3C3CD26FA51>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00993" .
<urn:domeoclient:uuid:D640727D-6442-4274-B453-64F04BD595E3>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:0961EB1D-39A9-4A01-9D9B-C2BC3222987E> .
<urn:domeoclient:uuid:44BBF444-A1D4-4182-8B05-775BFFCA0DF4>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:F1F72593-1500-4B06-AE14-AE29B3EAE9B1> .
<urn:linkedspls:uuid:75D988CE-7527-421D-AAA6-0C9C0D4B30DF>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:52601F35-C2AB-4602-BD13-6B9999A0266A>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:linkedspls:uuid:75D456DC-1DB0-4F96-A11F-551CC8425889>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:domeoclient:uuid:79AEDAF0-0AC0-4A44-9F6D-05B14ECEF74F>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:E014618E-3373-4F61-BAF6-4ABD45885081> .
<urn:domeoclient:uuid:3665D7A9-FCD1-4278-8B7F-5EA5B3CC19D3>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:7E666CF4-DD19-4B4B-AE7B-EF4BCEA0181C> .
<urn:domeoclient:uuid:EE521BAD-75B0-418A-A885-F72D473E4567>	<http://purl.org/pav/createdOn>	"2014-06-30 13:25:13 -0400" .
<urn:domeoclient:uuid:9992ADBC-4BAB-4529-BAC4-9D7AFD34F098>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:5239657F-5948-4803-B690-76D953D60764> .
<urn:linkedspls:uuid:FEF94E24-725D-433B-8F55-9E75E14CECB9>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006121" .
<urn:linkedspls:uuid:A48D46C7-8F7E-4426-8C3D-CCA08F946DB0>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:43CE071E-85A3-4BC0-AEAC-4FC4DCBB3D02>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:31115D88-2436-4D8C-B5E2-A7636A9DA498> .
<urn:linkedspls:uuid:B9375CD1-7E67-42D6-B380-D95AD08BF64B>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MonitoringRecommendation>	"Change monitoring strategy" .
<urn:linkedspls:uuid:45EDCED8-9B43-464F-AC7F-898A9009649D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Azathioprine" .
<urn:linkedspls:uuid:C904A0A3-252D-4872-B966-44B63E18E430>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:domeoclient:uuid:7084C584-8C84-42A3-AFAB-F66F243A2817>	<http://purl.org/pav/createdOn>	"2014-06-30 13:01:21 -0400" .
<urn:domeoclient:uuid:C24DFA02-2096-4634-974B-1866183BFD0B>	<http://purl.org/pav/createdOn>	"2014-06-30 13:22:29 -0400" .
<urn:linkedspls:uuid:68B37481-F382-41B9-AEF5-DB241FA9325F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006121" .
<urn:linkedspls:uuid:D1D85749-709E-4FD8-A464-C8E7CD8158BB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:linkedspls:uuid:56D95EC4-D0D7-4BD6-B13C-E145F6A4E568>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:53541A7F-ACF6-4030-A4B7-7BA865CDF82F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:C904A0A3-252D-4872-B966-44B63E18E430>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:domeoclient:uuid:7084C584-8C84-42A3-AFAB-F66F243A2817>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:8E738FB7-477C-4524-B024-29343F2936EA> .
<urn:linkedspls:uuid:74BDDF82-70E1-44A8-B130-17D04DE86798>	<http://semanticscience.org/resource/SIO_000111>	"34075-2 LABORATORY TESTS SECTION" .
<urn:domeoclient:uuid:0D044EC4-5762-411E-A3D7-4BF4908C494F>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:7CE2D02E-F446-465D-9CBE-27C213ACCC89> .
<urn:linkedspls:uuid:9692B313-0E4E-4D52-9D7C-456D2EE68F54>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:domeoclient:uuid:2BEFD527-0C92-4B61-A2B9-12F931EDC707>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:2BEFD527-0C92-4B61-A2B9-12F931EDC707> .
<urn:linkedspls:uuid:3728C2D2-73B4-4F3A-A648-FD42247BA4EE>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Influences Drug Response" .
<urn:domeoclient:uuid:232C5C6E-F6FE-44B8-AE5A-7E1BD427D626>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:DB8F110F-7415-4B13-AB5B-23F1D7A1C6BF> .
<urn:domeoclient:uuid:55ED86AA-B414-4220-94FD-868AFE2D1278>	<http://purl.org/pav/createdOn>	"2014-06-30 13:03:17 -0400" .
<urn:domeoclient:uuid:43CE071E-85A3-4BC0-AEAC-4FC4DCBB3D02>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:14BA7077-8D33-42DD-A380-DD27F50087AD> .
<urn:linkedspls:uuid:108444AC-C8D7-42EE-A011-BE98A3F592F0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:4663B6D5-B11D-4039-8F32-F7E3BFC2537E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:CE1DC1EA-085A-4CF9-8165-5A14A411A633>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:30201CA6-94D8-4A83-9451-AF1497A97E75> .
<urn:linkedspls:uuid:7AE1124F-F104-4EB3-9415-257F81B2E3CE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:3846BD3B-067C-4D62-AAA4-6A53131A2A2B>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:3846BD3B-067C-4D62-AAA4-6A53131A2A2B> .
<urn:domeoclient:uuid:9E9B14EC-233F-4ABE-B627-6150C0C5A5A4>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:27F9E2A8-C54A-4F87-A02D-4F8EFF5D382F> .
<urn:linkedspls:uuid:21B282F1-F0CA-488A-B703-88611F099D16>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:0961EB1D-39A9-4A01-9D9B-C2BC3222987E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:763ABA1D-A316-42DE-AA02-A7123411CD6C>	<http://semanticscience.org/resource/SIO_000111>	"43679-0 MECHANISM OF ACTION SECTION" .
<urn:domeoclient:uuid:201331AB-54CD-4BE2-81C9-806CCB6E5915>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:201331AB-54CD-4BE2-81C9-806CCB6E5915> .
<urn:linkedspls:uuid:933C6C55-0C1F-4A1C-B72F-98683FD68184>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:linkedspls:uuid:194FD718-B3CA-4D25-B3D2-56D36C1ECB60>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"VKORC1" .
<urn:domeoclient:uuid:7FD03E69-B442-41B6-B8EB-38BD572E8F45>	<http://www.w3.org/ns/oa#exact>	"Treatment of breast cancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive or receptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy, adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents). These interventions lead to decreased tumor mass or delayed progression of tumor growth in some women." .
<urn:domeoclient:uuid:CDE45635-21AB-4AC7-89FF-C772F3A15A2C>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:2D0B9A22-6129-4786-B0A4-7384B3324DF0> .
<urn:domeoclient:uuid:0ED7B264-E15A-44A2-9037-2D21B5180CD2>	<http://www.w3.org/ns/oa#exact>	"If the patient is of unknown HLA-B*5701 status, screening for the allele is recommended prior to reinitiation of ZIAGEN." .
<urn:linkedspls:uuid:75C4424E-2C9D-40D9-82CF-7E02CFDCA301>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:linkedspls:uuid:FEF94E24-725D-433B-8F55-9E75E14CECB9>	<http://semanticscience.org/resource/SIO_000111>	"43685-7 WARNINGS AND PRECAUTIONS SECTION" .
<urn:domeoclient:uuid:CA417E62-D7D9-4F45-8359-10CCF8D13F90>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:2446A882-2020-42F8-AD24-FE3B4F839958> .
<urn:domeoclient:uuid:C89E80EC-0820-406B-99C8-D495EC5F054E>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:39A685C2-1AA3-415F-8F2F-3F82C6914A2D> .
<urn:domeoclient:uuid:10B1EB06-38FD-41C2-A3B7-625B2825B889>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02" .
<urn:linkedspls:uuid:4777BC06-68FA-4171-A52D-68668AD25547>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:36FDCB4E-5E54-4CBA-BC44-04B836C019F0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:8BDFDC96-47AF-489E-8F96-DF9B26C6ECBE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2621" .
<urn:domeoclient:uuid:55544593-2536-44D4-B561-50DB89250F52>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:55544593-2536-44D4-B561-50DB89250F52> .
<urn:domeoclient:uuid:99AB6350-6929-4C24-B144-7B97EBF09B3F>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:6347DAEC-6E58-45D7-9A9D-16BE602F4930> .
<urn:domeoclient:uuid:60CFE292-6834-41FC-8255-B81A3D584EE2>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:232C5C6E-F6FE-44B8-AE5A-7E1BD427D626>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:0B3E23EF-1696-4FF7-BEEB-8158BDA84294> .
<urn:domeoclient:uuid:D32E2B19-3891-4F8B-98F3-B65344B0F6A8>	<http://www.w3.org/ns/oa#exact>	" Identification of risk factors for bleeding and certain genetic variations in CYP2C9 and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses " .
<urn:domeoclient:uuid:C6988919-6455-4291-92FF-E4F63DF9F9BF>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:C6988919-6455-4291-92FF-E4F63DF9F9BF> .
<urn:linkedspls:uuid:BF7AF633-8B36-41BF-AC4F-0BA548A0DB2F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:linkedspls:uuid:43B85AB2-533A-4A3B-932F-7CD7177449ED>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:0A10CE73-592A-4D92-84AF-63395C43C0F9>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02" .
<urn:linkedspls:uuid:75D988CE-7527-421D-AAA6-0C9C0D4B30DF>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"Add test result" .
<urn:domeoclient:uuid:A6AED276-0422-482B-8802-87BDABE2C035>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:745C184B-12B3-435F-99C5-252556EB53B9> .
<urn:linkedspls:uuid:21B282F1-F0CA-488A-B703-88611F099D16>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:linkedspls:uuid:B24A699D-7127-47C1-BFAE-C1ABB6819E2F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:028082D6-59BF-44E8-9117-CC155DA8D008>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:3746E014-4500-4C39-A007-7B912571A900>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:3467" .
<urn:linkedspls:uuid:D64C9075-1FB5-47EA-9312-70A065865D71>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00993" .
<urn:linkedspls:uuid:84646AA6-8E85-4656-8515-E49CB15EADB4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2D6" .
<urn:domeoclient:uuid:55ED86AA-B414-4220-94FD-868AFE2D1278>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:461FDA58-8FAB-4951-B04A-F969D73C634D> .
<urn:domeoclient:uuid:86565D69-8F9C-4519-9A52-CD2A2980DEE3>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:9C09D2F8-83BE-446D-A17A-75402666EE4B> .
<urn:linkedspls:uuid:C2A76A18-A463-4D7B-9A00-33BEFE84F768>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:9837A225-376D-44A6-959D-05A7DCB03CCE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2D6" .
<urn:domeoclient:uuid:8B74A738-1124-4DAC-BE25-F15C78CFBA15>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:8B74A738-1124-4DAC-BE25-F15C78CFBA15> .
<urn:linkedspls:uuid:74EA2B44-40D9-44F0-90BA-33EFF2D1B5AA>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:4DD1AE8C-CB2C-4887-993E-A8A44B2A06CB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Azathioprine" .
<urn:linkedspls:uuid:4CFDD438-5250-4D24-9933-43397A6F2E0F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:domeoclient:uuid:216A1896-63FD-45FE-ACBB-80F82EB9ACE5>	<http://www.w3.org/ns/oa#exact>	"HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients." .
<urn:domeoclient:uuid:91050818-2692-4B82-B3D8-A52A364F00D7>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:84646AA6-8E85-4656-8515-E49CB15EADB4> .
<urn:domeoclient:uuid:5CCA20AA-4D3C-40F4-BAED-C832E665FA35>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:8026784E-DC9A-4F18-963D-495E0532BB97> .
<urn:linkedspls:uuid:F9A68240-FAD6-4604-8DEE-1B0E4AF9BD21>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Discontinue/Do not restart" .
<urn:linkedspls:uuid:CE76789E-AB5D-4F50-AF22-F3C2D4249992>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:3467" .
<urn:linkedspls:uuid:2CE69763-0812-4DFF-A359-2A8D8FF706AD>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MonitoringRecommendation>	"Recommended" .
<urn:linkedspls:uuid:9DCD19CE-D636-45D6-B994-A9BDBCA32621>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:9C843591-806D-42E0-88A9-58DC59076B3D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER_receptor" .
<urn:linkedspls:uuid:09071EE6-03DB-49CA-BA67-1589B0E2FDBD>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"biomarker-positive" .
<urn:domeoclient:uuid:910F9AE9-8398-400D-8505-D971512A67C6>	<http://www.w3.org/ns/oa#exact>	"Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir." .
<urn:linkedspls:uuid:FBD3A076-17BF-416E-9EEC-89C39FD558A3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:F880CCED-A2A0-4330-B02F-070F7BF5AF00>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:F2C1F1F7-17ED-4AE1-91F9-3A2EE9802A65> .
<urn:linkedspls:uuid:461FDA58-8FAB-4951-B04A-F969D73C634D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2623" .
<urn:linkedspls:uuid:7E666CF4-DD19-4B4B-AE7B-EF4BCEA0181C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:E06F2653-44AD-435F-AB2C-133712B039A6>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:domeoclient:uuid:9DDE5A30-59ED-49D7-B9B6-316245562477>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:20FD83E0-8F9F-409B-BA60-7D4A2F8A54AF> .
<urn:domeoclient:uuid:23FACDDB-003E-40B5-AB79-B52F5FD124B3>	<http://purl.org/pav/createdOn>	"2014-06-09 15:55:39 -0400" .
<urn:linkedspls:uuid:E17574BF-3BA6-48DA-B0DA-6E8DF716A03D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:domeoclient:uuid:CE483709-CD8C-4493-A2B7-8E589B98BF31>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:E03CFE71-0FEF-4840-A587-1D360CBF035C> .
<urn:domeoclient:uuid:87228117-6F6A-41A0-9709-5D0977E83A06>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd" .
<urn:linkedspls:uuid:9837A225-376D-44A6-959D-05A7DCB03CCE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006121" .
<urn:domeoclient:uuid:B6570F9A-45F9-4786-BDA7-9D6B899F45DB>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:B6570F9A-45F9-4786-BDA7-9D6B899F45DB> .
<urn:linkedspls:uuid:4D27D69B-2F63-4940-AD74-710454AA1E6A>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:linkedspls:uuid:AC5F1BAD-8B6A-49DB-8147-AB1394EC169F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:domeoclient:uuid:88C2CEB5-469C-451E-8436-788ABE4338F5>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:1F2D1F90-DA97-42FE-836C-EBF3BAC56349> .
<urn:linkedspls:uuid:92FA8990-60EF-4140-9F60-C12E57E3B114>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:4CFDD438-5250-4D24-9933-43397A6F2E0F>	<http://semanticscience.org/resource/SIO_000111>	"BOXED WARNING (34066-1)" .
<urn:linkedspls:uuid:F0F7787E-5F9C-47A4-86B2-D64F1B7602B6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C9" .
<urn:linkedspls:uuid:F9A68240-FAD6-4604-8DEE-1B0E4AF9BD21>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:13F3B206-EA87-463E-9DA8-93AA056A9117>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:A903F38F-38D4-4052-A673-7FF19407E3DB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:CDE45635-21AB-4AC7-89FF-C772F3A15A2C>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:2185EE39-FD81-4C83-ABDF-E5D59B789F96> .
<urn:linkedspls:uuid:FEF94E24-725D-433B-8F55-9E75E14CECB9>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00318" .
<urn:linkedspls:uuid:53B64B1F-739B-46F0-99EE-89EF4131A8D2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:9F45C51D-C093-4FEB-A57B-7D59EB1E01DA>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:232C5C6E-F6FE-44B8-AE5A-7E1BD427D626>	<http://purl.org/pav/createdOn>	"2014-06-30 13:06:13 -0400" .
<urn:domeoclient:uuid:3CB531B1-A267-4A03-A0C5-D852AB638802>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:1D33EB0C-A03D-481F-991D-B71848865C38> .
<urn:domeoclient:uuid:29951346-424F-4492-B79A-EF5022CB7F05>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd" .
<urn:linkedspls:uuid:24265221-E0B1-4F13-A2EB-0E9D9DC6F5D4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER_receptor" .
<urn:linkedspls:uuid:FE990D63-4739-43A5-B062-7A946346B2AF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:94B53E9F-5329-43D3-AD42-03C430F6E877>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00993" .
<urn:linkedspls:uuid:2CE69763-0812-4DFF-A359-2A8D8FF706AD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:3D5D3473-95BD-41AF-81E6-ED19E81798E9>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:BC70D092-5124-4A5C-87C3-EA34E4868C05> .
<urn:linkedspls:uuid:BCCF3F22-38AE-4F01-87D0-22C1B07EC947>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:1706E63C-45AC-467E-80FD-06108C69A93D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Azathioprine" .
<urn:linkedspls:uuid:45844BA9-29ED-4EC6-94C0-81C9883F880F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:domeoclient:uuid:29951346-424F-4492-B79A-EF5022CB7F05>	<http://www.w3.org/ns/oa#exact>	"TPMT activity is controlled by a genetic polymorphism.1, 2, 3 For Caucasians and African Americans, approximately 10% of the population inherit one non-functional TPMT allele (heterozygous) conferring intermediate TPMT activity, and 0.3% inherit two TPMT non-functional alleles (homozygous) for low or absent TPMT activity. Non-functional alleles are less common in Asians. " .
<urn:domeoclient:uuid:94F5EFA2-DEF5-444E-B4C2-7268B36AF650>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:94F5EFA2-DEF5-444E-B4C2-7268B36AF650> .
<urn:linkedspls:uuid:2423954D-96B2-404E-8B04-9609825C795A>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:linkedspls:uuid:5E02C5AB-C35D-4ACA-8EF0-DF0F481E6A00>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*1502 " .
<urn:linkedspls:uuid:3A77F5FE-EF65-4FF1-9BCD-E358D4D5BC82>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00993" .
<urn:domeoclient:uuid:D888391C-2CE3-4955-850C-C8FA6291737A>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:D888391C-2CE3-4955-850C-C8FA6291737A> .
<urn:linkedspls:uuid:0B3E23EF-1696-4FF7-BEEB-8158BDA84294>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:linkedspls:uuid:F0F7787E-5F9C-47A4-86B2-D64F1B7602B6>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"CYP2C9*2 " .
<urn:linkedspls:uuid:3616601B-9F53-4ECD-985B-8205444D8F7C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:3467" .
<urn:linkedspls:uuid:44E81086-BA17-4D23-BE19-3D545D7F1B9D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:61B14255-647D-4AA2-83E5-B81256BF7A50>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Clopidogrel" .
<urn:linkedspls:uuid:3A77F5FE-EF65-4FF1-9BCD-E358D4D5BC82>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:linkedspls:uuid:4DD1AE8C-CB2C-4887-993E-A8A44B2A06CB>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"one non-functional allele (heterozygous)" .
<urn:linkedspls:uuid:0D634683-D28C-42DC-9911-DFD0C9EB289D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:68B37481-F382-41B9-AEF5-DB241FA9325F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00318" .
<urn:domeoclient:uuid:201331AB-54CD-4BE2-81C9-806CCB6E5915>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:domeoclient:uuid:ECE9E8AD-BAEE-4FC0-A880-67D03D8D2EED>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:36D17D73-1169-4131-94F5-24AFD369088A>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:9A5666BB-F43D-45F3-A856-0BDB0E745589> .
<urn:domeoclient:uuid:3665D7A9-FCD1-4278-8B7F-5EA5B3CC19D3>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:8A35BACC-77B7-4822-A677-4D72A3B91942> .
<urn:domeoclient:uuid:8CD7F86F-C041-47B7-B7D2-F7B48F523F56>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:5D87AC20-773F-4241-AA52-57BF86A4A93A> .
<urn:linkedspls:uuid:9A15D029-5B02-4107-A829-E2BD1B1219FE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Clopidogrel" .
<urn:linkedspls:uuid:70BE7DEB-6A8B-41E9-9333-F1F47AC7E1A0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:0D634683-D28C-42DC-9911-DFD0C9EB289D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:linkedspls:uuid:945EB72E-5C75-41B0-B8FC-637E1EF0AE7D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:27F9E2A8-C54A-4F87-A02D-4F8EFF5D382F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"add drop down choice to tests" .
<urn:linkedspls:uuid:75D988CE-7527-421D-AAA6-0C9C0D4B30DF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Azathioprine" .
<urn:linkedspls:uuid:905B00B5-CD9F-4F5A-BDCD-2E0771AC9B73>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:8BEEBA62-C519-4421-9038-113DCDFC9B2C>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:27F9E2A8-C54A-4F87-A02D-4F8EFF5D382F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Azathioprine" .
<urn:linkedspls:uuid:0BEDE64D-11D3-4746-9532-E747F6A427E0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:domeoclient:uuid:0E9FF6AD-98CE-4932-AD5D-E657F3B363B3>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:9739D8D8-F16D-4FF9-BD63-1945B116EEC4> .
<urn:domeoclient:uuid:38655F0E-DB25-4C1E-A99A-7E2B18134930>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:F3C6E27C-CBBA-4B36-810C-D42C3FA4AB93> .
<urn:domeoclient:uuid:38655F0E-DB25-4C1E-A99A-7E2B18134930>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:F9A68240-FAD6-4604-8DEE-1B0E4AF9BD21> .
<urn:linkedspls:uuid:68B37481-F382-41B9-AEF5-DB241FA9325F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2D6" .
<urn:domeoclient:uuid:A74CD0BB-2B56-45FC-B50D-C7952B9C9AE4>	<http://www.w3.org/ns/oa#exact>	"Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine." .
<urn:linkedspls:uuid:6E680A49-5B91-4058-A09E-25A6ED988EFC>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Azathioprine" .
<urn:linkedspls:uuid:75C4424E-2C9D-40D9-82CF-7E02CFDCA301>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:linkedspls:uuid:4CFDD438-5250-4D24-9933-43397A6F2E0F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"Need an option for discontinue" .
<urn:linkedspls:uuid:9692B313-0E4E-4D52-9D7C-456D2EE68F54>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:linkedspls:uuid:151DFA13-B2DF-4857-AAE9-51CADEC9A12F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C9" .
<urn:domeoclient:uuid:A74CD0BB-2B56-45FC-B50D-C7952B9C9AE4>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:A74CD0BB-2B56-45FC-B50D-C7952B9C9AE4> .
<urn:linkedspls:uuid:EF919E4C-C0B0-4D8B-A273-2F4A806A828D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"biomarker-positive" .
<urn:linkedspls:uuid:31115D88-2436-4D8C-B5E2-A7636A9DA498>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:3467" .
<urn:linkedspls:uuid:F270E3B3-9983-425D-98FB-66F62E36340F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:8D91E7D5-B379-4649-9834-0D01A948DFF8>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:6F41EB64-7E4B-4DAA-86FE-348F6836D46E> .
<urn:domeoclient:uuid:23FACDDB-003E-40B5-AB79-B52F5FD124B3>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:8431F83B-801B-499C-A34F-25B983A4B198> .
<urn:linkedspls:uuid:D939C426-7E0B-4A32-80F1-7344D702AA97>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"poor-metabolizer-positive" .
<urn:domeoclient:uuid:60281E0C-D291-4163-9B6F-E83A4142CB8E>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:72D8F9E8-4B4D-4FC2-81A2-A19C5BF05098> .
<urn:domeoclient:uuid:CA417E62-D7D9-4F45-8359-10CCF8D13F90>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:EBA440A2-4EF9-40CD-89BF-56AB858385E6> .
<urn:linkedspls:uuid:2510C893-9155-453B-922C-CF116136DD88>	<http://semanticscience.org/resource/SIO_000111>	"34073-7 DRUG INTERACTIONS SECTION" .
<urn:linkedspls:uuid:CE3D1055-4EAF-4F2F-A2ED-AA9B95C45024>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:FEF94E24-725D-433B-8F55-9E75E14CECB9>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2D6" .
<urn:linkedspls:uuid:2446A882-2020-42F8-AD24-FE3B4F839958>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000017303" .
<urn:domeoclient:uuid:91050818-2692-4B82-B3D8-A52A364F00D7>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:DF1A2A13-1CD9-47EC-A75C-192353959653> .
<urn:domeoclient:uuid:3C70DFC4-2BEA-46AE-A49C-D4BE3E7466B8>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:1FCB6C74-C406-41C1-8A44-C9D033D5834C> .
<urn:linkedspls:uuid:94B53E9F-5329-43D3-AD42-03C430F6E877>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:12014" .
<urn:linkedspls:uuid:A24FCBC0-9830-43DC-87D5-5716D3136B02>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01238" .
<urn:domeoclient:uuid:3419ECAE-A4FF-4BE4-8679-16B52BA748AC>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:74BB3F3E-AD24-438C-9250-4357E959069E> .
<urn:domeoclient:uuid:AC31138E-D96E-46FA-AD16-E8C5C6855989>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:87228117-6F6A-41A0-9709-5D0977E83A06> .
<urn:linkedspls:uuid:402D9368-C611-4289-8004-8EEC1A409CCF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:D66FA8C3-8BAB-4A6F-8234-6DD134876578>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:563CB9E8-A4E7-43EF-9686-1F5B71F4169D>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:563CB9E8-A4E7-43EF-9686-1F5B71F4169D> .
<urn:linkedspls:uuid:75D456DC-1DB0-4F96-A11F-551CC8425889>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:domeoclient:uuid:EBA440A2-4EF9-40CD-89BF-56AB858385E6>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:linkedspls:uuid:5239657F-5948-4803-B690-76D953D60764>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:8B036858-70F5-4077-8333-F34F19A042EC>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:5BA0362C-1EF8-4647-8A30-017F5378F48F> .
<urn:domeoclient:uuid:408C86B9-FFBA-4A7F-A6EC-ECD348FD4782>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:F0BBC254-D123-49BE-A254-67148370DC96> .
<urn:domeoclient:uuid:F7D9EE5F-E5C0-4296-9825-534C2F768855>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02" .
<urn:linkedspls:uuid:74BB3F3E-AD24-438C-9250-4357E959069E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:407F8565-3B9C-4CF8-B785-C8286BCD86A2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2623" .
<urn:domeoclient:uuid:C37B19E6-A2FE-4CF4-9914-61A4EF8E7827>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:216A1896-63FD-45FE-ACBB-80F82EB9ACE5> .
<urn:linkedspls:uuid:2446A882-2020-42F8-AD24-FE3B4F839958>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"VKORC1-1639G>A" .
<urn:domeoclient:uuid:79AEDAF0-0AC0-4A44-9F6D-05B14ECEF74F>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:9F45C51D-C093-4FEB-A57B-7D59EB1E01DA> .
<urn:linkedspls:uuid:BC70D092-5124-4A5C-87C3-EA34E4868C05>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:375DD3AE-F16E-43E9-BB3E-D521613E10AF>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:375DD3AE-F16E-43E9-BB3E-D521613E10AF> .
<urn:linkedspls:uuid:6E680A49-5B91-4058-A09E-25A6ED988EFC>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#VariantFrequency>	"Variant Frequency" .
<urn:domeoclient:uuid:136CA05A-B32D-4CAF-B985-0FB9EF4F0455>	<http://www.w3.org/ns/oa#exact>	"Tamoxifen citrate tablets are a prescription medicine that is like estrogen (female hormone) in some ways and different in other ways. In the breast, tamoxifen can block estrogen's effects. Because it does this, tamoxifen may block the growth of breast cancers that need estrogen to grow (cancers that are estrogen- or progesterone-receptor positive)." .
<urn:linkedspls:uuid:25348450-1CCF-4BEC-84EF-0EA92F67DD3A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:09071EE6-03DB-49CA-BA67-1589B0E2FDBD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Letrozole" .
<urn:linkedspls:uuid:905B00B5-CD9F-4F5A-BDCD-2E0771AC9B73>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Discontinue/Do not restart" .
<urn:domeoclient:uuid:D640727D-6442-4274-B453-64F04BD595E3>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:9982EFEC-057D-47A7-8241-37ACB3F049AA> .
<urn:domeoclient:uuid:C37B19E6-A2FE-4CF4-9914-61A4EF8E7827>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:96D6F8F1-F51A-4EBC-BFF7-C799690B4401> .
<urn:domeoclient:uuid:5CCA20AA-4D3C-40F4-BAED-C832E665FA35>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:A8189564-74C8-463F-9927-917478975C75> .
<urn:domeoclient:uuid:7FA5409D-3EA5-4F92-B738-8577DCEB4D97>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:4B11E300-2DF5-4B21-9D43-4D0A02109A59> .
<urn:linkedspls:uuid:D3EDFFC9-9EE3-45DD-B147-801DAB72DF3D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2D6" .
<urn:domeoclient:uuid:55700EE9-88B8-49B7-BD64-1A87D99DCC15>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:151DFA13-B2DF-4857-AAE9-51CADEC9A12F> .
<urn:linkedspls:uuid:8C44EE5A-5A11-4743-B389-617115FC82BB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:1D33EB0C-A03D-481F-991D-B71848865C38>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd" .
<urn:linkedspls:uuid:BF7AF633-8B36-41BF-AC4F-0BA548A0DB2F>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:linkedspls:uuid:31115D88-2436-4D8C-B5E2-A7636A9DA498>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:domeoclient:uuid:C1908624-6F0B-47BD-8D70-8EACD877F4A9>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:C1908624-6F0B-47BD-8D70-8EACD877F4A9> .
<urn:linkedspls:uuid:9837A225-376D-44A6-959D-05A7DCB03CCE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00318" .
<urn:linkedspls:uuid:D64C9075-1FB5-47EA-9312-70A065865D71>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:12014" .
<urn:linkedspls:uuid:8C0132CB-1BA7-4320-8C5F-E55761BC596E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:3467" .
<urn:linkedspls:uuid:055AAAC1-3544-4B8E-BF06-C99328A12B6E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Recommend" .
<urn:domeoclient:uuid:A1F7627F-2636-46AA-A344-F9978C2AA71C>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:linkedspls:uuid:4B11E300-2DF5-4B21-9D43-4D0A02109A59>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:FB3C226D-314F-473A-AA0D-98DCD192D7AF>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:239D0F43-DA9B-4ED8-A683-6BF29DB82241> .
<urn:linkedspls:uuid:81525CE9-0714-4D48-9149-6C8B8671E117>	<http://semanticscience.org/resource/SIO_000111>	"43685-7 WARNINGS AND PRECAUTIONS SECTION" .
<urn:domeoclient:uuid:90768224-544A-41CF-9969-E08884F1434D>	<http://purl.org/pav/createdOn>	"2014-04-28 15:51:09 -0400" .
<urn:linkedspls:uuid:D26DCABA-C665-4147-A57B-F26195C0188E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"biomarker-positive" .
<urn:domeoclient:uuid:C7EAEB14-8213-4EF8-AC67-469D0609826B>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:C7EAEB14-8213-4EF8-AC67-469D0609826B> .
<urn:domeoclient:uuid:3D5D3473-95BD-41AF-81E6-ED19E81798E9>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:6E7BEB44-17B2-4A01-8866-7DAFBEA17CC6> .
<urn:linkedspls:uuid:52601F35-C2AB-4602-BD13-6B9999A0266A>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:linkedspls:uuid:BCCF3F22-38AE-4F01-87D0-22C1B07EC947>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Do not restart" .
<urn:domeoclient:uuid:C1908624-6F0B-47BD-8D70-8EACD877F4A9>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:domeoclient:uuid:A1F7627F-2636-46AA-A344-F9978C2AA71C>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:A1F7627F-2636-46AA-A344-F9978C2AA71C> .
<urn:linkedspls:uuid:5D87AC20-773F-4241-AA52-57BF86A4A93A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:9258FFBC-DCDC-4C6C-A375-9FC03C323B54>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00993" .
<urn:domeoclient:uuid:BBD1EA14-A142-47FF-A3B5-D848FFAED44F>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:BBD1EA14-A142-47FF-A3B5-D848FFAED44F> .
<urn:domeoclient:uuid:78CB3193-D01C-49AA-B39B-C35887919EED>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:domeoclient:uuid:0E9FF6AD-98CE-4932-AD5D-E657F3B363B3>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:45B95464-0287-435F-86B4-0253D73E6DA8> .
<urn:domeoclient:uuid:C427075F-5339-47EB-A313-AA6B94EB8753>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd" .
<urn:domeoclient:uuid:4743B32B-A374-4701-B3BA-DD766AB522F6>	<http://www.w3.org/ns/oa#exact>	"Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction." .
<urn:linkedspls:uuid:44A37F21-E420-40D5-A9E0-5CEDEFAEF40B>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Take note that tests are avaliable" .
<urn:domeoclient:uuid:8525CDF6-1EFA-4AA5-BD43-C9DDE92E0196>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:F7D9EE5F-E5C0-4296-9825-534C2F768855> .
<urn:linkedspls:uuid:FBEDA24D-50C7-407C-9337-9A08D9456999>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2623" .
<urn:domeoclient:uuid:9DDE5A30-59ED-49D7-B9B6-316245562477>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:B7B25E99-EE57-41AC-BDE2-45DCC1447471> .
<urn:linkedspls:uuid:F9A68240-FAD6-4604-8DEE-1B0E4AF9BD21>	<http://semanticscience.org/resource/SIO_000111>	"34075-2 LABORATORY TESTS SECTION" .
<urn:linkedspls:uuid:CE76789E-AB5D-4F50-AF22-F3C2D4249992>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER_receptor" .
<urn:domeoclient:uuid:86565D69-8F9C-4519-9A52-CD2A2980DEE3>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:D9543430-9668-4C09-8709-B8D20B095EEA> .
<urn:linkedspls:uuid:BCCF3F22-38AE-4F01-87D0-22C1B07EC947>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:domeoclient:uuid:942AE26F-116C-4165-9118-723E840DFB17>	<http://purl.org/pav/createdOn>	"2014-04-28 15:43:59 -0400" .
<urn:linkedspls:uuid:CD7BE61C-D111-48EB-A232-1241D41AB8BC>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:AC5F1BAD-8B6A-49DB-8147-AB1394EC169F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:domeoclient:uuid:F30A3592-1EDA-414B-8C7B-2B931B766619>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:domeoclient:uuid:36D17D73-1169-4131-94F5-24AFD369088A>	<http://purl.org/pav/createdOn>	"2014-04-21 13:08:32 -0400" .
<urn:domeoclient:uuid:F10FC0DB-5D49-46E9-A2C2-3CFFC5FBF692>	<http://purl.org/pav/createdOn>	"2014-06-30 13:02:40 -0400" .
<urn:linkedspls:uuid:4B11E300-2DF5-4B21-9D43-4D0A02109A59>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Recommend" .
<urn:domeoclient:uuid:DBCD24FF-6ABB-4810-A5CA-DF8F85FF2241>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:10D9A112-25CB-425E-899B-C3AAA3CF633A>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:10D9A112-25CB-425E-899B-C3AAA3CF633A> .
<urn:linkedspls:uuid:055AAAC1-3544-4B8E-BF06-C99328A12B6E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:8525CDF6-1EFA-4AA5-BD43-C9DDE92E0196>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:E719DBCC-60BF-47C9-A2A6-B5AD564ED472> .
<urn:linkedspls:uuid:6F731CE1-E6B4-41AA-98C6-30C94B771E61>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:linkedspls:uuid:09071EE6-03DB-49CA-BA67-1589B0E2FDBD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01006" .
<urn:domeoclient:uuid:9E9B14EC-233F-4ABE-B627-6150C0C5A5A4>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:878D746A-3252-462C-AA1E-A857E2FC63AF> .
<urn:linkedspls:uuid:461FDA58-8FAB-4951-B04A-F969D73C634D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:domeoclient:uuid:AF427FC6-54B8-4CA4-9C51-233E64726500>	<http://www.w3.org/ns/oa#exact>	"An anastrozole adjuvant trial was conducted in 9,366 postmenopausal women with operable breast cancer who were randomized to receive adjuvant treatment with either anastrozole 1 mg daily, tamoxifen 20 mg daily, or a combination of these two treatments for 5 years or until recurrence of the disease. At a median follow-up of 33 months, the combination of anastrozole and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen therapy alone in all patients as well as in the hormone receptor positive subpopulation. This treatment arm was discontinued from the trial." .
<urn:linkedspls:uuid:D66FA8C3-8BAB-4A6F-8234-6DD134876578>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:domeoclient:uuid:99AB6350-6929-4C24-B144-7B97EBF09B3F>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:F270E3B3-9983-425D-98FB-66F62E36340F> .
<urn:domeoclient:uuid:4F5C1D0C-9AFC-4B3A-83EC-AC9CB72FB0C9>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:5B91F78A-EEB0-41A3-8995-90B920D09520> .
<urn:domeoclient:uuid:55700EE9-88B8-49B7-BD64-1A87D99DCC15>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:61BA8ACB-D63A-46FF-8B5D-79E9326A61A3> .
<urn:domeoclient:uuid:7B209F2D-47BE-4267-B895-92D67A47AE61>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:DEE1B9FD-09F4-4AD6-9BEB-55CF10F2FDDB> .
<urn:linkedspls:uuid:81525CE9-0714-4D48-9149-6C8B8671E117>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:A3C1B92C-CBE0-4BA8-A41C-D3C3CD26FA51>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:12014" .
<urn:domeoclient:uuid:98B929B0-EA85-44FF-B8CA-9D5AC804EBBB>	<http://purl.org/pav/createdOn>	"2014-04-14 14:18:30 -0400" .
<urn:domeoclient:uuid:1DB91157-FBA4-4FE0-BAB1-68BB8A5A145E>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:1DB91157-FBA4-4FE0-BAB1-68BB8A5A145E> .
<urn:domeoclient:uuid:DF1A2A13-1CD9-47EC-A75C-192353959653>	<http://www.w3.org/ns/oa#exact>	"Advise patients that some people have a genetic variation that results in codeine changing into morphine more rapidly and completely than other people. Most people are unaware of whether they are an ultra-rapid codeine metabolizer or not. These higher-than-normal levels of morphine in the blood may lead to life-threatening or fatal respiratory depression or signs of overdose such as extreme sleepiness, confusion, or shallow breathing. Children with this genetic variation who were prescribed codeine after tonsillectomy and/or adenoidectomy for obstructive sleep apnea may be at greatest risk based on reports of several deaths in this population due to respiratory depression." .
<urn:linkedspls:uuid:558D142F-DBE9-4EB9-9F46-4244D63F2FAF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:CE3D1055-4EAF-4F2F-A2ED-AA9B95C45024>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:45844BA9-29ED-4EC6-94C0-81C9883F880F>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:linkedspls:uuid:9837A225-376D-44A6-959D-05A7DCB03CCE>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:linkedspls:uuid:4D27D69B-2F63-4940-AD74-710454AA1E6A>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:linkedspls:uuid:CE3D1055-4EAF-4F2F-A2ED-AA9B95C45024>	<http://semanticscience.org/resource/SIO_000111>	"43685-7 WARNINGS AND PRECAUTIONS SECTION" .
<urn:domeoclient:uuid:64BC1D21-CAE1-4F85-A596-73342A9D5388>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:194FD718-B3CA-4D25-B3D2-56D36C1ECB60>	<http://semanticscience.org/resource/SIO_000111>	"43679-0 MECHANISM OF ACTION SECTION" .
<urn:domeoclient:uuid:BF8C1810-3B2F-446D-95FB-F6382AEE1DC0>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:BF8C1810-3B2F-446D-95FB-F6382AEE1DC0> .
<urn:domeoclient:uuid:4BED623F-9685-4D95-8EAD-FDE3617D193B>	<http://purl.org/pav/createdOn>	"2014-06-30 12:41:32 -0400" .
<urn:linkedspls:uuid:B7B25E99-EE57-41AC-BDE2-45DCC1447471>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:855697DF-EBFA-4343-B2F2-023B6F284D48>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00993" .
<urn:domeoclient:uuid:ABB77F0A-DE6D-4F3D-87F3-CFA59807AA63>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:ABB77F0A-DE6D-4F3D-87F3-CFA59807AA63> .
<urn:domeoclient:uuid:33D89E0F-4370-431E-8DB5-094F3AF78C75>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd" .
<urn:linkedspls:uuid:2510C893-9155-453B-922C-CF116136DD88>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00993" .
<urn:domeoclient:uuid:F7D9EE5F-E5C0-4296-9825-534C2F768855>	<http://www.w3.org/ns/oa#exact>	"Letrozole tablets was initially studied at doses of 0.1 mg to 5.0 mg daily in six non-comparative Phase I/II trials in 181 postmenopausal estrogen/progesterone receptor positive or unknown advanced breast cancer patients previously treated with at least antiestrogen therapy. Patients had received other hormonal therapies and also may have received cytotoxic therapy. Eight (20%) of forty patients treated with letrozole tablets 2.5 mg daily in Phase I/II trials achieved an objective tumor response (complete or partial response)." .
<urn:linkedspls:uuid:75D456DC-1DB0-4F96-A11F-551CC8425889>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Discontinue/Do not restart" .
<urn:linkedspls:uuid:6F731CE1-E6B4-41AA-98C6-30C94B771E61>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2D6" .
<urn:linkedspls:uuid:27F9E2A8-C54A-4F87-A02D-4F8EFF5D382F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"low-or-absent-activity" .
<urn:linkedspls:uuid:F0F7787E-5F9C-47A4-86B2-D64F1B7602B6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:linkedspls:uuid:31115D88-2436-4D8C-B5E2-A7636A9DA498>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"poor-metabolizer-positive" .
<urn:domeoclient:uuid:398416DB-3813-458C-AEAD-1E703244DEC7>	<http://www.w3.org/ns/oa#exact>	"Lipid\u00A0Study: In a phase 3 safety trial in 262 post menopausal women with resected receptor positive early breast cancer at 24 months comparing the effects on lipid profiles of adjuvant letrozole to tamoxifen, 12% of patients on letrozole had at least one total cholesterol value of a higher CTCAE grade than at baseline compared with 4% of patients on tamoxifen." .
<urn:domeoclient:uuid:79AEDAF0-0AC0-4A44-9F6D-05B14ECEF74F>	<http://purl.org/pav/createdOn>	"2014-04-14 14:52:36 -0400" .
<urn:linkedspls:uuid:407F8565-3B9C-4CF8-B785-C8286BCD86A2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C9" .
<urn:linkedspls:uuid:2510C893-9155-453B-922C-CF116136DD88>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Azathioprine" .
<urn:linkedspls:uuid:6E680A49-5B91-4058-A09E-25A6ED988EFC>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"low-or-absent-activity" .
<urn:linkedspls:uuid:6F731CE1-E6B4-41AA-98C6-30C94B771E61>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00318" .
<urn:linkedspls:uuid:855697DF-EBFA-4343-B2F2-023B6F284D48>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Azathioprine" .
<urn:linkedspls:uuid:855BF4FE-7082-466C-AEC2-BA37C5A2F93C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"VKORC1" .
<urn:linkedspls:uuid:86480047-DD43-4A54-B258-3772C18237F7>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"VKORC1" .
<urn:linkedspls:uuid:36FDCB4E-5E54-4CBA-BC44-04B836C019F0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:D26DCABA-C665-4147-A57B-F26195C0188E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:3467" .
<urn:domeoclient:uuid:7BFF4A61-D45D-4C1F-9599-BD435EF039B8>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:151DFA13-B2DF-4857-AAE9-51CADEC9A12F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:linkedspls:uuid:4777BC06-68FA-4171-A52D-68668AD25547>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:linkedspls:uuid:9BD38C7E-B2D9-4C83-903C-F86556F46EF2>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"biomarker-positive" .
<urn:linkedspls:uuid:169DB9DD-C966-431C-85FE-C3AC1F8E31D3>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MonitoringRecommendation>	"Recommended" .
<urn:linkedspls:uuid:8C44EE5A-5A11-4743-B389-617115FC82BB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:8C0132CB-1BA7-4320-8C5F-E55761BC596E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER_receptor" .
<urn:linkedspls:uuid:0961EB1D-39A9-4A01-9D9B-C2BC3222987E>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:linkedspls:uuid:071CEC58-02E9-4DA2-8259-93E87A6EFD3B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:53541A7F-ACF6-4030-A4B7-7BA865CDF82F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:linkedspls:uuid:4663B6D5-B11D-4039-8F32-F7E3BFC2537E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006121" .
<urn:linkedspls:uuid:FE990D63-4739-43A5-B062-7A946346B2AF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:4A5BB36A-D20C-4306-8958-609D3F9A13D0>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:6B4C9D47-E3BF-4D75-A661-0D5A649108C6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Clopidogrel" .
<urn:domeoclient:uuid:141D5512-1FE5-4684-BAA6-CA59DA362006>	<http://www.w3.org/ns/oa#exact>	"A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metabolizer groups, evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg per day and 600 mg followed by 150 mg per day, each for a total of 5 days. Decreased active metabolite exposure and diminished inhibition of platelet aggregation were observed in the poor metabolizers as compared to the other groups. When poor metabolizers received the 600 mg/150 mg regimen, active metabolite exposure and antiplatelet response were greater than with the 300 mg/75 mg regimen (see Table 3). An appropriate dose regimen for this patient population has not been established in clinical outcome trials." .
<urn:linkedspls:uuid:9739D8D8-F16D-4FF9-BD63-1945B116EEC4>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:linkedspls:uuid:81525CE9-0714-4D48-9149-6C8B8671E117>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:13F3B206-EA87-463E-9DA8-93AA056A9117>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:3616601B-9F53-4ECD-985B-8205444D8F7C>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"biomarker-positive" .
<urn:linkedspls:uuid:F5AE3B3E-B864-4A19-B48C-DC1343C799A3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Clopidogrel" .
<urn:linkedspls:uuid:68B37481-F382-41B9-AEF5-DB241FA9325F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:8B74A738-1124-4DAC-BE25-F15C78CFBA15>	<http://www.w3.org/ns/oa#exact>	" Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction." .
<urn:domeoclient:uuid:121CDD92-5195-42C0-A613-F40D095DA06D>	<http://purl.org/pav/createdOn>	"2014-04-21 12:45:02 -0400" .
<urn:domeoclient:uuid:6E7BEB44-17B2-4A01-8866-7DAFBEA17CC6>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:A48D46C7-8F7E-4426-8C3D-CCA08F946DB0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006121" .
<urn:linkedspls:uuid:FEF94E24-725D-433B-8F55-9E75E14CECB9>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:linkedspls:uuid:108444AC-C8D7-42EE-A011-BE98A3F592F0>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:linkedspls:uuid:9258FFBC-DCDC-4C6C-A375-9FC03C323B54>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:12014" .
<urn:linkedspls:uuid:27F9E2A8-C54A-4F87-A02D-4F8EFF5D382F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Take note that tests are avaliable" .
<urn:domeoclient:uuid:55709DA6-0396-4327-B704-FE38E5F01C43>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:878D746A-3252-462C-AA1E-A857E2FC63AF>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd" .
<urn:linkedspls:uuid:1B973C15-149D-4D98-90E2-4A06A2F30ABD>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:linkedspls:uuid:0BEDE64D-11D3-4746-9532-E747F6A427E0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:151DFA13-B2DF-4857-AAE9-51CADEC9A12F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2623" .
<urn:linkedspls:uuid:A24FCBC0-9830-43DC-87D5-5716D3136B02>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2D6" .
<urn:linkedspls:uuid:4663B6D5-B11D-4039-8F32-F7E3BFC2537E>	<http://semanticscience.org/resource/SIO_000111>	"43685-7 WARNINGS AND PRECAUTIONS SECTION" .
<urn:domeoclient:uuid:2BB0E9F3-52F1-4631-B37B-DBFB53B3B0C9>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:A460766E-6EF1-468A-A8D7-D8163DEDE490>	<http://semanticscience.org/resource/SIO_000111>	"34092-7 CLINICAL STUDIES SECTION" .
<urn:linkedspls:uuid:94B53E9F-5329-43D3-AD42-03C430F6E877>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:D66A54D7-BD47-4E22-B2F3-09A5D190955A>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:51C4FEDD-5F25-4F57-92BC-5456BC2E4846>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:linkedspls:uuid:7AE1124F-F104-4EB3-9415-257F81B2E3CE>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:domeoclient:uuid:903F27DB-914A-44A2-B01F-A36164AAC4DB>	<http://www.w3.org/ns/oa#exact>	"For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk." .
<urn:linkedspls:uuid:44E81086-BA17-4D23-BE19-3D545D7F1B9D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:F0F7787E-5F9C-47A4-86B2-D64F1B7602B6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2623" .
<urn:linkedspls:uuid:08308CA2-E50D-41DB-873B-E57372B5FBDB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2D6" .
<urn:linkedspls:uuid:9F45C51D-C093-4FEB-A57B-7D59EB1E01DA>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Recommend" .
<urn:linkedspls:uuid:EE534BB0-3042-44F4-9B63-01291E28FA45>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Not Important" .
<urn:linkedspls:uuid:169DB9DD-C966-431C-85FE-C3AC1F8E31D3>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:linkedspls:uuid:D939C426-7E0B-4A32-80F1-7344D702AA97>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"Doesn't really say decreased metabolism for PK outcome, it says increased levels or exposure, but not a choice." .
<urn:linkedspls:uuid:3A77F5FE-EF65-4FF1-9BCD-E358D4D5BC82>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"Add test result" .
<urn:linkedspls:uuid:EE534BB0-3042-44F4-9B63-01291E28FA45>	<http://semanticscience.org/resource/SIO_000111>	"34071-1 WARNINGS SECTION" .
<urn:linkedspls:uuid:A48D46C7-8F7E-4426-8C3D-CCA08F946DB0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2D6" .
<urn:linkedspls:uuid:25348450-1CCF-4BEC-84EF-0EA92F67DD3A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:FED638A3-F491-4246-B5EC-651C306CF76E>	<http://semanticscience.org/resource/SIO_000111>	"34066-1 BOXED WARNING SECTION" .
<urn:linkedspls:uuid:74EA2B44-40D9-44F0-90BA-33EFF2D1B5AA>	<http://semanticscience.org/resource/SIO_000111>	"43685-7 WARNINGS AND PRECAUTIONS SECTION" .
<urn:linkedspls:uuid:9F45C51D-C093-4FEB-A57B-7D59EB1E01DA>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:domeoclient:uuid:98FB995B-3B3B-4C86-ACA3-EE4F9F310F41>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:linkedspls:uuid:4777BC06-68FA-4171-A52D-68668AD25547>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Recommend" .
<urn:linkedspls:uuid:BDEED6AF-6C6D-44F0-8470-40D3A54778C5>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:linkedspls:uuid:A903F38F-38D4-4052-A673-7FF19407E3DB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:905B00B5-CD9F-4F5A-BDCD-2E0771AC9B73>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:domeoclient:uuid:EEA90F54-8E00-4B5E-B685-11848BFBA55A>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:linkedspls:uuid:2510C893-9155-453B-922C-CF116136DD88>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"Add test result to drop down" .
<urn:linkedspls:uuid:B24A699D-7127-47C1-BFAE-C1ABB6819E2F>	<http://semanticscience.org/resource/SIO_000111>	"34066-1 BOXED WARNING SECTION" .
<urn:domeoclient:uuid:55544593-2536-44D4-B561-50DB89250F52>	<http://www.w3.org/ns/oa#exact>	"Your doctor may do genetic tests to make sure clopidogrel tablets are right for you." .
<urn:domeoclient:uuid:DCF9A15D-3781-426E-B12E-C37A11772BAD>	<http://purl.org/pav/createdOn>	"2014-04-28 15:21:03 -0400" .
<urn:linkedspls:uuid:4663B6D5-B11D-4039-8F32-F7E3BFC2537E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2D6" .
<urn:linkedspls:uuid:402D9368-C611-4289-8004-8EEC1A409CCF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:CE76789E-AB5D-4F50-AF22-F3C2D4249992>	<http://semanticscience.org/resource/SIO_000111>	"34092-7 CLINICAL STUDIES SECTION" .
<urn:domeoclient:uuid:F3C6E27C-CBBA-4B36-810C-D42C3FA4AB93>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd" .
<urn:linkedspls:uuid:29A5252E-79CA-41F6-BF34-26789C947F8D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:linkedspls:uuid:4663B6D5-B11D-4039-8F32-F7E3BFC2537E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00318" .
<urn:linkedspls:uuid:763ABA1D-A316-42DE-AA02-A7123411CD6C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Letrozole" .
<urn:linkedspls:uuid:B30B41E3-5A67-4530-BC81-938E6B016FDF>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:linkedspls:uuid:763ABA1D-A316-42DE-AA02-A7123411CD6C>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"Add drug selection recommendation of \"indicated for\"" .
<urn:linkedspls:uuid:3616601B-9F53-4ECD-985B-8205444D8F7C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER_receptor" .
<urn:linkedspls:uuid:9739D8D8-F16D-4FF9-BD63-1945B116EEC4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:linkedspls:uuid:C2A76A18-A463-4D7B-9A00-33BEFE84F768>	<http://semanticscience.org/resource/SIO_000111>	"34066-1 BOXED WARNING SECTION" .
<urn:linkedspls:uuid:F9A68240-FAD6-4604-8DEE-1B0E4AF9BD21>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MonitoringRecommendation>	"Required" .
<urn:linkedspls:uuid:EF919E4C-C0B0-4D8B-A273-2F4A806A828D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Letrozole" .
<urn:domeoclient:uuid:5630014D-C820-4E31-A061-529A1A06548B>	<http://purl.org/pav/createdOn>	"2014-03-22 22:10:26 -0400" .
<urn:linkedspls:uuid:D1D85749-709E-4FD8-A464-C8E7CD8158BB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00215" .
<urn:linkedspls:uuid:7CE2D02E-F446-465D-9CBE-27C213ACCC89>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:56D95EC4-D0D7-4BD6-B13C-E145F6A4E568>	<http://semanticscience.org/resource/SIO_000111>	"34071-1 WARNINGS SECTION" .
<urn:linkedspls:uuid:A48D46C7-8F7E-4426-8C3D-CCA08F946DB0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00318" .
<urn:linkedspls:uuid:53B64B1F-739B-46F0-99EE-89EF4131A8D2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2D6" .
<urn:linkedspls:uuid:4C36F11A-E282-4BFB-849D-B93A233A50FB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"No gene symbol for protein C (PROC) and protein S.  Add a not there for the future." .
<urn:linkedspls:uuid:558D142F-DBE9-4EB9-9F46-4244D63F2FAF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:24265221-E0B1-4F13-A2EB-0E9D9DC6F5D4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:3467" .
<urn:domeoclient:uuid:B79BAC9C-6B3B-4FF1-9F24-2BD40CE200BF>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:35B89AC4-DAE5-4207-B319-F9479AE77CDE>	<http://purl.org/pav/createdOn>	"2014-03-22 22:09:39 -0400" .
<urn:domeoclient:uuid:10D9A112-25CB-425E-899B-C3AAA3CF633A>	<http://www.w3.org/ns/oa#exact>	"If you are of Asian descent you may need a genetic blood test before you take Carbamazepine Extended-Release Capsules to see if you are at a higher risk for serious skin reactions with this medicine." .
<urn:linkedspls:uuid:75D988CE-7527-421D-AAA6-0C9C0D4B30DF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00993" .
<urn:linkedspls:uuid:905B00B5-CD9F-4F5A-BDCD-2E0771AC9B73>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:0BEDE64D-11D3-4746-9532-E747F6A427E0>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Do not restart" .
<urn:linkedspls:uuid:7E666CF4-DD19-4B4B-AE7B-EF4BCEA0181C>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Increase" .
<urn:linkedspls:uuid:5E02C5AB-C35D-4ACA-8EF0-DF0F481E6A00>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:2386BDBC-D4E5-43AD-9B96-93D7943C7169>	<http://purl.org/pav/createdOn>	"2014-04-14 13:50:32 -0400" .
<urn:domeoclient:uuid:BC0C42BD-3C98-4864-9F9C-50F72712CEC9>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd" .
<urn:linkedspls:uuid:9C843591-806D-42E0-88A9-58DC59076B3D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:3467" .
<urn:linkedspls:uuid:84646AA6-8E85-4656-8515-E49CB15EADB4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:92FA8990-60EF-4140-9F60-C12E57E3B114>	<http://semanticscience.org/resource/SIO_000111>	"34066-1 BOXED WARNING SECTION" .
<urn:domeoclient:uuid:90E4AF52-01F4-4371-B3ED-D400FF8B1C1E>	<http://purl.org/pav/createdOn>	"2014-06-30 12:36:03 -0400" .
<urn:linkedspls:uuid:92FA8990-60EF-4140-9F60-C12E57E3B114>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:linkedspls:uuid:9DCD19CE-D636-45D6-B994-A9BDBCA32621>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Increase" .
<urn:linkedspls:uuid:9DCD19CE-D636-45D6-B994-A9BDBCA32621>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2D6" .
<urn:linkedspls:uuid:1B973C15-149D-4D98-90E2-4A06A2F30ABD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2623" .
<urn:linkedspls:uuid:1769615F-FAC0-4900-9DC6-5021630F8524>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Efficacy" .
<urn:linkedspls:uuid:42FA1C17-B780-423F-B993-EAF8D8DF0329>	<http://semanticscience.org/resource/SIO_000111>	"43685-7 WARNINGS AND PRECAUTIONS SECTION" .
<urn:linkedspls:uuid:055AAAC1-3544-4B8E-BF06-C99328A12B6E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:3A77F5FE-EF65-4FF1-9BCD-E358D4D5BC82>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:12014" .
<urn:linkedspls:uuid:7E666CF4-DD19-4B4B-AE7B-EF4BCEA0181C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2D6" .
<urn:domeoclient:uuid:72569EC5-72D5-43F3-9028-CE31C726B1D0>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02" .
<urn:domeoclient:uuid:4743B32B-A374-4701-B3BA-DD766AB522F6>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:domeoclient:uuid:9A074D82-152F-415F-84A1-93EDCC8179B1>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1" .
<urn:linkedspls:uuid:599459E0-8D98-4627-BC38-BA5B6BEC6B33>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:ED9FC62F-6F5A-4AEC-B2EB-900F4C21E312>	<http://semanticscience.org/resource/SIO_000111>	"34071-1 WARNINGS SECTION" .
<urn:linkedspls:uuid:1706E63C-45AC-467E-80FD-06108C69A93D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00993" .
<urn:linkedspls:uuid:964EBF55-DC67-43A9-93E2-DBC843BB8D2A>	<http://semanticscience.org/resource/SIO_000111>	"43685-7 WARNINGS AND PRECAUTIONS SECTION" .
<urn:linkedspls:uuid:FBD3A076-17BF-416E-9EEC-89C39FD558A3>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:linkedspls:uuid:53B64B1F-739B-46F0-99EE-89EF4131A8D2>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Increase" .
<urn:linkedspls:uuid:29A5252E-79CA-41F6-BF34-26789C947F8D>	<http://semanticscience.org/resource/SIO_000111>	"34092-7 CLINICAL STUDIES SECTION" .
<urn:linkedspls:uuid:7AE1124F-F104-4EB3-9415-257F81B2E3CE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:855BF4FE-7082-466C-AEC2-BA37C5A2F93C>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Influences Drug Response" .
<urn:linkedspls:uuid:21B282F1-F0CA-488A-B703-88611F099D16>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:domeoclient:uuid:C37B19E6-A2FE-4CF4-9914-61A4EF8E7827>	<http://purl.org/pav/createdOn>	"2014-04-14 14:04:16 -0400" .
<urn:linkedspls:uuid:43B85AB2-533A-4A3B-932F-7CD7177449ED>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:domeoclient:uuid:82F247F1-5E0B-472B-8C42-4074C2A25CD0>	<http://www.w3.org/ns/oa#exact>	"Citalopram steady state levels were not significantly different in poor metabolizers and extensive metabolizers of CYP2D6." .
<urn:linkedspls:uuid:A48D46C7-8F7E-4426-8C3D-CCA08F946DB0>	<http://semanticscience.org/resource/SIO_000111>	"34066-1 BOXED WARNING SECTION" .
<urn:linkedspls:uuid:EF919E4C-C0B0-4D8B-A273-2F4A806A828D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01006" .
<urn:linkedspls:uuid:5D87AC20-773F-4241-AA52-57BF86A4A93A>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:linkedspls:uuid:45EDCED8-9B43-464F-AC7F-898A9009649D>	<http://semanticscience.org/resource/SIO_000111>	"34071-1 WARNINGS SECTION" .
<urn:linkedspls:uuid:B24A699D-7127-47C1-BFAE-C1ABB6819E2F>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:linkedspls:uuid:94B53E9F-5329-43D3-AD42-03C430F6E877>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"homozygous for non-functional alleles" .
<urn:linkedspls:uuid:74BB3F3E-AD24-438C-9250-4357E959069E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#VariantFrequency>	"Variant Frequency" .
<urn:linkedspls:uuid:D66FA8C3-8BAB-4A6F-8234-6DD134876578>	<http://semanticscience.org/resource/SIO_000111>	"WARNINGS AND PRECAUTIONS (43685-7)" .
<urn:linkedspls:uuid:D1D85749-709E-4FD8-A464-C8E7CD8158BB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>	"Decrease from baseline" .
<urn:linkedspls:uuid:C9CADF5C-CD94-4A8C-B6CF-12220ED65397>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2623" .
<urn:linkedspls:uuid:4777BC06-68FA-4171-A52D-68668AD25547>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:domeoclient:uuid:9982EFEC-057D-47A7-8241-37ACB3F049AA>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:2423954D-96B2-404E-8B04-9609825C795A>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Recommend" .
<urn:linkedspls:uuid:74EA2B44-40D9-44F0-90BA-33EFF2D1B5AA>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:domeoclient:uuid:237CBF43-3113-4746-AC7C-0EEE2CD7D926>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:8C44EE5A-5A11-4743-B389-617115FC82BB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:F270E3B3-9983-425D-98FB-66F62E36340F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:linkedspls:uuid:2CE69763-0812-4DFF-A359-2A8D8FF706AD>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:linkedspls:uuid:4DD1AE8C-CB2C-4887-993E-A8A44B2A06CB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00993" .
<urn:linkedspls:uuid:691E83A1-1BFF-4939-996A-35C56D0CF2DF>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:linkedspls:uuid:27F9E2A8-C54A-4F87-A02D-4F8EFF5D382F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:E17574BF-3BA6-48DA-B0DA-6E8DF716A03D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Discontinue/Do not restart" .
<urn:linkedspls:uuid:A24FCBC0-9830-43DC-87D5-5716D3136B02>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Decrease" .
<urn:linkedspls:uuid:6E680A49-5B91-4058-A09E-25A6ED988EFC>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:domeoclient:uuid:76AEC8EC-841B-4618-8A97-4D6655CE39F4>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:0D634683-D28C-42DC-9911-DFD0C9EB289D>	<http://semanticscience.org/resource/SIO_000111>	"34066-1 BOXED WARNING SECTION" .
<urn:linkedspls:uuid:D1D85749-709E-4FD8-A464-C8E7CD8158BB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"poor-metabolizer" .
<urn:linkedspls:uuid:5239657F-5948-4803-B690-76D953D60764>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:05DBF40D-ECCF-4BC6-9077-742EBADF41F9>	<http://semanticscience.org/resource/SIO_000111>	"34067-9 INDICATIONS AND USAGE SECTION" .
<urn:linkedspls:uuid:96D6F8F1-F51A-4EBC-BFF7-C799690B4401>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:D2A8C2D7-9A3E-4307-BC2B-4EA4FC30E8A5>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:linkedspls:uuid:BC70D092-5124-4A5C-87C3-EA34E4868C05>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:C904A0A3-252D-4872-B966-44B63E18E430>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Decrease" .
<urn:domeoclient:uuid:8431F83B-801B-499C-A34F-25B983A4B198>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02" .
<urn:linkedspls:uuid:055AAAC1-3544-4B8E-BF06-C99328A12B6E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:domeoclient:uuid:A6AED276-0422-482B-8802-87BDABE2C035>	<http://purl.org/pav/createdOn>	"2014-06-30 12:20:40 -0400" .
<urn:linkedspls:uuid:A3C1B92C-CBE0-4BA8-A41C-D3C3CD26FA51>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000016583" .
<urn:linkedspls:uuid:D3EDFFC9-9EE3-45DD-B147-801DAB72DF3D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006121" .
<urn:linkedspls:uuid:8C0132CB-1BA7-4320-8C5F-E55761BC596E>	<http://semanticscience.org/resource/SIO_000111>	"34092-7 CLINICAL STUDIES SECTION" .
<urn:linkedspls:uuid:F270E3B3-9983-425D-98FB-66F62E36340F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:E719DBCC-60BF-47C9-A2A6-B5AD564ED472>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Letrozole" .
<urn:linkedspls:uuid:E06F2653-44AD-435F-AB2C-133712B039A6>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Take note that tests are avaliable" .
<urn:domeoclient:uuid:616A0715-5B79-4DD8-8392-1FDEF99E9911>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:BCCF3F22-38AE-4F01-87D0-22C1B07EC947>	<http://semanticscience.org/resource/SIO_000111>	"WARNINGS AND PRECAUTIONS (43685-7)" .
<urn:domeoclient:uuid:9C2B48AD-A4E0-4C6C-9246-E6FD6CF712C8>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:linkedspls:uuid:9739D8D8-F16D-4FF9-BD63-1945B116EEC4>	<http://semanticscience.org/resource/SIO_000111>	"43685-7 WARNINGS AND PRECAUTIONS SECTION" .
<urn:linkedspls:uuid:558D142F-DBE9-4EB9-9F46-4244D63F2FAF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:9692B313-0E4E-4D52-9D7C-456D2EE68F54>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Recommend" .
<urn:domeoclient:uuid:6E1788A3-66E3-4952-B193-2C5E9B1AB551>	<http://purl.org/pav/createdOn>	"2014-06-30 13:17:54 -0400" .
<urn:linkedspls:uuid:5D87AC20-773F-4241-AA52-57BF86A4A93A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:91050818-2692-4B82-B3D8-A52A364F00D7>	<http://purl.org/pav/createdOn>	"2014-06-02 14:39:24 -0400" .
<urn:linkedspls:uuid:CD7BE61C-D111-48EB-A232-1241D41AB8BC>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:BF7AF633-8B36-41BF-AC4F-0BA548A0DB2F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Take note that tests are avaliable" .
<urn:domeoclient:uuid:B3811262-7FB7-4610-8AF2-DDBEC1F3F734>	<http://purl.org/pav/createdOn>	"2014-04-14 14:12:22 -0400" .
<urn:linkedspls:uuid:D64C9075-1FB5-47EA-9312-70A065865D71>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000016583" .
<urn:linkedspls:uuid:45EDCED8-9B43-464F-AC7F-898A9009649D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:domeoclient:uuid:0A45211F-B49B-48F5-A9B9-D593DF301DA5>	<http://purl.org/pav/createdOn>	"2014-04-21 12:22:10 -0400" .
<urn:linkedspls:uuid:2510C893-9155-453B-922C-CF116136DD88>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>	"Decrease from baseline" .
<urn:linkedspls:uuid:4C36F11A-E282-4BFB-849D-B93A233A50FB>	<http://semanticscience.org/resource/SIO_000111>	"34071-1 WARNINGS SECTION" .
<urn:domeoclient:uuid:481D46BB-D4FB-4587-B147-C2FC166A7A51>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:domeoclient:uuid:74EB8F8A-FCEA-41C8-BAB2-B4DFA1190D34>	<http://www.w3.org/ns/oa#exact>	" Patients carrying at least one copy of the CYP2C9*2 allele required a mean daily warfarin dose that was 17% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele" .
<urn:domeoclient:uuid:4019443F-CB02-40D7-BB18-37DDB00B1548>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:B9375CD1-7E67-42D6-B380-D95AD08BF64B>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>	"Decrease from baseline" .
<urn:domeoclient:uuid:0AB99582-A22B-403F-9604-C35A9897CE91>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:linkedspls:uuid:4B11E300-2DF5-4B21-9D43-4D0A02109A59>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:151DFA13-B2DF-4857-AAE9-51CADEC9A12F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"Did not say provided specific dose recommendations." .
<urn:linkedspls:uuid:8026784E-DC9A-4F18-963D-495E0532BB97>	<http://semanticscience.org/resource/SIO_000111>	"34066-1 BOXED WARNING SECTION" .
<urn:linkedspls:uuid:169DB9DD-C966-431C-85FE-C3AC1F8E31D3>	<http://semanticscience.org/resource/SIO_000111>	"43685-7 WARNINGS AND PRECAUTIONS SECTION" .
<urn:linkedspls:uuid:9F45C51D-C093-4FEB-A57B-7D59EB1E01DA>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:4DD1AE8C-CB2C-4887-993E-A8A44B2A06CB>	<http://semanticscience.org/resource/SIO_000111>	"34068-7 DOSAGE AND ADMINISTRATION SECTION" .
<urn:linkedspls:uuid:0961EB1D-39A9-4A01-9D9B-C2BC3222987E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Discontinue/Do not restart" .
<urn:linkedspls:uuid:A903F38F-38D4-4052-A673-7FF19407E3DB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:42FA1C17-B780-423F-B993-EAF8D8DF0329>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:linkedspls:uuid:94B53E9F-5329-43D3-AD42-03C430F6E877>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000016583" .
<urn:linkedspls:uuid:855697DF-EBFA-4343-B2F2-023B6F284D48>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:12014" .
<urn:linkedspls:uuid:FC766D1F-0C5B-4C57-8386-30CC6B3408B5>	<http://semanticscience.org/resource/SIO_000111>	"34075-2 LABORATORY TESTS SECTION" .
<urn:domeoclient:uuid:976BDFF3-2BFA-4838-B6A0-327B2921E1B7>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1" .
<urn:linkedspls:uuid:1A9E2879-AD9B-48F5-B672-AB5C06A28080>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Letrozole" .
<urn:domeoclient:uuid:037A2873-CACE-474F-B3EB-1EF6E0A58FCF>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:81525CE9-0714-4D48-9149-6C8B8671E117>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:linkedspls:uuid:2510C893-9155-453B-922C-CF116136DD88>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:12014" .
<urn:linkedspls:uuid:52601F35-C2AB-4602-BD13-6B9999A0266A>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Recommend" .
<urn:domeoclient:uuid:BC59C368-6171-459A-BA88-9B57AAC67FD8>	<http://www.w3.org/ns/oa#exact>	"Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir." .
<urn:linkedspls:uuid:96D6F8F1-F51A-4EBC-BFF7-C799690B4401>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:linkedspls:uuid:F270E3B3-9983-425D-98FB-66F62E36340F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:CE76789E-AB5D-4F50-AF22-F3C2D4249992>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"biomarker-positive" .
<urn:domeoclient:uuid:14099187-A7EA-4F77-905D-B1B942FF80D7>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb" .
<urn:linkedspls:uuid:8C44EE5A-5A11-4743-B389-617115FC82BB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:linkedspls:uuid:071CEC58-02E9-4DA2-8259-93E87A6EFD3B>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"multiple copies of the gene for cytochrome P450 isoenzyme 2D6 [CYP2D6] " .
<urn:linkedspls:uuid:402D9368-C611-4289-8004-8EEC1A409CCF>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:linkedspls:uuid:599459E0-8D98-4627-BC38-BA5B6BEC6B33>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Take note that tests are avaliable" .
<urn:linkedspls:uuid:31115D88-2436-4D8C-B5E2-A7636A9DA498>	<http://semanticscience.org/resource/SIO_000111>	"34092-7 CLINICAL STUDIES SECTION" .
<urn:linkedspls:uuid:BC70D092-5124-4A5C-87C3-EA34E4868C05>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:C904A0A3-252D-4872-B966-44B63E18E430>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Decreased Efficacy" .
<urn:linkedspls:uuid:45EDCED8-9B43-464F-AC7F-898A9009649D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:12014" .
<urn:linkedspls:uuid:B24A699D-7127-47C1-BFAE-C1ABB6819E2F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:9BD38C7E-B2D9-4C83-903C-F86556F46EF2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01006" .
<urn:linkedspls:uuid:5239657F-5948-4803-B690-76D953D60764>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:domeoclient:uuid:201331AB-54CD-4BE2-81C9-806CCB6E5915>	<http://www.w3.org/ns/oa#exact>	" Numerous factors, alone or in combination, including changes in diet, medications, botanicals and genetic variations in the CYP2C9 and VKORC1 enzymes (seeCLINICAL PHARMACOLOGY,Pharmacogenomics) may influence the response of the patient to warfarin." .
<urn:linkedspls:uuid:A24FCBC0-9830-43DC-87D5-5716D3136B02>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#VariantFrequency>	"Variant Frequency" .
<urn:linkedspls:uuid:C2A76A18-A463-4D7B-9A00-33BEFE84F768>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Do not start" .
<urn:linkedspls:uuid:905B00B5-CD9F-4F5A-BDCD-2E0771AC9B73>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:9837A225-376D-44A6-959D-05A7DCB03CCE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2D6" .
<urn:linkedspls:uuid:25348450-1CCF-4BEC-84EF-0EA92F67DD3A>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:domeoclient:uuid:78CB3193-D01C-49AA-B39B-C35887919EED>	<http://www.w3.org/ns/oa#exact>	"Identification of risk factors for bleeding and certain genetic variations in CYP2C9 and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses " .
<urn:linkedspls:uuid:74EA2B44-40D9-44F0-90BA-33EFF2D1B5AA>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:4B11E300-2DF5-4B21-9D43-4D0A02109A59>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:domeoclient:uuid:D92166A3-0B32-4545-B4CA-719FEDAF410D>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1" .
<urn:linkedspls:uuid:3A77F5FE-EF65-4FF1-9BCD-E358D4D5BC82>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000016583" .
<urn:linkedspls:uuid:071CEC58-02E9-4DA2-8259-93E87A6EFD3B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2D6" .
<urn:domeoclient:uuid:7D50A614-4F2B-42C6-A175-0BF3C158B5DA>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1" .
<urn:linkedspls:uuid:43B85AB2-533A-4A3B-932F-7CD7177449ED>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:36FDCB4E-5E54-4CBA-BC44-04B836C019F0>	<http://semanticscience.org/resource/SIO_000111>	"34066-1 BOXED WARNING SECTION" .
<urn:linkedspls:uuid:CD7BE61C-D111-48EB-A232-1241D41AB8BC>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:domeoclient:uuid:F1D12488-2CA1-4EAD-9A8A-C92106847342>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1" .
<urn:linkedspls:uuid:61B14255-647D-4AA2-83E5-B81256BF7A50>	<http://semanticscience.org/resource/SIO_000111>	"34066-1 BOXED WARNING SECTION" .
<urn:linkedspls:uuid:84646AA6-8E85-4656-8515-E49CB15EADB4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006121" .
<urn:domeoclient:uuid:D5C1D543-12A2-4AD2-973F-CFDA436726C9>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1" .
<urn:linkedspls:uuid:44E81086-BA17-4D23-BE19-3D545D7F1B9D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:linkedspls:uuid:45EDCED8-9B43-464F-AC7F-898A9009649D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"Add new test result." .
<urn:linkedspls:uuid:5D87AC20-773F-4241-AA52-57BF86A4A93A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:domeoclient:uuid:B79BAC9C-6B3B-4FF1-9F24-2BD40CE200BF>	<http://www.w3.org/ns/oa#exact>	"Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir." .
<urn:linkedspls:uuid:6B4C9D47-E3BF-4D75-A661-0D5A649108C6>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"poor-metabolizer" .
<urn:linkedspls:uuid:7AE1124F-F104-4EB3-9415-257F81B2E3CE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:45844BA9-29ED-4EC6-94C0-81C9883F880F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:domeoclient:uuid:DB8F110F-7415-4B13-AB5B-23F1D7A1C6BF>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:domeoclient:uuid:F10DDB11-A5F0-4B5E-B3CE-47B1F2145E34>	<http://www.w3.org/ns/oa#exact>	"Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir." .
<urn:linkedspls:uuid:9C09D2F8-83BE-446D-A17A-75402666EE4B>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#VariantFrequency>	"Variant Frequency" .
<urn:linkedspls:uuid:1769615F-FAC0-4900-9DC6-5021630F8524>	<http://semanticscience.org/resource/SIO_000111>	"34092-7 CLINICAL STUDIES SECTION" .
<urn:linkedspls:uuid:FBD3A076-17BF-416E-9EEC-89C39FD558A3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:7C3837BB-DAF7-4544-9D2C-A63E2F406BAC>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Increase" .
<urn:linkedspls:uuid:396CB021-3C85-4E20-B020-3714CE558E2D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2623" .
<urn:domeoclient:uuid:4BED623F-9685-4D95-8EAD-FDE3617D193B>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:61BA8ACB-D63A-46FF-8B5D-79E9326A61A3>	<http://www.w3.org/ns/oa#exact>	" In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.5 Similar observations have been reported in Asian patients." .
<urn:linkedspls:uuid:BCCF3F22-38AE-4F01-87D0-22C1B07EC947>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:linkedspls:uuid:9DCD19CE-D636-45D6-B994-A9BDBCA32621>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#VariantFrequency>	"Variant Frequency" .
<urn:domeoclient:uuid:0D044EC4-5762-411E-A3D7-4BF4908C494F>	<http://purl.org/pav/createdOn>	"2014-04-28 15:54:29 -0400" .
<urn:domeoclient:uuid:90E4AF52-01F4-4371-B3ED-D400FF8B1C1E>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:1532F8ED-1CF3-45D5-8A36-00FA8FD6060D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2623" .
<urn:domeoclient:uuid:B6B4A58C-16B0-408F-A838-47FC8649B72D>	<http://www.w3.org/ns/oa#exact>	"VKORC1CYP2C9*Ranges are derived from multiple published clinical studies. Other clinical factors (e.g., age, race, body weight, sex, concomitant medications, and comorbidities) are generally accounted for along with genotype in the ranges expressed in the Table. VKORC11639 G(rs9923231) variant is used in this table. Other co-inherited VKORC1 variants may also be important determinants of warfarin dose. Patients with CYP2C9 *1/*3, *2/*2, *2/*3 and *3/*3 may require more prolonged time (>2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen.*1/*1*1/*2*1/*3*2/*2*2/*3*3/*3GG5 to 7 mg5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mgAG5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mgAA3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg" .
<urn:domeoclient:uuid:5229A912-1F9A-40AD-9994-79886D701F6C>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:9258FFBC-DCDC-4C6C-A375-9FC03C323B54>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000016583" .
<urn:linkedspls:uuid:D2A8C2D7-9A3E-4307-BC2B-4EA4FC30E8A5>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:EF161740-C79C-4D2A-9002-4B0A139BF81E>	<http://www.w3.org/ns/oa#exact>	"In a small substudy (N = 81) of the NSABP P-1 trial, there appeared to be no benefit to screening women for Factor V Leiden and Prothrombin mutations G20210A as a means to identify those who may not be appropriate candidates for tamoxifen therapy." .
<urn:linkedspls:uuid:CE3D1055-4EAF-4F2F-A2ED-AA9B95C45024>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:domeoclient:uuid:51CDF79D-8F09-44DB-AE3B-91C93D13095C>	<http://purl.org/pav/createdOn>	"2014-03-31 09:09:18 -0400" .
<urn:linkedspls:uuid:CE76789E-AB5D-4F50-AF22-F3C2D4249992>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Efficacy" .
<urn:domeoclient:uuid:FB8FC7BE-DF14-4ABF-B790-607DABB38F49>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:FC766D1F-0C5B-4C57-8386-30CC6B3408B5>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Recommend" .
<urn:domeoclient:uuid:33D89E0F-4370-431E-8DB5-094F3AF78C75>	<http://www.w3.org/ns/oa#exact>	"Patients receiving azathioprine tablets and allopurinol concomitantly should have a dose reduction of azathioprine tablets, to approximately \u2153 to \u00BC the usual dose. It is recommended that a further dose reduction or alternative therapies be considered for patients with low or absent TPMT activity receiving azathioprine tablets and allopurinol because both TPMT and XO inactivation pathways are affected" .
<urn:linkedspls:uuid:68B37481-F382-41B9-AEF5-DB241FA9325F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2D6" .
<urn:linkedspls:uuid:70BE7DEB-6A8B-41E9-9333-F1F47AC7E1A0>	<http://semanticscience.org/resource/SIO_000111>	"34071-1 WARNINGS SECTION" .
<urn:linkedspls:uuid:4DD1AE8C-CB2C-4887-993E-A8A44B2A06CB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:12014" .
<urn:domeoclient:uuid:BC0A4D53-4B45-488A-8775-B46BF1E9B010>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:FEF94E24-725D-433B-8F55-9E75E14CECB9>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2D6" .
<urn:linkedspls:uuid:D66FA8C3-8BAB-4A6F-8234-6DD134876578>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:domeoclient:uuid:ED2F98CA-60F0-4D49-9803-FED968AA3114>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:74BDDF82-70E1-44A8-B130-17D04DE86798>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Decrease" .
<urn:domeoclient:uuid:5EE59E00-2977-4F09-A933-867C3E165210>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:071CEC58-02E9-4DA2-8259-93E87A6EFD3B>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"multiple copies of gene in allele section?" .
<urn:linkedspls:uuid:691E83A1-1BFF-4939-996A-35C56D0CF2DF>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Decrease" .
<urn:domeoclient:uuid:CA5A93F5-5D2A-44BF-8951-9EF6DFE12F1B>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:E17574BF-3BA6-48DA-B0DA-6E8DF716A03D>	<http://semanticscience.org/resource/SIO_000111>	"43685-7 WARNINGS AND PRECAUTIONS SECTION" .
<urn:linkedspls:uuid:74EA2B44-40D9-44F0-90BA-33EFF2D1B5AA>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Discontinue/Do not restart" .
<urn:linkedspls:uuid:850F3B60-ADC8-42A5-8E7E-B50B1E9D39BE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00675" .
<urn:domeoclient:uuid:F10FC0DB-5D49-46E9-A2C2-3CFFC5FBF692>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:4777BC06-68FA-4171-A52D-68668AD25547>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:69B50E0E-4BB4-49DC-AE8B-4326D0F0A959>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:EED39F7C-032A-4628-9022-2253559E7FEE>	<http://purl.org/pav/createdOn>	"2014-04-14 14:54:36 -0400" .
<urn:linkedspls:uuid:84646AA6-8E85-4656-8515-E49CB15EADB4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00318" .
<urn:linkedspls:uuid:E17574BF-3BA6-48DA-B0DA-6E8DF716A03D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:3A77F5FE-EF65-4FF1-9BCD-E358D4D5BC82>	<http://semanticscience.org/resource/SIO_000111>	"34071-1 WARNINGS SECTION" .
<urn:domeoclient:uuid:9C2B48AD-A4E0-4C6C-9246-E6FD6CF712C8>	<http://www.w3.org/ns/oa#exact>	" For patients carrying at least one copy of the CYP2C9*3 allele, the mean daily warfarin dose was 37% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele." .
<urn:domeoclient:uuid:8B4BE2A8-5AB2-47D3-A46D-2D1D5E7AC42F>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:44E81086-BA17-4D23-BE19-3D545D7F1B9D>	<http://semanticscience.org/resource/SIO_000111>	"WARNINGS AND PRECAUTIONS (43685-7)" .
<urn:linkedspls:uuid:1706E63C-45AC-467E-80FD-06108C69A93D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:12014" .
<urn:linkedspls:uuid:4CFDD438-5250-4D24-9933-43397A6F2E0F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:1BEAB346-F7B3-40D8-AE65-17ACEB48A7A4>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:90768224-544A-41CF-9969-E08884F1434D>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:071CEC58-02E9-4DA2-8259-93E87A6EFD3B>	<http://semanticscience.org/resource/SIO_000111>	"43685-7 WARNINGS AND PRECAUTIONS SECTION" .
<urn:linkedspls:uuid:4DD1AE8C-CB2C-4887-993E-A8A44B2A06CB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>	"Decrease from baseline" .
<urn:linkedspls:uuid:402D9368-C611-4289-8004-8EEC1A409CCF>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:domeoclient:uuid:F498E725-B59B-4357-806F-4F316B1EAB6C>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:7D37999E-F183-41DD-8FEF-19696FD23D30>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:6E680A49-5B91-4058-A09E-25A6ED988EFC>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:12014" .
<urn:linkedspls:uuid:0BEDE64D-11D3-4746-9532-E747F6A427E0>	<http://semanticscience.org/resource/SIO_000111>	"WARNINGS AND PRECAUTIONS (43685-7)" .
<urn:linkedspls:uuid:44E81086-BA17-4D23-BE19-3D545D7F1B9D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:domeoclient:uuid:CE3C3FF6-F83D-47D2-8C4F-944687265F2B>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:linkedspls:uuid:75D988CE-7527-421D-AAA6-0C9C0D4B30DF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:12014" .
<urn:linkedspls:uuid:4D27D69B-2F63-4940-AD74-710454AA1E6A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:EF919E4C-C0B0-4D8B-A273-2F4A806A828D>	<http://semanticscience.org/resource/SIO_000111>	"34092-7 CLINICAL STUDIES SECTION" .
<urn:linkedspls:uuid:81525CE9-0714-4D48-9149-6C8B8671E117>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:domeoclient:uuid:97CDCA51-103C-4EB7-BA80-9670B117D103>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:05DBF40D-ECCF-4BC6-9077-742EBADF41F9>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Letrozole" .
<urn:linkedspls:uuid:05DBF40D-ECCF-4BC6-9077-742EBADF41F9>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"Add drug selection recommendation of \"indicated for\"" .
<urn:linkedspls:uuid:071CEC58-02E9-4DA2-8259-93E87A6EFD3B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006121" .
<urn:linkedspls:uuid:84646AA6-8E85-4656-8515-E49CB15EADB4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2D6" .
<urn:domeoclient:uuid:47718F61-F7FA-4A83-BB17-C13189D5E884>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:linkedspls:uuid:F0B7C43C-792D-49E5-B282-D2303F858889>	<http://semanticscience.org/resource/SIO_000111>	"34068-7 DOSAGE AND ADMINISTRATION SECTION" .
<urn:linkedspls:uuid:27F9E2A8-C54A-4F87-A02D-4F8EFF5D382F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:12014" .
<urn:domeoclient:uuid:745C184B-12B3-435F-99C5-252556EB53B9>	<http://www.w3.org/ns/oa#exact>	"Benefit is less clear for women with ER poor breast cancer in whom the proportional reduction in recurrence was 10% (2p = 0.007) for all durations taken together, or 9% (2p = 0.02) if contralateral breast cancers are excluded. The corresponding reduction in mortality was 6% (NS)." .
<urn:domeoclient:uuid:1E6D8BE7-AC23-449A-83E2-9806683F8162>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:75C4424E-2C9D-40D9-82CF-7E02CFDCA301>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Recommend" .
<urn:linkedspls:uuid:BF7AF633-8B36-41BF-AC4F-0BA548A0DB2F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:45844BA9-29ED-4EC6-94C0-81C9883F880F>	<http://semanticscience.org/resource/SIO_000111>	"43685-7 WARNINGS AND PRECAUTIONS SECTION" .
<urn:linkedspls:uuid:25348450-1CCF-4BEC-84EF-0EA92F67DD3A>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:domeoclient:uuid:9D01B1F5-3775-4CA3-BDFA-97BF6089AE2E>	<http://www.w3.org/ns/oa#exact>	"Risk Factor: HLA-B*5701 Allele: Studies have shown that carriage of the HLA-B*5701 allele is associated with a significantly increased risk of a hypersensitivity reaction to abacavir." .
<urn:domeoclient:uuid:B2CCF84A-A981-4564-8227-DE5688CB1FED>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:domeoclient:uuid:98743D23-3B02-4029-840D-D16A4F390F95>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:D26DCABA-C665-4147-A57B-F26195C0188E>	<http://semanticscience.org/resource/SIO_000111>	"34092-7 CLINICAL STUDIES SECTION" .
<urn:domeoclient:uuid:4364906C-8414-403A-BB1D-1DDCC5F6A4DA>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:linkedspls:uuid:FBEDA24D-50C7-407C-9337-9A08D9456999>	<http://semanticscience.org/resource/SIO_000111>	"34068-7 DOSAGE AND ADMINISTRATION SECTION" .
<urn:domeoclient:uuid:2EDDDF15-34C4-4321-9EF6-7ACDEBEFD237>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:FE1B382B-9F39-4CAA-8A59-17376ED6F061>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00675" .
<urn:linkedspls:uuid:F0F7787E-5F9C-47A4-86B2-D64F1B7602B6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C9" .
<urn:linkedspls:uuid:75C4424E-2C9D-40D9-82CF-7E02CFDCA301>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:0BEDE64D-11D3-4746-9532-E747F6A427E0>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:domeoclient:uuid:C97CADE4-3861-4CB6-A21E-09BF0AEB1F88>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:linkedspls:uuid:0F7B1E31-9D8A-45AA-8F34-A942EE6FBB80>	<http://semanticscience.org/resource/SIO_000111>	"34068-7 DOSAGE AND ADMINISTRATION SECTION" .
<urn:domeoclient:uuid:F777C391-7D5E-4F49-948B-5B9ACB2587FA>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:35B89AC4-DAE5-4207-B319-F9479AE77CDE>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:linkedspls:uuid:2423954D-96B2-404E-8B04-9609825C795A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:420A3DFE-8247-4E9B-8E6C-368F1A2C415C>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:9739D8D8-F16D-4FF9-BD63-1945B116EEC4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:75D456DC-1DB0-4F96-A11F-551CC8425889>	<http://semanticscience.org/resource/SIO_000111>	"43685-7 WARNINGS AND PRECAUTIONS SECTION" .
<urn:linkedspls:uuid:9A15D029-5B02-4107-A829-E2BD1B1219FE>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"poor-metabolizer" .
<urn:domeoclient:uuid:C1BF7FF6-707B-4750-BA47-274111148F96>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:domeoclient:uuid:DBBF90A0-6468-4792-B1CC-02DDD21B4A08>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:84646AA6-8E85-4656-8515-E49CB15EADB4>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Increase" .
<urn:linkedspls:uuid:61B14255-647D-4AA2-83E5-B81256BF7A50>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"poor-metabolizer" .
<urn:domeoclient:uuid:E6578AA5-3295-46D7-B3F2-55CD3CFB5B0F>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:linkedspls:uuid:2CE69763-0812-4DFF-A359-2A8D8FF706AD>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Do not restart" .
<urn:domeoclient:uuid:B3811262-7FB7-4610-8AF2-DDBEC1F3F734>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:2510C893-9155-453B-922C-CF116136DD88>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000016583" .
<urn:domeoclient:uuid:86218E9C-9C50-4CF1-BDF5-7480485335DE>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:domeoclient:uuid:0B13BA6D-FAED-4224-BF7E-64E31E595AD6>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:domeoclient:uuid:D03D6753-24D2-4897-9947-4D727F406A9D>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:9982EFEC-057D-47A7-8241-37ACB3F049AA>	<http://www.w3.org/ns/oa#exact>	"Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible" .
<urn:linkedspls:uuid:855697DF-EBFA-4343-B2F2-023B6F284D48>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000016583" .
<urn:linkedspls:uuid:5239657F-5948-4803-B690-76D953D60764>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-negative" .
<urn:domeoclient:uuid:5630014D-C820-4E31-A061-529A1A06548B>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:domeoclient:uuid:B35B25D3-31CE-48B5-885E-844B46E97203>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:E6B02E4B-FDE8-473A-A978-02F98D0FE07D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Letrozole" .
<urn:domeoclient:uuid:F5C240E5-0680-4CDA-ACC9-4DB8C5A0984B>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:domeoclient:uuid:9EBC36A6-A85E-4348-8EBC-5B071D8A79FB>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:7FA5409D-3EA5-4F92-B738-8577DCEB4D97>	<http://purl.org/pav/createdOn>	"2014-04-14 14:34:53 -0400" .
<urn:linkedspls:uuid:BC70D092-5124-4A5C-87C3-EA34E4868C05>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-negative" .
<urn:domeoclient:uuid:CE5D6919-6972-4689-B658-C5432A02F905>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:domeoclient:uuid:405A5AAA-08FD-470C-9B50-67E44ED1462F>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:53541A7F-ACF6-4030-A4B7-7BA865CDF82F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:domeoclient:uuid:65BD7CC9-2CFA-43C3-A5F0-FBC0221449BF>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:2D0B9A22-6129-4786-B0A4-7384B3324DF0>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1" .
<urn:linkedspls:uuid:24265221-E0B1-4F13-A2EB-0E9D9DC6F5D4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00675" .
<urn:linkedspls:uuid:3616601B-9F53-4ECD-985B-8205444D8F7C>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Efficacy" .
<urn:linkedspls:uuid:F0B7C43C-792D-49E5-B282-D2303F858889>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:12530" .
<urn:linkedspls:uuid:D6235B22-042E-4C36-A104-B353CF92CEB8>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Influences Drug Response" .
<urn:domeoclient:uuid:671F2493-9F0B-4BB9-94E6-4B432F418763>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:5949C0ED-ECE8-4C36-B91D-8E58F7A36AAC>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:linkedspls:uuid:1769615F-FAC0-4900-9DC6-5021630F8524>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER and PgR_receptor" .
<urn:linkedspls:uuid:52601F35-C2AB-4602-BD13-6B9999A0266A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:0F8A06DC-D6FE-466C-AF73-CF9E7A8C2707>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:9C843591-806D-42E0-88A9-58DC59076B3D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00675" .
<urn:linkedspls:uuid:13F3B206-EA87-463E-9DA8-93AA056A9117>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:linkedspls:uuid:BDEED6AF-6C6D-44F0-8470-40D3A54778C5>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Recommend" .
<urn:domeoclient:uuid:2083D2DB-07EF-4969-A4BB-F5823A134875>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:20FD83E0-8F9F-409B-BA60-7D4A2F8A54AF>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1" .
<urn:linkedspls:uuid:4D27D69B-2F63-4940-AD74-710454AA1E6A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:74BDDF82-70E1-44A8-B130-17D04DE86798>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#VariantFrequency>	"Variant Frequency" .
<urn:domeoclient:uuid:AE6AF907-607C-4B15-B108-FAD4D3010CA4>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:B9375CD1-7E67-42D6-B380-D95AD08BF64B>	<http://semanticscience.org/resource/SIO_000111>	"42232-9 PRECAUTIONS SECTION" .
<urn:linkedspls:uuid:0961EB1D-39A9-4A01-9D9B-C2BC3222987E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:6F731CE1-E6B4-41AA-98C6-30C94B771E61>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2D6" .
<urn:linkedspls:uuid:691E83A1-1BFF-4939-996A-35C56D0CF2DF>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#VariantFrequency>	"Variant Frequency" .
<urn:linkedspls:uuid:D66FA8C3-8BAB-4A6F-8234-6DD134876578>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:domeoclient:uuid:B8BA0ADB-2437-4F14-9102-2EC16B13EE4C>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:108444AC-C8D7-42EE-A011-BE98A3F592F0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:071CEC58-02E9-4DA2-8259-93E87A6EFD3B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00318" .
<urn:domeoclient:uuid:3419ECAE-A4FF-4BE4-8679-16B52BA748AC>	<http://purl.org/pav/createdOn>	"2014-04-28 15:43:27 -0400" .
<urn:domeoclient:uuid:217B566B-E501-4A3D-A7B5-BFA5CE66147B>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:41CC62A5-5C3A-449F-B7A3-675F76FA4085>	<http://purl.org/pav/createdOn>	"2014-04-28 15:07:12 -0400" .
<urn:domeoclient:uuid:942AE26F-116C-4165-9118-723E840DFB17>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:850F3B60-ADC8-42A5-8E7E-B50B1E9D39BE>	<http://semanticscience.org/resource/SIO_000111>	"34071-1 WARNINGS SECTION" .
<urn:linkedspls:uuid:4CFDD438-5250-4D24-9933-43397A6F2E0F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:53541A7F-ACF6-4030-A4B7-7BA865CDF82F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Recommend" .
<urn:linkedspls:uuid:D939C426-7E0B-4A32-80F1-7344D702AA97>	<http://semanticscience.org/resource/SIO_000111>	"43682-4 PHARMACOKINETICS SECTION" .
<urn:domeoclient:uuid:0A45211F-B49B-48F5-A9B9-D593DF301DA5>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:D3EDFFC9-9EE3-45DD-B147-801DAB72DF3D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00215" .
<urn:linkedspls:uuid:933C6C55-0C1F-4A1C-B72F-98683FD68184>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:linkedspls:uuid:407F8565-3B9C-4CF8-B785-C8286BCD86A2>	<http://semanticscience.org/resource/SIO_000111>	"42232-9 PRECAUTIONS SECTION" .
<urn:domeoclient:uuid:75A79304-2BD1-4F33-9391-4BB93929D4E6>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:8026784E-DC9A-4F18-963D-495E0532BB97>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:E6B02E4B-FDE8-473A-A978-02F98D0FE07D>	<http://semanticscience.org/resource/SIO_000111>	"34067-9 INDICATIONS AND USAGE SECTION" .
<urn:linkedspls:uuid:51C4FEDD-5F25-4F57-92BC-5456BC2E4846>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:396CB021-3C85-4E20-B020-3714CE558E2D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:linkedspls:uuid:75D456DC-1DB0-4F96-A11F-551CC8425889>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:FE73DA30-2D2E-4D34-AC2F-B160599E5ADD>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:E6B02E4B-FDE8-473A-A978-02F98D0FE07D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01006" .
<urn:linkedspls:uuid:7AE1124F-F104-4EB3-9415-257F81B2E3CE>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Take note that tests are avaliable" .
<urn:domeoclient:uuid:7FDE7EC5-68D1-4D11-A164-0B2DA9D73292>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:38B0D49A-8B7C-4D71-B2CE-0388425D3B66>	<http://www.w3.org/ns/oa#exact>	"PATIENTS TESTING POSITIVE FOR THE ALLELE SHOULD NOT BE TREATED WITH CARBAMAZEPINE EXTENDED-RELEASE CAPSULES UNLESS THE BENEFIT CLEARLY OUTWEIGHS THE RISK" .
<urn:linkedspls:uuid:F9A68240-FAD6-4604-8DEE-1B0E4AF9BD21>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Take note that tests are avaliable" .
<urn:linkedspls:uuid:BDEED6AF-6C6D-44F0-8470-40D3A54778C5>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:36FDCB4E-5E54-4CBA-BC44-04B836C019F0>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701" .
<urn:linkedspls:uuid:2423954D-96B2-404E-8B04-9609825C795A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:9BD38C7E-B2D9-4C83-903C-F86556F46EF2>	<http://semanticscience.org/resource/SIO_000111>	"34084-4 ADVERSE REACTIONS SECTION" .
<urn:domeoclient:uuid:58D07047-AF21-4623-8E4E-4CB2945F5986>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:8525CDF6-1EFA-4AA5-BD43-C9DDE92E0196>	<http://purl.org/pav/createdOn>	"2014-06-09 15:59:09 -0400" .
<urn:domeoclient:uuid:0DA7AAE6-C82C-4935-9D33-40D96FDB2416>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:linkedspls:uuid:9692B313-0E4E-4D52-9D7C-456D2EE68F54>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:F19D3DA9-E091-415D-A43E-483BEC7B68FB>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:2185EE39-FD81-4C83-ABDF-E5D59B789F96>	<http://semanticscience.org/resource/SIO_000111>	"34066-1 BOXED WARNING SECTION" .
<urn:linkedspls:uuid:1A9E2879-AD9B-48F5-B672-AB5C06A28080>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"Add drug selection recommendation of \"indicated for\"" .
<urn:linkedspls:uuid:D3EDFFC9-9EE3-45DD-B147-801DAB72DF3D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2D6" .
<urn:linkedspls:uuid:ED9FC62F-6F5A-4AEC-B2EB-900F4C21E312>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Recommend" .
<urn:domeoclient:uuid:139D3D04-C6A8-40B1-A6F1-5FBFB1B6B7CE>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:E6578AA5-3295-46D7-B3F2-55CD3CFB5B0F>	<http://purl.org/pav/createdOn>	"2014-03-22 22:20:08 -0400" .
<urn:domeoclient:uuid:74EB8F8A-FCEA-41C8-BAB2-B4DFA1190D34>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b" .
<urn:linkedspls:uuid:169DB9DD-C966-431C-85FE-C3AC1F8E31D3>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Do not start" .
<urn:domeoclient:uuid:CE2D417D-24B3-4A7E-BE0B-FBF0E34B509B>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:B30B41E3-5A67-4530-BC81-938E6B016FDF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01048" .
<urn:linkedspls:uuid:FE990D63-4739-43A5-B062-7A946346B2AF>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"HLA-B*5701" .
<urn:linkedspls:uuid:EF919E4C-C0B0-4D8B-A273-2F4A806A828D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER and PgR_receptor" .
<urn:linkedspls:uuid:24265221-E0B1-4F13-A2EB-0E9D9DC6F5D4>	<http://semanticscience.org/resource/SIO_000111>	"34092-7 CLINICAL STUDIES SECTION" .
<urn:domeoclient:uuid:DEA4B73A-145A-4D61-A6E1-ABAE37F63480>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:850F3B60-ADC8-42A5-8E7E-B50B1E9D39BE>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Not necessary" .
<urn:domeoclient:uuid:AC31138E-D96E-46FA-AD16-E8C5C6855989>	<http://purl.org/pav/createdOn>	"2014-04-21 13:06:35 -0400" .
<urn:linkedspls:uuid:8C0132CB-1BA7-4320-8C5F-E55761BC596E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Efficacy" .
<urn:linkedspls:uuid:FE1B382B-9F39-4CAA-8A59-17376ED6F061>	<http://semanticscience.org/resource/SIO_000111>	"34071-1 WARNINGS SECTION" .
<urn:linkedspls:uuid:1769615F-FAC0-4900-9DC6-5021630F8524>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00675" .
<urn:domeoclient:uuid:E1E45497-D882-456B-B573-7A640A307AFB>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:9C843591-806D-42E0-88A9-58DC59076B3D>	<http://semanticscience.org/resource/SIO_000111>	"34092-7 CLINICAL STUDIES SECTION" .
<urn:domeoclient:uuid:224ACECA-832C-4CE1-B586-4BB3E2AC8018>	<http://www.w3.org/ns/oa#exact>	"Retrospective case-control studies have found that in patients of Chinese ancestry there is a strong association between the risk of developing SJS/TEN with carbamazepine treatment and the presence of an inherited variant of the HLA-B gene, HLA-B*1502. The occurrence of higher rates of these reactions in countries with higher frequencies of this allele suggests that the risk may be increased in allele-positive individuals of any ethnicity.\\nAcross Asian populations, notable variation exists in the prevalence of HLA-B*1502. Greater than 15% of the population is reported positive in Hong Kong, Thailand, Malaysia, and parts of the Philippines, compared to about 10% in Taiwan and 4% in North China. South Asians, including Indians, appear to have intermediate prevalence of HLA-B*1502, averaging 2 to 4%, but higher in some groups. HLA-B*1502 is present in <1% of the population in Japan and Korea.\\nHLA-B*1502 is largely absent in individuals not of Asian origin (e.g., Caucasians, African-Americans, Hispanics, and Native Americans)" .
<urn:domeoclient:uuid:CE4F247F-F7CB-4776-A379-05B0401FC08D>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:09730EE5-3645-4E22-8362-E17C60539840>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:55544593-2536-44D4-B561-50DB89250F52>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1" .
<urn:linkedspls:uuid:6B9F2EDD-8EC9-441C-9B9C-6DE4ED079F50>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"low-or-absent-activity" .
<urn:domeoclient:uuid:9F23E4DD-C825-4CCC-BD6E-1514188AFFA7>	<http://purl.org/pav/createdOn>	"2014-04-28 14:50:56 -0400" .
<urn:linkedspls:uuid:61B14255-647D-4AA2-83E5-B81256BF7A50>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00758" .
<urn:linkedspls:uuid:7CE2D02E-F446-465D-9CBE-27C213ACCC89>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Decrease" .
<urn:domeoclient:uuid:3D5B3334-40F5-4B23-8773-AFED2978DC1D>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:1532F8ED-1CF3-45D5-8A36-00FA8FD6060D>	<http://semanticscience.org/resource/SIO_000111>	"34068-7 DOSAGE AND ADMINISTRATION SECTION" .
<urn:domeoclient:uuid:C6988919-6455-4291-92FF-E4F63DF9F9BF>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1" .
<urn:linkedspls:uuid:52601F35-C2AB-4602-BD13-6B9999A0266A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:9A15D029-5B02-4107-A829-E2BD1B1219FE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00758" .
<urn:linkedspls:uuid:7CE2D02E-F446-465D-9CBE-27C213ACCC89>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Decreased Efficacy" .
<urn:linkedspls:uuid:45844BA9-29ED-4EC6-94C0-81C9883F880F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:95EEC2FF-D292-48FE-8FD7-FEF64E2F00E4>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:E17574BF-3BA6-48DA-B0DA-6E8DF716A03D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:5D7649B4-7723-40DE-B9AD-4926156D8C0A>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:1FAA2AB1-96D9-4225-A9E1-763F045EE2CD>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Take note that tests are avaliable" .
<urn:linkedspls:uuid:FE1B382B-9F39-4CAA-8A59-17376ED6F061>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Not necessary" .
<urn:linkedspls:uuid:56D95EC4-D0D7-4BD6-B13C-E145F6A4E568>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"No gene symbol for protein S. Add a not there for the future.  Should we just remove this annotation" .
<urn:domeoclient:uuid:87228117-6F6A-41A0-9709-5D0977E83A06>	<http://www.w3.org/ns/oa#exact>	"Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity from azathioprine tablets if conventional doses are given. Physicians may consider alternative therapies for patients who have low or absent TPMT activity (homozygous for non-functional alleles)." .
<urn:linkedspls:uuid:E06F2653-44AD-435F-AB2C-133712B039A6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:2386BDBC-D4E5-43AD-9B96-93D7943C7169>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:9692B313-0E4E-4D52-9D7C-456D2EE68F54>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:1706E63C-45AC-467E-80FD-06108C69A93D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000016583" .
<urn:domeoclient:uuid:6E1788A3-66E3-4952-B193-2C5E9B1AB551>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:933C6C55-0C1F-4A1C-B72F-98683FD68184>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:domeoclient:uuid:74791FAB-E4B4-4EA3-9557-BD68EDB49B01>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:75D456DC-1DB0-4F96-A11F-551CC8425889>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*5701" .
<urn:linkedspls:uuid:6E680A49-5B91-4058-A09E-25A6ED988EFC>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000016583" .
<urn:linkedspls:uuid:C2A76A18-A463-4D7B-9A00-33BEFE84F768>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:domeoclient:uuid:EE521BAD-75B0-418A-A885-F72D473E4567>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:3616601B-9F53-4ECD-985B-8205444D8F7C>	<http://semanticscience.org/resource/SIO_000111>	"42232-9 PRECAUTIONS SECTION" .
<urn:linkedspls:uuid:75D988CE-7527-421D-AAA6-0C9C0D4B30DF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000016583" .
<urn:linkedspls:uuid:9DCD19CE-D636-45D6-B994-A9BDBCA32621>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006121" .
<urn:linkedspls:uuid:F0B7C43C-792D-49E5-B282-D2303F858889>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>	"Use specific" .
<urn:domeoclient:uuid:C24DFA02-2096-4634-974B-1866183BFD0B>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:407F8565-3B9C-4CF8-B785-C8286BCD86A2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C9" .
<urn:linkedspls:uuid:27F9E2A8-C54A-4F87-A02D-4F8EFF5D382F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000016583" .
<urn:linkedspls:uuid:7E666CF4-DD19-4B4B-AE7B-EF4BCEA0181C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006121" .
<urn:linkedspls:uuid:74BB3F3E-AD24-438C-9250-4357E959069E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Decrease" .
<urn:linkedspls:uuid:F270E3B3-9983-425D-98FB-66F62E36340F>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701 " .
<urn:linkedspls:uuid:75C4424E-2C9D-40D9-82CF-7E02CFDCA301>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:7D8A9803-9C09-4301-8254-AF8BCE7E83F8>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:F5AE3B3E-B864-4A19-B48C-DC1343C799A3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00758" .
<urn:domeoclient:uuid:59E6E4F8-DCB3-4875-86B2-D5885FD80EF7>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:4DD1AE8C-CB2C-4887-993E-A8A44B2A06CB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000016583" .
<urn:linkedspls:uuid:BF7AF633-8B36-41BF-AC4F-0BA548A0DB2F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:5B7239DA-6BB5-450F-B107-37E66914C66D>	<http://purl.org/pav/createdOn>	"2014-06-30 12:24:05 -0400" .
<urn:domeoclient:uuid:240C39EC-A129-42D3-8602-5C743EC412D2>	<http://www.w3.org/ns/oa#exact>	"Based on this study, it is estimated that 61% of patients with the HLA-B*5701 allele will develop a clinically suspected hypersensitivity reaction during the course of abacavir treatment compared with 4% of patients who do not have the HLA-B*5701 allele." .
<urn:linkedspls:uuid:855BF4FE-7082-466C-AEC2-BA37C5A2F93C>	<http://semanticscience.org/resource/SIO_000111>	"34068-7 DOSAGE AND ADMINISTRATION SECTION" .
<urn:domeoclient:uuid:AAB53C8F-FB14-4216-82D9-D7CD0AB15000>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:53B64B1F-739B-46F0-99EE-89EF4131A8D2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006121" .
<urn:linkedspls:uuid:4663B6D5-B11D-4039-8F32-F7E3BFC2537E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Codeine" .
<urn:domeoclient:uuid:1B1E4FE2-11FA-4FB0-85F2-014750705FED>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:905B00B5-CD9F-4F5A-BDCD-2E0771AC9B73>	<http://semanticscience.org/resource/SIO_000111>	"34066-1 BOXED WARNING SECTION" .
<urn:domeoclient:uuid:3D5D3473-95BD-41AF-81E6-ED19E81798E9>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:D26DCABA-C665-4147-A57B-F26195C0188E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00675" .
<urn:domeoclient:uuid:5D85FB52-BA95-409A-8974-2E14C9527722>	<http://www.w3.org/ns/oa#exact>	"Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible." .
<urn:linkedspls:uuid:5E02C5AB-C35D-4ACA-8EF0-DF0F481E6A00>	<http://semanticscience.org/resource/SIO_000111>	"34071-1 WARNINGS SECTION" .
<urn:domeoclient:uuid:217B566B-E501-4A3D-A7B5-BFA5CE66147B>	<http://purl.org/pav/createdOn>	"2014-04-21 13:35:09 -0400" .
<urn:domeoclient:uuid:C427075F-5339-47EB-A313-AA6B94EB8753>	<http://www.w3.org/ns/oa#exact>	"It is recommended that consideration be given to either genotype or phenotype patients for TPMT. Phenotyping and genotyping methods are commercially available." .
<urn:domeoclient:uuid:CDE45635-21AB-4AC7-89FF-C772F3A15A2C>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:9DCD19CE-D636-45D6-B994-A9BDBCA32621>	<http://semanticscience.org/resource/SIO_000111>	"43685-7 WARNINGS AND PRECAUTIONS SECTION" .
<urn:linkedspls:uuid:A48D46C7-8F7E-4426-8C3D-CCA08F946DB0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Codeine" .
<urn:linkedspls:uuid:396CB021-3C85-4E20-B020-3714CE558E2D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:domeoclient:uuid:38655F0E-DB25-4C1E-A99A-7E2B18134930>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:44A37F21-E420-40D5-A9E0-5CEDEFAEF40B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Clopidogrel" .
<urn:linkedspls:uuid:2CE69763-0812-4DFF-A359-2A8D8FF706AD>	<http://semanticscience.org/resource/SIO_000111>	"WARNINGS AND PRECAUTIONS (43685-7)" .
<urn:domeoclient:uuid:8B036858-70F5-4077-8333-F34F19A042EC>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:A3C1B92C-CBE0-4BA8-A41C-D3C3CD26FA51>	<http://semanticscience.org/resource/SIO_000111>	"34068-7 DOSAGE AND ADMINISTRATION SECTION" .
<urn:domeoclient:uuid:ED2F98CA-60F0-4D49-9803-FED968AA3114>	<http://purl.org/pav/createdOn>	"2014-04-28 14:53:37 -0400" .
<urn:linkedspls:uuid:1532F8ED-1CF3-45D5-8A36-00FA8FD6060D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:linkedspls:uuid:C9CADF5C-CD94-4A8C-B6CF-12220ED65397>	<http://semanticscience.org/resource/SIO_000111>	"34068-7 DOSAGE AND ADMINISTRATION SECTION" .
<urn:domeoclient:uuid:8CD7F86F-C041-47B7-B7D2-F7B48F523F56>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:F9A68240-FAD6-4604-8DEE-1B0E4AF9BD21>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00993" .
<urn:linkedspls:uuid:FC766D1F-0C5B-4C57-8386-30CC6B3408B5>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000002010" .
<urn:domeoclient:uuid:43CE071E-85A3-4BC0-AEAC-4FC4DCBB3D02>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:EE8AF84A-98F2-4EED-8B54-4312A50FBA31>	<http://purl.org/pav/createdOn>	"2014-03-22 22:11:34 -0400" .
<urn:domeoclient:uuid:B2CCF84A-A981-4564-8227-DE5688CB1FED>	<http://purl.org/pav/createdOn>	"2014-03-31 09:10:10 -0400" .
<urn:linkedspls:uuid:08308CA2-E50D-41DB-873B-E57372B5FBDB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006121" .
<urn:linkedspls:uuid:AC5F1BAD-8B6A-49DB-8147-AB1394EC169F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Decrease" .
<urn:linkedspls:uuid:9A15D029-5B02-4107-A829-E2BD1B1219FE>	<http://semanticscience.org/resource/SIO_000111>	"34068-7 DOSAGE AND ADMINISTRATION SECTION" .
<urn:domeoclient:uuid:2BEFD527-0C92-4B61-A2B9-12F931EDC707>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1" .
<urn:domeoclient:uuid:4F5C1D0C-9AFC-4B3A-83EC-AC9CB72FB0C9>	<http://purl.org/pav/createdOn>	"2014-06-02 14:16:25 -0400" .
<urn:linkedspls:uuid:1532F8ED-1CF3-45D5-8A36-00FA8FD6060D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C9" .
<urn:linkedspls:uuid:AC5F1BAD-8B6A-49DB-8147-AB1394EC169F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Decreased Efficacy" .
<urn:domeoclient:uuid:5CCA20AA-4D3C-40F4-BAED-C832E665FA35>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:6B4C9D47-E3BF-4D75-A661-0D5A649108C6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00758" .
<urn:linkedspls:uuid:6B9F2EDD-8EC9-441C-9B9C-6DE4ED079F50>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00993" .
<urn:linkedspls:uuid:EF919E4C-C0B0-4D8B-A273-2F4A806A828D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:8910" .
<urn:domeoclient:uuid:2F3B0124-31A3-451B-BA81-5652303A452C>	<http://www.w3.org/ns/oa#exact>	"Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible." .
<urn:linkedspls:uuid:D1D85749-709E-4FD8-A464-C8E7CD8158BB>	<http://semanticscience.org/resource/SIO_000111>	"43682-4 PHARMACOKINETICS SECTION" .
<urn:linkedspls:uuid:071CEC58-02E9-4DA2-8259-93E87A6EFD3B>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"ultra-metabolizer" .
<urn:linkedspls:uuid:396CB021-3C85-4E20-B020-3714CE558E2D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C9" .
<urn:domeoclient:uuid:9DDE5A30-59ED-49D7-B9B6-316245562477>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:A24FCBC0-9830-43DC-87D5-5716D3136B02>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006121" .
<urn:domeoclient:uuid:D640727D-6442-4274-B453-64F04BD595E3>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:8C0132CB-1BA7-4320-8C5F-E55761BC596E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00675" .
<urn:linkedspls:uuid:763ABA1D-A316-42DE-AA02-A7123411CD6C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:8910" .
<urn:linkedspls:uuid:45EDCED8-9B43-464F-AC7F-898A9009649D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000016583" .
<urn:domeoclient:uuid:1042FEEA-5AF3-4E50-B2A1-053451F2236C>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:6B4C9D47-E3BF-4D75-A661-0D5A649108C6>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"poor-metabolizer-positive" .
<urn:linkedspls:uuid:D64C9075-1FB5-47EA-9312-70A065865D71>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#VariantFrequency>	"Variant Frequency" .
<urn:linkedspls:uuid:B7B25E99-EE57-41AC-BDE2-45DCC1447471>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Decreased Efficacy" .
<urn:domeoclient:uuid:F880CCED-A2A0-4330-B02F-070F7BF5AF00>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:C8824A36-9C96-4389-B215-2638B48B5437>	<http://www.w3.org/ns/oa#exact>	"Among women with ER positive or unknown breast cancer and positive nodes who received about 5 years of treatment, overall survival at 10 years was 61.4% for tamoxifen vs. 50.5% for control (logrank 2p < 0.00001). The recurrence-free rate at 10 years was 59.7% for tamoxifen vs. 44.5% for control (logrank 2p < 0.00001). Among women with ER positive or unknown breast cancer and negative nodes who received about 5 years of treatment, overall survival at 10 years was 78.9% for tamoxifen vs. 73.3% for control (logrank 2p < 0.00001). The recurrence-free rate at 10 years was 79.2% for tamoxifen vs. 64.3% for control (logrank 2p < 0.00001)." .
<urn:linkedspls:uuid:9DCD19CE-D636-45D6-B994-A9BDBCA32621>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00318" .
<urn:domeoclient:uuid:D66A54D7-BD47-4E22-B2F3-09A5D190955A>	<http://www.w3.org/ns/oa#exact>	"For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk." .
<urn:domeoclient:uuid:408C86B9-FFBA-4A7F-A6EC-ECD348FD4782>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:7E666CF4-DD19-4B4B-AE7B-EF4BCEA0181C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00318" .
<urn:linkedspls:uuid:9F45C51D-C093-4FEB-A57B-7D59EB1E01DA>	<http://semanticscience.org/resource/SIO_000111>	"43685-7 WARNINGS AND PRECAUTIONS SECTION" .
<urn:linkedspls:uuid:74BDDF82-70E1-44A8-B130-17D04DE86798>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00993" .
<urn:domeoclient:uuid:3D5B3334-40F5-4B23-8773-AFED2978DC1D>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:8525CDF6-1EFA-4AA5-BD43-C9DDE92E0196>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:21B282F1-F0CA-488A-B703-88611F099D16>	<http://semanticscience.org/resource/SIO_000111>	"WARNINGS AND PRECAUTIONS (43685-7)" .
<urn:domeoclient:uuid:95EEC2FF-D292-48FE-8FD7-FEF64E2F00E4>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:CE4F247F-F7CB-4776-A379-05B0401FC08D>	<http://purl.org/pav/createdOn>	"2014-06-30 13:24:52 -0400" .
<urn:domeoclient:uuid:3CB531B1-A267-4A03-A0C5-D852AB638802>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:84646AA6-8E85-4656-8515-E49CB15EADB4>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"ultra-metabolizer" .
<urn:domeoclient:uuid:5D7649B4-7723-40DE-B9AD-4926156D8C0A>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:7FA5409D-3EA5-4F92-B738-8577DCEB4D97>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:1FAA2AB1-96D9-4225-A9E1-763F045EE2CD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00993" .
<urn:domeoclient:uuid:2386BDBC-D4E5-43AD-9B96-93D7943C7169>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:F9A68240-FAD6-4604-8DEE-1B0E4AF9BD21>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:12014" .
<urn:linkedspls:uuid:A3C1B92C-CBE0-4BA8-A41C-D3C3CD26FA51>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Take note that tests are avaliable" .
<urn:domeoclient:uuid:88C2CEB5-469C-451E-8436-788ABE4338F5>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:53B64B1F-739B-46F0-99EE-89EF4131A8D2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00318" .
<urn:domeoclient:uuid:AC31138E-D96E-46FA-AD16-E8C5C6855989>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:7084C584-8C84-42A3-AFAB-F66F243A2817>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:6E1788A3-66E3-4952-B193-2C5E9B1AB551>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:0D634683-D28C-42DC-9911-DFD0C9EB289D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#VariantFrequency>	"Variant Frequency" .
<urn:domeoclient:uuid:9E9B14EC-233F-4ABE-B627-6150C0C5A5A4>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:1042FEEA-5AF3-4E50-B2A1-053451F2236C>	<http://purl.org/pav/createdOn>	"2014-04-28 15:26:56 -0400" .
<urn:linkedspls:uuid:70BE7DEB-6A8B-41E9-9333-F1F47AC7E1A0>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#VariantFrequency>	"Variant Frequency" .
<urn:linkedspls:uuid:905B00B5-CD9F-4F5A-BDCD-2E0771AC9B73>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701 " .
<urn:domeoclient:uuid:CE1DC1EA-085A-4CF9-8165-5A14A411A633>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:A3C1B92C-CBE0-4BA8-A41C-D3C3CD26FA51>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"low-or-absent-activity" .
<urn:linkedspls:uuid:461FDA58-8FAB-4951-B04A-F969D73C634D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C9" .
<urn:domeoclient:uuid:420A3DFE-8247-4E9B-8E6C-368F1A2C415C>	<http://purl.org/pav/createdOn>	"2014-04-14 14:25:51 -0400" .
<urn:domeoclient:uuid:9F0CE910-4782-4E6D-B7E2-C7C784B10B90>	<http://www.w3.org/ns/oa#exact>	"Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN. Consideration should be given to avoiding use of other drugs associated with SJS/TEN in HLA-B* 1502 positive patients, when alternative therapies are otherwise equally acceptable." .
<urn:domeoclient:uuid:74791FAB-E4B4-4EA3-9557-BD68EDB49B01>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:3419ECAE-A4FF-4BE4-8679-16B52BA748AC>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:4B11E300-2DF5-4B21-9D43-4D0A02109A59>	<http://semanticscience.org/resource/SIO_000111>	"43685-7 WARNINGS AND PRECAUTIONS SECTION" .
<urn:domeoclient:uuid:EE521BAD-75B0-418A-A885-F72D473E4567>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:08308CA2-E50D-41DB-873B-E57372B5FBDB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00215" .
<urn:domeoclient:uuid:8D91E7D5-B379-4649-9834-0D01A948DFF8>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:C24DFA02-2096-4634-974B-1866183BFD0B>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:94B53E9F-5329-43D3-AD42-03C430F6E877>	<http://semanticscience.org/resource/SIO_000111>	"34068-7 DOSAGE AND ADMINISTRATION SECTION" .
<urn:domeoclient:uuid:9098E55C-952E-46DF-904C-2A3E63492B3A>	<http://www.w3.org/ns/oa#exact>	"In CYP2C19 poor metabolizers, citalopram steady state Cmax and AUC was increased by 68% and 107%, respectively." .
<urn:linkedspls:uuid:396CB021-3C85-4E20-B020-3714CE558E2D>	<http://semanticscience.org/resource/SIO_000111>	"43682-4 PHARMACOKINETICS SECTION" .
<urn:linkedspls:uuid:74BB3F3E-AD24-438C-9250-4357E959069E>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8" .
<urn:linkedspls:uuid:E719DBCC-60BF-47C9-A2A6-B5AD564ED472>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01006" .
<urn:domeoclient:uuid:7D8A9803-9C09-4301-8254-AF8BCE7E83F8>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:1769615F-FAC0-4900-9DC6-5021630F8524>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:8910" .
<urn:linkedspls:uuid:3616601B-9F53-4ECD-985B-8205444D8F7C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00675" .
<urn:domeoclient:uuid:4F5C1D0C-9AFC-4B3A-83EC-AC9CB72FB0C9>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:59E6E4F8-DCB3-4875-86B2-D5885FD80EF7>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:8BDFDC96-47AF-489E-8F96-DF9B26C6ECBE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00215" .
<urn:linkedspls:uuid:86480047-DD43-4A54-B258-3772C18237F7>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:domeoclient:uuid:23FACDDB-003E-40B5-AB79-B52F5FD124B3>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:81525CE9-0714-4D48-9149-6C8B8671E117>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Do not start" .
<urn:linkedspls:uuid:24265221-E0B1-4F13-A2EB-0E9D9DC6F5D4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:domeoclient:uuid:99AB6350-6929-4C24-B144-7B97EBF09B3F>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:AAB53C8F-FB14-4216-82D9-D7CD0AB15000>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:8BDFDC96-47AF-489E-8F96-DF9B26C6ECBE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ConcomitantMedicationOfConcern>	"Concomitant medication concern" .
<urn:linkedspls:uuid:5239657F-5948-4803-B690-76D953D60764>	<http://semanticscience.org/resource/SIO_000111>	"43685-7 WARNINGS AND PRECAUTIONS SECTION" .
<urn:linkedspls:uuid:27F9E2A8-C54A-4F87-A02D-4F8EFF5D382F>	<http://semanticscience.org/resource/SIO_000111>	"34084-4 ADVERSE REACTIONS SECTION" .
<urn:linkedspls:uuid:396CB021-3C85-4E20-B020-3714CE558E2D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#VariantFrequency>	"Variant Frequency" .
<urn:domeoclient:uuid:1B1E4FE2-11FA-4FB0-85F2-014750705FED>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:9C843591-806D-42E0-88A9-58DC59076B3D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:domeoclient:uuid:79AEDAF0-0AC0-4A44-9F6D-05B14ECEF74F>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:A24FCBC0-9830-43DC-87D5-5716D3136B02>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ConcomitantMedicationOfConcern>	"Concomitant medication concern" .
<urn:linkedspls:uuid:75D988CE-7527-421D-AAA6-0C9C0D4B30DF>	<http://semanticscience.org/resource/SIO_000111>	"34090-1 CLINICAL PHARMACOLOGY SECTION" .
<urn:domeoclient:uuid:98226070-C5AF-407A-B6D1-D521CD001163>	<http://www.w3.org/ns/oa#exact>	"Prior to initiating Carbamazepine Extended-Release Capsule therapy, testing for HLA-B*1502 should be performed in patients with ancestry in populations in which HLA-B*1502 may be present. In deciding which patients to screen, the rates provided above for the prevalence of HLA-B*1502 may offer a rough guide, keeping in mind the limitations of these figures due to wide variability in rates even within ethnic groups, the difficulty in ascertaining ethnic ancestry, and the likelihood of mixed ancestry." .
<urn:linkedspls:uuid:6E680A49-5B91-4058-A09E-25A6ED988EFC>	<http://semanticscience.org/resource/SIO_000111>	"34090-1 CLINICAL PHARMACOLOGY SECTION" .
<urn:domeoclient:uuid:009DEEE9-9289-445E-8C79-81457BE96692>	<http://www.w3.org/ns/oa#exact>	"Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible." .
<urn:domeoclient:uuid:B8BA0ADB-2437-4F14-9102-2EC16B13EE4C>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:9E02315A-EB6D-4693-B3E4-4FB4B99D4253>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:217B566B-E501-4A3D-A7B5-BFA5CE66147B>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:169DB9DD-C966-431C-85FE-C3AC1F8E31D3>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-positive" .
<urn:domeoclient:uuid:59E6E4F8-DCB3-4875-86B2-D5885FD80EF7>	<http://purl.org/pav/createdOn>	"2014-04-21 13:19:11 -0400" .
<urn:domeoclient:uuid:C89E80EC-0820-406B-99C8-D495EC5F054E>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:98FB995B-3B3B-4C86-ACA3-EE4F9F310F41>	<http://www.w3.org/ns/oa#exact>	"The dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. The maintenance dose needed to achieve a target PT/INR is influenced by:\\n\u25CF\\n\u00A0\u00A0\u00A0\u00A0\u00A0Clinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and\\n\u25CF\\n\u00A0\u00A0\u00A0\u00A0\u00A0Genetic factors (CYP2C9 and VKORC1 genotypes)." .
<urn:domeoclient:uuid:FE73DA30-2D2E-4D34-AC2F-B160599E5ADD>	<http://purl.org/pav/createdOn>	"2014-06-09 15:37:59 -0400" .
<urn:linkedspls:uuid:9C09D2F8-83BE-446D-A17A-75402666EE4B>	<http://semanticscience.org/resource/SIO_000111>	"34092-7 CLINICAL STUDIES SECTION" .
<urn:domeoclient:uuid:942AE26F-116C-4165-9118-723E840DFB17>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:9A5666BB-F43D-45F3-A856-0BDB0E745589>	<http://www.w3.org/ns/oa#exact>	"Azathioprine tablets should be administered with caution to patients having one non-functional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in patients with reduced TPMT activity." .
<urn:linkedspls:uuid:194FD718-B3CA-4D25-B3D2-56D36C1ECB60>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:domeoclient:uuid:C37B19E6-A2FE-4CF4-9914-61A4EF8E7827>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:9A15D029-5B02-4107-A829-E2BD1B1219FE>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"poor-metabolizer-positive" .
<urn:linkedspls:uuid:F270E3B3-9983-425D-98FB-66F62E36340F>	<http://semanticscience.org/resource/SIO_000111>	"43685-7 WARNINGS AND PRECAUTIONS SECTION" .
<urn:domeoclient:uuid:0A45211F-B49B-48F5-A9B9-D593DF301DA5>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:A460766E-6EF1-468A-A8D7-D8163DEDE490>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER and PgR_receptor" .
<urn:domeoclient:uuid:91050818-2692-4B82-B3D8-A52A364F00D7>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:61B14255-647D-4AA2-83E5-B81256BF7A50>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"poor-metabolizer-positive" .
<urn:linkedspls:uuid:6F731CE1-E6B4-41AA-98C6-30C94B771E61>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Codeine" .
<urn:domeoclient:uuid:75A79304-2BD1-4F33-9391-4BB93929D4E6>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:83E53A9A-8702-4167-A12D-1370E2D26E06>	<http://purl.org/pav/createdOn>	"2014-04-14 13:58:14 -0400" .
<urn:linkedspls:uuid:42FA1C17-B780-423F-B993-EAF8D8DF0329>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Decreased Toxicity Risk" .
<urn:domeoclient:uuid:FE73DA30-2D2E-4D34-AC2F-B160599E5ADD>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:FE154A72-C1D3-4027-8C73-C71A948D0F52>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:E719DBCC-60BF-47C9-A2A6-B5AD564ED472>	<http://semanticscience.org/resource/SIO_000111>	"34092-7 CLINICAL STUDIES SECTION" .
<urn:linkedspls:uuid:3746E014-4500-4C39-A007-7B912571A900>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1" .
<urn:domeoclient:uuid:43CE071E-85A3-4BC0-AEAC-4FC4DCBB3D02>	<http://purl.org/pav/createdOn>	"2014-06-30 12:18:51 -0400" .
<urn:domeoclient:uuid:7FDE7EC5-68D1-4D11-A164-0B2DA9D73292>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:3665D7A9-FCD1-4278-8B7F-5EA5B3CC19D3>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:E1E45497-D882-456B-B573-7A640A307AFB>	<http://purl.org/pav/createdOn>	"2014-04-28 15:34:27 -0400" .
<urn:domeoclient:uuid:408C86B9-FFBA-4A7F-A6EC-ECD348FD4782>	<http://purl.org/pav/createdOn>	"2014-04-28 15:31:28 -0400" .
<urn:linkedspls:uuid:0BEDE64D-11D3-4746-9532-E747F6A427E0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:5B7239DA-6BB5-450F-B107-37E66914C66D>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:58D07047-AF21-4623-8E4E-4CB2945F5986>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:C7EAEB14-8213-4EF8-AC67-469D0609826B>	<http://www.w3.org/ns/oa#exact>	"Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible." .
<urn:domeoclient:uuid:232C5C6E-F6FE-44B8-AE5A-7E1BD427D626>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:14099187-A7EA-4F77-905D-B1B942FF80D7>	<http://www.w3.org/ns/oa#exact>	"Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction." .
<urn:linkedspls:uuid:1A9E2879-AD9B-48F5-B672-AB5C06A28080>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01006" .
<urn:domeoclient:uuid:F19D3DA9-E091-415D-A43E-483BEC7B68FB>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:0D044EC4-5762-411E-A3D7-4BF4908C494F>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:94B53E9F-5329-43D3-AD42-03C430F6E877>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"low-or-absent-activity" .
<urn:domeoclient:uuid:139D3D04-C6A8-40B1-A6F1-5FBFB1B6B7CE>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:0E9FF6AD-98CE-4932-AD5D-E657F3B363B3>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:CE2D417D-24B3-4A7E-BE0B-FBF0E34B509B>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:CE76789E-AB5D-4F50-AF22-F3C2D4249992>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1" .
<urn:linkedspls:uuid:A460766E-6EF1-468A-A8D7-D8163DEDE490>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00675" .
<urn:domeoclient:uuid:36D17D73-1169-4131-94F5-24AFD369088A>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:44E81086-BA17-4D23-BE19-3D545D7F1B9D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:DEA4B73A-145A-4D61-A6E1-ABAE37F63480>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:C9CADF5C-CD94-4A8C-B6CF-12220ED65397>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C9" .
<urn:domeoclient:uuid:CE483709-CD8C-4493-A2B7-8E589B98BF31>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:F45F585A-05C5-49B5-BABB-73BFBE9E9753>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00758" .
<urn:linkedspls:uuid:9258FFBC-DCDC-4C6C-A375-9FC03C323B54>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#VariantFrequency>	"Variant Frequency" .
<urn:domeoclient:uuid:E1E45497-D882-456B-B573-7A640A307AFB>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:0B39F957-E88F-427C-AC41-F1B9DC711A02>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:linkedspls:uuid:25348450-1CCF-4BEC-84EF-0EA92F67DD3A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:55ED86AA-B414-4220-94FD-868AFE2D1278>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:CE4F247F-F7CB-4776-A379-05B0401FC08D>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:0E9FF6AD-98CE-4932-AD5D-E657F3B363B3>	<http://purl.org/pav/createdOn>	"2014-04-14 14:51:08 -0400" .
<urn:domeoclient:uuid:09730EE5-3645-4E22-8362-E17C60539840>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:9992ADBC-4BAB-4529-BAC4-9D7AFD34F098>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:3A77F5FE-EF65-4FF1-9BCD-E358D4D5BC82>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"low-or-absent-activity" .
<urn:domeoclient:uuid:1E6D8BE7-AC23-449A-83E2-9806683F8162>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:C9CADF5C-CD94-4A8C-B6CF-12220ED65397>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:domeoclient:uuid:C692DA9C-1ECF-4A5B-867C-ABAF23492F10>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:0B13BA6D-FAED-4224-BF7E-64E31E595AD6>	<http://www.w3.org/ns/oa#exact>	"The dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. The maintenance dose needed to achieve a target PT/INR is influenced by:\\n\u25CF\\n\u00A0\u00A0\u00A0\u00A0\u00A0Clinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and\\n\u25CF\\n\u00A0\u00A0\u00A0\u00A0\u00A0Genetic factors (CYP2C9 and VKORC1 genotypes)." .
<urn:linkedspls:uuid:FBD3A076-17BF-416E-9EEC-89C39FD558A3>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-negative" .
<urn:domeoclient:uuid:98743D23-3B02-4029-840D-D16A4F390F95>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:44BBF444-A1D4-4182-8B05-775BFFCA0DF4>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:402D9368-C611-4289-8004-8EEC1A409CCF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:964EBF55-DC67-43A9-93E2-DBC843BB8D2A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00758" .
<urn:domeoclient:uuid:2EDDDF15-34C4-4321-9EF6-7ACDEBEFD237>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:D939C426-7E0B-4A32-80F1-7344D702AA97>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:domeoclient:uuid:A753145C-8800-49A8-BE99-D558A1390DAE>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:CE76789E-AB5D-4F50-AF22-F3C2D4249992>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00675" .
<urn:linkedspls:uuid:53B64B1F-739B-46F0-99EE-89EF4131A8D2>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"PATIENT COUNSELING SECTION still not listed.  How do we code advise patients?" .
<urn:domeoclient:uuid:38B0D49A-8B7C-4D71-B2CE-0388425D3B66>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee15d911-73c7-4bc6-96f2-089a8aa64e18" .
<urn:domeoclient:uuid:F777C391-7D5E-4F49-948B-5B9ACB2587FA>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:D64C9075-1FB5-47EA-9312-70A065865D71>	<http://semanticscience.org/resource/SIO_000111>	"34090-1 CLINICAL PHARMACOLOGY SECTION" .
<urn:domeoclient:uuid:46C63D3B-0000-404E-BC76-FB01C42DC7B2>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:055AAAC1-3544-4B8E-BF06-C99328A12B6E>	<http://semanticscience.org/resource/SIO_000111>	"43685-7 WARNINGS AND PRECAUTIONS SECTION" .
<urn:domeoclient:uuid:420A3DFE-8247-4E9B-8E6C-368F1A2C415C>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:A3C1B92C-CBE0-4BA8-A41C-D3C3CD26FA51>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MonitoringRecommendation>	"Required" .
<urn:domeoclient:uuid:56ECCD1C-D5DA-4A5F-A470-A96F404E1CB8>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:945EB72E-5C75-41B0-B8FC-637E1EF0AE7D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Take note that tests are avaliable" .
<urn:linkedspls:uuid:E6B02E4B-FDE8-473A-A978-02F98D0FE07D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"Add drug selection recommendation of \"indicated for\"" .
<urn:domeoclient:uuid:DBBF90A0-6468-4792-B1CC-02DDD21B4A08>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:1B973C15-149D-4D98-90E2-4A06A2F30ABD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C9" .
<urn:domeoclient:uuid:55700EE9-88B8-49B7-BD64-1A87D99DCC15>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:29A5252E-79CA-41F6-BF34-26789C947F8D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1" .
<urn:domeoclient:uuid:B3811262-7FB7-4610-8AF2-DDBEC1F3F734>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:BF7AF633-8B36-41BF-AC4F-0BA548A0DB2F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:86565D69-8F9C-4519-9A52-CD2A2980DEE3>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:D03D6753-24D2-4897-9947-4D727F406A9D>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:FB3C226D-314F-473A-AA0D-98DCD192D7AF>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:87B8F5B0-8381-4CA7-AE0B-30C481D164B4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:linkedspls:uuid:09071EE6-03DB-49CA-BA67-1589B0E2FDBD>	<http://semanticscience.org/resource/SIO_000111>	"34084-4 ADVERSE REACTIONS SECTION" .
<urn:linkedspls:uuid:75C4424E-2C9D-40D9-82CF-7E02CFDCA301>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:B35B25D3-31CE-48B5-885E-844B46E97203>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:0B39F957-E88F-427C-AC41-F1B9DC711A02>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ConcomitantMedicationOfConcern>	"Concomitant medication concern" .
<urn:domeoclient:uuid:7B209F2D-47BE-4267-B895-92D67A47AE61>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:CA5A93F5-5D2A-44BF-8951-9EF6DFE12F1B>	<http://purl.org/pav/createdOn>	"2014-04-28 15:01:50 -0400" .
<urn:linkedspls:uuid:4DD1AE8C-CB2C-4887-993E-A8A44B2A06CB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"to generic for allele vs leaving phenotype on its own?" .
<urn:domeoclient:uuid:CF0F356A-4BD3-4AB3-80E4-DF7EF3CD5F00>	<http://www.w3.org/ns/oa#exact>	" In a small substudy (N = 81) of the NSABP P-1 trial, there appeared to be no benefit to screening women for Factor V Leiden and Prothrombin mutations G20210A as a means to identify those who may not be appropriate candidates for tamoxifen therapy." .
<urn:linkedspls:uuid:FED638A3-F491-4246-B5EC-651C306CF76E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00758" .
<urn:linkedspls:uuid:0961EB1D-39A9-4A01-9D9B-C2BC3222987E>	<http://semanticscience.org/resource/SIO_000111>	"42229-5 SPL UNCLASSIFIED SECTION" .
<urn:domeoclient:uuid:9EBC36A6-A85E-4348-8EBC-5B071D8A79FB>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:1B973C15-149D-4D98-90E2-4A06A2F30ABD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:domeoclient:uuid:405A5AAA-08FD-470C-9B50-67E44ED1462F>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:09071EE6-03DB-49CA-BA67-1589B0E2FDBD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:8910" .
<urn:linkedspls:uuid:44A37F21-E420-40D5-A9E0-5CEDEFAEF40B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:domeoclient:uuid:3C70DFC4-2BEA-46AE-A49C-D4BE3E7466B8>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:65BD7CC9-2CFA-43C3-A5F0-FBC0221449BF>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:A6AED276-0422-482B-8802-87BDABE2C035>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:FED638A3-F491-4246-B5EC-651C306CF76E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:linkedspls:uuid:4663B6D5-B11D-4039-8F32-F7E3BFC2537E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"ultra-metabolizer-positive" .
<urn:domeoclient:uuid:671F2493-9F0B-4BB9-94E6-4B432F418763>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:DCF9A15D-3781-426E-B12E-C37A11772BAD>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:36FDCB4E-5E54-4CBA-BC44-04B836C019F0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:0F8A06DC-D6FE-466C-AF73-CF9E7A8C2707>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:84646AA6-8E85-4656-8515-E49CB15EADB4>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:60281E0C-D291-4163-9B6F-E83A4142CB8E>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:0B3E23EF-1696-4FF7-BEEB-8158BDA84294>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C9" .
<urn:linkedspls:uuid:0B39F957-E88F-427C-AC41-F1B9DC711A02>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00215" .
<urn:domeoclient:uuid:2083D2DB-07EF-4969-A4BB-F5823A134875>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:3C852929-ADD4-4383-A351-2D9CF492A6E9>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:FEF94E24-725D-433B-8F55-9E75E14CECB9>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Codeine" .
<urn:linkedspls:uuid:74EA2B44-40D9-44F0-90BA-33EFF2D1B5AA>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-negative" .
<urn:linkedspls:uuid:6E680A49-5B91-4058-A09E-25A6ED988EFC>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Decrease" .
<urn:domeoclient:uuid:AE6AF907-607C-4B15-B108-FAD4D3010CA4>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:1924E2D5-9E52-46A8-925D-043869F8F777>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:domeoclient:uuid:4EEB4B8C-B4AE-42C6-9E9C-805907F3A548>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1" .
<urn:domeoclient:uuid:CA417E62-D7D9-4F45-8359-10CCF8D13F90>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:68B37481-F382-41B9-AEF5-DB241FA9325F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Codeine" .
<urn:linkedspls:uuid:A48D46C7-8F7E-4426-8C3D-CCA08F946DB0>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"ultra-metabolizer-positive" .
<urn:domeoclient:uuid:4BED623F-9685-4D95-8EAD-FDE3617D193B>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:EE8AF84A-98F2-4EED-8B54-4312A50FBA31>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:linkedspls:uuid:EF919E4C-C0B0-4D8B-A273-2F4A806A828D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:linkedspls:uuid:FE990D63-4739-43A5-B062-7A946346B2AF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:763ABA1D-A316-42DE-AA02-A7123411CD6C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:linkedspls:uuid:7C3837BB-DAF7-4544-9D2C-A63E2F406BAC>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00318" .
<urn:linkedspls:uuid:2185EE39-FD81-4C83-ABDF-E5D59B789F96>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:domeoclient:uuid:90E4AF52-01F4-4371-B3ED-D400FF8B1C1E>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:5229A912-1F9A-40AD-9994-79886D701F6C>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:13F3B206-EA87-463E-9DA8-93AA056A9117>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:964EBF55-DC67-43A9-93E2-DBC843BB8D2A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:domeoclient:uuid:1FCB6C74-C406-41C1-8A44-C9D033D5834C>	<http://www.w3.org/ns/oa#exact>	"Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible." .
<urn:domeoclient:uuid:8BEEBA62-C519-4421-9038-113DCDFC9B2C>	<http://www.w3.org/ns/oa#exact>	"Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a hypersensitivity reaction." .
<urn:domeoclient:uuid:FB8FC7BE-DF14-4ABF-B790-607DABB38F49>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:D62A1217-AE83-41D2-B678-FDCD04344D8B>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:linkedspls:uuid:D26DCABA-C665-4147-A57B-F26195C0188E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:linkedspls:uuid:9258FFBC-DCDC-4C6C-A375-9FC03C323B54>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"low-or-absent-activity" .
<urn:domeoclient:uuid:563CB9E8-A4E7-43EF-9686-1F5B71F4169D>	<http://www.w3.org/ns/oa#exact>	"In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estrogen- and progesterone-receptor levels less than 10 fmol. In women aged 60 to 70 years, there was a trend toward a beneficial effect of tamoxifen without any clear relationship to estrogen- or progesterone-receptor status." .
<urn:linkedspls:uuid:8C44EE5A-5A11-4743-B389-617115FC82BB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:B752346E-6167-497D-B585-83983FA71DA2>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:domeoclient:uuid:BC0A4D53-4B45-488A-8775-B46BF1E9B010>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:5E02C5AB-C35D-4ACA-8EF0-DF0F481E6A00>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ConcomitantMedicationOfConcern>	"Concomitant medication concern" .
<urn:domeoclient:uuid:ED2F98CA-60F0-4D49-9803-FED968AA3114>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:ABB77F0A-DE6D-4F3D-87F3-CFA59807AA63>	<http://www.w3.org/ns/oa#exact>	"For genetically at-risk patients [See WARNINGS], high-resolution 'HLA-B*1502 typing' is recommended. The test is positive if either one or two HLA-B*1502 alleles are detected and negative if no HLA-B*1502 alleles are detected." .
<urn:domeoclient:uuid:D03D6753-24D2-4897-9947-4D727F406A9D>	<http://purl.org/pav/createdOn>	"2014-04-14 15:33:19 -0400" .
<urn:linkedspls:uuid:071CEC58-02E9-4DA2-8259-93E87A6EFD3B>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:5EE59E00-2977-4F09-A933-867C3E165210>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:FC7D109F-F404-4287-BE4A-D7C5AA057401>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:domeoclient:uuid:5464F1B8-CF3D-4DA9-99F4-5F156C14CE70>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:domeoclient:uuid:CA5A93F5-5D2A-44BF-8951-9EF6DFE12F1B>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:F45F585A-05C5-49B5-BABB-73BFBE9E9753>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:linkedspls:uuid:29A5252E-79CA-41F6-BF34-26789C947F8D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"mixing terminology... positive and high/low for biomarker test results" .
<urn:domeoclient:uuid:8B50CE5B-C2BB-4D97-838E-E1C2600020BC>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:domeoclient:uuid:F10FC0DB-5D49-46E9-A2C2-3CFFC5FBF692>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:1FAA2AB1-96D9-4225-A9E1-763F045EE2CD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:12014" .
<urn:domeoclient:uuid:D62A1217-AE83-41D2-B678-FDCD04344D8B>	<http://purl.org/pav/createdOn>	"2014-03-22 22:13:30 -0400" .
<urn:linkedspls:uuid:B9375CD1-7E67-42D6-B380-D95AD08BF64B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:domeoclient:uuid:B752346E-6167-497D-B585-83983FA71DA2>	<http://purl.org/pav/createdOn>	"2014-03-22 22:07:26 -0400" .
<urn:domeoclient:uuid:D5CF7A64-E07F-419A-8900-15F969F2D51F>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:linkedspls:uuid:0B3E23EF-1696-4FF7-BEEB-8158BDA84294>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:8C0132CB-1BA7-4320-8C5F-E55761BC596E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1" .
<urn:domeoclient:uuid:69B50E0E-4BB4-49DC-AE8B-4326D0F0A959>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:56D95EC4-D0D7-4BD6-B13C-E145F6A4E568>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:linkedspls:uuid:D1D85749-709E-4FD8-A464-C8E7CD8158BB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:linkedspls:uuid:4C36F11A-E282-4BFB-849D-B93A233A50FB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:domeoclient:uuid:8B4BE2A8-5AB2-47D3-A46D-2D1D5E7AC42F>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:51CDF79D-8F09-44DB-AE3B-91C93D13095C>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:linkedspls:uuid:45844BA9-29ED-4EC6-94C0-81C9883F880F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:F0B7C43C-792D-49E5-B282-D2303F858889>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:linkedspls:uuid:05DBF40D-ECCF-4BC6-9077-742EBADF41F9>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01006" .
<urn:domeoclient:uuid:1BEAB346-F7B3-40D8-AE65-17ACEB48A7A4>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:8BDFDC96-47AF-489E-8F96-DF9B26C6ECBE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:domeoclient:uuid:89320F5F-262D-4657-8A52-4432EC0101F8>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:domeoclient:uuid:4A5BB36A-D20C-4306-8958-609D3F9A13D0>	<http://www.w3.org/ns/oa#exact>	" NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status" .
<urn:linkedspls:uuid:9BD38C7E-B2D9-4C83-903C-F86556F46EF2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER and PgR_receptor" .
<urn:domeoclient:uuid:DF92C1E1-A223-4737-8028-06DD03B558D2>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:domeoclient:uuid:90768224-544A-41CF-9969-E08884F1434D>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:E6B02E4B-FDE8-473A-A978-02F98D0FE07D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:D939C426-7E0B-4A32-80F1-7344D702AA97>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Decrease" .
<urn:linkedspls:uuid:FBEDA24D-50C7-407C-9337-9A08D9456999>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:domeoclient:uuid:524C3AB2-2955-4538-A46C-63CDD0BC11D2>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:domeoclient:uuid:F498E725-B59B-4357-806F-4F316B1EAB6C>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:407F8565-3B9C-4CF8-B785-C8286BCD86A2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:linkedspls:uuid:74BDDF82-70E1-44A8-B130-17D04DE86798>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:12014" .
<urn:linkedspls:uuid:0F7B1E31-9D8A-45AA-8F34-A942EE6FBB80>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:domeoclient:uuid:D3B78E07-8B27-4774-B221-CC47DAC8365E>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.0alpha-040" .
<urn:domeoclient:uuid:7D37999E-F183-41DD-8FEF-19696FD23D30>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:9E9B14EC-233F-4ABE-B627-6150C0C5A5A4>	<http://purl.org/pav/createdOn>	"2014-04-21 13:01:24 -0400" .
<urn:domeoclient:uuid:60281E0C-D291-4163-9B6F-E83A4142CB8E>	<http://purl.org/pav/createdOn>	"2014-04-21 12:25:24 -0400" .
<urn:domeoclient:uuid:97CDCA51-103C-4EB7-BA80-9670B117D103>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:E17574BF-3BA6-48DA-B0DA-6E8DF716A03D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:6B9F2EDD-8EC9-441C-9B9C-6DE4ED079F50>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:12014" .
<urn:linkedspls:uuid:1769615F-FAC0-4900-9DC6-5021630F8524>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:linkedspls:uuid:D6235B22-042E-4C36-A104-B353CF92CEB8>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:8910" .
<urn:linkedspls:uuid:2510C893-9155-453B-922C-CF116136DD88>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"low-or-absent-activity" .
<urn:linkedspls:uuid:9837A225-376D-44A6-959D-05A7DCB03CCE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Codeine" .
<urn:linkedspls:uuid:E06F2653-44AD-435F-AB2C-133712B039A6>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:C692DA9C-1ECF-4A5B-867C-ABAF23492F10>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:147B38AF-9E51-4D8A-B5CF-D7FAE7375257>	<http://www.w3.org/ns/oa#exact>	" Tamoxifen decreased the incidence of small estrogen receptor positive tumors, but did not alter the incidence of estrogen receptor negative tumors or larger tumors." .
<urn:domeoclient:uuid:403ED560-E6D3-4B1C-BAF1-DD0E0D87AA3F>	<http://www.w3.org/ns/oa#exact>	"Tests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy." .
<urn:domeoclient:uuid:44BBF444-A1D4-4182-8B05-775BFFCA0DF4>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:C904A0A3-252D-4872-B966-44B63E18E430>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:domeoclient:uuid:F498E725-B59B-4357-806F-4F316B1EAB6C>	<http://purl.org/pav/createdOn>	"2014-06-30 12:30:35 -0400" .
<urn:domeoclient:uuid:79C530FF-637A-43C8-AECE-CA81458FB5EE>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee15d911-73c7-4bc6-96f2-089a8aa64e18" .
<urn:domeoclient:uuid:A753145C-8800-49A8-BE99-D558A1390DAE>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:81525CE9-0714-4D48-9149-6C8B8671E117>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:46C63D3B-0000-404E-BC76-FB01C42DC7B2>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:96D6F8F1-F51A-4EBC-BFF7-C799690B4401>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:F45F585A-05C5-49B5-BABB-73BFBE9E9753>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Take note that tests are avaliable" .
<urn:domeoclient:uuid:3D5D3473-95BD-41AF-81E6-ED19E81798E9>	<http://purl.org/pav/createdOn>	"2014-04-14 13:44:33 -0400" .
<urn:domeoclient:uuid:56ECCD1C-D5DA-4A5F-A470-A96F404E1CB8>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:3616601B-9F53-4ECD-985B-8205444D8F7C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1" .
<urn:linkedspls:uuid:4C36F11A-E282-4BFB-849D-B93A233A50FB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:9179" .
<urn:linkedspls:uuid:3746E014-4500-4C39-A007-7B912571A900>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER_receptor" .
<urn:domeoclient:uuid:55700EE9-88B8-49B7-BD64-1A87D99DCC15>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:BCCF3F22-38AE-4F01-87D0-22C1B07EC947>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:52601F35-C2AB-4602-BD13-6B9999A0266A>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:86565D69-8F9C-4519-9A52-CD2A2980DEE3>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:FB3C226D-314F-473A-AA0D-98DCD192D7AF>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:8C0132CB-1BA7-4320-8C5F-E55761BC596E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:linkedspls:uuid:E17574BF-3BA6-48DA-B0DA-6E8DF716A03D>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*5701 " .
<urn:domeoclient:uuid:7B209F2D-47BE-4267-B895-92D67A47AE61>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:3C70DFC4-2BEA-46AE-A49C-D4BE3E7466B8>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:86480047-DD43-4A54-B258-3772C18237F7>	<http://semanticscience.org/resource/SIO_000111>	"42232-9 PRECAUTIONS SECTION" .
<urn:domeoclient:uuid:1BEAB346-F7B3-40D8-AE65-17ACEB48A7A4>	<http://purl.org/pav/createdOn>	"2014-06-30 12:31:59 -0400" .
<urn:domeoclient:uuid:A6AED276-0422-482B-8802-87BDABE2C035>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:53B64B1F-739B-46F0-99EE-89EF4131A8D2>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"ultra-metabolizer" .
<urn:domeoclient:uuid:DCF9A15D-3781-426E-B12E-C37A11772BAD>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:31115D88-2436-4D8C-B5E2-A7636A9DA498>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1" .
<urn:domeoclient:uuid:60281E0C-D291-4163-9B6F-E83A4142CB8E>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:933C6C55-0C1F-4A1C-B72F-98683FD68184>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:29B0BAC9-227E-4C4D-96D2-143CC457E50C>	<http://purl.org/pav/createdOn>	"2014-04-28 14:49:07 -0400" .
<urn:linkedspls:uuid:3616601B-9F53-4ECD-985B-8205444D8F7C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:linkedspls:uuid:A460766E-6EF1-468A-A8D7-D8163DEDE490>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:8910" .
<urn:domeoclient:uuid:60CFE292-6834-41FC-8255-B81A3D584EE2>	<http://www.w3.org/ns/oa#exact>	"Discontinue ZIAGEN as soon as a hypersensitivity reaction is suspected. Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible." .
<urn:domeoclient:uuid:3C852929-ADD4-4383-A351-2D9CF492A6E9>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:5A997B78-0557-4495-BDBD-42F5B4B30412>	<http://www.w3.org/ns/oa#exact>	"Citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation" .
<urn:domeoclient:uuid:CA417E62-D7D9-4F45-8359-10CCF8D13F90>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:8431F83B-801B-499C-A34F-25B983A4B198>	<http://www.w3.org/ns/oa#exact>	"A double-blind, randomized, placebo-controlled trial of letrozole tablets\u00A0was performed in over 5,100 postmenopausal women with receptor-positive or unknown primary breast cancer who were disease free after 5 years of adjuvant treatment with tamoxifen." .
<urn:linkedspls:uuid:CE3D1055-4EAF-4F2F-A2ED-AA9B95C45024>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:FED638A3-F491-4246-B5EC-651C306CF76E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Take note that tests are avaliable" .
<urn:linkedspls:uuid:7E666CF4-DD19-4B4B-AE7B-EF4BCEA0181C>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"ultra-metabolizer" .
<urn:domeoclient:uuid:9E02315A-EB6D-4693-B3E4-4FB4B99D4253>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:56ECCD1C-D5DA-4A5F-A470-A96F404E1CB8>	<http://purl.org/pav/createdOn>	"2014-06-30 12:38:14 -0400" .
<urn:linkedspls:uuid:691E83A1-1BFF-4939-996A-35C56D0CF2DF>	<http://semanticscience.org/resource/SIO_000111>	"43682-4 PHARMACOKINETICS SECTION" .
<urn:linkedspls:uuid:9BD38C7E-B2D9-4C83-903C-F86556F46EF2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:domeoclient:uuid:6F41EB64-7E4B-4DAA-86FE-348F6836D46E>	<http://www.w3.org/ns/oa#exact>	"Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may have life-threatening or fatal respiratory depression or experience signs of overdose (such as extreme sleepiness, confusion, or shallow breathing)" .
<urn:linkedspls:uuid:9DCD19CE-D636-45D6-B994-A9BDBCA32621>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"ultra-metabolizer" .
<urn:linkedspls:uuid:B7B25E99-EE57-41AC-BDE2-45DCC1447471>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:C89E80EC-0820-406B-99C8-D495EC5F054E>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:9E003EB3-2B97-41C7-BD14-5EAF744BB5F2>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:D66FA8C3-8BAB-4A6F-8234-6DD134876578>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:9692B313-0E4E-4D52-9D7C-456D2EE68F54>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:C37B19E6-A2FE-4CF4-9914-61A4EF8E7827>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:FBD3A076-17BF-416E-9EEC-89C39FD558A3>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"how do we code \\\\\\\\\\\\\\\"tell your doctor\\\\\\\\\\\\\\\"" .
<urn:linkedspls:uuid:0F7B1E31-9D8A-45AA-8F34-A942EE6FBB80>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:domeoclient:uuid:29B0BAC9-227E-4C4D-96D2-143CC457E50C>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:2BB0E9F3-52F1-4631-B37B-DBFB53B3B0C9>	<http://www.w3.org/ns/oa#exact>	"Before starting ZIAGEN, tell your doctor about all of your medical conditions, including if you:\\nhave been tested and know whether or not you have a particular gene variation called HLA-B*5701." .
<urn:domeoclient:uuid:91050818-2692-4B82-B3D8-A52A364F00D7>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:FBEDA24D-50C7-407C-9337-9A08D9456999>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:domeoclient:uuid:98B929B0-EA85-44FF-B8CA-9D5AC804EBBB>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:97CDCA51-103C-4EB7-BA80-9670B117D103>	<http://purl.org/pav/createdOn>	"2014-06-30 12:16:47 -0400" .
<urn:linkedspls:uuid:29A5252E-79CA-41F6-BF34-26789C947F8D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER_receptor" .
<urn:domeoclient:uuid:F880CCED-A2A0-4330-B02F-070F7BF5AF00>	<http://purl.org/pav/createdOn>	"2014-06-02 14:05:25 -0400" .
<urn:linkedspls:uuid:31115D88-2436-4D8C-B5E2-A7636A9DA498>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:linkedspls:uuid:7CE2D02E-F446-465D-9CBE-27C213ACCC89>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00758" .
<urn:domeoclient:uuid:95EEC2FF-D292-48FE-8FD7-FEF64E2F00E4>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:C427075F-5339-47EB-A313-AA6B94EB8753> .
<urn:domeoclient:uuid:FE154A72-C1D3-4027-8C73-C71A948D0F52>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:F0F7787E-5F9C-47A4-86B2-D64F1B7602B6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:linkedspls:uuid:21B282F1-F0CA-488A-B703-88611F099D16>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:E34142C5-1680-4612-AC76-D96D8F82364F>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:7FDE7EC5-68D1-4D11-A164-0B2DA9D73292>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:481D46BB-D4FB-4587-B147-C2FC166A7A51> .
<urn:domeoclient:uuid:3665D7A9-FCD1-4278-8B7F-5EA5B3CC19D3>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:4C36F11A-E282-4BFB-849D-B93A233A50FB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:linkedspls:uuid:56D95EC4-D0D7-4BD6-B13C-E145F6A4E568>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:linkedspls:uuid:6F731CE1-E6B4-41AA-98C6-30C94B771E61>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"ultra-metabolizer-positive" .
<urn:linkedspls:uuid:43B85AB2-533A-4A3B-932F-7CD7177449ED>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:5B7239DA-6BB5-450F-B107-37E66914C66D>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:E7B4486A-24AB-4642-ADB0-B78FF5AF0E42>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:B9375CD1-7E67-42D6-B380-D95AD08BF64B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:linkedspls:uuid:9BD38C7E-B2D9-4C83-903C-F86556F46EF2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:domeoclient:uuid:720F1FAF-C317-4375-8323-04DFEE0FAAFE>	<http://www.w3.org/ns/oa#exact>	"TPMT genotyping or phenotyping (red blood cell TPMT activity) can help identify patients who are at an increased risk for developing azathioprine tablets toxicity.2, 3, 7, 8, 9 Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions" .
<urn:linkedspls:uuid:599459E0-8D98-4627-BC38-BA5B6BEC6B33>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00758" .
<urn:domeoclient:uuid:232C5C6E-F6FE-44B8-AE5A-7E1BD427D626>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:B24A699D-7127-47C1-BFAE-C1ABB6819E2F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:6A2E1BD4-3863-4A37-AD9D-6B54F3CF3E54>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:7FDE7EC5-68D1-4D11-A164-0B2DA9D73292>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:1DA28968-6C74-475E-AB4F-5E6E22DFF8BD>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:0D044EC4-5762-411E-A3D7-4BF4908C494F>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:90768224-544A-41CF-9969-E08884F1434D>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:F1D12488-2CA1-4EAD-9A8A-C92106847342> .
<urn:linkedspls:uuid:CE76789E-AB5D-4F50-AF22-F3C2D4249992>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:linkedspls:uuid:74EA2B44-40D9-44F0-90BA-33EFF2D1B5AA>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:0E9FF6AD-98CE-4932-AD5D-E657F3B363B3>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:9BD38C7E-B2D9-4C83-903C-F86556F46EF2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:8910" .
<urn:linkedspls:uuid:6B4C9D47-E3BF-4D75-A661-0D5A649108C6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:domeoclient:uuid:87D0F0C2-6038-41AA-B84E-85497D292836>	<http://www.w3.org/ns/oa#exact>	"NSABP B-14, a prospective, double-blind, randomized study, compared tamoxifen to placebo in women with axillary node-negative, estrogen receptor positive (\u2265 10 fmol/mg cytosol protein) breast cancer (as adjuvant therapy, following total mastectomy and axillary dissection, or segmental resection, axillary dissection, and breast radiation). After 5 years of treatment, there was a significant improvement in disease-free survival in women receiving tamoxifen. This benefit was apparent both in women under age 50 and in women at or beyond age 50." .
<urn:linkedspls:uuid:7C3837BB-DAF7-4544-9D2C-A63E2F406BAC>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"ultra-metabolizer" .
<urn:domeoclient:uuid:75A79304-2BD1-4F33-9391-4BB93929D4E6>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:9DDE5A30-59ED-49D7-B9B6-316245562477>	<http://purl.org/pav/createdOn>	"2014-04-28 15:20:04 -0400" .
<urn:linkedspls:uuid:FBEDA24D-50C7-407C-9337-9A08D9456999>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C9" .
<urn:domeoclient:uuid:36D17D73-1169-4131-94F5-24AFD369088A>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:55709DA6-0396-4327-B704-FE38E5F01C43>	<http://www.w3.org/ns/oa#exact>	"Before starting ZIAGEN, tell your doctor about all of your medical conditions, including if you:\\nhave been tested and know whether or not you have a particular gene variation called HLA-B*5701." .
<urn:linkedspls:uuid:691E83A1-1BFF-4939-996A-35C56D0CF2DF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C9" .
<urn:domeoclient:uuid:FE73DA30-2D2E-4D34-AC2F-B160599E5ADD>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:F9A68240-FAD6-4604-8DEE-1B0E4AF9BD21>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000016583" .
<urn:domeoclient:uuid:C1908624-6F0B-47BD-8D70-8EACD877F4A9>	<http://www.w3.org/ns/oa#exact>	"VKORC1CYP2C9*Ranges are derived from multiple published clinical studies. Other clinical factors (e.g., age, race, body weight, sex, concomitant medications, and comorbidities) are generally accounted for along with genotype in the ranges expressed in the Table. VKORC11639 G(rs9923231) variant is used in this table. Other co-inherited VKORC1 variants may also be important determinants of warfarin dose. Patients with CYP2C9 *1/*3, *2/*2, *2/*3 and *3/*3 may require more prolonged time (>2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen.*1/*1*1/*2*1/*3*2/*2*2/*3*3/*3GG5 to 7 mg5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mgAG5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mgAA3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg" .
<urn:linkedspls:uuid:FBD3A076-17BF-416E-9EEC-89C39FD558A3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:CE483709-CD8C-4493-A2B7-8E589B98BF31>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:6D4DAD4D-1B63-4482-8060-787D97F917D2>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:1DA28968-6C74-475E-AB4F-5E6E22DFF8BD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00675" .
<urn:linkedspls:uuid:D1D85749-709E-4FD8-A464-C8E7CD8158BB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"poor-metabolizer-positive" .
<urn:linkedspls:uuid:E06F2653-44AD-435F-AB2C-133712B039A6>	<http://semanticscience.org/resource/SIO_000111>	"34071-1 WARNINGS SECTION" .
<urn:domeoclient:uuid:942AE26F-116C-4165-9118-723E840DFB17>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:CE2D417D-24B3-4A7E-BE0B-FBF0E34B509B>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:691E83A1-1BFF-4939-996A-35C56D0CF2DF> .
<urn:domeoclient:uuid:BCAE5E0C-30F2-4E8B-8D8E-687ADD4CA18B>	<http://www.w3.org/ns/oa#exact>	"Some individuals may be ultra-rapid metabolizers because of a specific CYP2D6 genotype (gene duplications denoted as *1/*1xN or *1/*2xN). The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. " .
<urn:domeoclient:uuid:BC0A4D53-4B45-488A-8775-B46BF1E9B010>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:D32E2B19-3891-4F8B-98F3-B65344B0F6A8> .
<urn:domeoclient:uuid:B8BA0ADB-2437-4F14-9102-2EC16B13EE4C>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:1A9E2879-AD9B-48F5-B672-AB5C06A28080> .
<urn:domeoclient:uuid:55ED86AA-B414-4220-94FD-868AFE2D1278>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:A24FCBC0-9830-43DC-87D5-5716D3136B02>	<http://semanticscience.org/resource/SIO_000111>	"43682-4 PHARMACOKINETICS SECTION" .
<urn:domeoclient:uuid:1BEAB346-F7B3-40D8-AE65-17ACEB48A7A4>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:D6235B22-042E-4C36-A104-B353CF92CEB8> .
<urn:domeoclient:uuid:0A45211F-B49B-48F5-A9B9-D593DF301DA5>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:8B4BE2A8-5AB2-47D3-A46D-2D1D5E7AC42F>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:29A5252E-79CA-41F6-BF34-26789C947F8D> .
<urn:linkedspls:uuid:169DB9DD-C966-431C-85FE-C3AC1F8E31D3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:domeoclient:uuid:9F23E4DD-C825-4CCC-BD6E-1514188AFFA7>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:A8189564-74C8-463F-9927-917478975C75>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1" .
<urn:domeoclient:uuid:B8BA0ADB-2437-4F14-9102-2EC16B13EE4C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:9992ADBC-4BAB-4529-BAC4-9D7AFD34F098>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:F498E725-B59B-4357-806F-4F316B1EAB6C>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:3746E014-4500-4C39-A007-7B912571A900> .
<urn:domeoclient:uuid:141D5512-1FE5-4684-BAA6-CA59DA362006>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1" .
<urn:domeoclient:uuid:217B566B-E501-4A3D-A7B5-BFA5CE66147B>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:375DD3AE-F16E-43E9-BB3E-D521613E10AF>	<http://www.w3.org/ns/oa#exact>	"In the Hubay study, patients with a positive (more than 3 fmol) estrogen receptor were more likely to benefit." .
<urn:linkedspls:uuid:3728C2D2-73B4-4F3A-A648-FD42247BA4EE>	<http://semanticscience.org/resource/SIO_000111>	"42232-9 PRECAUTIONS SECTION" .
<urn:domeoclient:uuid:8525CDF6-1EFA-4AA5-BD43-C9DDE92E0196>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:8C0132CB-1BA7-4320-8C5F-E55761BC596E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:domeoclient:uuid:F498E725-B59B-4357-806F-4F316B1EAB6C>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:FBA8BE44-2409-4673-8D2F-0E2947538FCE> .
<urn:domeoclient:uuid:BC0A4D53-4B45-488A-8775-B46BF1E9B010>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:407F8565-3B9C-4CF8-B785-C8286BCD86A2> .
<urn:domeoclient:uuid:CF35511B-7BED-446A-B970-33FEE5C13C88>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:A460766E-6EF1-468A-A8D7-D8163DEDE490>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:domeoclient:uuid:CE4F247F-F7CB-4776-A379-05B0401FC08D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:7D37999E-F183-41DD-8FEF-19696FD23D30>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:9A074D82-152F-415F-84A1-93EDCC8179B1> .
<urn:domeoclient:uuid:3CB531B1-A267-4A03-A0C5-D852AB638802>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:92FA8990-60EF-4140-9F60-C12E57E3B114>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:8026784E-DC9A-4F18-963D-495E0532BB97>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:domeoclient:uuid:83E53A9A-8702-4167-A12D-1370E2D26E06>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:151DFA13-B2DF-4857-AAE9-51CADEC9A12F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:domeoclient:uuid:09730EE5-3645-4E22-8362-E17C60539840>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:7FA5409D-3EA5-4F92-B738-8577DCEB4D97>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:F10FC0DB-5D49-46E9-A2C2-3CFFC5FBF692>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:F0F7787E-5F9C-47A4-86B2-D64F1B7602B6> .
<urn:domeoclient:uuid:8F4ED235-6F4A-4BDD-A23F-6F2D9FC7A396>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:1DB91157-FBA4-4FE0-BAB1-68BB8A5A145E>	<http://www.w3.org/ns/oa#exact>	"Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir." .
<urn:domeoclient:uuid:DEA4B73A-145A-4D61-A6E1-ABAE37F63480>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:D3B78E07-8B27-4774-B221-CC47DAC8365E>	<http://purl.org/pav/createdOn>	"2014-03-22 22:02:44 -0400" .
<urn:linkedspls:uuid:9837A225-376D-44A6-959D-05A7DCB03CCE>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"ultra-metabolizer-positive" .
<urn:linkedspls:uuid:74BB3F3E-AD24-438C-9250-4357E959069E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:linkedspls:uuid:8BDFDC96-47AF-489E-8F96-DF9B26C6ECBE>	<http://semanticscience.org/resource/SIO_000111>	"WARNINGS (34071-1)" .
<urn:domeoclient:uuid:88C2CEB5-469C-451E-8436-788ABE4338F5>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:FB17C9EA-111C-4784-80AC-30417D974CE8>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:139D3D04-C6A8-40B1-A6F1-5FBFB1B6B7CE>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:98226070-C5AF-407A-B6D1-D521CD001163> .
<urn:domeoclient:uuid:E1E45497-D882-456B-B573-7A640A307AFB>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:AC31138E-D96E-46FA-AD16-E8C5C6855989>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:C09E3379-98EF-4D6C-8046-8C000B4A6C99>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:2CE69763-0812-4DFF-A359-2A8D8FF706AD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:2EDDDF15-34C4-4321-9EF6-7ACDEBEFD237>	<http://purl.org/pav/createdOn>	"2014-04-14 14:23:14 -0400" .
<urn:domeoclient:uuid:DEE1B9FD-09F4-4AD6-9BEB-55CF10F2FDDB>	<http://www.w3.org/ns/oa#exact>	"Respiratory depression and death have occurred in children who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 [CYP2D6] or high morphine concentrations)" .
<urn:domeoclient:uuid:F0BBC254-D123-49BE-A254-67148370DC96>	<http://www.w3.org/ns/oa#exact>	"CYP2C19 poor metabolizer status is associated with diminished antiplatelet response to clopidogrel. Although a higher dose regimen in poor metabolizers increases antiplatelet response [see Clinical Pharmacology (12.5)], an appropriate dose regimen for this patient population has not been established." .
<urn:domeoclient:uuid:139D3D04-C6A8-40B1-A6F1-5FBFB1B6B7CE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:7AE1124F-F104-4EB3-9415-257F81B2E3CE>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:B35B25D3-31CE-48B5-885E-844B46E97203>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:FBD3A076-17BF-416E-9EEC-89C39FD558A3> .
<urn:domeoclient:uuid:65BD7CC9-2CFA-43C3-A5F0-FBC0221449BF>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:976BDFF3-2BFA-4838-B6A0-327B2921E1B7> .
<urn:domeoclient:uuid:7084C584-8C84-42A3-AFAB-F66F243A2817>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:8B50CE5B-C2BB-4D97-838E-E1C2600020BC>	<http://purl.org/pav/createdOn>	"2014-03-22 22:15:46 -0400" .
<urn:domeoclient:uuid:720C5233-AF5F-4538-891A-259FD3EE6895>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:90E4AF52-01F4-4371-B3ED-D400FF8B1C1E>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:CF0F356A-4BD3-4AB3-80E4-DF7EF3CD5F00> .
<urn:domeoclient:uuid:CE2D417D-24B3-4A7E-BE0B-FBF0E34B509B>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:74BDDF82-70E1-44A8-B130-17D04DE86798>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000016583" .
<urn:domeoclient:uuid:4BED623F-9685-4D95-8EAD-FDE3617D193B>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:136CA05A-B32D-4CAF-B985-0FB9EF4F0455> .
<urn:domeoclient:uuid:9E9B14EC-233F-4ABE-B627-6150C0C5A5A4>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:CF0E7639-6AE6-4519-9A14-41BF8AB6A508>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:1B973C15-149D-4D98-90E2-4A06A2F30ABD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:linkedspls:uuid:EE534BB0-3042-44F4-9B63-01291E28FA45>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:domeoclient:uuid:58D07047-AF21-4623-8E4E-4CB2945F5986>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:53B64B1F-739B-46F0-99EE-89EF4131A8D2>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:CE1DC1EA-085A-4CF9-8165-5A14A411A633>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:56D95EC4-D0D7-4BD6-B13C-E145F6A4E568>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:9179" .
<urn:domeoclient:uuid:40B2A403-27A7-43FE-A0AC-5D87E3545981>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:F19D3DA9-E091-415D-A43E-483BEC7B68FB>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:6B9F2EDD-8EC9-441C-9B9C-6DE4ED079F50>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000016583" .
<urn:linkedspls:uuid:F9A68240-FAD6-4604-8DEE-1B0E4AF9BD21>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:D2A8C2D7-9A3E-4307-BC2B-4EA4FC30E8A5>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:3419ECAE-A4FF-4BE4-8679-16B52BA748AC>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:42FA1C17-B780-423F-B993-EAF8D8DF0329>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:121CDD92-5195-42C0-A613-F40D095DA06D>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:7C3837BB-DAF7-4544-9D2C-A63E2F406BAC>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Codeine" .
<urn:linkedspls:uuid:84646AA6-8E85-4656-8515-E49CB15EADB4>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"PATIENT COUNSELING SECTION still not listed.  How do we code advise patients?" .
<urn:linkedspls:uuid:F5AE3B3E-B864-4A19-B48C-DC1343C799A3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:domeoclient:uuid:6E1788A3-66E3-4952-B193-2C5E9B1AB551>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:8D91E7D5-B379-4649-9834-0D01A948DFF8>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:C24DFA02-2096-4634-974B-1866183BFD0B>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:98FB995B-3B3B-4C86-ACA3-EE4F9F310F41> .
<urn:linkedspls:uuid:08308CA2-E50D-41DB-873B-E57372B5FBDB>	<http://semanticscience.org/resource/SIO_000111>	"43682-4 PHARMACOKINETICS SECTION" .
<urn:domeoclient:uuid:CF0E7639-6AE6-4519-9A14-41BF8AB6A508>	<http://purl.org/pav/createdOn>	"2014-04-28 14:54:20 -0400" .
<urn:linkedspls:uuid:7E666CF4-DD19-4B4B-AE7B-EF4BCEA0181C>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:F777C391-7D5E-4F49-948B-5B9ACB2587FA>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:6E680A49-5B91-4058-A09E-25A6ED988EFC> .
<urn:domeoclient:uuid:4F5C1D0C-9AFC-4B3A-83EC-AC9CB72FB0C9>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:6B4C9D47-E3BF-4D75-A661-0D5A649108C6>	<http://semanticscience.org/resource/SIO_000111>	"42229-5 SPL UNCLASSIFIED SECTION" .
<urn:domeoclient:uuid:D3CF5A34-A1A9-4AFC-83F2-A5A1DD6DBB7F>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:linkedspls:uuid:A460766E-6EF1-468A-A8D7-D8163DEDE490>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Not Important" .
<urn:domeoclient:uuid:75A79304-2BD1-4F33-9391-4BB93929D4E6>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:0B13BA6D-FAED-4224-BF7E-64E31E595AD6> .
<urn:linkedspls:uuid:FEF94E24-725D-433B-8F55-9E75E14CECB9>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"ultra-metabolizer-positive" .
<urn:domeoclient:uuid:23FACDDB-003E-40B5-AB79-B52F5FD124B3>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:5EE59E00-2977-4F09-A933-867C3E165210>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:78CB3193-D01C-49AA-B39B-C35887919EED> .
<urn:domeoclient:uuid:231E14A4-5E1D-443C-B50C-8E3E00BBAF15>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:0A45211F-B49B-48F5-A9B9-D593DF301DA5>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:29951346-424F-4492-B79A-EF5022CB7F05> .
<urn:linkedspls:uuid:8026784E-DC9A-4F18-963D-495E0532BB97>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Clopidogrel" .
<urn:domeoclient:uuid:5D7649B4-7723-40DE-B9AD-4926156D8C0A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:F1D12488-2CA1-4EAD-9A8A-C92106847342>	<http://www.w3.org/ns/oa#exact>	"The relationship between CYP2C19 genotype and clopidogrel bisulfate treatment outcome was evaluated in retrospective analyses of clopidogrel bisulfate-treated subjects in CHARISMA (n=2428) and TRITON-TIMI 38 (n=1477), and in several published cohort studies. In TRITON-TIMI 38 and the majority of the cohort studies, the combined group of patients with either intermediate or poor metabolizer status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolizers. In CHARISMA and one cohort study, the increased event rate was observed only in poor metabolizers." .
<urn:linkedspls:uuid:AC5F1BAD-8B6A-49DB-8147-AB1394EC169F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00758" .
<urn:domeoclient:uuid:6E1788A3-66E3-4952-B193-2C5E9B1AB551>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:EEA90F54-8E00-4B5E-B685-11848BFBA55A> .
<urn:linkedspls:uuid:B7B25E99-EE57-41AC-BDE2-45DCC1447471>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:domeoclient:uuid:99AB6350-6929-4C24-B144-7B97EBF09B3F>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:F0BBC254-D123-49BE-A254-67148370DC96>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1" .
<urn:linkedspls:uuid:D6235B22-042E-4C36-A104-B353CF92CEB8>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:domeoclient:uuid:2386BDBC-D4E5-43AD-9B96-93D7943C7169>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:D26DCABA-C665-4147-A57B-F26195C0188E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1" .
<urn:linkedspls:uuid:1706E63C-45AC-467E-80FD-06108C69A93D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Take note that tests are avaliable" .
<urn:domeoclient:uuid:EED39F7C-032A-4628-9022-2253559E7FEE>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:5D7649B4-7723-40DE-B9AD-4926156D8C0A>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:224ACECA-832C-4CE1-B586-4BB3E2AC8018> .
<urn:domeoclient:uuid:3D5B3334-40F5-4B23-8773-AFED2978DC1D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:1A9E2879-AD9B-48F5-B672-AB5C06A28080>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:79AEDAF0-0AC0-4A44-9F6D-05B14ECEF74F>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:41CC62A5-5C3A-449F-B7A3-675F76FA4085>	<http://purl.org/pav/createdWith>	"urn:domeo:software:id:Domeo-2.1alpha-050" .
<urn:domeoclient:uuid:FE73DA30-2D2E-4D34-AC2F-B160599E5ADD>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:E6B02E4B-FDE8-473A-A978-02F98D0FE07D> .
<urn:domeoclient:uuid:1E6D8BE7-AC23-449A-83E2-9806683F8162>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:E826D255-0A7E-4F3C-A59F-675E8A9B606E> .
<urn:domeoclient:uuid:95EEC2FF-D292-48FE-8FD7-FEF64E2F00E4>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:3D5D3473-95BD-41AF-81E6-ED19E81798E9>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:AAB53C8F-FB14-4216-82D9-D7CD0AB15000>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:0961EB1D-39A9-4A01-9D9B-C2BC3222987E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:domeoclient:uuid:EBA440A2-4EF9-40CD-89BF-56AB858385E6>	<http://www.w3.org/ns/oa#exact>	"Certain single nucleotide polymorphisms in the VKORC1 gene (especially the -1639G>A allele) have been associated with lower dose requirements for warfarin. In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.5 Similar observations have been reported in Asian patients." .
<urn:domeoclient:uuid:94F5EFA2-DEF5-444E-B4C2-7268B36AF650>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee15d911-73c7-4bc6-96f2-089a8aa64e18" .
<urn:domeoclient:uuid:1B1E4FE2-11FA-4FB0-85F2-014750705FED>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:4777BC06-68FA-4171-A52D-68668AD25547>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:8026784E-DC9A-4F18-963D-495E0532BB97>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Decreased Efficacy" .
<urn:domeoclient:uuid:8B4BE2A8-5AB2-47D3-A46D-2D1D5E7AC42F>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:87D0F0C2-6038-41AA-B84E-85497D292836> .
<urn:domeoclient:uuid:CDE45635-21AB-4AC7-89FF-C772F3A15A2C>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:217B566B-E501-4A3D-A7B5-BFA5CE66147B>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:E06F2653-44AD-435F-AB2C-133712B039A6> .
<urn:linkedspls:uuid:9DCD19CE-D636-45D6-B994-A9BDBCA32621>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Codeine" .
<urn:domeoclient:uuid:F5C240E5-0680-4CDA-ACC9-4DB8C5A0984B>	<http://purl.org/pav/createdOn>	"2014-03-22 22:01:43 -0400" .
<urn:domeoclient:uuid:AE6AF907-607C-4B15-B108-FAD4D3010CA4>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:977E5F5B-8852-45BE-A6FC-8DEB91191DED> .
<urn:linkedspls:uuid:68B37481-F382-41B9-AEF5-DB241FA9325F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"ultra-metabolizer-positive" .
<urn:domeoclient:uuid:59E6E4F8-DCB3-4875-86B2-D5885FD80EF7>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:1FAA2AB1-96D9-4225-A9E1-763F045EE2CD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000016583" .
<urn:domeoclient:uuid:38655F0E-DB25-4C1E-A99A-7E2B18134930>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:6E1788A3-66E3-4952-B193-2C5E9B1AB551>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:3728C2D2-73B4-4F3A-A648-FD42247BA4EE> .
<urn:linkedspls:uuid:7E666CF4-DD19-4B4B-AE7B-EF4BCEA0181C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Codeine" .
<urn:linkedspls:uuid:29A5252E-79CA-41F6-BF34-26789C947F8D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:linkedspls:uuid:9A15D029-5B02-4107-A829-E2BD1B1219FE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:linkedspls:uuid:FBD3A076-17BF-416E-9EEC-89C39FD558A3>	<http://semanticscience.org/resource/SIO_000111>	"42231-1 SPL MEDGUIDE SECTION" .
<urn:domeoclient:uuid:8B036858-70F5-4077-8333-F34F19A042EC>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:CE2D417D-24B3-4A7E-BE0B-FBF0E34B509B>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:0DA7AAE6-C82C-4935-9D33-40D96FDB2416> .
<urn:linkedspls:uuid:194FD718-B3CA-4D25-B3D2-56D36C1ECB60>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Influences Drug Response" .
<urn:domeoclient:uuid:46C63D3B-0000-404E-BC76-FB01C42DC7B2>	<http://purl.org/pav/createdOn>	"2014-04-21 13:17:29 -0400" .
<urn:domeoclient:uuid:7D8A9803-9C09-4301-8254-AF8BCE7E83F8>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:0AB99582-A22B-403F-9604-C35A9897CE91> .
<urn:linkedspls:uuid:461FDA58-8FAB-4951-B04A-F969D73C634D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:linkedspls:uuid:61B14255-647D-4AA2-83E5-B81256BF7A50>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:linkedspls:uuid:9837A225-376D-44A6-959D-05A7DCB03CCE>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"ultra-metabolizer" .
<urn:domeoclient:uuid:C24DFA02-2096-4634-974B-1866183BFD0B>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:ED9FC62F-6F5A-4AEC-B2EB-900F4C21E312>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:domeoclient:uuid:8CD7F86F-C041-47B7-B7D2-F7B48F523F56>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:C904A0A3-252D-4872-B966-44B63E18E430>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:F1F72593-1500-4B06-AE14-AE29B3EAE9B1>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1" .
<urn:domeoclient:uuid:B00F626B-2496-40FE-8B44-A026746EF9DB>	<http://www.w3.org/ns/oa#exact>	"Approximately 8% of Caucasians lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are extensive metabolizers (EM). PMs have about an 80% increase in aripiprazole exposure and about a 30% decrease in exposure to the active metabolite compared to EMs, resulting in about a 60% higher exposure to the total active moieties from a given dose of aripiprazole compared to EMs. Coadministration of ABILIFY with known inhibitors of CYP2D6, such as quinidine or fluoxetine in EMs, approximately doubles aripiprazole plasma exposure, and dose adjustment is needed [see DRUG INTERACTIONS (7.1)]. The mean elimination half-lives are about 75 hours and 146 hours for aripiprazole in EMs and PMs, respectively." .
<urn:linkedspls:uuid:9739D8D8-F16D-4FF9-BD63-1945B116EEC4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:domeoclient:uuid:7D8A9803-9C09-4301-8254-AF8BCE7E83F8>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:B7B25E99-EE57-41AC-BDE2-45DCC1447471>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00758" .
<urn:domeoclient:uuid:7BFF4A61-D45D-4C1F-9599-BD435EF039B8>	<http://www.w3.org/ns/oa#exact>	"Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible." .
<urn:domeoclient:uuid:43CE071E-85A3-4BC0-AEAC-4FC4DCBB3D02>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:5229A912-1F9A-40AD-9994-79886D701F6C>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:EF161740-C79C-4D2A-9002-4B0A139BF81E> .
<urn:domeoclient:uuid:90768224-544A-41CF-9969-E08884F1434D>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:C904A0A3-252D-4872-B966-44B63E18E430> .
<urn:linkedspls:uuid:3728C2D2-73B4-4F3A-A648-FD42247BA4EE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C9" .
<urn:domeoclient:uuid:74791FAB-E4B4-4EA3-9557-BD68EDB49B01>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:403ED560-E6D3-4B1C-BAF1-DD0E0D87AA3F>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1" .
<urn:linkedspls:uuid:6B9F2EDD-8EC9-441C-9B9C-6DE4ED079F50>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"Added test results (or categorize as poor?)" .
<urn:linkedspls:uuid:53B64B1F-739B-46F0-99EE-89EF4131A8D2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Codeine" .
<urn:domeoclient:uuid:97CDCA51-103C-4EB7-BA80-9670B117D103>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:C8824A36-9C96-4389-B215-2638B48B5437> .
<urn:domeoclient:uuid:EE521BAD-75B0-418A-A885-F72D473E4567>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:C6988919-6455-4291-92FF-E4F63DF9F9BF>	<http://www.w3.org/ns/oa#exact>	"Some published studies suggest that intermediate metabolizers have decreased active metabolite exposure and diminished antiplatelet effects.\\\\r\\n\\\\r\\nThe relationship between CYP2C19 genotype and clopidogrel bisulfate treatment outcome was evaluated in retrospective analyses of clopidogrel bisulfate-treated subjects in CHARISMA (n=2428) and TRITON-TIMI 38 (n=1477), and in several published cohort studies. In TRITON-TIMI 38 and the majority of the cohort studies, the combined group of patients with either intermediate or poor metabolizer status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolizers. In CHARISMA and one cohort study, the increased event rate was observed only in poor metabolizers." .
<urn:linkedspls:uuid:A903F38F-38D4-4052-A673-7FF19407E3DB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:AC5F1BAD-8B6A-49DB-8147-AB1394EC169F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:linkedspls:uuid:ED9FC62F-6F5A-4AEC-B2EB-900F4C21E312>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"MErge with above annoation due to \\\"rates provided above\\\"?" .
<urn:linkedspls:uuid:A24FCBC0-9830-43DC-87D5-5716D3136B02>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Aripiprazole" .
<urn:domeoclient:uuid:5949C0ED-ECE8-4C36-B91D-8E58F7A36AAC>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:9D01B1F5-3775-4CA3-BDFA-97BF6089AE2E> .
<urn:domeoclient:uuid:5EE59E00-2977-4F09-A933-867C3E165210>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:6E680A49-5B91-4058-A09E-25A6ED988EFC>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00993" .
<urn:domeoclient:uuid:5CCA20AA-4D3C-40F4-BAED-C832E665FA35>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:6B9F2EDD-8EC9-441C-9B9C-6DE4ED079F50>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:E1E45497-D882-456B-B573-7A640A307AFB>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:7D50A614-4F2B-42C6-A175-0BF3C158B5DA> .
<urn:domeoclient:uuid:CA5A93F5-5D2A-44BF-8951-9EF6DFE12F1B>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:9739D8D8-F16D-4FF9-BD63-1945B116EEC4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:671F2493-9F0B-4BB9-94E6-4B432F418763>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:FC766D1F-0C5B-4C57-8386-30CC6B3408B5> .
<urn:domeoclient:uuid:FE73DA30-2D2E-4D34-AC2F-B160599E5ADD>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:BCC8E4C0-518C-4CB7-86BA-64CE75086359> .
<urn:linkedspls:uuid:C9CADF5C-CD94-4A8C-B6CF-12220ED65397>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Influences Drug Response" .
<urn:linkedspls:uuid:5E02C5AB-C35D-4ACA-8EF0-DF0F481E6A00>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:linkedspls:uuid:27F9E2A8-C54A-4F87-A02D-4F8EFF5D382F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00993" .
<urn:domeoclient:uuid:BC0A4D53-4B45-488A-8775-B46BF1E9B010>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:F19D3DA9-E091-415D-A43E-483BEC7B68FB>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:398416DB-3813-458C-AEAD-1E703244DEC7> .
<urn:domeoclient:uuid:9DDE5A30-59ED-49D7-B9B6-316245562477>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:DEA4B73A-145A-4D61-A6E1-ABAE37F63480>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:74EA2B44-40D9-44F0-90BA-33EFF2D1B5AA> .
<urn:linkedspls:uuid:FE1B382B-9F39-4CAA-8A59-17376ED6F061>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:3535" .
<urn:linkedspls:uuid:7C3837BB-DAF7-4544-9D2C-A63E2F406BAC>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:ED2F98CA-60F0-4D49-9803-FED968AA3114>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:D640727D-6442-4274-B453-64F04BD595E3>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:58D07047-AF21-4623-8E4E-4CB2945F5986>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:7FD03E69-B442-41B6-B8EB-38BD572E8F45> .
<urn:domeoclient:uuid:F777C391-7D5E-4F49-948B-5B9ACB2587FA>	<http://purl.org/pav/createdOn>	"2014-04-21 12:22:51 -0400" .
<urn:linkedspls:uuid:558D142F-DBE9-4EB9-9F46-4244D63F2FAF>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:linkedspls:uuid:C904A0A3-252D-4872-B966-44B63E18E430>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Clopidogrel" .
<urn:domeoclient:uuid:8A35BACC-77B7-4822-A677-4D72A3B91942>	<http://www.w3.org/ns/oa#exact>	"Respiratory depression and death have occurred in children with obstructive sleep apnea who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 or high morphine concentrations). These children may be particularly sensitive to the respiratory depressant effects of codeine that has been rapidly metabolized to morphine." .
<urn:domeoclient:uuid:5229A912-1F9A-40AD-9994-79886D701F6C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:9C09D2F8-83BE-446D-A17A-75402666EE4B>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:8026784E-DC9A-4F18-963D-495E0532BB97>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Decrease" .
<urn:domeoclient:uuid:1042FEEA-5AF3-4E50-B2A1-053451F2236C>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:31115D88-2436-4D8C-B5E2-A7636A9DA498>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER_receptor" .
<urn:linkedspls:uuid:A460766E-6EF1-468A-A8D7-D8163DEDE490>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:linkedspls:uuid:194FD718-B3CA-4D25-B3D2-56D36C1ECB60>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:domeoclient:uuid:139D3D04-C6A8-40B1-A6F1-5FBFB1B6B7CE>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:ED9FC62F-6F5A-4AEC-B2EB-900F4C21E312> .
<urn:domeoclient:uuid:ED2F98CA-60F0-4D49-9803-FED968AA3114>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:08308CA2-E50D-41DB-873B-E57372B5FBDB> .
<urn:domeoclient:uuid:FB8FC7BE-DF14-4ABF-B790-607DABB38F49>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:1BEAB346-F7B3-40D8-AE65-17ACEB48A7A4>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:15924106-592A-47E7-A01C-764A16E257DC> .
<urn:linkedspls:uuid:108444AC-C8D7-42EE-A011-BE98A3F592F0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:F880CCED-A2A0-4330-B02F-070F7BF5AF00>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:58D07047-AF21-4623-8E4E-4CB2945F5986>	<http://purl.org/pav/createdOn>	"2014-06-09 15:47:23 -0400" .
<urn:domeoclient:uuid:2083D2DB-07EF-4969-A4BB-F5823A134875>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:4D27D69B-2F63-4940-AD74-710454AA1E6A> .
<urn:linkedspls:uuid:1FAA2AB1-96D9-4225-A9E1-763F045EE2CD>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:FA0C425E-2A1E-4059-BAC2-34BD4239836F>	<http://www.w3.org/ns/oa#exact>	"In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estrogen- and progesterone-receptor levels less than 10 fmol. In women aged 60 to 70 years, there was a trend toward a beneficial effect of tamoxifen without any clear relationship to estrogen- or progesterone-receptor status." .
<urn:domeoclient:uuid:1E6D8BE7-AC23-449A-83E2-9806683F8162>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:BF7AF633-8B36-41BF-AC4F-0BA548A0DB2F> .
<urn:domeoclient:uuid:4BED623F-9685-4D95-8EAD-FDE3617D193B>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:0961EB1D-39A9-4A01-9D9B-C2BC3222987E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:408C86B9-FFBA-4A7F-A6EC-ECD348FD4782>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:C9CADF5C-CD94-4A8C-B6CF-12220ED65397>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:domeoclient:uuid:C24DFA02-2096-4634-974B-1866183BFD0B>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:855BF4FE-7082-466C-AEC2-BA37C5A2F93C> .
<urn:linkedspls:uuid:74BB3F3E-AD24-438C-9250-4357E959069E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00758" .
<urn:domeoclient:uuid:90E4AF52-01F4-4371-B3ED-D400FF8B1C1E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:905B00B5-CD9F-4F5A-BDCD-2E0771AC9B73>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:CA5A93F5-5D2A-44BF-8951-9EF6DFE12F1B>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:8BDFDC96-47AF-489E-8F96-DF9B26C6ECBE> .
<urn:domeoclient:uuid:98743D23-3B02-4029-840D-D16A4F390F95>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:4019443F-CB02-40D7-BB18-37DDB00B1548> .
<urn:domeoclient:uuid:CF35511B-7BED-446A-B970-33FEE5C13C88>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:942AE26F-116C-4165-9118-723E840DFB17>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:D92166A3-0B32-4545-B4CA-719FEDAF410D> .
<urn:linkedspls:uuid:53541A7F-ACF6-4030-A4B7-7BA865CDF82F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:9C09D2F8-83BE-446D-A17A-75402666EE4B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00675" .
<urn:domeoclient:uuid:D03D6753-24D2-4897-9947-4D727F406A9D>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:B00F626B-2496-40FE-8B44-A026746EF9DB> .
<urn:domeoclient:uuid:2083D2DB-07EF-4969-A4BB-F5823A134875>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:2BB0E9F3-52F1-4631-B37B-DBFB53B3B0C9> .
<urn:domeoclient:uuid:72569EC5-72D5-43F3-9028-CE31C726B1D0>	<http://www.w3.org/ns/oa#exact>	"Bone Study: Results of a phase 3 safety trial in 262 post menopausal women with resected receptor positive early breast cancer in the adjuvant setting comparing the effect on lumbar spine (L2-L4) bone mineral density (BMD) of adjuvant treatment with letrozole to that with tamoxifen showed at 24 months a median decrease in lumbar spine BMD of 4.1% in the letrozole arm compared to a median increase of 0.3% in the tamoxifen arm (difference = 4.4%) (P<0.0001). No patients with a normal BMD at baseline became osteoporotic over the 2 years and only 1 patient with osteopenia at baseline (T score of -1.9) developed osteoporosis during the treatment period (assessment by central review). The results for total hip BMD were similar, although the differences between the two treatments were less pronounced. During the 2 year period, fractures were reported by 4 of 103 patients (4%) in the letrozole arm, and 6 of 97 patients (6%) in the tamoxifen arm." .
<urn:domeoclient:uuid:7D37999E-F183-41DD-8FEF-19696FD23D30>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:E719DBCC-60BF-47C9-A2A6-B5AD564ED472>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:83E53A9A-8702-4167-A12D-1370E2D26E06>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:97CDCA51-103C-4EB7-BA80-9670B117D103>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:8F4ED235-6F4A-4BDD-A23F-6F2D9FC7A396>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:B35B25D3-31CE-48B5-885E-844B46E97203>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:55709DA6-0396-4327-B704-FE38E5F01C43> .
<urn:domeoclient:uuid:98743D23-3B02-4029-840D-D16A4F390F95>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:45844BA9-29ED-4EC6-94C0-81C9883F880F> .
<urn:domeoclient:uuid:90768224-544A-41CF-9969-E08884F1434D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:DBBF90A0-6468-4792-B1CC-02DDD21B4A08>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:72569EC5-72D5-43F3-9028-CE31C726B1D0> .
<urn:linkedspls:uuid:FC766D1F-0C5B-4C57-8386-30CC6B3408B5>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:FB17C9EA-111C-4784-80AC-30417D974CE8>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:74791FAB-E4B4-4EA3-9557-BD68EDB49B01>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:F30A3592-1EDA-414B-8C7B-2B931B766619> .
<urn:linkedspls:uuid:4DD1AE8C-CB2C-4887-993E-A8A44B2A06CB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:domeoclient:uuid:14099187-A7EA-4F77-905D-B1B942FF80D7>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:3746E014-4500-4C39-A007-7B912571A900>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:domeoclient:uuid:237CBF43-3113-4746-AC7C-0EEE2CD7D926>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:9F0CE910-4782-4E6D-B7E2-C7C784B10B90>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee15d911-73c7-4bc6-96f2-089a8aa64e18" .
<urn:linkedspls:uuid:9837A225-376D-44A6-959D-05A7DCB03CCE>	<http://semanticscience.org/resource/SIO_000111>	"34080-2 NURSING MOTHERS SECTION" .
<urn:linkedspls:uuid:763ABA1D-A316-42DE-AA02-A7123411CD6C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB01006" .
<urn:domeoclient:uuid:F498E725-B59B-4357-806F-4F316B1EAB6C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:AE6AF907-607C-4B15-B108-FAD4D3010CA4>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:75D456DC-1DB0-4F96-A11F-551CC8425889> .
<urn:linkedspls:uuid:24265221-E0B1-4F13-A2EB-0E9D9DC6F5D4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1" .
<urn:domeoclient:uuid:C09E3379-98EF-4D6C-8046-8C000B4A6C99>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:7CE2D02E-F446-465D-9CBE-27C213ACCC89>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:9982EFEC-057D-47A7-8241-37ACB3F049AA>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:82F247F1-5E0B-472B-8C42-4074C2A25CD0>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:68B37481-F382-41B9-AEF5-DB241FA9325F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"ultra-metabolizer" .
<urn:domeoclient:uuid:8B4BE2A8-5AB2-47D3-A46D-2D1D5E7AC42F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:B8BA0ADB-2437-4F14-9102-2EC16B13EE4C>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:10B1EB06-38FD-41C2-A3B7-625B2825B889> .
<urn:linkedspls:uuid:44A37F21-E420-40D5-A9E0-5CEDEFAEF40B>	<http://semanticscience.org/resource/SIO_000111>	"42231-1 SPL MEDGUIDE SECTION" .
<urn:domeoclient:uuid:720C5233-AF5F-4538-891A-259FD3EE6895>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:F0BBC254-D123-49BE-A254-67148370DC96>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:5D87AC20-773F-4241-AA52-57BF86A4A93A>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:1BEAB346-F7B3-40D8-AE65-17ACEB48A7A4>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:FEF94E24-725D-433B-8F55-9E75E14CECB9>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"ultra-metabolizer" .
<urn:domeoclient:uuid:D92166A3-0B32-4545-B4CA-719FEDAF410D>	<http://www.w3.org/ns/oa#exact>	"Tests are available to determine a patient\u2019s CYP2C19 genotype." .
<urn:domeoclient:uuid:CF0E7639-6AE6-4519-9A14-41BF8AB6A508>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:96D6F8F1-F51A-4EBC-BFF7-C799690B4401>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-negative" .
<urn:linkedspls:uuid:BC70D092-5124-4A5C-87C3-EA34E4868C05>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:CE76789E-AB5D-4F50-AF22-F3C2D4249992>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:domeoclient:uuid:F10FC0DB-5D49-46E9-A2C2-3CFFC5FBF692>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:599459E0-8D98-4627-BC38-BA5B6BEC6B33>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:40B2A403-27A7-43FE-A0AC-5D87E3545981>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:BDEED6AF-6C6D-44F0-8470-40D3A54778C5>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:5D7649B4-7723-40DE-B9AD-4926156D8C0A>	<http://purl.org/pav/createdOn>	"2014-04-21 13:23:42 -0400" .
<urn:domeoclient:uuid:AAB53C8F-FB14-4216-82D9-D7CD0AB15000>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:44A37F21-E420-40D5-A9E0-5CEDEFAEF40B> .
<urn:domeoclient:uuid:DB8F110F-7415-4B13-AB5B-23F1D7A1C6BF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:76AEC8EC-841B-4618-8A97-4D6655CE39F4>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:5630014D-C820-4E31-A061-529A1A06548B>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:1DB91157-FBA4-4FE0-BAB1-68BB8A5A145E> .
<urn:linkedspls:uuid:09071EE6-03DB-49CA-BA67-1589B0E2FDBD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:domeoclient:uuid:69B50E0E-4BB4-49DC-AE8B-4326D0F0A959>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:AAB53C8F-FB14-4216-82D9-D7CD0AB15000>	<http://purl.org/pav/createdOn>	"2014-04-28 15:56:23 -0400" .
<urn:linkedspls:uuid:5239657F-5948-4803-B690-76D953D60764>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:121CDD92-5195-42C0-A613-F40D095DA06D>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:75D988CE-7527-421D-AAA6-0C9C0D4B30DF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:855BF4FE-7082-466C-AEC2-BA37C5A2F93C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:domeoclient:uuid:CE483709-CD8C-4493-A2B7-8E589B98BF31>	<http://purl.org/pav/createdOn>	"2014-06-02 14:43:54 -0400" .
<urn:domeoclient:uuid:B3811262-7FB7-4610-8AF2-DDBEC1F3F734>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:84646AA6-8E85-4656-8515-E49CB15EADB4>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:EE521BAD-75B0-418A-A885-F72D473E4567>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:B6B4A58C-16B0-408F-A838-47FC8649B72D> .
<urn:linkedspls:uuid:402D9368-C611-4289-8004-8EEC1A409CCF>	<http://semanticscience.org/resource/SIO_000111>	"42229-5 SPL UNCLASSIFIED SECTION" .
<urn:domeoclient:uuid:037A2873-CACE-474F-B3EB-1EF6E0A58FCF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:5630014D-C820-4E31-A061-529A1A06548B>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:D66FA8C3-8BAB-4A6F-8234-6DD134876578> .
<urn:domeoclient:uuid:D03D6753-24D2-4897-9947-4D727F406A9D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:42FA1C17-B780-423F-B993-EAF8D8DF0329>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:51C4FEDD-5F25-4F57-92BC-5456BC2E4846>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:EE521BAD-75B0-418A-A885-F72D473E4567>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:F0B7C43C-792D-49E5-B282-D2303F858889> .
<urn:domeoclient:uuid:2EDDDF15-34C4-4321-9EF6-7ACDEBEFD237>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:055AAAC1-3544-4B8E-BF06-C99328A12B6E> .
<urn:linkedspls:uuid:9C843591-806D-42E0-88A9-58DC59076B3D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1" .
<urn:domeoclient:uuid:47718F61-F7FA-4A83-BB17-C13189D5E884>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:FE990D63-4739-43A5-B062-7A946346B2AF> .
<urn:domeoclient:uuid:420A3DFE-8247-4E9B-8E6C-368F1A2C415C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:850F3B60-ADC8-42A5-8E7E-B50B1E9D39BE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"F5" .
<urn:linkedspls:uuid:599459E0-8D98-4627-BC38-BA5B6BEC6B33>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:linkedspls:uuid:F0B7C43C-792D-49E5-B282-D2303F858889>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"UGT1A1" .
<urn:domeoclient:uuid:D3CF5A34-A1A9-4AFC-83F2-A5A1DD6DBB7F>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:4BED623F-9685-4D95-8EAD-FDE3617D193B>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:1DA28968-6C74-475E-AB4F-5E6E22DFF8BD> .
<urn:domeoclient:uuid:87228117-6F6A-41A0-9709-5D0977E83A06>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:1DA28968-6C74-475E-AB4F-5E6E22DFF8BD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:8910" .
<urn:domeoclient:uuid:DBBF90A0-6468-4792-B1CC-02DDD21B4A08>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:ABB77F0A-DE6D-4F3D-87F3-CFA59807AA63>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee15d911-73c7-4bc6-96f2-089a8aa64e18" .
<urn:domeoclient:uuid:231E14A4-5E1D-443C-B50C-8E3E00BBAF15>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:5CCA20AA-4D3C-40F4-BAED-C832E665FA35>	<http://purl.org/pav/createdOn>	"2014-04-28 15:25:28 -0400" .
<urn:linkedspls:uuid:F270E3B3-9983-425D-98FB-66F62E36340F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:1706E63C-45AC-467E-80FD-06108C69A93D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:68B37481-F382-41B9-AEF5-DB241FA9325F>	<http://semanticscience.org/resource/SIO_000111>	"42229-5 SPL UNCLASSIFIED SECTION" .
<urn:linkedspls:uuid:1B973C15-149D-4D98-90E2-4A06A2F30ABD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:domeoclient:uuid:2386BDBC-D4E5-43AD-9B96-93D7943C7169>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:F54825B6-3CF9-4465-A4BE-7C6747734A6E> .
<urn:domeoclient:uuid:4019443F-CB02-40D7-BB18-37DDB00B1548>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:2EDDDF15-34C4-4321-9EF6-7ACDEBEFD237>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:D03D6753-24D2-4897-9947-4D727F406A9D>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:A24FCBC0-9830-43DC-87D5-5716D3136B02> .
<urn:linkedspls:uuid:CD7BE61C-D111-48EB-A232-1241D41AB8BC>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:2386BDBC-D4E5-43AD-9B96-93D7943C7169>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:B24A699D-7127-47C1-BFAE-C1ABB6819E2F> .
<urn:domeoclient:uuid:8CD7F86F-C041-47B7-B7D2-F7B48F523F56>	<http://purl.org/pav/createdOn>	"2014-04-14 13:34:44 -0400" .
<urn:domeoclient:uuid:1B1E4FE2-11FA-4FB0-85F2-014750705FED>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:EE534BB0-3042-44F4-9B63-01291E28FA45> .
<urn:linkedspls:uuid:0B39F957-E88F-427C-AC41-F1B9DC711A02>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:domeoclient:uuid:69B50E0E-4BB4-49DC-AE8B-4326D0F0A959>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:AF427FC6-54B8-4CA4-9C51-233E64726500> .
<urn:domeoclient:uuid:A8189564-74C8-463F-9927-917478975C75>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:C1BF7FF6-707B-4750-BA47-274111148F96>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:BCCF3F22-38AE-4F01-87D0-22C1B07EC947> .
<urn:domeoclient:uuid:F1F72593-1500-4B06-AE14-AE29B3EAE9B1>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:10D9A112-25CB-425E-899B-C3AAA3CF633A>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee15d911-73c7-4bc6-96f2-089a8aa64e18" .
<urn:domeoclient:uuid:F777C391-7D5E-4F49-948B-5B9ACB2587FA>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:EED39F7C-032A-4628-9022-2253559E7FEE>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:86480047-DD43-4A54-B258-3772C18237F7>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Influences Drug Response" .
<urn:domeoclient:uuid:1B1E4FE2-11FA-4FB0-85F2-014750705FED>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:79C530FF-637A-43C8-AECE-CA81458FB5EE> .
<urn:domeoclient:uuid:147B38AF-9E51-4D8A-B5CF-D7FAE7375257>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:141D5512-1FE5-4684-BAA6-CA59DA362006>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:1E6D8BE7-AC23-449A-83E2-9806683F8162>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:41CC62A5-5C3A-449F-B7A3-675F76FA4085>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:CE76789E-AB5D-4F50-AF22-F3C2D4249992>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Tamoxifen" .
<urn:domeoclient:uuid:B3811262-7FB7-4610-8AF2-DDBEC1F3F734>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:905B00B5-CD9F-4F5A-BDCD-2E0771AC9B73> .
<urn:domeoclient:uuid:403ED560-E6D3-4B1C-BAF1-DD0E0D87AA3F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:58D07047-AF21-4623-8E4E-4CB2945F5986>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:763ABA1D-A316-42DE-AA02-A7123411CD6C> .
<urn:domeoclient:uuid:98743D23-3B02-4029-840D-D16A4F390F95>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:75C4424E-2C9D-40D9-82CF-7E02CFDCA301>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:5D87AC20-773F-4241-AA52-57BF86A4A93A>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:7CE2D02E-F446-465D-9CBE-27C213ACCC89>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:linkedspls:uuid:25348450-1CCF-4BEC-84EF-0EA92F67DD3A>	<http://semanticscience.org/resource/SIO_000111>	"34070-3 CONTRAINDICATIONS SECTION" .
<urn:domeoclient:uuid:F3C6E27C-CBBA-4B36-810C-D42C3FA4AB93>	<http://www.w3.org/ns/oa#exact>	"Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions. TPMT testing may also be considered in patients with abnormal CBC results that do not respond to dose reduction. Early drug discontinuation in these patients is advisable. TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING AZATHIOPRINE TABLETS" .
<urn:domeoclient:uuid:72569EC5-72D5-43F3-9028-CE31C726B1D0>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:6E7BEB44-17B2-4A01-8866-7DAFBEA17CC6>	<http://www.w3.org/ns/oa#exact>	"Discontinue ZIAGEN as soon as a hypersensitivity reaction is suspected. Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible." .
<urn:linkedspls:uuid:24265221-E0B1-4F13-A2EB-0E9D9DC6F5D4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:domeoclient:uuid:9098E55C-952E-46DF-904C-2A3E63492B3A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:2083D2DB-07EF-4969-A4BB-F5823A134875>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:F10FC0DB-5D49-46E9-A2C2-3CFFC5FBF692>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:74EB8F8A-FCEA-41C8-BAB2-B4DFA1190D34> .
<urn:linkedspls:uuid:05DBF40D-ECCF-4BC6-9077-742EBADF41F9>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:72D8F9E8-4B4D-4FC2-81A2-A19C5BF05098>	<http://www.w3.org/ns/oa#exact>	"Patients with intermediate TPMT activity may be at increased risk of myelotoxicity if receiving conventional doses of azathioprine tablets." .
<urn:linkedspls:uuid:6B9F2EDD-8EC9-441C-9B9C-6DE4ED079F50>	<http://semanticscience.org/resource/SIO_000111>	"34090-1 CLINICAL PHARMACOLOGY SECTION" .
<urn:domeoclient:uuid:9E003EB3-2B97-41C7-BD14-5EAF744BB5F2>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:92FA8990-60EF-4140-9F60-C12E57E3B114>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:7C3837BB-DAF7-4544-9D2C-A63E2F406BAC>	<http://semanticscience.org/resource/SIO_000111>	"42229-5 SPL UNCLASSIFIED SECTION" .
<urn:domeoclient:uuid:65BD7CC9-2CFA-43C3-A5F0-FBC0221449BF>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:87B8F5B0-8381-4CA7-AE0B-30C481D164B4> .
<urn:domeoclient:uuid:DEA4B73A-145A-4D61-A6E1-ABAE37F63480>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:CFEF239C-B763-4864-8DD8-A917EFD12673> .
<urn:linkedspls:uuid:F270E3B3-9983-425D-98FB-66F62E36340F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:14BA7077-8D33-42DD-A380-DD27F50087AD>	<http://www.w3.org/ns/oa#exact>	"The effect of the scheduled duration of tamoxifen may be described as follows. In women with ER positive or unknown breast cancer receiving 1 year or less, 2 years or about 5 years of tamoxifen, the proportional reductions in mortality were 12%, 17% and 26%, respectively (trend significant at 2p < 0.003). The corresponding reductions in breast cancer recurrence were 21%, 29% and 47% (trend significant at 2p < 0.00001)." .
<urn:domeoclient:uuid:616A0715-5B79-4DD8-8392-1FDEF99E9911>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:AE6AF907-607C-4B15-B108-FAD4D3010CA4>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:BF7AF633-8B36-41BF-AC4F-0BA548A0DB2F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:ED2F98CA-60F0-4D49-9803-FED968AA3114>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:82F247F1-5E0B-472B-8C42-4074C2A25CD0> .
<urn:linkedspls:uuid:3746E014-4500-4C39-A007-7B912571A900>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Tamoxifen" .
<urn:domeoclient:uuid:29B0BAC9-227E-4C4D-96D2-143CC457E50C>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:29951346-424F-4492-B79A-EF5022CB7F05>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:B00F626B-2496-40FE-8B44-A026746EF9DB>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:BBD1EA14-A142-47FF-A3B5-D848FFAED44F>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee15d911-73c7-4bc6-96f2-089a8aa64e18" .
<urn:domeoclient:uuid:671F2493-9F0B-4BB9-94E6-4B432F418763>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:domeoclient:uuid:B3811262-7FB7-4610-8AF2-DDBEC1F3F734>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:7BFF4A61-D45D-4C1F-9599-BD435EF039B8> .
<urn:domeoclient:uuid:98B929B0-EA85-44FF-B8CA-9D5AC804EBBB>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:B30B41E3-5A67-4530-BC81-938E6B016FDF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:D939C426-7E0B-4A32-80F1-7344D702AA97>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00215" .
<urn:linkedspls:uuid:86480047-DD43-4A54-B258-3772C18237F7>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:domeoclient:uuid:B00F626B-2496-40FE-8B44-A026746EF9DB>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:29951346-424F-4492-B79A-EF5022CB7F05>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:0F8A06DC-D6FE-466C-AF73-CF9E7A8C2707>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:FBD3A076-17BF-416E-9EEC-89C39FD558A3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:D3EDFFC9-9EE3-45DD-B147-801DAB72DF3D>	<http://semanticscience.org/resource/SIO_000111>	"43682-4 PHARMACOKINETICS SECTION" .
<urn:linkedspls:uuid:169DB9DD-C966-431C-85FE-C3AC1F8E31D3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:405A5AAA-08FD-470C-9B50-67E44ED1462F>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:6B9F2EDD-8EC9-441C-9B9C-6DE4ED079F50> .
<urn:domeoclient:uuid:616A0715-5B79-4DD8-8392-1FDEF99E9911>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:3C70DFC4-2BEA-46AE-A49C-D4BE3E7466B8>	<http://purl.org/pav/createdOn>	"2014-04-14 14:29:31 -0400" .
<urn:linkedspls:uuid:45EDCED8-9B43-464F-AC7F-898A9009649D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00993" .
<urn:domeoclient:uuid:405A5AAA-08FD-470C-9B50-67E44ED1462F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:75C4424E-2C9D-40D9-82CF-7E02CFDCA301>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:E34142C5-1680-4612-AC76-D96D8F82364F>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:5E02C5AB-C35D-4ACA-8EF0-DF0F481E6A00>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:9098E55C-952E-46DF-904C-2A3E63492B3A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:72569EC5-72D5-43F3-9028-CE31C726B1D0>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:65BD7CC9-2CFA-43C3-A5F0-FBC0221449BF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:74EA2B44-40D9-44F0-90BA-33EFF2D1B5AA>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:7C3837BB-DAF7-4544-9D2C-A63E2F406BAC>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:C2A76A18-A463-4D7B-9A00-33BEFE84F768>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:1FAA2AB1-96D9-4225-A9E1-763F045EE2CD>	<http://semanticscience.org/resource/SIO_000111>	"34090-1 CLINICAL PHARMACOLOGY SECTION" .
<urn:linkedspls:uuid:A460766E-6EF1-468A-A8D7-D8163DEDE490>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Tamoxifen" .
<urn:linkedspls:uuid:87B8F5B0-8381-4CA7-AE0B-30C481D164B4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:domeoclient:uuid:403ED560-E6D3-4B1C-BAF1-DD0E0D87AA3F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:9C843591-806D-42E0-88A9-58DC59076B3D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:domeoclient:uuid:B35B25D3-31CE-48B5-885E-844B46E97203>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:E17574BF-3BA6-48DA-B0DA-6E8DF716A03D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:E7B4486A-24AB-4642-ADB0-B78FF5AF0E42>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:BF7AF633-8B36-41BF-AC4F-0BA548A0DB2F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:87B8F5B0-8381-4CA7-AE0B-30C481D164B4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Clopidogrel" .
<urn:domeoclient:uuid:147B38AF-9E51-4D8A-B5CF-D7FAE7375257>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:141D5512-1FE5-4684-BAA6-CA59DA362006>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:9EBC36A6-A85E-4348-8EBC-5B071D8A79FB>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SPLAnnotation> .
<urn:linkedspls:uuid:B24A699D-7127-47C1-BFAE-C1ABB6819E2F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:E06F2653-44AD-435F-AB2C-133712B039A6>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:6A2E1BD4-3863-4A37-AD9D-6B54F3CF3E54>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:domeoclient:uuid:F1F72593-1500-4B06-AE14-AE29B3EAE9B1>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:A8189564-74C8-463F-9927-917478975C75>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:4C36F11A-E282-4BFB-849D-B93A233A50FB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"POLG" .
<urn:linkedspls:uuid:1FAA2AB1-96D9-4225-A9E1-763F045EE2CD>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:4019443F-CB02-40D7-BB18-37DDB00B1548>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:55BCCCDC-ED3F-427D-AFFE-0E80E459C63A>	<http://www.w3.org/ns/oa#exact>	"Screening for carriage of the HLA -B*5701 allele is recommended prior to initiating treatment with abacavir. " .
<urn:linkedspls:uuid:36FDCB4E-5E54-4CBA-BC44-04B836C019F0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:domeoclient:uuid:87228117-6F6A-41A0-9709-5D0977E83A06>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:1532F8ED-1CF3-45D5-8A36-00FA8FD6060D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:linkedspls:uuid:055AAAC1-3544-4B8E-BF06-C99328A12B6E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:E6B02E4B-FDE8-473A-A978-02F98D0FE07D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:6D4DAD4D-1B63-4482-8060-787D97F917D2>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:396CB021-3C85-4E20-B020-3714CE558E2D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:domeoclient:uuid:037A2873-CACE-474F-B3EB-1EF6E0A58FCF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:2510C893-9155-453B-922C-CF116136DD88>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Alternative Recommended" .
<urn:linkedspls:uuid:0B3E23EF-1696-4FF7-BEEB-8158BDA84294>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:A903F38F-38D4-4052-A673-7FF19407E3DB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:9F23E4DD-C825-4CCC-BD6E-1514188AFFA7>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e143044e90f26014518a19cf70063" .
<urn:linkedspls:uuid:45844BA9-29ED-4EC6-94C0-81C9883F880F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:0B3E23EF-1696-4FF7-BEEB-8158BDA84294>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:domeoclient:uuid:DB8F110F-7415-4B13-AB5B-23F1D7A1C6BF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:76AEC8EC-841B-4618-8A97-4D6655CE39F4>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:3C852929-ADD4-4383-A351-2D9CF492A6E9>	<http://purl.org/pav/createdOn>	"2014-04-21 13:39:30 -0400" .
<urn:linkedspls:uuid:13F3B206-EA87-463E-9DA8-93AA056A9117>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:domeoclient:uuid:F0BBC254-D123-49BE-A254-67148370DC96>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:CDE45635-21AB-4AC7-89FF-C772F3A15A2C>	<http://purl.org/pav/createdOn>	"2014-04-28 15:28:34 -0400" .
<urn:linkedspls:uuid:BC70D092-5124-4A5C-87C3-EA34E4868C05>	<http://semanticscience.org/resource/SIO_000111>	"42229-5 SPL UNCLASSIFIED SECTION" .
<urn:linkedspls:uuid:F45F585A-05C5-49B5-BABB-73BFBE9E9753>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:2185EE39-FD81-4C83-ABDF-E5D59B789F96>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:domeoclient:uuid:9982EFEC-057D-47A7-8241-37ACB3F049AA>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:82F247F1-5E0B-472B-8C42-4074C2A25CD0>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:9C843591-806D-42E0-88A9-58DC59076B3D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Not Important" .
<urn:linkedspls:uuid:C904A0A3-252D-4872-B966-44B63E18E430>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00758" .
<urn:linkedspls:uuid:071CEC58-02E9-4DA2-8259-93E87A6EFD3B>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:29A5252E-79CA-41F6-BF34-26789C947F8D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Tamoxifen" .
<urn:domeoclient:uuid:14099187-A7EA-4F77-905D-B1B942FF80D7>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:237CBF43-3113-4746-AC7C-0EEE2CD7D926>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:70BE7DEB-6A8B-41E9-9333-F1F47AC7E1A0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:linkedspls:uuid:E6B02E4B-FDE8-473A-A978-02F98D0FE07D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:domeoclient:uuid:74791FAB-E4B4-4EA3-9557-BD68EDB49B01>	<http://purl.org/pav/createdOn>	"2014-06-30 12:54:57 -0400" .
<urn:linkedspls:uuid:CE3D1055-4EAF-4F2F-A2ED-AA9B95C45024>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:domeoclient:uuid:5BA0362C-1EF8-4647-8A30-017F5378F48F>	<http://www.w3.org/ns/oa#exact>	"Nursing mothers who are ultra-rapid metabolizers may also experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of codeine during breastfeeding" .
<urn:linkedspls:uuid:D6235B22-042E-4C36-A104-B353CF92CEB8>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Tamoxifen" .
<urn:linkedspls:uuid:6B9F2EDD-8EC9-441C-9B9C-6DE4ED079F50>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:964EBF55-DC67-43A9-93E2-DBC843BB8D2A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:domeoclient:uuid:7FDE7EC5-68D1-4D11-A164-0B2DA9D73292>	<http://purl.org/pav/createdOn>	"2014-06-30 12:49:25 -0400" .
<urn:linkedspls:uuid:B7B25E99-EE57-41AC-BDE2-45DCC1447471>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:13F3B206-EA87-463E-9DA8-93AA056A9117>	<http://semanticscience.org/resource/SIO_000111>	"34070-3 CONTRAINDICATIONS SECTION" .
<urn:domeoclient:uuid:1D33EB0C-A03D-481F-991D-B71848865C38>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:4A5BB36A-D20C-4306-8958-609D3F9A13D0>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:9692B313-0E4E-4D52-9D7C-456D2EE68F54>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:8431F83B-801B-499C-A34F-25B983A4B198>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:1769615F-FAC0-4900-9DC6-5021630F8524>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:domeoclient:uuid:AF427FC6-54B8-4CA4-9C51-233E64726500>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:61B14255-647D-4AA2-83E5-B81256BF7A50>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:linkedspls:uuid:558D142F-DBE9-4EB9-9F46-4244D63F2FAF>	<http://semanticscience.org/resource/SIO_000111>	"CLINICAL STUDIES (34092-7)" .
<urn:domeoclient:uuid:55709DA6-0396-4327-B704-FE38E5F01C43>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:9A15D029-5B02-4107-A829-E2BD1B1219FE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:linkedspls:uuid:945EB72E-5C75-41B0-B8FC-637E1EF0AE7D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:933C6C55-0C1F-4A1C-B72F-98683FD68184>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:3728C2D2-73B4-4F3A-A648-FD42247BA4EE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:linkedspls:uuid:2510C893-9155-453B-922C-CF116136DD88>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:945EB72E-5C75-41B0-B8FC-637E1EF0AE7D>	<http://semanticscience.org/resource/SIO_000111>	"42231-1 SPL MEDGUIDE SECTION" .
<urn:domeoclient:uuid:C427075F-5339-47EB-A313-AA6B94EB8753>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:8B036858-70F5-4077-8333-F34F19A042EC>	<http://purl.org/pav/createdOn>	"2014-06-02 14:30:33 -0400" .
<urn:linkedspls:uuid:70BE7DEB-6A8B-41E9-9333-F1F47AC7E1A0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:75D456DC-1DB0-4F96-A11F-551CC8425889>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:855697DF-EBFA-4343-B2F2-023B6F284D48>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:E6B02E4B-FDE8-473A-A978-02F98D0FE07D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:8910" .
<urn:domeoclient:uuid:4743B32B-A374-4701-B3BA-DD766AB522F6>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:6E7BEB44-17B2-4A01-8866-7DAFBEA17CC6>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:D26DCABA-C665-4147-A57B-F26195C0188E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:linkedspls:uuid:25348450-1CCF-4BEC-84EF-0EA92F67DD3A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:linkedspls:uuid:45844BA9-29ED-4EC6-94C0-81C9883F880F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:0D634683-D28C-42DC-9911-DFD0C9EB289D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:5D87AC20-773F-4241-AA52-57BF86A4A93A>	<http://semanticscience.org/resource/SIO_000111>	"42229-5 SPL UNCLASSIFIED SECTION" .
<urn:linkedspls:uuid:8BDFDC96-47AF-489E-8F96-DF9B26C6ECBE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:domeoclient:uuid:6F41EB64-7E4B-4DAA-86FE-348F6836D46E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:E17574BF-3BA6-48DA-B0DA-6E8DF716A03D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:AC5F1BAD-8B6A-49DB-8147-AB1394EC169F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:53B64B1F-739B-46F0-99EE-89EF4131A8D2>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:D66A54D7-BD47-4E22-B2F3-09A5D190955A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:2185EE39-FD81-4C83-ABDF-E5D59B789F96>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Clopidogrel" .
<urn:linkedspls:uuid:24265221-E0B1-4F13-A2EB-0E9D9DC6F5D4>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"biomarker-level-low" .
<urn:domeoclient:uuid:E03CFE71-0FEF-4840-A587-1D360CBF035C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:96D6F8F1-F51A-4EBC-BFF7-C799690B4401>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:FED638A3-F491-4246-B5EC-651C306CF76E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:domeoclient:uuid:A8189564-74C8-463F-9927-917478975C75>	<http://www.w3.org/ns/oa#exact>	"The effectiveness of clopidogrel bisulfate is dependent on its activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 [see Warnings and Precautions (5.1)]. Clopidogrel bisulfate at recommended doses forms less of that metabolite and has a smaller effect on platelet function in patients who are CYP2C19 poor metabolizers" .
<urn:domeoclient:uuid:74B97B42-8CF1-41BB-84AD-CF0995E7508C>	<http://www.w3.org/ns/oa#exact>	"One additional randomized study (NATO) demonstrated improved disease-free survival for tamoxifen compared to no adjuvant therapy following total mastectomy and axillary dissection in postmenopausal women with axillary node-negative breast cancer. In this study, the benefits of tamoxifen appeared to be independent of estrogen receptor status." .
<urn:domeoclient:uuid:2BB0E9F3-52F1-4631-B37B-DBFB53B3B0C9>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:B79BAC9C-6B3B-4FF1-9F24-2BD40CE200BF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:E8587041-73D9-4727-A9F5-7445BAF204E3>	<http://www.w3.org/ns/oa#exact>	"The patient's CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose. Table 5 describes the range of stable maintenance doses observed in multiple patients having different combinations of CYP2C9 and VKORC1 gene variants. Consider these ranges in choosing the initial dose." .
<urn:linkedspls:uuid:402D9368-C611-4289-8004-8EEC1A409CCF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:linkedspls:uuid:D3EDFFC9-9EE3-45DD-B147-801DAB72DF3D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:5BA0362C-1EF8-4647-8A30-017F5378F48F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:6B4C9D47-E3BF-4D75-A661-0D5A649108C6>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Alternative Recommended" .
<urn:linkedspls:uuid:81525CE9-0714-4D48-9149-6C8B8671E117>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:7E666CF4-DD19-4B4B-AE7B-EF4BCEA0181C>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:74EB8F8A-FCEA-41C8-BAB2-B4DFA1190D34>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:33D89E0F-4370-431E-8DB5-094F3AF78C75>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:6B4C9D47-E3BF-4D75-A661-0D5A649108C6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:linkedspls:uuid:6F731CE1-E6B4-41AA-98C6-30C94B771E61>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"ultra-metabolizer" .
<urn:domeoclient:uuid:F1F72593-1500-4B06-AE14-AE29B3EAE9B1>	<http://www.w3.org/ns/oa#exact>	"Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers." .
<urn:linkedspls:uuid:8C0132CB-1BA7-4320-8C5F-E55761BC596E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Tamoxifen" .
<urn:linkedspls:uuid:C904A0A3-252D-4872-B966-44B63E18E430>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:linkedspls:uuid:84646AA6-8E85-4656-8515-E49CB15EADB4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Codeine" .
<urn:domeoclient:uuid:0B13BA6D-FAED-4224-BF7E-64E31E595AD6>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:39A685C2-1AA3-415F-8F2F-3F82C6914A2D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:2185EE39-FD81-4C83-ABDF-E5D59B789F96>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00758" .
<urn:linkedspls:uuid:52601F35-C2AB-4602-BD13-6B9999A0266A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:8BDFDC96-47AF-489E-8F96-DF9B26C6ECBE>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Excretion Decrease" .
<urn:domeoclient:uuid:0DA7AAE6-C82C-4935-9D33-40D96FDB2416>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:2446A882-2020-42F8-AD24-FE3B4F839958>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:domeoclient:uuid:0DA7AAE6-C82C-4935-9D33-40D96FDB2416>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:05DBF40D-ECCF-4BC6-9077-742EBADF41F9>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:8910" .
<urn:linkedspls:uuid:D939C426-7E0B-4A32-80F1-7344D702AA97>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:domeoclient:uuid:39A685C2-1AA3-415F-8F2F-3F82C6914A2D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:0B13BA6D-FAED-4224-BF7E-64E31E595AD6>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:0D634683-D28C-42DC-9911-DFD0C9EB289D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:domeoclient:uuid:224ACECA-832C-4CE1-B586-4BB3E2AC8018>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee15d911-73c7-4bc6-96f2-089a8aa64e18" .
<urn:domeoclient:uuid:74EB8F8A-FCEA-41C8-BAB2-B4DFA1190D34>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:F5AE3B3E-B864-4A19-B48C-DC1343C799A3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:linkedspls:uuid:D26DCABA-C665-4147-A57B-F26195C0188E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Not Important" .
<urn:domeoclient:uuid:33D89E0F-4370-431E-8DB5-094F3AF78C75>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:70BE7DEB-6A8B-41E9-9333-F1F47AC7E1A0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:domeoclient:uuid:5BA0362C-1EF8-4647-8A30-017F5378F48F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:945EB72E-5C75-41B0-B8FC-637E1EF0AE7D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:linkedspls:uuid:461FDA58-8FAB-4951-B04A-F969D73C634D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:52601F35-C2AB-4602-BD13-6B9999A0266A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:EF919E4C-C0B0-4D8B-A273-2F4A806A828D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ClinicalTrial>	"Clinical Trial" .
<urn:domeoclient:uuid:B79BAC9C-6B3B-4FF1-9F24-2BD40CE200BF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:2BB0E9F3-52F1-4631-B37B-DBFB53B3B0C9>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:7D8A9803-9C09-4301-8254-AF8BCE7E83F8>	<http://purl.org/pav/createdOn>	"2014-06-30 13:23:21 -0400" .
<urn:linkedspls:uuid:4663B6D5-B11D-4039-8F32-F7E3BFC2537E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:45EDCED8-9B43-464F-AC7F-898A9009649D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"intermediate-activity" .
<urn:linkedspls:uuid:2423954D-96B2-404E-8B04-9609825C795A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:E03CFE71-0FEF-4840-A587-1D360CBF035C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:D66A54D7-BD47-4E22-B2F3-09A5D190955A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:56D95EC4-D0D7-4BD6-B13C-E145F6A4E568>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"POLG" .
<urn:linkedspls:uuid:8026784E-DC9A-4F18-963D-495E0532BB97>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:domeoclient:uuid:6F41EB64-7E4B-4DAA-86FE-348F6836D46E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:F5AE3B3E-B864-4A19-B48C-DC1343C799A3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:linkedspls:uuid:FED638A3-F491-4246-B5EC-651C306CF76E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:linkedspls:uuid:31115D88-2436-4D8C-B5E2-A7636A9DA498>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Tamoxifen" .
<urn:linkedspls:uuid:7E666CF4-DD19-4B4B-AE7B-EF4BCEA0181C>	<http://semanticscience.org/resource/SIO_000111>	"34081-0 PEDIATRIC USE SECTION" .
<urn:domeoclient:uuid:6E7BEB44-17B2-4A01-8866-7DAFBEA17CC6>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:4743B32B-A374-4701-B3BA-DD766AB522F6>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:9C09D2F8-83BE-446D-A17A-75402666EE4B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1" .
<urn:domeoclient:uuid:BBD1EA14-A142-47FF-A3B5-D848FFAED44F>	<http://www.w3.org/ns/oa#exact>	"STUDIES IN PATIENTS OF CHINESE ANCESTRY HAVE FOUND A STRONG ASSOCIATION BETWEEN THE RISK OF DEVELOPING SJS/TEN AND THE PRESENCE OF HLA-B*1502, AN INHERITED ALLELIC VARIANT OF THE HLA-B GENE. HLA-B*1502 IS FOUND ALMOST EXCLUSIVELY IN PATIENTS WITH ANCESTRY ACROSS BROAD AREAS OF ASIA. PATIENTS WITH ANCESTRY IN GENETICALLY AT-RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH CARBAMAZEPINE EXTENDED-RELEASE CAPSULES." .
<urn:linkedspls:uuid:44A37F21-E420-40D5-A9E0-5CEDEFAEF40B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:linkedspls:uuid:4D27D69B-2F63-4940-AD74-710454AA1E6A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:A48D46C7-8F7E-4426-8C3D-CCA08F946DB0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:domeoclient:uuid:C427075F-5339-47EB-A313-AA6B94EB8753>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:87B8F5B0-8381-4CA7-AE0B-30C481D164B4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00758" .
<urn:linkedspls:uuid:1DA28968-6C74-475E-AB4F-5E6E22DFF8BD>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:CE3D1055-4EAF-4F2F-A2ED-AA9B95C45024>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:linkedspls:uuid:92FA8990-60EF-4140-9F60-C12E57E3B114>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Discontinue/Do not restart" .
<urn:linkedspls:uuid:933C6C55-0C1F-4A1C-B72F-98683FD68184>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:55709DA6-0396-4327-B704-FE38E5F01C43>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:3CB531B1-A267-4A03-A0C5-D852AB638802>	<http://purl.org/pav/createdOn>	"2014-04-21 12:35:45 -0400" .
<urn:linkedspls:uuid:5E02C5AB-C35D-4ACA-8EF0-DF0F481E6A00>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"Drug selection refers to other drugs not drug of interest.  ?  Add Drug selection recommendation or not?" .
<urn:linkedspls:uuid:74BB3F3E-AD24-438C-9250-4357E959069E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:75D456DC-1DB0-4F96-A11F-551CC8425889>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:AF427FC6-54B8-4CA4-9C51-233E64726500>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:6F731CE1-E6B4-41AA-98C6-30C94B771E61>	<http://semanticscience.org/resource/SIO_000111>	"34080-2 NURSING MOTHERS SECTION" .
<urn:linkedspls:uuid:7CE2D02E-F446-465D-9CBE-27C213ACCC89>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Clopidogrel" .
<urn:domeoclient:uuid:8431F83B-801B-499C-A34F-25B983A4B198>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:964EBF55-DC67-43A9-93E2-DBC843BB8D2A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:linkedspls:uuid:13F3B206-EA87-463E-9DA8-93AA056A9117>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:4CFDD438-5250-4D24-9933-43397A6F2E0F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:1D33EB0C-A03D-481F-991D-B71848865C38>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:4A5BB36A-D20C-4306-8958-609D3F9A13D0>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:1DA28968-6C74-475E-AB4F-5E6E22DFF8BD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:linkedspls:uuid:A48D46C7-8F7E-4426-8C3D-CCA08F946DB0>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"ultra-metabolizer" .
<urn:domeoclient:uuid:55700EE9-88B8-49B7-BD64-1A87D99DCC15>	<http://purl.org/pav/createdOn>	"2014-06-30 13:11:19 -0400" .
<urn:domeoclient:uuid:98226070-C5AF-407A-B6D1-D521CD001163>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee15d911-73c7-4bc6-96f2-089a8aa64e18" .
<urn:linkedspls:uuid:599459E0-8D98-4627-BC38-BA5B6BEC6B33>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Clopidogrel" .
<urn:linkedspls:uuid:9692B313-0E4E-4D52-9D7C-456D2EE68F54>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:53B64B1F-739B-46F0-99EE-89EF4131A8D2>	<http://semanticscience.org/resource/SIO_000111>	"42229-5 SPL UNCLASSIFIED SECTION" .
<urn:domeoclient:uuid:7BFF4A61-D45D-4C1F-9599-BD435EF039B8>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:C89E80EC-0820-406B-99C8-D495EC5F054E>	<http://purl.org/pav/createdOn>	"2014-06-02 14:03:56 -0400" .
<urn:linkedspls:uuid:A48D46C7-8F7E-4426-8C3D-CCA08F946DB0>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"THIS ONE IS BROKEN, LOCATION OF ANNOTATION IS APPLIED TO IS INCORRECT." .
<urn:linkedspls:uuid:4CFDD438-5250-4D24-9933-43397A6F2E0F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:878D746A-3252-462C-AA1E-A857E2FC63AF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:4663B6D5-B11D-4039-8F32-F7E3BFC2537E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"ultra-metabolizer" .
<urn:linkedspls:uuid:4777BC06-68FA-4171-A52D-68668AD25547>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:36FDCB4E-5E54-4CBA-BC44-04B836C019F0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:3616601B-9F53-4ECD-985B-8205444D8F7C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Tamoxifen" .
<urn:domeoclient:uuid:0A10CE73-592A-4D92-84AF-63395C43C0F9>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:224ACECA-832C-4CE1-B586-4BB3E2AC8018>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:94B53E9F-5329-43D3-AD42-03C430F6E877>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Alternative Recommended" .
<urn:linkedspls:uuid:F45F585A-05C5-49B5-BABB-73BFBE9E9753>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:linkedspls:uuid:1A9E2879-AD9B-48F5-B672-AB5C06A28080>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:5A997B78-0557-4495-BDBD-42F5B4B30412>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:4EEB4B8C-B4AE-42C6-9E9C-805907F3A548>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:E826D255-0A7E-4F3C-A59F-675E8A9B606E>	<http://www.w3.org/ns/oa#exact>	"Patients taking ZIAGEN may have a serious allergic reaction (hypersensitivity reaction) that can cause death. Your risk of this allergic reaction is much higher if you have a gene variation called HLA-B*5701 than if you do not. Your doctor can determine with a blood test if you have this gene variation." .
<urn:linkedspls:uuid:3728C2D2-73B4-4F3A-A648-FD42247BA4EE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:9837A225-376D-44A6-959D-05A7DCB03CCE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2625" .
<urn:domeoclient:uuid:C97CADE4-3861-4CB6-A21E-09BF0AEB1F88>	<http://purl.org/pav/createdOn>	"2014-03-31 08:59:45 -0400" .
<urn:domeoclient:uuid:09730EE5-3645-4E22-8362-E17C60539840>	<http://purl.org/pav/createdOn>	"2014-06-30 13:24:15 -0400" .
<urn:linkedspls:uuid:071CEC58-02E9-4DA2-8259-93E87A6EFD3B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Codeine" .
<urn:domeoclient:uuid:F7D9EE5F-E5C0-4296-9825-534C2F768855>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:EEA90F54-8E00-4B5E-B685-11848BFBA55A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:ED9FC62F-6F5A-4AEC-B2EB-900F4C21E312>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*1502" .
<urn:linkedspls:uuid:D1D85749-709E-4FD8-A464-C8E7CD8158BB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:linkedspls:uuid:4D27D69B-2F63-4940-AD74-710454AA1E6A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:3A77F5FE-EF65-4FF1-9BCD-E358D4D5BC82>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:domeoclient:uuid:98FB995B-3B3B-4C86-ACA3-EE4F9F310F41>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:763ABA1D-A316-42DE-AA02-A7123411CD6C>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:0D634683-D28C-42DC-9911-DFD0C9EB289D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00564" .
<urn:linkedspls:uuid:7E666CF4-DD19-4B4B-AE7B-EF4BCEA0181C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:64BC1D21-CAE1-4F85-A596-73342A9D5388>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:70BE7DEB-6A8B-41E9-9333-F1F47AC7E1A0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00564" .
<urn:linkedspls:uuid:1A9E2879-AD9B-48F5-B672-AB5C06A28080>	<http://semanticscience.org/resource/SIO_000111>	"42229-5 SPL UNCLASSIFIED SECTION" .
<urn:domeoclient:uuid:76AEC8EC-841B-4618-8A97-4D6655CE39F4>	<http://www.w3.org/ns/oa#exact>	"Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible." .
<urn:linkedspls:uuid:9DCD19CE-D636-45D6-B994-A9BDBCA32621>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:F3C6E27C-CBBA-4B36-810C-D42C3FA4AB93>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:976BDFF3-2BFA-4838-B6A0-327B2921E1B7>	<http://www.w3.org/ns/oa#exact>	"The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional." .
<urn:linkedspls:uuid:945EB72E-5C75-41B0-B8FC-637E1EF0AE7D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00564" .
<urn:domeoclient:uuid:2D0B9A22-6129-4786-B0A4-7384B3324DF0>	<http://www.w3.org/ns/oa#exact>	"Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers" .
<urn:domeoclient:uuid:CE5D6919-6972-4689-B658-C5432A02F905>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:linkedspls:uuid:2423954D-96B2-404E-8B04-9609825C795A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:F5C240E5-0680-4CDA-ACC9-4DB8C5A0984B>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:linkedspls:uuid:691E83A1-1BFF-4939-996A-35C56D0CF2DF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:linkedspls:uuid:53B64B1F-739B-46F0-99EE-89EF4131A8D2>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:5630014D-C820-4E31-A061-529A1A06548B>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:domeoclient:uuid:DBCD24FF-6ABB-4810-A5CA-DF8F85FF2241>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:81525CE9-0714-4D48-9149-6C8B8671E117>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:linkedspls:uuid:F9A68240-FAD6-4604-8DEE-1B0E4AF9BD21>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:86218E9C-9C50-4CF1-BDF5-7480485335DE>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:linkedspls:uuid:1769615F-FAC0-4900-9DC6-5021630F8524>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Tamoxifen" .
<urn:linkedspls:uuid:691E83A1-1BFF-4939-996A-35C56D0CF2DF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:domeoclient:uuid:C8824A36-9C96-4389-B215-2638B48B5437>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:7AE1124F-F104-4EB3-9415-257F81B2E3CE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:402D9368-C611-4289-8004-8EEC1A409CCF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:6F731CE1-E6B4-41AA-98C6-30C94B771E61>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:D1D85749-709E-4FD8-A464-C8E7CD8158BB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:linkedspls:uuid:2446A882-2020-42F8-AD24-FE3B4F839958>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:96D6F8F1-F51A-4EBC-BFF7-C799690B4401>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:5949C0ED-ECE8-4C36-B91D-8E58F7A36AAC>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:linkedspls:uuid:F5AE3B3E-B864-4A19-B48C-DC1343C799A3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:domeoclient:uuid:BC0C42BD-3C98-4864-9F9C-50F72712CEC9>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:FEF94E24-725D-433B-8F55-9E75E14CECB9>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2625" .
<urn:linkedspls:uuid:74BB3F3E-AD24-438C-9250-4357E959069E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:linkedspls:uuid:96D6F8F1-F51A-4EBC-BFF7-C799690B4401>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:domeoclient:uuid:BC0C42BD-3C98-4864-9F9C-50F72712CEC9>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:151DFA13-B2DF-4857-AAE9-51CADEC9A12F>	<http://semanticscience.org/resource/SIO_000111>	"66106-6 PHARMACOGENOMICS SECTION" .
<urn:linkedspls:uuid:E719DBCC-60BF-47C9-A2A6-B5AD564ED472>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:25348450-1CCF-4BEC-84EF-0EA92F67DD3A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:domeoclient:uuid:4364906C-8414-403A-BB1D-1DDCC5F6A4DA>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:domeoclient:uuid:C8824A36-9C96-4389-B215-2638B48B5437>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:1A9E2879-AD9B-48F5-B672-AB5C06A28080>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:8910" .
<urn:linkedspls:uuid:42FA1C17-B780-423F-B993-EAF8D8DF0329>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:linkedspls:uuid:7AE1124F-F104-4EB3-9415-257F81B2E3CE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:B2CCF84A-A981-4564-8227-DE5688CB1FED>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:domeoclient:uuid:DBCD24FF-6ABB-4810-A5CA-DF8F85FF2241>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:0B39F957-E88F-427C-AC41-F1B9DC711A02>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"poor-metabolizer" .
<urn:linkedspls:uuid:8BDFDC96-47AF-489E-8F96-DF9B26C6ECBE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:47718F61-F7FA-4A83-BB17-C13189D5E884>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:linkedspls:uuid:1A9E2879-AD9B-48F5-B672-AB5C06A28080>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:linkedspls:uuid:905B00B5-CD9F-4F5A-BDCD-2E0771AC9B73>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:68B37481-F382-41B9-AEF5-DB241FA9325F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2625" .
<urn:domeoclient:uuid:CE3C3FF6-F83D-47D2-8C4F-944687265F2B>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:linkedspls:uuid:9C09D2F8-83BE-446D-A17A-75402666EE4B>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:FC7D109F-F404-4287-BE4A-D7C5AA057401>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:44E81086-BA17-4D23-BE19-3D545D7F1B9D> .
<urn:domeoclient:uuid:E6578AA5-3295-46D7-B3F2-55CD3CFB5B0F>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:domeoclient:uuid:F3C6E27C-CBBA-4B36-810C-D42C3FA4AB93>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:86480047-DD43-4A54-B258-3772C18237F7>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:23663" .
<urn:domeoclient:uuid:D66A54D7-BD47-4E22-B2F3-09A5D190955A>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:D66A54D7-BD47-4E22-B2F3-09A5D190955A> .
<urn:linkedspls:uuid:08308CA2-E50D-41DB-873B-E57372B5FBDB>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:C1BF7FF6-707B-4750-BA47-274111148F96>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:linkedspls:uuid:74BB3F3E-AD24-438C-9250-4357E959069E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Clopidogrel" .
<urn:domeoclient:uuid:64BC1D21-CAE1-4F85-A596-73342A9D5388>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:EE534BB0-3042-44F4-9B63-01291E28FA45>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*1502" .
<urn:domeoclient:uuid:35B89AC4-DAE5-4207-B319-F9479AE77CDE>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:linkedspls:uuid:071CEC58-02E9-4DA2-8259-93E87A6EFD3B>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:linkedspls:uuid:D3EDFFC9-9EE3-45DD-B147-801DAB72DF3D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"extensive-metabolizer" .
<urn:domeoclient:uuid:C97CADE4-3861-4CB6-A21E-09BF0AEB1F88>	<http://purl.org/pav/createdBy>	"urn:person:uuid:080e14304488c4b70144896f4a03000b" .
<urn:domeoclient:uuid:2BB0E9F3-52F1-4631-B37B-DBFB53B3B0C9>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:2BB0E9F3-52F1-4631-B37B-DBFB53B3B0C9> .
<urn:linkedspls:uuid:6B4C9D47-E3BF-4D75-A661-0D5A649108C6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:D26DCABA-C665-4147-A57B-F26195C0188E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Tamoxifen" .
<urn:domeoclient:uuid:98FB995B-3B3B-4C86-ACA3-EE4F9F310F41>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:74EB8F8A-FCEA-41C8-BAB2-B4DFA1190D34>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:74EB8F8A-FCEA-41C8-BAB2-B4DFA1190D34> .
<urn:linkedspls:uuid:855BF4FE-7082-466C-AEC2-BA37C5A2F93C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:23663" .
<urn:domeoclient:uuid:D5CF7A64-E07F-419A-8900-15F969F2D51F>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:0BEDE64D-11D3-4746-9532-E747F6A427E0> .
<urn:linkedspls:uuid:763ABA1D-A316-42DE-AA02-A7123411CD6C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER and PgR_receptor" .
<urn:linkedspls:uuid:9258FFBC-DCDC-4C6C-A375-9FC03C323B54>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:B7B25E99-EE57-41AC-BDE2-45DCC1447471>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:domeoclient:uuid:F7D9EE5F-E5C0-4296-9825-534C2F768855>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:5BA0362C-1EF8-4647-8A30-017F5378F48F>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:5BA0362C-1EF8-4647-8A30-017F5378F48F> .
<urn:domeoclient:uuid:EEA90F54-8E00-4B5E-B685-11848BFBA55A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:D5CF7A64-E07F-419A-8900-15F969F2D51F>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:8B74A738-1124-4DAC-BE25-F15C78CFBA15> .
<urn:linkedspls:uuid:A24FCBC0-9830-43DC-87D5-5716D3136B02>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:0B3E23EF-1696-4FF7-BEEB-8158BDA84294>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:5A997B78-0557-4495-BDBD-42F5B4B30412>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:4EEB4B8C-B4AE-42C6-9E9C-805907F3A548>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:4DD1AE8C-CB2C-4887-993E-A8A44B2A06CB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"TPMT" .
<urn:linkedspls:uuid:9F45C51D-C093-4FEB-A57B-7D59EB1E01DA>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:0DA7AAE6-C82C-4935-9D33-40D96FDB2416>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:0DA7AAE6-C82C-4935-9D33-40D96FDB2416> .
<urn:domeoclient:uuid:0A10CE73-592A-4D92-84AF-63395C43C0F9>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:45844BA9-29ED-4EC6-94C0-81C9883F880F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:224ACECA-832C-4CE1-B586-4BB3E2AC8018>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:FED638A3-F491-4246-B5EC-651C306CF76E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:domeoclient:uuid:39A685C2-1AA3-415F-8F2F-3F82C6914A2D>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:39A685C2-1AA3-415F-8F2F-3F82C6914A2D> .
<urn:linkedspls:uuid:A903F38F-38D4-4052-A673-7FF19407E3DB>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:F0F7787E-5F9C-47A4-86B2-D64F1B7602B6>	<http://semanticscience.org/resource/SIO_000111>	"66106-6 PHARMACOGENOMICS SECTION" .
<urn:linkedspls:uuid:B7B25E99-EE57-41AC-BDE2-45DCC1447471>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Clopidogrel" .
<urn:domeoclient:uuid:878D746A-3252-462C-AA1E-A857E2FC63AF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:44A37F21-E420-40D5-A9E0-5CEDEFAEF40B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:linkedspls:uuid:C904A0A3-252D-4872-B966-44B63E18E430>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:4A5BB36A-D20C-4306-8958-609D3F9A13D0>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:4A5BB36A-D20C-4306-8958-609D3F9A13D0> .
<urn:linkedspls:uuid:A3C1B92C-CBE0-4BA8-A41C-D3C3CD26FA51>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:domeoclient:uuid:7BFF4A61-D45D-4C1F-9599-BD435EF039B8>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:8431F83B-801B-499C-A34F-25B983A4B198>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:8431F83B-801B-499C-A34F-25B983A4B198> .
<urn:linkedspls:uuid:84646AA6-8E85-4656-8515-E49CB15EADB4>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:linkedspls:uuid:EE534BB0-3042-44F4-9B63-01291E28FA45>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Carbamazepine" .
<urn:linkedspls:uuid:4777BC06-68FA-4171-A52D-68668AD25547>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:855697DF-EBFA-4343-B2F2-023B6F284D48>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Recommend" .
<urn:linkedspls:uuid:E719DBCC-60BF-47C9-A2A6-B5AD564ED472>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:8910" .
<urn:linkedspls:uuid:F0B7C43C-792D-49E5-B282-D2303F858889>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000017048" .
<urn:linkedspls:uuid:9F45C51D-C093-4FEB-A57B-7D59EB1E01DA>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:481D46BB-D4FB-4587-B147-C2FC166A7A51>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:94B53E9F-5329-43D3-AD42-03C430F6E877>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"add to drop down; alleles necessary?" .
<urn:domeoclient:uuid:79C530FF-637A-43C8-AECE-CA81458FB5EE>	<http://www.w3.org/ns/oa#exact>	"The HLA-B*1502 allele has not been found to predict risk of less severe adverse cutaneous reactions from carbamazepine, such as anticonvulsant hypersensitivity syndrome or non-serious rash (maculopapular eruption [MPE])" .
<urn:linkedspls:uuid:A903F38F-38D4-4052-A673-7FF19407E3DB>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:05DBF40D-ECCF-4BC6-9077-742EBADF41F9>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:9A15D029-5B02-4107-A829-E2BD1B1219FE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:domeoclient:uuid:6E7BEB44-17B2-4A01-8866-7DAFBEA17CC6>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:6E7BEB44-17B2-4A01-8866-7DAFBEA17CC6> .
<urn:linkedspls:uuid:3728C2D2-73B4-4F3A-A648-FD42247BA4EE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:linkedspls:uuid:9C09D2F8-83BE-446D-A17A-75402666EE4B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:domeoclient:uuid:FA0C425E-2A1E-4059-BAC2-34BD4239836F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:43B85AB2-533A-4A3B-932F-7CD7177449ED>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:4B11E300-2DF5-4B21-9D43-4D0A02109A59>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:524C3AB2-2955-4538-A46C-63CDD0BC11D2>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:5D85FB52-BA95-409A-8974-2E14C9527722> .
<urn:linkedspls:uuid:B7B25E99-EE57-41AC-BDE2-45DCC1447471>	<http://semanticscience.org/resource/SIO_000111>	"42229-5 SPL UNCLASSIFIED SECTION" .
<urn:linkedspls:uuid:AC5F1BAD-8B6A-49DB-8147-AB1394EC169F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:linkedspls:uuid:61B14255-647D-4AA2-83E5-B81256BF7A50>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:domeoclient:uuid:EF161740-C79C-4D2A-9002-4B0A139BF81E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:CE1DC1EA-085A-4CF9-8165-5A14A411A633>	<http://purl.org/pav/createdOn>	"2014-04-14 14:27:46 -0400" .
<urn:domeoclient:uuid:55709DA6-0396-4327-B704-FE38E5F01C43>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:55709DA6-0396-4327-B704-FE38E5F01C43> .
<urn:domeoclient:uuid:ECE9E8AD-BAEE-4FC0-A880-67D03D8D2EED>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:AC5F1BAD-8B6A-49DB-8147-AB1394EC169F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Clopidogrel" .
<urn:linkedspls:uuid:1706E63C-45AC-467E-80FD-06108C69A93D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"TPMT" .
<urn:linkedspls:uuid:055AAAC1-3544-4B8E-BF06-C99328A12B6E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:6B4C9D47-E3BF-4D75-A661-0D5A649108C6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:linkedspls:uuid:9258FFBC-DCDC-4C6C-A375-9FC03C323B54>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"include test results in dropdown" .
<urn:linkedspls:uuid:5D87AC20-773F-4241-AA52-57BF86A4A93A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:B24A699D-7127-47C1-BFAE-C1ABB6819E2F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:linkedspls:uuid:6E680A49-5B91-4058-A09E-25A6ED988EFC>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"TPMT" .
<urn:domeoclient:uuid:1D33EB0C-A03D-481F-991D-B71848865C38>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:1D33EB0C-A03D-481F-991D-B71848865C38> .
<urn:linkedspls:uuid:9DCD19CE-D636-45D6-B994-A9BDBCA32621>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"CYP2D6*1/*1xN, CYP2D6*1/*2xN" .
<urn:linkedspls:uuid:964EBF55-DC67-43A9-93E2-DBC843BB8D2A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:linkedspls:uuid:CD7BE61C-D111-48EB-A232-1241D41AB8BC>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:74EA2B44-40D9-44F0-90BA-33EFF2D1B5AA>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:AF427FC6-54B8-4CA4-9C51-233E64726500>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:AF427FC6-54B8-4CA4-9C51-233E64726500> .
<urn:linkedspls:uuid:E719DBCC-60BF-47C9-A2A6-B5AD564ED472>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:linkedspls:uuid:5E02C5AB-C35D-4ACA-8EF0-DF0F481E6A00>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:C2A76A18-A463-4D7B-9A00-33BEFE84F768>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:linkedspls:uuid:74EA2B44-40D9-44F0-90BA-33EFF2D1B5AA>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:linkedspls:uuid:27F9E2A8-C54A-4F87-A02D-4F8EFF5D382F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"TPMT" .
<urn:domeoclient:uuid:47718F61-F7FA-4A83-BB17-C13189D5E884>	<http://purl.org/pav/createdOn>	"2014-03-31 08:55:42 -0400" .
<urn:domeoclient:uuid:9C2B48AD-A4E0-4C6C-9246-E6FD6CF712C8>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:8BEEBA62-C519-4421-9038-113DCDFC9B2C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:691E83A1-1BFF-4939-996A-35C56D0CF2DF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:B24A699D-7127-47C1-BFAE-C1ABB6819E2F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:2446A882-2020-42F8-AD24-FE3B4F839958>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:linkedspls:uuid:BF7AF633-8B36-41BF-AC4F-0BA548A0DB2F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:028082D6-59BF-44E8-9117-CC155DA8D008>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:6FC50BDC-78A6-4D50-8D6E-7FEB6DAFF0E2>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:4C36F11A-E282-4BFB-849D-B93A233A50FB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"biomarker-level-low" .
<urn:linkedspls:uuid:F45F585A-05C5-49B5-BABB-73BFBE9E9753>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:linkedspls:uuid:CE3D1055-4EAF-4F2F-A2ED-AA9B95C45024>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Discontinue/Do not restart" .
<urn:linkedspls:uuid:75D988CE-7527-421D-AAA6-0C9C0D4B30DF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"TPMT" .
<urn:linkedspls:uuid:0F7B1E31-9D8A-45AA-8F34-A942EE6FBB80>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>	"Use specific" .
<urn:linkedspls:uuid:F270E3B3-9983-425D-98FB-66F62E36340F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:FBD3A076-17BF-416E-9EEC-89C39FD558A3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:domeoclient:uuid:8D91E7D5-B379-4649-9834-0D01A948DFF8>	<http://purl.org/pav/createdOn>	"2014-06-02 14:22:39 -0400" .
<urn:linkedspls:uuid:45EDCED8-9B43-464F-AC7F-898A9009649D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"TPMT" .
<urn:domeoclient:uuid:B752346E-6167-497D-B585-83983FA71DA2>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:21B282F1-F0CA-488A-B703-88611F099D16> .
<urn:domeoclient:uuid:4743B32B-A374-4701-B3BA-DD766AB522F6>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:4743B32B-A374-4701-B3BA-DD766AB522F6> .
<urn:domeoclient:uuid:98226070-C5AF-407A-B6D1-D521CD001163>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:15924106-592A-47E7-A01C-764A16E257DC>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:4B11E300-2DF5-4B21-9D43-4D0A02109A59>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:FBEDA24D-50C7-407C-9337-9A08D9456999>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>	"Use specific" .
<urn:linkedspls:uuid:905B00B5-CD9F-4F5A-BDCD-2E0771AC9B73>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:9837A225-376D-44A6-959D-05A7DCB03CCE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:domeoclient:uuid:CF35511B-7BED-446A-B970-33FEE5C13C88>	<http://purl.org/pav/createdOn>	"2014-06-30 12:29:04 -0400" .
<urn:domeoclient:uuid:60CFE292-6834-41FC-8255-B81A3D584EE2>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:C427075F-5339-47EB-A313-AA6B94EB8753>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:C427075F-5339-47EB-A313-AA6B94EB8753> .
<urn:linkedspls:uuid:31115D88-2436-4D8C-B5E2-A7636A9DA498>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:9C09D2F8-83BE-446D-A17A-75402666EE4B>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER_receptor" .
<urn:linkedspls:uuid:92FA8990-60EF-4140-9F60-C12E57E3B114>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:linkedspls:uuid:FE1B382B-9F39-4CAA-8A59-17376ED6F061>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Tamoxifen" .
<urn:domeoclient:uuid:5B91F78A-EEB0-41A3-8995-90B920D09520>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:194FD718-B3CA-4D25-B3D2-56D36C1ECB60>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:23663" .
<urn:linkedspls:uuid:5239657F-5948-4803-B690-76D953D60764>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:5E02C5AB-C35D-4ACA-8EF0-DF0F481E6A00>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*1502" .
<urn:domeoclient:uuid:15924106-592A-47E7-A01C-764A16E257DC>	<http://www.w3.org/ns/oa#exact>	"The estrogen- and progesterone-receptor values may help to predict whether adjuvant tamoxifen citrate tablet therapy is likely to be beneficial." .
<urn:domeoclient:uuid:89320F5F-262D-4657-8A52-4432EC0101F8>	<http://purl.org/pav/createdOn>	"2014-03-31 09:04:12 -0400" .
<urn:domeoclient:uuid:8F4ED235-6F4A-4BDD-A23F-6F2D9FC7A396>	<http://purl.org/pav/createdOn>	"2014-06-02 14:28:28 -0400" .
<urn:linkedspls:uuid:ED9FC62F-6F5A-4AEC-B2EB-900F4C21E312>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Carbamazepine" .
<urn:linkedspls:uuid:2185EE39-FD81-4C83-ABDF-E5D59B789F96>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:8026784E-DC9A-4F18-963D-495E0532BB97>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:domeoclient:uuid:6F41EB64-7E4B-4DAA-86FE-348F6836D46E>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:6F41EB64-7E4B-4DAA-86FE-348F6836D46E> .
<urn:domeoclient:uuid:E34142C5-1680-4612-AC76-D96D8F82364F>	<http://purl.org/pav/createdOn>	"2014-04-14 13:45:50 -0400" .
<urn:linkedspls:uuid:8026784E-DC9A-4F18-963D-495E0532BB97>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00758" .
<urn:domeoclient:uuid:E03CFE71-0FEF-4840-A587-1D360CBF035C>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:E03CFE71-0FEF-4840-A587-1D360CBF035C> .
<urn:linkedspls:uuid:BC70D092-5124-4A5C-87C3-EA34E4868C05>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:1FAA2AB1-96D9-4225-A9E1-763F045EE2CD>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"TPMT" .
<urn:domeoclient:uuid:89320F5F-262D-4657-8A52-4432EC0101F8>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:2CE69763-0812-4DFF-A359-2A8D8FF706AD> .
<urn:domeoclient:uuid:745C184B-12B3-435F-99C5-252556EB53B9>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:0AB99582-A22B-403F-9604-C35A9897CE91>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:5D87AC20-773F-4241-AA52-57BF86A4A93A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:2185EE39-FD81-4C83-ABDF-E5D59B789F96>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"poor-metabolizer" .
<urn:domeoclient:uuid:C1BF7FF6-707B-4750-BA47-274111148F96>	<http://purl.org/pav/createdOn>	"2014-03-22 22:14:34 -0400" .
<urn:linkedspls:uuid:94B53E9F-5329-43D3-AD42-03C430F6E877>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:domeoclient:uuid:745C184B-12B3-435F-99C5-252556EB53B9>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:B79BAC9C-6B3B-4FF1-9F24-2BD40CE200BF>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:B79BAC9C-6B3B-4FF1-9F24-2BD40CE200BF> .
<urn:domeoclient:uuid:0AB99582-A22B-403F-9604-C35A9897CE91>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:D6235B22-042E-4C36-A104-B353CF92CEB8>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1, PGR" .
<urn:linkedspls:uuid:6B9F2EDD-8EC9-441C-9B9C-6DE4ED079F50>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:0B39F957-E88F-427C-AC41-F1B9DC711A02>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:FC7D109F-F404-4287-BE4A-D7C5AA057401>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:237CBF43-3113-4746-AC7C-0EEE2CD7D926> .
<urn:domeoclient:uuid:33D89E0F-4370-431E-8DB5-094F3AF78C75>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:33D89E0F-4370-431E-8DB5-094F3AF78C75> .
<urn:linkedspls:uuid:5239657F-5948-4803-B690-76D953D60764>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:F5AE3B3E-B864-4A19-B48C-DC1343C799A3>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"intermediate-metabolizer" .
<urn:linkedspls:uuid:850F3B60-ADC8-42A5-8E7E-B50B1E9D39BE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Tamoxifen" .
<urn:linkedspls:uuid:F5AE3B3E-B864-4A19-B48C-DC1343C799A3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:domeoclient:uuid:524C3AB2-2955-4538-A46C-63CDD0BC11D2>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:4CFDD438-5250-4D24-9933-43397A6F2E0F> .
<urn:domeoclient:uuid:1924E2D5-9E52-46A8-925D-043869F8F777>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:14099187-A7EA-4F77-905D-B1B942FF80D7> .
<urn:domeoclient:uuid:CE3C3FF6-F83D-47D2-8C4F-944687265F2B>	<http://purl.org/pav/createdOn>	"2014-03-31 09:01:41 -0400" .
<urn:linkedspls:uuid:27F9E2A8-C54A-4F87-A02D-4F8EFF5D382F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:5B91F78A-EEB0-41A3-8995-90B920D09520>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:F270E3B3-9983-425D-98FB-66F62E36340F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:BC70D092-5124-4A5C-87C3-EA34E4868C05>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:74BDDF82-70E1-44A8-B130-17D04DE86798>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"TPMT" .
<urn:domeoclient:uuid:1924E2D5-9E52-46A8-925D-043869F8F777>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:75C4424E-2C9D-40D9-82CF-7E02CFDCA301> .
<urn:domeoclient:uuid:0B13BA6D-FAED-4224-BF7E-64E31E595AD6>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:0B13BA6D-FAED-4224-BF7E-64E31E595AD6> .
<urn:linkedspls:uuid:FEF94E24-725D-433B-8F55-9E75E14CECB9>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:domeoclient:uuid:60CFE292-6834-41FC-8255-B81A3D584EE2>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:BC70D092-5124-4A5C-87C3-EA34E4868C05>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:domeoclient:uuid:F0BBC254-D123-49BE-A254-67148370DC96>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:F0BBC254-D123-49BE-A254-67148370DC96> .
<urn:linkedspls:uuid:F270E3B3-9983-425D-98FB-66F62E36340F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:D939C426-7E0B-4A32-80F1-7344D702AA97>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:linkedspls:uuid:EE534BB0-3042-44F4-9B63-01291E28FA45>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:linkedspls:uuid:F45F585A-05C5-49B5-BABB-73BFBE9E9753>	<http://semanticscience.org/resource/SIO_000111>	"66106-6 PHARMACOGENOMICS SECTION" .
<urn:linkedspls:uuid:6B9F2EDD-8EC9-441C-9B9C-6DE4ED079F50>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"TPMT" .
<urn:domeoclient:uuid:15924106-592A-47E7-A01C-764A16E257DC>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:05DBF40D-ECCF-4BC6-9077-742EBADF41F9>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000007205" .
<urn:domeoclient:uuid:98226070-C5AF-407A-B6D1-D521CD001163>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:25348450-1CCF-4BEC-84EF-0EA92F67DD3A>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Discontinue/Do not restart" .
<urn:linkedspls:uuid:08308CA2-E50D-41DB-873B-E57372B5FBDB>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"poor-metabolizer" .
<urn:linkedspls:uuid:74BDDF82-70E1-44A8-B130-17D04DE86798>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:671F2493-9F0B-4BB9-94E6-4B432F418763>	<http://purl.org/pav/createdOn>	"2014-04-21 13:36:34 -0400" .
<urn:domeoclient:uuid:028082D6-59BF-44E8-9117-CC155DA8D008>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:237CBF43-3113-4746-AC7C-0EEE2CD7D926>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:237CBF43-3113-4746-AC7C-0EEE2CD7D926> .
<urn:domeoclient:uuid:6FC50BDC-78A6-4D50-8D6E-7FEB6DAFF0E2>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:5239657F-5948-4803-B690-76D953D60764>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:055AAAC1-3544-4B8E-BF06-C99328A12B6E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:D2A8C2D7-9A3E-4307-BC2B-4EA4FC30E8A5>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:599459E0-8D98-4627-BC38-BA5B6BEC6B33>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:domeoclient:uuid:8BEEBA62-C519-4421-9038-113DCDFC9B2C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:9C2B48AD-A4E0-4C6C-9246-E6FD6CF712C8>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:9982EFEC-057D-47A7-8241-37ACB3F049AA>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:9982EFEC-057D-47A7-8241-37ACB3F049AA> .
<urn:linkedspls:uuid:87B8F5B0-8381-4CA7-AE0B-30C481D164B4>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:B00F626B-2496-40FE-8B44-A026746EF9DB>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=217e52b5-3a7b-4bbe-af3c-b18de7d426c3" .
<urn:linkedspls:uuid:6F731CE1-E6B4-41AA-98C6-30C94B771E61>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2625" .
<urn:linkedspls:uuid:407F8565-3B9C-4CF8-B785-C8286BCD86A2>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:D64C9075-1FB5-47EA-9312-70A065865D71>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:A460766E-6EF1-468A-A8D7-D8163DEDE490>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"biomarker-level-low" .
<urn:domeoclient:uuid:FBA8BE44-2409-4673-8D2F-0E2947538FCE>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0" .
<urn:linkedspls:uuid:8BDFDC96-47AF-489E-8F96-DF9B26C6ECBE>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"poor-metabolizer" .
<urn:linkedspls:uuid:1FAA2AB1-96D9-4225-A9E1-763F045EE2CD>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:5D87AC20-773F-4241-AA52-57BF86A4A93A>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:68B37481-F382-41B9-AEF5-DB241FA9325F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/Prodrug>	"Prodrug" .
<urn:linkedspls:uuid:402D9368-C611-4289-8004-8EEC1A409CCF>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Discontinue/Do not restart" .
<urn:linkedspls:uuid:A24FCBC0-9830-43DC-87D5-5716D3136B02>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"poor-metabolizer" .
<urn:linkedspls:uuid:CD7BE61C-D111-48EB-A232-1241D41AB8BC>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:7CE2D02E-F446-465D-9CBE-27C213ACCC89>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"CYP2C19" .
<urn:domeoclient:uuid:ECE9E8AD-BAEE-4FC0-A880-67D03D8D2EED>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:558D142F-DBE9-4EB9-9F46-4244D63F2FAF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:3D5B3334-40F5-4B23-8773-AFED2978DC1D>	<http://purl.org/pav/createdOn>	"2014-06-30 13:18:20 -0400" .
<urn:domeoclient:uuid:EF161740-C79C-4D2A-9002-4B0A139BF81E>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:76AEC8EC-841B-4618-8A97-4D6655CE39F4>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:76AEC8EC-841B-4618-8A97-4D6655CE39F4> .
<urn:linkedspls:uuid:C2A76A18-A463-4D7B-9A00-33BEFE84F768>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00564" .
<urn:domeoclient:uuid:DF92C1E1-A223-4737-8028-06DD03B558D2>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:76AEC8EC-841B-4618-8A97-4D6655CE39F4> .
<urn:linkedspls:uuid:0B3E23EF-1696-4FF7-BEEB-8158BDA84294>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:linkedspls:uuid:9C843591-806D-42E0-88A9-58DC59076B3D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Tamoxifen" .
<urn:domeoclient:uuid:FA0C425E-2A1E-4059-BAC2-34BD4239836F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:5E02C5AB-C35D-4ACA-8EF0-DF0F481E6A00>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:EE8AF84A-98F2-4EED-8B54-4312A50FBA31>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:D66A54D7-BD47-4E22-B2F3-09A5D190955A> .
<urn:domeoclient:uuid:481D46BB-D4FB-4587-B147-C2FC166A7A51>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:4663B6D5-B11D-4039-8F32-F7E3BFC2537E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Increase" .
<urn:linkedspls:uuid:402D9368-C611-4289-8004-8EEC1A409CCF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:61B14255-647D-4AA2-83E5-B81256BF7A50>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:linkedspls:uuid:7C3837BB-DAF7-4544-9D2C-A63E2F406BAC>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:EE8AF84A-98F2-4EED-8B54-4312A50FBA31>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:2423954D-96B2-404E-8B04-9609825C795A> .
<urn:linkedspls:uuid:169DB9DD-C966-431C-85FE-C3AC1F8E31D3>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:domeoclient:uuid:B6570F9A-45F9-4786-BDA7-9D6B899F45DB>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:9A15D029-5B02-4107-A829-E2BD1B1219FE>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"CYP2C19" .
<urn:linkedspls:uuid:C904A0A3-252D-4872-B966-44B63E18E430>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"poor-metabolizer" .
<urn:linkedspls:uuid:905B00B5-CD9F-4F5A-BDCD-2E0771AC9B73>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:linkedspls:uuid:1B973C15-149D-4D98-90E2-4A06A2F30ABD>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:F1F72593-1500-4B06-AE14-AE29B3EAE9B1>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:F1F72593-1500-4B06-AE14-AE29B3EAE9B1> .
<urn:linkedspls:uuid:4B11E300-2DF5-4B21-9D43-4D0A02109A59>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:D66FA8C3-8BAB-4A6F-8234-6DD134876578>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Recommend" .
<urn:linkedspls:uuid:A460766E-6EF1-468A-A8D7-D8163DEDE490>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1, PGR" .
<urn:linkedspls:uuid:FEF94E24-725D-433B-8F55-9E75E14CECB9>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:558D142F-DBE9-4EB9-9F46-4244D63F2FAF>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:domeoclient:uuid:B752346E-6167-497D-B585-83983FA71DA2>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:B79BAC9C-6B3B-4FF1-9F24-2BD40CE200BF> .
<urn:domeoclient:uuid:147B38AF-9E51-4D8A-B5CF-D7FAE7375257>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:147B38AF-9E51-4D8A-B5CF-D7FAE7375257> .
<urn:domeoclient:uuid:9098E55C-952E-46DF-904C-2A3E63492B3A>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:9098E55C-952E-46DF-904C-2A3E63492B3A> .
<urn:domeoclient:uuid:46A370D2-9D5B-4964-96D7-FECDB2FC0ED4>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:2423954D-96B2-404E-8B04-9609825C795A>	<http://semanticscience.org/resource/SIO_000111>	"WARNINGS AND PRECAUTIONS (43685-7)" .
<urn:domeoclient:uuid:5464F1B8-CF3D-4DA9-99F4-5F156C14CE70>	<http://purl.org/pav/createdOn>	"2014-03-31 09:02:38 -0400" .
<urn:domeoclient:uuid:403ED560-E6D3-4B1C-BAF1-DD0E0D87AA3F>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:403ED560-E6D3-4B1C-BAF1-DD0E0D87AA3F> .
<urn:linkedspls:uuid:25348450-1CCF-4BEC-84EF-0EA92F67DD3A>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:A48D46C7-8F7E-4426-8C3D-CCA08F946DB0>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Increase" .
<urn:linkedspls:uuid:24265221-E0B1-4F13-A2EB-0E9D9DC6F5D4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Tamoxifen" .
<urn:linkedspls:uuid:855BF4FE-7082-466C-AEC2-BA37C5A2F93C>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00682" .
<urn:domeoclient:uuid:94F5EFA2-DEF5-444E-B4C2-7268B36AF650>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:CE2D417D-24B3-4A7E-BE0B-FBF0E34B509B>	<http://purl.org/pav/createdOn>	"2014-06-30 12:51:53 -0400" .
<urn:linkedspls:uuid:68B37481-F382-41B9-AEF5-DB241FA9325F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:45EDCED8-9B43-464F-AC7F-898A9009649D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:B00F626B-2496-40FE-8B44-A026746EF9DB>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:B00F626B-2496-40FE-8B44-A026746EF9DB> .
<urn:linkedspls:uuid:D64C9075-1FB5-47EA-9312-70A065865D71>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:616A0715-5B79-4DD8-8392-1FDEF99E9911>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:616A0715-5B79-4DD8-8392-1FDEF99E9911> .
<urn:linkedspls:uuid:055AAAC1-3544-4B8E-BF06-C99328A12B6E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Abacavir" .
<urn:linkedspls:uuid:56D95EC4-D0D7-4BD6-B13C-E145F6A4E568>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"biomarker-level-low" .
<urn:linkedspls:uuid:2510C893-9155-453B-922C-CF116136DD88>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"TPMT" .
<urn:linkedspls:uuid:9739D8D8-F16D-4FF9-BD63-1945B116EEC4>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:E03CFE71-0FEF-4840-A587-1D360CBF035C>	<http://www.w3.org/ns/oa#exact>	"Advise patients that nursing mothers taking codeine can have higher morphine levels in their breast milk if they are ultra-rapid metabolizers. These higher levels of morphine in breast milk may lead to life-threatening or fatal side effects in nursing babies. Advise nursing mothers to watch for signs of morphine toxicity in their infants which includes increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness." .
<urn:domeoclient:uuid:87228117-6F6A-41A0-9709-5D0977E83A06>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:87228117-6F6A-41A0-9709-5D0977E83A06> .
<urn:linkedspls:uuid:855697DF-EBFA-4343-B2F2-023B6F284D48>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"TPMT" .
<urn:linkedspls:uuid:84646AA6-8E85-4656-8515-E49CB15EADB4>	<http://semanticscience.org/resource/SIO_000111>	"42229-5 SPL UNCLASSIFIED SECTION" .
<urn:domeoclient:uuid:4019443F-CB02-40D7-BB18-37DDB00B1548>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:4019443F-CB02-40D7-BB18-37DDB00B1548> .
<urn:linkedspls:uuid:9739D8D8-F16D-4FF9-BD63-1945B116EEC4>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:domeoclient:uuid:A8189564-74C8-463F-9927-917478975C75>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:A8189564-74C8-463F-9927-917478975C75> .
<urn:linkedspls:uuid:1532F8ED-1CF3-45D5-8A36-00FA8FD6060D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>	"Use specific" .
<urn:linkedspls:uuid:29A5252E-79CA-41F6-BF34-26789C947F8D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:7B209F2D-47BE-4267-B895-92D67A47AE61>	<http://purl.org/pav/createdOn>	"2014-06-02 14:14:35 -0400" .
<urn:linkedspls:uuid:ED9FC62F-6F5A-4AEC-B2EB-900F4C21E312>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:linkedspls:uuid:74BDDF82-70E1-44A8-B130-17D04DE86798>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"add intermediate to dropdown" .
<urn:linkedspls:uuid:2446A882-2020-42F8-AD24-FE3B4F839958>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-SNP-positive" .
<urn:domeoclient:uuid:141D5512-1FE5-4684-BAA6-CA59DA362006>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:141D5512-1FE5-4684-BAA6-CA59DA362006> .
<urn:linkedspls:uuid:2446A882-2020-42F8-AD24-FE3B4F839958>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>	"Decrease from baseline" .
<urn:linkedspls:uuid:44E81086-BA17-4D23-BE19-3D545D7F1B9D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:9F45C51D-C093-4FEB-A57B-7D59EB1E01DA>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"HLA-B" .
<urn:domeoclient:uuid:D3B78E07-8B27-4774-B221-CC47DAC8365E>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:CD7BE61C-D111-48EB-A232-1241D41AB8BC> .
<urn:linkedspls:uuid:599459E0-8D98-4627-BC38-BA5B6BEC6B33>	<http://semanticscience.org/resource/SIO_000111>	"42229-5 SPL UNCLASSIFIED SECTION" .
<urn:domeoclient:uuid:55544593-2536-44D4-B561-50DB89250F52>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:45EDCED8-9B43-464F-AC7F-898A9009649D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:88C2CEB5-469C-451E-8436-788ABE4338F5>	<http://purl.org/pav/createdOn>	"2014-04-21 13:04:12 -0400" .
<urn:linkedspls:uuid:13F3B206-EA87-463E-9DA8-93AA056A9117>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>	"Discontinue/Do not restart" .
<urn:linkedspls:uuid:9C843591-806D-42E0-88A9-58DC59076B3D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:037A2873-CACE-474F-B3EB-1EF6E0A58FCF>	<http://www.w3.org/ns/oa#exact>	" If the patient is of unknown HLA-B*5701 status, screening for the allele is recommended prior to reinitiation of ZIAGEN." .
<urn:domeoclient:uuid:89320F5F-262D-4657-8A52-4432EC0101F8>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:DBCD24FF-6ABB-4810-A5CA-DF8F85FF2241> .
<urn:linkedspls:uuid:964EBF55-DC67-43A9-93E2-DBC843BB8D2A>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Decrease" .
<urn:domeoclient:uuid:72569EC5-72D5-43F3-9028-CE31C726B1D0>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:72569EC5-72D5-43F3-9028-CE31C726B1D0> .
<urn:domeoclient:uuid:C6988919-6455-4291-92FF-E4F63DF9F9BF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:0D634683-D28C-42DC-9911-DFD0C9EB289D>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>	"Recommend" .
<urn:linkedspls:uuid:0961EB1D-39A9-4A01-9D9B-C2BC3222987E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:2BEFD527-0C92-4B61-A2B9-12F931EDC707>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:9739D8D8-F16D-4FF9-BD63-1945B116EEC4>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Increased Toxicity Risk" .
<urn:domeoclient:uuid:29951346-424F-4492-B79A-EF5022CB7F05>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:29951346-424F-4492-B79A-EF5022CB7F05> .
<urn:linkedspls:uuid:87B8F5B0-8381-4CA7-AE0B-30C481D164B4>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"extensive-metabolizer" .
<urn:linkedspls:uuid:24265221-E0B1-4F13-A2EB-0E9D9DC6F5D4>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:0961EB1D-39A9-4A01-9D9B-C2BC3222987E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:linkedspls:uuid:0BEDE64D-11D3-4746-9532-E747F6A427E0>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:2510C893-9155-453B-922C-CF116136DD88>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>	"Metabolism Decrease" .
<urn:linkedspls:uuid:599459E0-8D98-4627-BC38-BA5B6BEC6B33>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:domeoclient:uuid:45B95464-0287-435F-86B4-0253D73E6DA8>	<http://www.w3.org/ns/oa#exact>	"CNA106030 (PREDICT-1), a randomized, double-blind study, evaluated the clinical utility of prospective HLA-B*5701 screening on the incidence of abacavir hypersensitivity reaction in abacavir-naive HIV-1-infected adults (n\u00A0=\u00A01,650). In this study, use of pre-therapy screening for the HLA-B*5701 allele and exclusion of subjects with this allele reduced the incidence of clinically suspected abacavir hypersensitivity reactions from 7.8% (66/847) to 3.4% (27/803). Based on this study, it is estimated that 61% of patients with the HLA-B*5701 allele will develop a clinically suspected hypersensitivity reaction during the course of abacavir treatment compared with 4% of patients who do not have the HLA-B*5701 allele." .
<urn:domeoclient:uuid:201331AB-54CD-4BE2-81C9-806CCB6E5915>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:8BDFDC96-47AF-489E-8F96-DF9B26C6ECBE>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>	"Decrease from baseline" .
<urn:linkedspls:uuid:9BD38C7E-B2D9-4C83-903C-F86556F46EF2>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbol>	"ESR1, PGR" .
<urn:linkedspls:uuid:94B53E9F-5329-43D3-AD42-03C430F6E877>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:31115D88-2436-4D8C-B5E2-A7636A9DA498>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00675" .
<urn:domeoclient:uuid:3846BD3B-067C-4D62-AAA4-6A53131A2A2B>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:8B74A738-1124-4DAC-BE25-F15C78CFBA15>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:C2A76A18-A463-4D7B-9A00-33BEFE84F768>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Carbamazepine" .
<urn:linkedspls:uuid:9692B313-0E4E-4D52-9D7C-456D2EE68F54>	<http://semanticscience.org/resource/SIO_000111>	"WARNINGS AND PRECAUTIONS (43685-7)" .
<urn:domeoclient:uuid:3846BD3B-067C-4D62-AAA4-6A53131A2A2B>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:8B74A738-1124-4DAC-BE25-F15C78CFBA15>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:D3B78E07-8B27-4774-B221-CC47DAC8365E>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:64BC1D21-CAE1-4F85-A596-73342A9D5388> .
<urn:linkedspls:uuid:13F3B206-EA87-463E-9DA8-93AA056A9117>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:53541A7F-ACF6-4030-A4B7-7BA865CDF82F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:4663B6D5-B11D-4039-8F32-F7E3BFC2537E>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2625" .
<urn:domeoclient:uuid:201331AB-54CD-4BE2-81C9-806CCB6E5915>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:14099187-A7EA-4F77-905D-B1B942FF80D7>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:14099187-A7EA-4F77-905D-B1B942FF80D7> .
<urn:domeoclient:uuid:82F247F1-5E0B-472B-8C42-4074C2A25CD0>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:82F247F1-5E0B-472B-8C42-4074C2A25CD0> .
<urn:domeoclient:uuid:97CDCA51-103C-4EB7-BA80-9670B117D103>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:8C0132CB-1BA7-4320-8C5F-E55761BC596E> .
<urn:linkedspls:uuid:31115D88-2436-4D8C-B5E2-A7636A9DA498>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Comment>	"how to annotation increased effect with increased duration of therapy (PD?)" .
<urn:linkedspls:uuid:7CE2D02E-F446-465D-9CBE-27C213ACCC89>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006102" .
<urn:linkedspls:uuid:E06F2653-44AD-435F-AB2C-133712B039A6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"HLA-B*1502" .
<urn:domeoclient:uuid:2BEFD527-0C92-4B61-A2B9-12F931EDC707>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:037A2873-CACE-474F-B3EB-1EF6E0A58FCF>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:037A2873-CACE-474F-B3EB-1EF6E0A58FCF> .
<urn:linkedspls:uuid:FE1B382B-9F39-4CAA-8A59-17376ED6F061>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:BDEED6AF-6C6D-44F0-8470-40D3A54778C5>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:70BE7DEB-6A8B-41E9-9333-F1F47AC7E1A0>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*1502" .
<urn:domeoclient:uuid:C6988919-6455-4291-92FF-E4F63DF9F9BF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:9837A225-376D-44A6-959D-05A7DCB03CCE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:0D634683-D28C-42DC-9911-DFD0C9EB289D>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"HLA-B*1502" .
<urn:linkedspls:uuid:A48D46C7-8F7E-4426-8C3D-CCA08F946DB0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:2625" .
<urn:domeoclient:uuid:55544593-2536-44D4-B561-50DB89250F52>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:7D37999E-F183-41DD-8FEF-19696FD23D30>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:FED638A3-F491-4246-B5EC-651C306CF76E> .
<urn:domeoclient:uuid:9EBC36A6-A85E-4348-8EBC-5B071D8A79FB>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:C6988919-6455-4291-92FF-E4F63DF9F9BF> .
<urn:linkedspls:uuid:194FD718-B3CA-4D25-B3D2-56D36C1ECB60>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:BCC8E4C0-518C-4CB7-86BA-64CE75086359>	<http://www.w3.org/ns/oa#exact>	"Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. " .
<urn:domeoclient:uuid:DB8F110F-7415-4B13-AB5B-23F1D7A1C6BF>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:DB8F110F-7415-4B13-AB5B-23F1D7A1C6BF> .
<urn:domeoclient:uuid:8B50CE5B-C2BB-4D97-838E-E1C2600020BC>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:8C44EE5A-5A11-4743-B389-617115FC82BB> .
<urn:domeoclient:uuid:FA0C425E-2A1E-4059-BAC2-34BD4239836F>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:FA0C425E-2A1E-4059-BAC2-34BD4239836F> .
<urn:linkedspls:uuid:FE990D63-4739-43A5-B062-7A946346B2AF>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:407F8565-3B9C-4CF8-B785-C8286BCD86A2>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MonitoringRecommendation>	"Change monitoring strategy" .
<urn:domeoclient:uuid:10B1EB06-38FD-41C2-A3B7-625B2825B889>	<http://www.w3.org/ns/oa#exact>	"Letrozole tablet is an aromatase inhibitor indicated for:\u00A0\\nAdjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer (1.1)\\nExtended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy (1.2)\\nFirst and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer" .
<urn:linkedspls:uuid:51C4FEDD-5F25-4F57-92BC-5456BC2E4846>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:EF161740-C79C-4D2A-9002-4B0A139BF81E>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:EF161740-C79C-4D2A-9002-4B0A139BF81E> .
<urn:linkedspls:uuid:C9CADF5C-CD94-4A8C-B6CF-12220ED65397>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:42FA1C17-B780-423F-B993-EAF8D8DF0329>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-negative" .
<urn:domeoclient:uuid:E1199968-6650-4D2A-A5E4-EDFBFE7733AE>	<http://www.w3.org/ns/oa#exact>	"The maximum dose should be limited to 20 mg/day in patients who are CYP2C19 poor metabolizers or those patients who may be taking concomitant cimetidine or another CYP2C19 inhibitor, since higher citalopram exposures would be expected." .
<urn:domeoclient:uuid:420A3DFE-8247-4E9B-8E6C-368F1A2C415C>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:81525CE9-0714-4D48-9149-6C8B8671E117> .
<urn:linkedspls:uuid:461FDA58-8FAB-4951-B04A-F969D73C634D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Warfarin" .
<urn:linkedspls:uuid:0B39F957-E88F-427C-AC41-F1B9DC711A02>	<http://semanticscience.org/resource/SIO_000111>	"DOSAGE AND ADMINISTRATION (34068-7)" .
<urn:linkedspls:uuid:7E666CF4-DD19-4B4B-AE7B-EF4BCEA0181C>	<http://purl.bioontology.org/ontology/NCIT#Alleles>	"multiple copies of the gene for cytochrome P450 isoenzyme 2D6" .
<urn:linkedspls:uuid:A3C1B92C-CBE0-4BA8-A41C-D3C3CD26FA51>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:45844BA9-29ED-4EC6-94C0-81C9883F880F>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:linkedspls:uuid:09071EE6-03DB-49CA-BA67-1589B0E2FDBD>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:EE534BB0-3042-44F4-9B63-01291E28FA45>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:E17574BF-3BA6-48DA-B0DA-6E8DF716A03D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:domeoclient:uuid:8BEEBA62-C519-4421-9038-113DCDFC9B2C>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:8BEEBA62-C519-4421-9038-113DCDFC9B2C> .
<urn:linkedspls:uuid:F0B7C43C-792D-49E5-B282-D2303F858889>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"UGT1A1" .
<urn:linkedspls:uuid:36FDCB4E-5E54-4CBA-BC44-04B836C019F0>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:F9A68240-FAD6-4604-8DEE-1B0E4AF9BD21>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"TPMT" .
<urn:domeoclient:uuid:94F5EFA2-DEF5-444E-B4C2-7268B36AF650>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:E06F2653-44AD-435F-AB2C-133712B039A6>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/HGNCGeneSymbolURI>	"http://bio2rdf.org/hgnc:4932" .
<urn:domeoclient:uuid:CA5A93F5-5D2A-44BF-8951-9EF6DFE12F1B>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:E1199968-6650-4D2A-A5E4-EDFBFE7733AE> .
<urn:linkedspls:uuid:61B14255-647D-4AA2-83E5-B81256BF7A50>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:52601F35-C2AB-4602-BD13-6B9999A0266A>	<http://semanticscience.org/resource/SIO_000111>	"WARNINGS AND PRECAUTIONS (43685-7)" .
<urn:domeoclient:uuid:46A370D2-9D5B-4964-96D7-FECDB2FC0ED4>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:linkedspls:uuid:3746E014-4500-4C39-A007-7B912571A900>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrugURI>	"http://www.drugbank.ca/drugs/DB00675" .
<urn:domeoclient:uuid:405A5AAA-08FD-470C-9B50-67E44ED1462F>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:BF8C1810-3B2F-446D-95FB-F6382AEE1DC0> .
<urn:domeoclient:uuid:DBBF90A0-6468-4792-B1CC-02DDD21B4A08>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:09071EE6-03DB-49CA-BA67-1589B0E2FDBD> .
<urn:domeoclient:uuid:FB8FC7BE-DF14-4ABF-B790-607DABB38F49>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:2F3B0124-31A3-451B-BA81-5652303A452C> .
<urn:linkedspls:uuid:9A15D029-5B02-4107-A829-E2BD1B1219FE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:0F8A06DC-D6FE-466C-AF73-CF9E7A8C2707>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:563CB9E8-A4E7-43EF-9686-1F5B71F4169D> .
<urn:domeoclient:uuid:FB8FC7BE-DF14-4ABF-B790-607DABB38F49>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:92FA8990-60EF-4140-9F60-C12E57E3B114> .
<urn:domeoclient:uuid:9EBC36A6-A85E-4348-8EBC-5B071D8A79FB>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:F5AE3B3E-B864-4A19-B48C-DC1343C799A3> .
<urn:linkedspls:uuid:850F3B60-ADC8-42A5-8E7E-B50B1E9D39BE>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:domeoclient:uuid:5EE59E00-2977-4F09-A933-867C3E165210>	<http://www.w3.org/ns/oa#hasBody>	<urn:linkedspls:uuid:B9375CD1-7E67-42D6-B380-D95AD08BF64B> .
<urn:domeoclient:uuid:4EEB4B8C-B4AE-42C6-9E9C-805907F3A548>	<http://www.w3.org/ns/oa#exact>	"Clopidogrel tablets may not work as well in people who:\\\\r\\n\\\\r\\n    have certain genetic factors that affect how the body breaks down clopidogrel tablets." .
<urn:linkedspls:uuid:D6235B22-042E-4C36-A104-B353CF92CEB8>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>	"ER and PgR_receptor" .
<urn:domeoclient:uuid:ECE9E8AD-BAEE-4FC0-A880-67D03D8D2EED>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:ECE9E8AD-BAEE-4FC0-A880-67D03D8D2EED> .
<urn:linkedspls:uuid:1532F8ED-1CF3-45D5-8A36-00FA8FD6060D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006120" .
<urn:linkedspls:uuid:27F9E2A8-C54A-4F87-A02D-4F8EFF5D382F>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:domeoclient:uuid:6FC50BDC-78A6-4D50-8D6E-7FEB6DAFF0E2>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:6FC50BDC-78A6-4D50-8D6E-7FEB6DAFF0E2> .
<urn:domeoclient:uuid:F777C391-7D5E-4F49-948B-5B9ACB2587FA>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:46A370D2-9D5B-4964-96D7-FECDB2FC0ED4> .
<urn:domeoclient:uuid:B6570F9A-45F9-4786-BDA7-9D6B899F45DB>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:B30B41E3-5A67-4530-BC81-938E6B016FDF>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MedicalCondition>	"MedicalCondition" .
<urn:linkedspls:uuid:964EBF55-DC67-43A9-93E2-DBC843BB8D2A>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>	"Decreased Efficacy" .
<urn:domeoclient:uuid:15924106-592A-47E7-A01C-764A16E257DC>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:15924106-592A-47E7-A01C-764A16E257DC> .
<urn:domeoclient:uuid:C7EAEB14-8213-4EF8-AC67-469D0609826B>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:AE6AF907-607C-4B15-B108-FAD4D3010CA4>	<http://purl.org/pav/createdOn>	"2014-04-14 14:55:16 -0400" .
<urn:linkedspls:uuid:396CB021-3C85-4E20-B020-3714CE558E2D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarkerURI>	"http://purl.obolibrary.org/obo/PR_000006120" .
<urn:linkedspls:uuid:81525CE9-0714-4D48-9149-6C8B8671E117>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:945EB72E-5C75-41B0-B8FC-637E1EF0AE7D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Carbamazepine" .
<urn:domeoclient:uuid:563CB9E8-A4E7-43EF-9686-1F5B71F4169D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:A1F7627F-2636-46AA-A344-F9978C2AA71C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:2D0B9A22-6129-4786-B0A4-7384B3324DF0>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:9EBC36A6-A85E-4348-8EBC-5B071D8A79FB>	<http://purl.org/pav/createdOn>	"2014-04-28 15:49:18 -0400" .
<urn:domeoclient:uuid:671F2493-9F0B-4BB9-94E6-4B432F418763>	<http://www.w3.org/ns/oa#hasTarget>	<urn:domeoclient:uuid:ABB77F0A-DE6D-4F3D-87F3-CFA59807AA63> .
<urn:domeoclient:uuid:BD33E8D1-8AEF-4E43-9C57-35AB0263305D>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:D9543430-9668-4C09-8709-B8D20B095EEA>	<http://www.w3.org/ns/oa#hasSource>	"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0" .
<urn:linkedspls:uuid:74BB3F3E-AD24-438C-9250-4357E959069E>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#Variant>	"poor-metabolizer" .
<urn:linkedspls:uuid:92FA8990-60EF-4140-9F60-C12E57E3B114>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestResult>	"gene-haplotype-negative" .
<urn:linkedspls:uuid:855BF4FE-7082-466C-AEC2-BA37C5A2F93C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:0D634683-D28C-42DC-9911-DFD0C9EB289D>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Carbamazepine" .
<urn:domeoclient:uuid:C1908624-6F0B-47BD-8D70-8EACD877F4A9>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:10B1EB06-38FD-41C2-A3B7-625B2825B889>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:87D0F0C2-6038-41AA-B84E-85497D292836>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:linkedspls:uuid:1DA28968-6C74-475E-AB4F-5E6E22DFF8BD>	<http://semanticscience.org/resource/SIO_000111>	"42231-1 SPL MEDGUIDE SECTION" .
<urn:linkedspls:uuid:96D6F8F1-F51A-4EBC-BFF7-C799690B4401>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement> .
<urn:linkedspls:uuid:70BE7DEB-6A8B-41E9-9333-F1F47AC7E1A0>	<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>	"Carbamazepine" .
<urn:domeoclient:uuid:1FCB6C74-C406-41C1-8A44-C9D033D5834C>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#SpecificResource> .
<urn:domeoclient:uuid:CF0F356A-4BD3-4AB3-80E4-DF7EF3CD5F00>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/oa#PrefixSuffixTextSelector> .
<urn:domeoclient:uuid:745C184B-12B3-435F-99C5-252556EB53B9>	<http://www.w3.org/ns/oa#hasSelector>	<urn:domeoclient:uuid:745C184B-12B3-435F-99C5-252556EB53B9> .
